To O O
characterize O O
regulatory O O
sequences O O
important O O
for O O
promoter O O
activity O O
, O O
we O O
performed O O
linker O O
scanning O O
analysis O O
of O O
the O O
92-bp O O
CD11b O O
promoter O O
and O O
demonstrate O O
that O O
a O O
sequence O O
at O O
bp O O
-60 O O
is O O
essential O O
for O O
CD11b O O
promoter O O
activity O O
. O O

( O O
Transib1 O O
through O O
Transib5 O O
are O O
from O O
the O O
fruit O O
fly O O
D. O O
melanogaster O O
. O O
) O O

CD40 O O
ligation O O
on O O
MM O O
by O O
CD40L-transfected O O
murine O O
L-cells O O
or O O
by O O
a O O
soluble O O
CD40L O O
fusion O O
protein O O
up-regulated O O
their O O
expression O O
of O O
intercellular O O
adhesion O O
molecule-1 O O
and O O
MHC O O
class O O
I O O
and O O
class O O
II O O
molecules O O
and O O
their O O
secretion O O
of O O
IL-6 O O
, O O
IL-8 O O
, O O
tumor O O
necrosis O O
factor-a O O
, O O
and O O
granulocyte O O
macrophage O O
colony-stimulating O O
factor O O
and O O
also O O
induced O O
a O O
rapid O O
activation O O
of O O
the O O
transcription O O
factor O O
nuclear O O
factor O O
kappaB O O
. O O

Double-stimulation O O
was O O
used O O
to O O
demonstrate O O
that O O
, O O
in O O
a O O
T O O
lymphocytic O O
cell O O
line O O
( O O
CEM O O
) O O
, O O
phorbol O O
myristate O O
acetate O O
( O O
PMA O O
) O O
rapidly O O
induced O O
NF-kappa O O
B O O
through O O
a O O
signaling O O
pathway O O
which O O
did O O
not B-Negation B-Negation
involve I-Negation I-Negation
reactive I-Negation I-Negation
oxygen I-Negation I-Negation
species I-Negation I-Negation
( I-Negation I-Negation
ROS I-Negation I-Negation
) I-Negation I-Negation
and O O
was O O
different O O
from O O
the O O
activation O O
triggered O O
by O O
either O O
H2O2 O O
or O O
tumor O O
necrosis O O
factor-alpha O O
( O O
TNF-alpha O O
) O O
. O O

This O O
region O O
contains O O
elements O O
which O O
are O O
shared O O
with O O
the O O
transcriptional O O
enhancers O O
of O O
other O O
genes O O
including O O
interferon O O
regulatory O O
factor O O
1 O O
, O O
interferon O O
beta O O
, O O
and O O
interferon-inducible O O
genes O O
. O O

Mineralocorticoids O O
and O O
mineralocorticoid O O
receptors O O
in O O
mononuclear O O
leukocytes O O
in O O
patients O O
with O O
pregnancy-induced O O
hypertension O O
. O O

The O O
effects O O
of O O
GSSG O O
are O O
antagonized O O
by O O
reduced O O
thioredoxin O O
( O O
TRX O O
) O O
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
the O O
cooperation O O
of O O
different O O
transcription O O
factors O O
is O O
essential O O
for O O
IL-9 O O
gene O O
expression O O
in O O
T O O
cells O O
. O O

Induction O O
requirements O O
in O O
primary O O
human O O
T O O
cells O O
. O O

In O O
contrast O O
, O O
mild O O
oxidation O O
with O O
glucose O O
oxidase O O
selectively O O
inhibits O O
p75 O O
and O O
p85 O O
binding O O
while O O
not B-Negation B-Negation
blocking I-Negation I-Negation
p50 I-Negation I-Negation
and I-Negation I-Negation
p55 I-Negation I-Negation
interactions I-Negation I-Negation
. O O

In O O
contrast O O
to O O
the O O
decrease O O
in O O
GR O O
mRNA O O
seen O O
in O O
IM-9 O O
cells O O
after O O
treatment O O
with O O
1 O O
microM O O
dexamethasone O O
for O O
16-18 O O
h O O
, O O
treatment O O
of O O
6TG1.1 O O
cells O O
resulted O O
in O O
an O O
8-fold O O
increase O O
in O O
GR O O
mRNA O O
, O O
as O O
determined O O
by O O
Northern O O
blot O O
and O O
RNase O O
protection O O
analysis O O
, O O
with O O
a O O
corresponding O O
3- O O
to O O
4-fold O O
increase O O
in O O
GR O O
protein O O
. O O

This O O
might O O
affect O O
the O O
results O O
if O O
there O O
is O O
a O O
systematic O O
bias O O
on O O
the O O
composition O O
of O O
a O O
protein O O
interaction O O
set O O
. O O

Corticosteroids O O
are O O
the O O
preeminent O O
antiinflammatory O O
agents O O
although O O
the B-Negation B-Negation
molecular I-Negation I-Negation
mechanisms I-Negation I-Negation
that I-Negation I-Negation
impart I-Negation I-Negation
their I-Negation I-Negation
efficacy I-Negation I-Negation
have I-Negation I-Negation
not I-Negation I-Negation
been I-Negation I-Negation
defined I-Negation I-Negation
. O O

Recently O O
the O O
MHC O O
class O O
II O O
transactivator O O
( O O
CIITA O O
) O O
has O O
been O O
reported O O
to O O
be O O
a O O
major O O
regulatory O O
factor O O
for O O
both O O
the O O
constitutive O O
and O O
IFN O O
inducible O O
expression O O
of O O
MHC O O
class O O
II O O
genes O O
. O O

These O O
stimuli O O
also O O
induced O O
the O O
stress-activated O O
kinase O O
pathway O O
( O O
SAPK/JNK O O
) O O
, O O
which O O
was O O
required O O
for O O
the O O
maximal O O
induction O O
of O O
apoptosis O O
. O O

Much O O
attention O O
has O O
been O O
focused O O
on O O
the O O
interaction O O
of O O
Tat O O
with O O
a O O
specific O O
RNA O O
target O O
termed O O
TAR O O
( O O
transactivation O O
responsive O O
) O O
which O O
is O O
present O O
in O O
the O O
leader O O
sequence O O
of O O
all O O
HIV-1 O O
mRNAs O O
. O O

The O O
stimulation O O
of O O
interleukin-1 O O
alpha O O
production O O
by O O
okadaic O O
acid O O
was O O
more O O
modest O O
than O O
that O O
of O O
interleukin-1 O O
beta O O
. O O

In O O
vitro O O
translated O O
hGR O O
was O O
indistinguishable O O
from O O
native O O
hGR O O
, O O
as O O
determined O O
by O O
migration O O
on O O
sodium O O
dodecyl O O
sulfate-polyacrylamide O O
gels O O
, O O
sedimentation O O
on O O
sucrose O O
density O O
gradients O O
, O O
and O O
reactivity O O
with O O
antipeptide O O
antibodies O O
generated O O
against O O
hGR O O
. O O

Finally O O
, O O
we O O
demonstrate O O
that O O
thrombin O O
and O O
TRP O O
enhanced O O
CD69 O O
expression O O
and O O
interleukin O O
2 O O
production O O
induced O O
by O O
T O O
cell O O
receptor O O
cross-linking O O
in O O
both O O
Jurkat O O
T O O
cells O O
and O O
peripheral O O
blood O O
lymphocytes O O
. O O

We O O
then O O
studied O O
the O O
effect O O
of O O
the O O
antibody O O
on O O
aldosterone O O
and O O
progesterone O O
binding O O
to O O
the O O
hMR O O
. O O

Pretreatment O O
of O O
NK O O
cells O O
with O O
the O O
antioxidant O O
pyrrolidine O O
dithiocarbarmate O O
( O O
PDTC O O
) O O
leads O O
to O O
the O O
inhibition O O
of O O
NF-kappa O O
B O O
activation O O
but O O
the O O
AP-1 O O
binding O O
to O O
DNA O O
was O O
superinduced O O
. O O

Surprisingly O O
, O O
TRAF1 O O
, O O
-2 O O
, O O
or O O
-3 O O
does O O
not B-Negation B-Negation
interact I-Negation I-Negation
with I-Negation I-Negation
the I-Negation I-Negation
terminal I-Negation I-Negation
LMP1 I-Negation I-Negation
CT I-Negation I-Negation
aa I-Negation I-Negation
333 I-Negation I-Negation
to I-Negation I-Negation
386 I-Negation I-Negation
which I-Negation I-Negation
can I-Negation I-Negation
independently I-Negation I-Negation
mediate I-Negation I-Negation
NF-kappaB I-Negation I-Negation
activation I-Negation I-Negation
. O O

Promoter O O
analysis O O
revealed O O
that O O
a O O
GATA O O
site O O
in O O
a O O
cryptic O O
promoter O O
in O O
the O O
second O O
intron O O
was O O
essential O O
and O O
sufficient O O
for O O
the O O
TAL1- O O
and O O
LMO-dependent O O
transcriptional O O
activation O O
, O O
and O O
GATA3 O O
binds O O
to O O
this O O
site O O
. O O

Protein O O
kinase O O
C-zeta O O
mediates O O
NF-kappa O O
B O O
activation O O
in O O
human O O
immunodeficiency O O
virus-infected O O
monocytes O O
. O O

Immunoprecipitation O O
experiments O O
failed B-Negation B-Negation
to I-Negation I-Negation
demonstrate I-Negation I-Negation
an I-Negation I-Negation
association I-Negation I-Negation
between I-Negation I-Negation
nuclear I-Negation I-Negation
I I-Negation I-Negation
( I-Negation I-Negation
kappa I-Negation I-Negation
) I-Negation I-Negation
B I-Negation I-Negation
( I-Negation I-Negation
alpha I-Negation I-Negation
) I-Negation I-Negation
and I-Negation I-Negation
NF-kappaB I-Negation I-Negation
proteins I-Negation I-Negation
. O O

Using O O
liquid O O
chromatography O O
and O O
mass O O
spectrometry O O
of O O
deproteinated O O
hemolymph O O
samples O O
, O O
we O O
measured O O
adenosine O O
concentrations O O
in O O
hemolymph O O
of O O
mutant O O
and O O
wild-type O O
third-instar O O
larvae O O
. O O

Fab O O
fragment O O
of O O
anti-E. O O
chaffeensis O O
immunoglobulin O O
G O O
complexed O O
with O O
E. O O
chaffeensis O O
did O O
not B-Negation B-Negation
induce I-Negation I-Negation
any I-Negation I-Negation
of I-Negation I-Negation
these I-Negation I-Negation
three I-Negation I-Negation
cytokines I-Negation I-Negation
, O O
indicating O O
that O O
ehrlichial O O
binding O O
is O O
required O O
for O O
IL-1beta O O
mRNA O O
expression O O
and O O
that O O
binding O O
of O O
the O O
immune O O
complex O O
to O O
the O O
Fc O O
gamma O O
receptor O O
is O O
required O O
for O O
TNF-alpha O O
and O O
IL-6 O O
mRNA O O
expression O O
and O O
enhanced O O
IL-1beta O O
mRNA O O
expression O O
. O O

We O O
previously O O
identified O O
the O O
DNA O O
consensus O O
binding O O
site O O
recognized O O
by O O
the O O
two O O
DNA O O
binding O O
domains O O
. O O

Analysis O O
of O O
long O O
terminal O O
repeat-driven O O
secreted O O
alkaline O O
phosphatase O O
activity O O
in O O
transient O O
assays O O
showed O O
that O O
, O O
unlike O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
, O O
the O O
SIV O O
long O O
terminal O O
repeat O O
possesses O O
an O O
enhancer O O
region O O
just O O
upstream O O
of O O
the O O
NF-kappaB O O
element O O
which O O
maintains O O
significant O O
levels O O
of O O
basal O O
transcription O O
in O O
the O O
absence B-Negation O
of I-Negation O
NF-kappaB I-Negation O
and I-Negation O
Sp1 I-Negation O
sites I-Negation O
. O O

The O O
Ets O O
motifs O O
are O O
preferentially O O
bound O O
by O O
PU-1 O O
in O O
B O O
cell O O
extracts O O
from O O
all O O
stages O O
of O O
development O O
, O O
whereas O O
a O O
different O O
Ets O O
family O O
member O O
reacts O O
with O O
these O O
motifs O O
in O O
T O O
cell O O
extracts O O
. O O

The O O
constitutive O O
transcription O O
factor O O
SP1 O O
was O O
unaffected O O
by O O
addition O O
of O O
TPA O O
. O O

In O O
agreement O O
with O O
the O O
immunoprecipitation O O
results O O
, O O
they O O
found O O
that O O
an O O
intact O O
chromodomain O O
is O O
essential O O
for O O
RNA O O
binding O O
, O O
whereas O O
the O O
amino O O
terminus O O
or O O
the O O
HAT O O
domain O O
of O O
MOF O O
was O O
not O B-Negation
essential O I-Negation
. O O

Nevertheless O O
, O O
in O O
combination O O
with O O
traditional O O
approaches O O
including O O
genetics O O
and O O
biochemistry O O
, O O
knowledge O O
of O O
the O O
genome O O
sequence O O
for O O
model O O
organisms O O
will O O
undoubtedly O O
continue O O
to O O
drive O O
our O O
rapidly O O
increasing O O
insights O O
into O O
the O O
molecular O O
basis O O
of O O
programmed O O
cell O O
death O O
. O O

Non-gapped O O
alignment O O
of O O
consensus O O
sequences O O
of O O
5 O O
? O O
termini O O
of O O
transposons O O
from O O
22 O O
different O O
families O O
is O O
shown O O
beneath O O
the O O
RSS23 O O
consensus O O
sequence O O
, O O
composed O O
of O O
the O O
RSS O O
heptamer O O
and O O
nonamer O O
. O O

One O O
explanation O O
for O O
the O O
perpetuation O O
of O O
virus O O
infection O O
in O O
macrophages O O
could O O
be O O
sustained O O
nuclear O O
NF-kappa O O
B O O
expression O O
. O O

Figure O O
5 O O
shows O O
the O O
species O O
distribution O O
of O O
iPfam O O
domain O O
pairs O O
. O O

The O O
palindromic O O
site O O
( O O
site O O
B O O
) O O
recognized O O
by O O
this O O
protein O O
is O O
related O O
to O O
the O O
palindromic O O
binding O O
sites O O
of O O
members O O
of O O
the O O
steroid/thyroid O O
hormone O O
receptor O O
family O O
. O O

EBNA-2 O O
is O O
able O O
to O O
trans-activate O O
the O O
expression O O
of O O
the O O
LMP O O
gene O O
in O O
several O O
cell O O
lines O O
. O O

Taken O O
together O O
, O O
these O O
data O O
demonstrate O O
the O O
existence O O
of O O
an O O
HLA-DQ O O
isotype-specific O O
trans-acting O O
factor O O
, O O
which O O
functions O O
independently O O
of O O
CIITA O O
. O O

The O O
role O O
of O O
the O O
transcription O O
factor O O
NF-kappaB O O
in O O
the O O
pathogenesis O O
of O O
rheumatoid O O
arthritis O O
has O O
long O O
been O O
a O O
subject O O
of O O
controversy O O
. O O

Differential O O
utilization O O
of O O
Janus O O
kinase-signal O O
transducer O O
activator O O
of O O
transcription O O
signaling O O
pathways O O
in O O
the O O
stimulation O O
of O O
human O O
natural O O
killer O O
cells O O
by O O
IL-2 O O
, O O
IL-12 O O
, O O
and O O
IFN-alpha O O
. O O

While O O
all O O
the O O
M10-expressing O O
cell O O
lines O O
remained O O
infectable O O
by O O
HIV-1 O O
, O O
these O O
same O O
cells O O
failed B-Negation B-Negation
to I-Negation I-Negation
support I-Negation I-Negation
a I-Negation I-Negation
productive I-Negation I-Negation
replication I-Negation I-Negation
cycle I-Negation I-Negation
when I-Negation I-Negation
infected I-Negation I-Negation
with I-Negation I-Negation
a I-Negation I-Negation
cloned I-Negation I-Negation
isolate I-Negation I-Negation
of I-Negation I-Negation
HIV-1 I-Negation I-Negation
. O O

By O O
making O O
this O O
human O O
interaction O O
prediction O O
dataset O O
publicly O O
available O O
, O O
it O O
is O O
our O O
hope O O
that O O
it O O
will O O
help O O
to O O
identify O O
the O O
most O O
high-confidence O O
interactions O O
, O O
leading O O
to O O
a O O
more O O
complete O O
and O O
accurate O O
human O O
interaction O O
map O O
. O O

Mapping O O
of O O
the O O
structural O O
requirements O O
for O O
TRAF/RANK O O
interaction O O
revealed O O
multiple O O
TRAF O O
binding O O
sites O O
clustered O O
in O O
two O O
distinct O O
domains O O
in O O
the O O
RANK O O
cytoplasmic O O
tail O O
. O O

Survival O O
rate O O
and O O
melanotic O O
tumor O O
formation O O
were O O
compared O O
in O O
mutants O O
in O O
the O O
Toll O O
signaling O O
pathway O O
and O O
in O O
similar O O
mutants O O
with O O
overexpression O O
of O O
ADGF-A O O
using O O
the O O
HS-ADGF-A O O
construct O O
. O O

This O O
different O O
behavior O O
may O O
be O O
, O O
at O O
least O O
in O O
part O O
, O O
due O O
to O O
the O O
ability O O
of O O
HTB O O
and O O
triflusal O O
to O O
block O O
the O O
activation O O
of O O
the O O
transcription O O
factor O O
nuclear O O
factor-kappaB O O
to O O
a O O
higher O O
extent O O
than O O
aspirin O O
and O O
sodium O O
salicylate O O
. O O

The O O
abnormal O O
adherence O O
of O O
sickle O O
red O O
blood O O
cells O O
( O O
SS O O
RBC O O
) O O
to O O
endothelial O O
cells O O
has O O
been O O
thought O O
to O O
contribute O O
to O O
vascular O O
occlusion O O
, O O
a O O
major O O
cause O O
of O O
morbidity O O
in O O
sickle O O
cell O O
disease O O
( O O
SCD O O
) O O
. O O

Therefore O O
, O O
our O O
data O O
not O O
only O O
reveal O O
that O O
Nmi O O
can O O
potentiate O O
STAT-dependent O O
transcription O O
, O O
but O O
also O O
suggest O O
that O O
it O O
can O O
augment O O
coactivator O O
protein O O
recruitment O O
to O O
at O O
least O O
some O O
members O O
of O O
a O O
group O O
of O O
sequence-specific O O
transcription O O
factors O O
. O O

This O O
proves O O
that O O
the O O
observed O O
iPfam O O
coverage O O
is O O
significantly O O
higher O O
than O O
expected O O
and O O
iPfam O O
domain O O
pairs O O
are O O
enriched O O
in O O
real O O
experimental O O
protein O O
interactions O O
. O O

Cloning O O
and O O
expression O O
of O O
the O O
Epstein-Barr O O
virus-encoded O O
dUTPase O O
: O O
patients O O
with O O
acute O O
, O O
reactivated O O
or O O
chronic O O
virus O O
infection O O
develop O O
antibodies O O
against O O
the O O
enzyme O O
. O O

The O O
HTLV-I O O
LTR O O
contains O O
three O O
conserved O O
regulatory O O
elements O O
known O O
as O O
21 O O
base O O
pair O O
repeats O O
which O O
are O O
required O O
for O O
stimulation O O
of O O
gene O O
expression O O
by O O
the O O
transactivator O O
protein O O
tax O O
. O O

Differential O O
autoregulation O O
of O O
glucocorticoid O O
receptor O O
expression O O
in O O
human O O
T- O O
and O O
B-cell O O
lines O O
. O O

Tumor O O
necrosis O O
factor O O
receptor-1 O O
( O O
TNFR-1 O O
) O O
and O O
CD95 O O
( O O
also O O
called O O
Fas O O
or O O
APO-1 O O
) O O
are O O
cytokine O O
receptors O O
that O O
engage O O
the O O
apoptosis O O
pathway O O
through O O
a O O
region O O
of O O
intracellular O O
homology O O
, O O
designated O O
the O O
`` O O
death O O
domain. O O
`` O O

Comparison O O
of O O
cDNA O O
and O O
genomic O O
sequences O O
reveals O O
a O O
4-exon O O
structure O O
characteristic O O
of O O
the O O
FOS O O
family O O
of O O
genes O O
. O O

( O O
D–F O O
) O O
Expression O O
of O O
GFP-marked O O
glue O O
protein O O
( O O
Sgs O O
? O O
3-GFP O O
) O O
in O O
salivary O O
gland O O
of O O
the O O
adgf-a O O
mutant O O
larvae O O
and O O
pupae O O
. O O

Stimulation O O
of O O
U1 O O
cells O O
by O O
LPS O O
alone O O
induced O O
minimal O O
levels O O
of O O
HIV O O
expression O O
, O O
which O O
was O O
significantly O O
enhanced O O
by O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
( O O
GM-CSF O O
) O O
. O O

Being O O
compatible O O
with O O
those O O
results O O
, O O
Azeptin O O
( O O
10 O O
( O O
-5 O O
) O O
M O O
) O O
suppressed O O
activation O O
of O O
NF-kappa O O
B O O
in O O
PBL O O
, O O
HM O O
and O O
HF O O
. O O

Evidence O O
suggests O O
that O O
IL-10 O O
may O O
inhibit O O
activation O O
of O O
the O O
transcription O O
factor O O
nuclear O O
factor-kappaB O O
( O O
NF-kappaB O O
) O O
through O O
an O O
unknown O O
mechanism O O
. O O

To O O
find O O
genes O O
that O O
protect O O
cells O O
from O O
apoptosis O O
, O O
we O O
used O O
an O O
expression O O
cloning O O
strategy O O
and O O
identified O O
BHRF1 O O
, O O
an O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
early-lytic-cycle O O
protein O O
with O O
distant O O
homology O O
to O O
Bcl-2 O O
, O O
as O O
an O O
anti-apoptosis O O
protein O O
. O O

The O O
amino-terminal O O
domain O O
has O O
regions O O
homologous O O
to O O
the O O
oncogene O O
rel O O
and O O
to O O
the O O
developmentally O O
important O O
gene O O
dorsal O O
of O O
Drosophila O O
. O O

These O O
findings O O
were O O
associated O O
with O O
a O O
block O O
in O O
appearance O O
of O O
the O O
monocytic O O
phenotype O O
, O O
including O O
inhibition O O
of O O
TPA-induced O O
increases O O
in O O
lamin O O
A O O
, O O
lamin O O
C O O
, O O
and O O
vimentin O O
transcripts O O
. O O

Together O O
, O O
these O O
findings O O
demonstrate O O
that O O
cytokine O O
or O O
phorbol O O
ester O O
stimulation O O
of O O
KG1 O O
is O O
a O O
model O O
of O O
human O O
CD34+ O O
HPC O O
to O O
DC O O
differentiation O O
and O O
suggest O O
that O O
specific O O
intracellular O O
signaling O O
pathways O O
mediate O O
specific O O
events O O
in O O
DC O O
lineage O O
commitment O O
. O O

This O O
is O O
the O O
first O O
demonstration O O
that O O
lithium O O
can O O
alter O O
gene O O
expression O O
of O O
Tcf-responsive O O
genes O O
, O O
and O O
points O O
to O O
a O O
difference O O
in O O
regulation O O
of O O
Wnt O O
signaling O O
between O O
fibroblasts O O
and O O
lymphocytes O O
. O O

However O O
, O O
the B-Negation O
NF-kappaB I-Negation O
activation I-Negation O
pathway I-Negation O
involving I-Negation O
the I-Negation O
acidic I-Negation O
sphingomyelinase I-Negation O
of I-Negation O
the I-Negation O
endolysosomial I-Negation O
membrane I-Negation O
did I-Negation O
not I-Negation O
seem O O
to O O
participate O O
in O O
the O O
LPS-induced O O
NF-kappaB O O
activation O O
in O O
U937 O O
cells O O
. O O

IL-11 O O
mRNA O O
and O O
protein O O
were O O
both O O
up-regulated O O
during O O
the O O
course O O
of O O
this O O
inflammatory O O
response O O
. O O

Whether O O
endogenous O O
Neur O O
binds O O
and O O
activates O O
Ser O O
remains O O
to O O
be O O
tested O O
. O O

NF-kappa O O
B O O
is O O
a O O
nuclear O O
protein O O
of O O
the O O
rel O O
oncogene O O
family O O
capable O O
of O O
enhancing O O
transcription O O
of O O
several O O
cellular O O
genes O O
, O O
including O O
IL-2 O O
and O O
the O O
IL-2 O O
receptor O O
, O O
and O O
viral O O
genes O O
transcribed O O
from O O
the O O
HIV-1 O O
LTR O O
. O O

In O O
contrast O O
, O O
protein O O
kinase O O
C O O
stimulation O O
or O O
RelA O O
overexpression O O
does O O
not B-Negation B-Negation
affect I-Negation I-Negation
the I-Negation I-Negation
activity I-Negation I-Negation
of I-Negation I-Negation
a I-Negation I-Negation
human I-Negation I-Negation
IL4 I-Negation I-Negation
promoter I-Negation I-Negation
containing I-Negation I-Negation
a I-Negation I-Negation
mouse I-Negation I-Negation
P I-Negation I-Negation
sequence I-Negation I-Negation
, I-Negation O
which I-Negation O
is I-Negation O
a I-Negation O
higher-affinity I-Negation O
site I-Negation O
for I-Negation O
NF-ATp I-Negation O
and I-Negation O
a I-Negation O
lower-affinity I-Negation O
site I-Negation O
for I-Negation O
RelA I-Negation O
. O O

RNA O O
from O O
control O O
resting O O
cells O O
contained O O
low O O
to O O
undetectable O O
levels O O
of O O
c-jun O O
, O O
fibronectin O O
receptor O O
, O O
and O O
actin O O
mRNA O O
. O O

In O O
contrast O O
, O O
SCL O O
mRNA O O
levels O O
did O O
not B-Negation B-Negation
decrease I-Negation I-Negation
significantly I-Negation I-Negation
between I-Negation I-Negation
day I-Negation I-Negation
7 I-Negation I-Negation
and I-Negation I-Negation
day I-Negation I-Negation
14 I-Negation I-Negation
cells I-Negation I-Negation
, O O
suggesting O O
that O O
posttranscriptional O O
mechanisms O O
are O O
largely O O
responsible O O
for O O
the O O
decrease O O
in O O
SCL O O
protein O O
observed O O
. O O

Glucocorticoids O O
are O O
known O O
to O O
downregulate O O
interleukin-1 O O
beta O O
production O O
in O O
monocytic O O
cells O O
by O O
two O O
different O O
mechanims O O
: O O
direct O O
inhibition O O
of O O
the O O
gene O O
transcription O O
and O O
destabilization O O
of O O
the O O
preformed O O
interleukin-1 O O
beta O O
mRNA O O
. O O

Super-shift O O
analysis O O
revealed O O
that O O
the O O
NF-kappa O O
B O O
complex O O
of O O
costimulated O O
CD4+ O O
T O O
cells O O
contained O O
large O O
amounts O O
of O O
p50 O O
, O O
substantial O O
amounts O O
of O O
p65 O O
, O O
and O O
marginal O O
levels O O
of O O
c-Rel O O
proteins O O
. O O

The O O
BZLF1 O O
protein O O
of O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
is O O
a O O
key O O
immediate-early O O
protein O O
which O O
has O O
been O O
shown O O
to O O
disrupt O O
virus O O
latency O O
in O O
EBV-infected O O
B O O
cells O O
. O O

Two O O
opposite O O
phenotypes O O
were O O
found O O
, O O
which O O
depended O O
on O O
the O O
intracellular O O
localization O O
of O O
Nef O O
. O O

These O O
LTRs O O
differ O O
by O O
five O O
point O O
mutations O O
and O O
a O O
22-bp O O
duplication O O
in O O
SIVsmmPBj14 O O
, O O
which O O
includes O O
a O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
kappa O O
B O O
) O O
site O O
. O O

Inhibition O O
of O O
cytokine O O
production O O
was O O
gene O O
selective O O
and O O
not B-Negation B-Negation
due I-Negation I-Negation
to I-Negation I-Negation
general I-Negation I-Negation
effects I-Negation I-Negation
on I-Negation I-Negation
protein I-Negation I-Negation
synthesis I-Negation I-Negation
. O O

The O O
protein O O
expressed O O
in O O
insect O O
cells O O
was O O
used O O
to O O
test O O
for O O
the O O
presence O O
of O O
specific O O
antibodies O O
in O O
sera O O
from O O
normal O O
, O O
healthy O O
carriers O O
and O O
from O O
patients O O
with O O
various O O
diseases O O
. O O

LPMC O O
exhibited O O
increased O O
IL-2 O O
production O O
in O O
response O O
to O O
CD28 O O
costimulation O O
, O O
compared O O
with O O
cells O O
activated O O
through O O
CD2 O O
alone O O
. O O

The O O
lack B-Negation B-Negation
of I-Negation I-Negation
Cut I-Negation I-Negation
expression I-Negation I-Negation
in I-Negation I-Negation
wild-type I-Negation I-Negation
ventral I-Negation I-Negation
cells I-Negation I-Negation
abutting I-Negation I-Negation
the I-Negation I-Negation
D-V I-Negation I-Negation
boundary I-Negation I-Negation
indicates O O
that O O
D-mib O O
is O O
required O O
for O O
Ser O O
signaling O O
by O O
dorsal O O
cells O O
and O O
acts O O
in O O
a O O
non-autonomous O O
manner O O
to O O
activate O O
N O O
in O O
ventral O O
cells O O
. O O

Here O O
we O O
report O O
that O O
LTB4 O O
induces O O
synthesis O O
of O O
interleukin O O
( O O
IL O O
) O O
-6 O O
by O O
human O O
blood O O
monocytes O O
through O O
transcriptional O O
activation O O
of O O
the O O
IL-6 O O
gene O O
. O O

Nuclear O O
factor-kappa O O
B O O
( O O
NF-kappa O O
B O O
) O O
/Rel O O
transcription O O
factors O O
may O O
be O O
involved O O
in O O
atherosclerosis O O
, O O
as O O
is O O
suggested O O
by O O
the O O
presence O O
of O O
activated O O
NF-kappa O O
B O O
in O O
human O O
atherosclerotic O O
lesions O O
. O O

The O O
first O O
problem O O
is O O
that O O
even O O
if O O
an O O
iORF O O
has O O
homologs O O
in O O
other O O
species O O
, O O
it O O
could O O
be O O
a O O
pseudogene O O
or O O
a O O
product O O
of O O
sequencing O O
error O O
. O O

However O O
, O O
in O O
Jurkat O O
cells O O
, O O
TNF-alpha O O
dramatically O O
enhanced O O
the O O
spread O O
of O O
HIV-1 O O
through O O
the O O
cell O O
population O O
and O O
increased O O
viral O O
RNA O O
synthesis O O
, O O
indicating O O
that O O
in O O
T O O
cells O O
HIV-1 O O
multiplication O O
was O O
stimulated O O
by O O
TNF-alpha O O
treatment O O
. O O

One O O
of O O
the O O
5-bp O O
TSDs O O
flanking O O
the O O
3 O O
? O O
terminus O O
of O O
a O O
Transib O O
was O O
excluded O O
in O O
each O O
case O O
. O O

Transcriptional O O
repression O O
of O O
the O O
interleukin-2 O O
gene O O
by O O
vitamin O O
D3 O O
: O O
direct O O
inhibition O O
of O O
NFATp/AP-1 O O
complex O O
formation O O
by O O
a O O
nuclear O O
hormone O O
receptor O O
. O O

Before O O
exposure O O
to O O
low O O
shear O O
( O O
2 O O
dyn/cm2 O O
) O O
for O O
6 O O
h O O
, O O
HAEC O O
were O O
preincubated O O
with O O
or O O
without B-Negation B-Negation
the I-Negation I-Negation
antioxidants I-Negation I-Negation
pyrrolidine I-Negation I-Negation
dithiocarbamate I-Negation I-Negation
( I-Negation I-Negation
PDTC I-Negation I-Negation
) I-Negation I-Negation
or I-Negation I-Negation
N-acetyl-L-cysteine I-Negation I-Negation
( I-Negation I-Negation
NAC I-Negation I-Negation
) I-Negation I-Negation
. O O

Since O O
these O O
latter O O
compounds O O
were O O
known O O
to O O
activate O O
NF-kappa O O
B O O
translocation O O
in O O
a O O
redox-sensitive O O
way O O
, O O
we O O
have O O
demonstrated O O
that O O
NF-kappa O O
B O O
activation O O
by O O
PMA O O
was O O
resistant O O
to O O
antioxidant O O
N-acetyl-L-cysteine O O
( O O
NAC O O
) O O
and O O
sensitive O O
to O O
kinase O O
inhibitors O O
staurosporine O O
and O O
H7 O O
while O O
activation O O
by O O
H2O2 O O
or O O
TNF-alpha O O
were O O
not B-Negation B-Negation
. O O

Cytomegalovirus O O
IE O O
gene O O
products O O
significantly O O
enhanced O O
LPS O O
stimulation O O
of O O
IL-6 O O
promoter O O
activity O O
in O O
both O O
IL-6 O O
CAT O O
and O O
IL-6 O O
luciferase O O
assays O O
. O O

It O O
is O O
also O O
worth O O
noting O O
that O O
this O O
portion O O
corresponds O O
to O O
a O O
separate O O
exon O O
in O O
some O O
teleosts O O
( O O
see O O
Discussion O O
) O O
. O O

To O O
further O O
clarify O O
the O O
complex O O
transcriptional O O
regulation O O
of O O
the O O
human O O
GM-CSF O O
gene O O
, O O
which O O
was O O
extensively O O
investigated O O
in O O
activated O O
T O O
cells O O
, O O
we O O
have O O
studied O O
the O O
role O O
of O O
an O O
upstream O O
NF-kappaB O O
like O O
site O O
in O O
the O O
5637 O O
non-lymphoid O O
cell O O
line O O
, O O
which O O
derives O O
from O O
a O O
bladder O O
carcinoma O O
and O O
constitutively O O
produces O O
GM-CSF O O
. O O

Similarly O O
to O O
the O O
expression O O
of O O
the O O
Ser O O
gene O O
, O O
Ser-GAL4 O O
expression O O
is O O
restricted O O
to O O
dorsal O O
cells O O
in O O
second/early O O
third O O
instar O O
larvae O O
and O O
is O O
weakly O O
expressed O O
in O O
ventral O O
cells O O
in O O
mid/late O O
third O O
instar O O
larvae O O
, O O
i.e. O O
, O O
after O O
margin O O
cell O O
specification O O
[ O O
49,50 O O
] O O
. O O

All O O
of O O
procedure O O
were O O
done O O
in O O
vitro O O
. O O

In O O
the O O
absence B-Negation O
of I-Negation O
TCR-mediated I-Negation O
activation I-Negation O
, O O
Vpr O O
induces O O
apoptosis O O
whereas O O
in O O
its O O
presence O O
, O O
Vpr O O
interrupts O O
the O O
expected O O
induction O O
of O O
apoptosis O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
analysed O O
the O O
function O O
of O O
these O O
cis-acting O O
regulatory O O
sites O O
in O O
the O O
context O O
of O O
the O O
native O O
IL-2 O O
enhancer O O
and O O
promoter O O
sequence O O
. O O

Copies O O
of O O
Pegasus O O
, O O
HATN4_AG O O
, O O
and O O
HAT2N_AG O O
were O O
identified O O
in O O
the O O
mosquito O O
A. O O
gambiae O O
genome O O
; O O
Hobo O O
and O O
hAT-1N_DP O O
in O O
the O O
D. O O
melanogaster O O
and O O
D. O O
pseudoobscura O O
fruit O O
fly O O
genomes O O
, O O
respectively O O
; O O
HAT-1N_SP O O
in O O
the O O
sea O O
urchin O O
genome O O
; O O
and O O
HAT1N_DR O O
, O O
HAT-2N1_DR O O
, O O
and O O
HAT-N19_DR O O
in O O
the O O
zebrafish O O
genome O O
. O O

It O O
is O O
one O O
of O O
the O O
most O O
severe O O
human O O
immunodeficiencies O O
and O O
is O O
associated O O
with O O
depletion O O
of O O
all O O
three O O
major O O
categories O O
of O O
lymphocytes O O
: O O
T O O
cells O O
, O O
B O O
cells O O
, O O
and O O
natural O O
killer O O
cells O O
, O O
resulting O O
in O O
impaired O O
cellular O O
immunity O O
and O O
decreased O O
production O O
of O O
immunoglobulins O O
[ O O
2 O O
] O O
. O O

Thus O O
, O O
Elf-1 O O
is O O
a O O
novel O O
transcription O O
factor O O
that O O
appears O O
to O O
be O O
required O O
for O O
the O O
T-cell-receptor-mediated O O
trans O O
activation O O
of O O
HIV-2 O O
gene O O
expression O O
. O O

Lipopolysaccharide O O
induction O O
of O O
tissue O O
factor O O
gene O O
expression O O
in O O
monocytic O O
cells O O
is O O
mediated O O
by O O
binding O O
of O O
c-Rel/p65 O O
heterodimers O O
to O O
a O O
kappa O O
B-like O O
site O O
. O O

In O O
addition O O
to O O
these O O
novel O O
E2F O O
complexes O O
, O O
three O O
distinct O O
forms O O
of O O
unbound O O
( O O
free O O
) O O
E2F O O
were O O
resolved O O
in O O
gel O O
shift O O
experiments O O
. O O

Examination O O
of O O
IkappaB O O
alpha O O
regulation O O
revealed O O
that O O
TNF-alpha-mediated O O
degradation O O
of O O
IkappaB O O
alpha O O
in O O
both O O
memory O O
and O O
naive O O
T O O
cells O O
from O O
the O O
elderly O O
was O O
severely O O
impaired O O
, O O
thus O O
contributing O O
to O O
the O O
lowered O O
induction O O
of O O
the O O
observed O O
NFkappaB O O
. O O

CONCLUSION O O
. O O

These O O
results O O
indicate O O
the O O
utility O O
of O O
this O O
FISH O O
technique O O
for O O
a O O
better O O
definition O O
of O O
the O O
biological O O
characteristics O O
of O O
ductal O O
carcinomas O O
. O O

HB24 O O
is O O
likely O O
to O O
have O O
an O O
important O O
role O O
in O O
lymphocytes O O
as O O
well O O
as O O
in O O
certain O O
developing O O
tissues O O
. O O

Overexpression O O
of O O
full-length O O
SCL O O
protein O O
in O O
the O O
lymphoid O O
cell O O
lines O O
, O O
SupT1 O O
and O O
Raji O O
, O O
did O O
not B-Negation B-Negation
alter I-Negation I-Negation
cell I-Negation I-Negation
phenotype I-Negation I-Negation
and O O
there O O
was O O
no B-Negation B-Negation
evidence I-Negation I-Negation
for I-Negation I-Negation
autoregulation I-Negation I-Negation
of I-Negation I-Negation
SCL I-Negation I-Negation
transcription I-Negation I-Negation
. O O

Fusion O O
proteins O O
involving O O
the O O
retinoic O O
acid O O
receptor O O
alpha O O
( O O
RAR O O
alpha O O
) O O
and O O
the O O
PML O O
or O O
PLZF O O
nuclear O O
protein O O
are O O
the O O
genetic O O
markers O O
of O O
acute O O
promyelocytic O O
leukemias O O
( O O
APLs O O
) O O
. O O

Recently O O
, O O
the O O
cat O O
eye O O
syndrome O O
critical O O
region O O
protein O O
1 O O
( O O
CECR1 O O
) O O
gene O O
was O O
identified O O
and O O
shown O O
to O O
encode O O
a O O
protein O O
representing O O
a O O
subfamily O O
of O O
proteins O O
related O O
to O O
but O O
distinct O O
from O O
classical O O
ADAs O O
[ O O
9 O O
] O O
. O O

NF-kappa O O
B O O
, O O
a O O
50 O O
kDa/65 O O
kDa O O
( O O
p50/p65 O O
) O O
heterodimer O O
, O O
is O O
a O O
ubiquitous O O
transcription O O
factor O O
involved O O
in O O
the O O
positive O O
regulation O O
of O O
various O O
immune O O
genes O O
. O O

The O O
cDNA O O
clone O O
encodes O O
a O O
new O O
isoform O O
, O O
NFATc.beta O O
, O O
of O O
the O O
NFAT O O
gene O O
family O O
member O O
NFATc O O
( O O
designated O O
here O O
NFATc.alpha O O
) O O
. O O

Two O O
groups O O
of O O
U937 O O
promonocytic O O
cells O O
were O O
obtained O O
by O O
limiting O O
dilution O O
cloning O O
which O O
differed O O
strikingly O O
in O O
their O O
ability O O
to O O
support O O
human O O
immunodeficiency O O
virus O O
1 O O
( O O
HIV-1 O O
) O O
replication O O
. O O

This O O
result O O
demonstrates O O
that O O
Tyr-492 O O
and O O
Tyr-493 O O
are O O
not B-Negation O
responsible I-Negation O
for I-Negation O
the I-Negation O
Src I-Negation O
homology I-Negation O
domain I-Negation O
2-mediated I-Negation O
association I-Negation O
of I-Negation O
p56 I-Negation O
( I-Negation O
lck I-Negation O
) I-Negation O
with I-Negation O
ZAP-70 I-Negation O
. O O

The O O
IFN-dependent O O
increase O O
in O O
RAR O O
( O O
alpha O O
) O O
levels O O
and O O
the O O
enhancing O O
effect O O
of O O
the O O
cytokine O O
on O O
retinoid-dependent O O
granulocytic O O
markers O O
expression O O
may O O
be O O
a O O
characteristic O O
of O O
PML-RAR O O
positive O O
cells O O
, O O
since O O
the B-Negation B-Negation
phenomena I-Negation I-Negation
are I-Negation I-Negation
not I-Negation I-Negation
observed I-Negation I-Negation
in I-Negation I-Negation
HL-60 I-Negation I-Negation
promyelocytes I-Negation I-Negation
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
using O O
protein O O
extracts O O
from O O
EBV-B O O
cells O O
and O O
the O O
IL-2 O O
NF-chi O O
B O O
probe O O
revealed O O
the O O
constitutive O O
generation O O
of O O
chi O O
B O O
complexes O O
in O O
IL-2-secreting O O
cells O O
consisting O O
mainly O O
of O O
heterodimeric O O
p50/p65 O O
complexes O O
. O O

Thus O O
, O O
CD45 O O
plays O O
an O O
active O O
role O O
in O O
the O O
physiology O O
of O O
T O O
cells O O
and O O
in O O
the O O
replication O O
of O O
HIV-1 O O
. O O

There O O
was O O
no B-Negation B-Negation
detectable I-Negation I-Negation
binding I-Negation I-Negation
of I-Negation I-Negation
in I-Negation I-Negation
vitro I-Negation I-Negation
translated I-Negation I-Negation
Jun/Fos I-Negation I-Negation
heterodimer I-Negation I-Negation
( I-Negation I-Negation
AP-1 I-Negation I-Negation
) I-Negation I-Negation
to I-Negation I-Negation
the I-Negation I-Negation
NF-AT I-Negation I-Negation
sequence I-Negation I-Negation
, O O
and O O
the O O
NF-AT O O
sequence O O
was O O
unable B-Negation B-Negation
to I-Negation I-Negation
inhibit I-Negation I-Negation
the I-Negation I-Negation
binding I-Negation I-Negation
of I-Negation I-Negation
Jun/Fos I-Negation I-Negation
to I-Negation I-Negation
the I-Negation I-Negation
AP-1 I-Negation I-Negation
sequence I-Negation I-Negation
. O O

the O O
number O O
of O O
glucocorticoid O O
receptors O O
per O O
cell O O
( O O
Ro O O
) O O
and O O
the O O
binding O O
affinity O O
( O O
Kd O O
) O O
for O O
dexamethasone O O
were O O
, O O
however O O
, O O
not O O
significantly O O
different O O
( O O
Ro O O
: O O
7687 O O
± O O
1750 O O
vs O O
7347 O O
± O O
1285 O O
sites/cell O O
; O O
Kd O O
: O O
7.7 O O
± O O
2.4 O O
vs O O
7.4 O O
± O O
1.7 O O
nM O O
at O O
24 O O
degrees O O
C O O
) O O
. O O

IL13 O O
induces O O
the O O
same O O
biological O O
effects O O
as O O
IL4 O O
in O O
normal O O
human O O
B O O
cells O O
. O O

Although O O
removal O O
of O O
the O O
first O O
67 O O
amino O O
acids O O
of O O
p95vav O O
activates O O
its O O
transforming O O
potential O O
in O O
NIH O O
3T3 O O
cells O O
, O O
this O O
region O O
appears O O
to O O
be O O
required O O
for O O
its O O
function O O
in O O
T O O
cells O O
. O O

The O O
cDNA O O
has O O
an O O
open O O
reading O O
frame O O
of O O
900 O O
amino O O
acids O O
capable O O
of O O
encoding O O
a O O
97-kDa O O
protein O O
. O O

However O O
, O O
although O O
Wnt O O
signals O O
are O O
known O O
to O O
inhibit O O
the O O
activity O O
of O O
the O O
negative O O
regulatory O O
protein O O
kinase O O
glycogen O O
synthase O O
kinase-3beta O O
( O O
GSK-3beta O O
) O O
, O O
resulting O O
in O O
increased O O
levels O O
of O O
beta-catenin O O
, O O
we O O
find O O
no B-Negation B-Negation
evidence I-Negation I-Negation
for I-Negation I-Negation
involvement I-Negation I-Negation
of I-Negation I-Negation
GSK-3beta I-Negation I-Negation
in I-Negation I-Negation
Tcf-mediated I-Negation I-Negation
transcription I-Negation I-Negation
in I-Negation I-Negation
T I-Negation I-Negation
cells I-Negation I-Negation
. O O

One O O
gene O O
product O O
, O O
when O O
overexpressed O O
in O O
Jurkat O O
T O O
cells O O
, O O
specifically O O
induced O O
transcription O O
from O O
the O O
interleukin-2 O O
enhancer O O
, O O
by O O
activating O O
the O O
T-cell-specific O O
transcription O O
factors O O
NF-AT O O
and O O
NF-IL2A O O
. O O

Extracellular O O
adenosine O O
is O O
now O O
considered O O
an O O
important O O
stress O O
hormone O O
that O O
is O O
released O O
in O O
excessive O O
amounts O O
in O O
the O O
vicinity O O
of O O
immune O O
cells O O
during O O
both O O
systemic O O
and O O
cellular O O
stress O O
[ O O
6 O O
] O O
. O O

MLE O O
appears O O
to O O
be O O
the O O
next O O
protein O O
to O O
join O O
the O O
growing O O
DCC O O
as O O
it O O
is O O
found O O
at O O
reduced O O
levels O O
at O O
some O O
of O O
these O O
35 O O
sites O O
when O O
the O O
remaining O O
two O O
proteins O O
, O O
MSL3 O O
and O O
MOF O O
, O O
are O O
absent O O
[ O O
16 O O
] O O
. O O

This O O
review O O
analyzes O O
various O O
molecular O O
alterations O O
responsible O O
for O O
the O O
deficient O O
response O O
to O O
corticosteroid O O
treatment O O
observed O O
in O O
steroid-resistant O O
bronchial O O
asthmatic O O
subjects O O
. O O

Switching O O
gears O O
during O O
T-cell O O
maturation O O
: O O
RANTES O O
and O O
late O O
transcription O O
. O O

Nevertheless O O
, O O
our O O
observation O O
that O O
D-mib O O
could B-Negation O
not I-Negation O
compensate I-Negation O
for I-Negation O
the I-Negation O
loss I-Negation O
of I-Negation O
neur I-Negation O
activity I-Negation O
in I-Negation O
the I-Negation O
embryo I-Negation O
indicates O O
that O O
D-mib O O
and O O
Neur O O
have O O
overlapping O O
rather O O
than O O
identical O O
molecular O O
activities O O
. O O

OBJECTIVE O O
: O O
We O O
investigated O O
the O O
production O O
of O O
IL-5 O O
, O O
a O O
potent O O
growth O O
factor O O
and O O
chemotactic O O
factor O O
for O O
eosinophils O O
, O O
by O O
CD4+ O O
T O O
lymphocytes O O
in O O
patients O O
with O O
asthma O O
. O O

Experiments O O
in O O
COS-1 O O
and O O
EL-4 O O
cells O O
confirmed O O
both O O
hypotheses O O
and O O
revealed O O
that O O
the O O
second O O
factor O O
activated O O
by O O
Tpl-2 O O
is O O
NF-kappaB O O
. O O

We O O
used O O
an O O
adenoviral O O
technique O O
of O O
blocking O O
NF-kappaB O O
through O O
overexpression O O
of O O
the O O
inhibitory O O
subunit O O
IkappaBalpha O O
, O O
which O O
has O O
the O O
advantage O O
that O O
it O O
can O O
be O O
used O O
in O O
the O O
diseased O O
tissue O O
itself O O
, O O
with O O
> O O
90 O O
% O O
of O O
the O O
synovial O O
macrophages O O
, O O
fibroblasts O O
, O O
and O O
T O O
cells O O
infected O O
. O O

The O O
Combined O O
module O O
considers O O
simultaneously O O
three O O
distinct O O
features O O
: O O
the O O
co-occurrence O O
of O O
both O O
domains O O
and O O
PTMs O O
as O O
well O O
as O O
the O O
subcellular O O
co-localization O O
of O O
proteins O O
. O O

Characterization O O
of O O
this O O
cDNA O O
clone O O
revealed O O
that O O
its O O
induction O O
was O O
dependent O O
on O O
LPS O O
activation O O
of O O
THP-1 O O
cells O O
; O O
hence O O
, O O
the O O
name O O
LPS-induced O O
TNF-alpha O O
factor O O
( O O
LITAF O O
) O O
. O O

Transcription O O
factor O O
requirements O O
for O O
U2 O O
snRNA-encoding O O
gene O O
activation O O
in O O
B O O
lymphoid O O
cells O O
. O O

I O O
kappa O O
B-alpha O O
inhibits O O
transcription O O
factor O O
NF-kappa O O
B O O
by O O
retaining O O
it O O
in O O
the O O
cytoplasm O O
. O O

However O O
, O O
the O O
phosphorylation O O
of O O
the O O
precursor O O
interleukin-1 O O
alpha O O
cytokine O O
was O O
increased O O
. O O

Those O O
cytokines O O
may O O
modulate O O
the O O
differentiation O O
of O O
monocytes O O
by O O
CSFs O O
. O O

The O O
ERK O O
pathway-specific O O
inhibitor O O
PD98059 O O
inhibited O O
IL-6 O O
secretion O O
from O O
monocytes O O
. O O

V3-BH10 O O
neither B-Negation B-Negation
blocked I-Negation I-Negation
radiolabeled I-Negation I-Negation
IL-2 I-Negation I-Negation
binding I-Negation I-Negation
to I-Negation I-Negation
IL-2 I-Negation I-Negation
receptors I-Negation I-Negation
nor I-Negation I-Negation
affected I-Negation I-Negation
tyrosyl I-Negation I-Negation
phosphorylation I-Negation I-Negation
of I-Negation I-Negation
several I-Negation I-Negation
cellular I-Negation I-Negation
proteins I-Negation I-Negation
( I-Negation I-Negation
p120 I-Negation I-Negation
, I-Negation I-Negation
p98 I-Negation I-Negation
, I-Negation I-Negation
p96 I-Negation I-Negation
, I-Negation I-Negation
p54 I-Negation I-Negation
, I-Negation I-Negation
and I-Negation I-Negation
p38 I-Negation I-Negation
) I-Negation I-Negation
, I-Negation O
which I-Negation O
is I-Negation O
immediately I-Negation O
induced I-Negation O
by I-Negation O
IL-2 I-Negation O
stimulation I-Negation O
. O O

Moreover O O
, O O
since O O
succinimide O O
intermediates O O
of O O
deamidated O O
peptides O O
can O O
occasionally O O
be O O
very O O
stable O O
, O O
these O O
peptides O O
have O O
the O O
potential O O
to O O
act O O
as O O
altered O O
self-Ags O O
with O O
significant O O
implications O O
for O O
autoimmunity O O
. O O

DNA-protein O O
binding O O
studies O O
indicated O O
that O O
NF-kappaB O O
, O O
c-Jun O O
, O O
and O O
potentially O O
novel O O
proteins O O
( O O
around O O
35 O O
kDa O O
) O O
can O O
bind O O
to O O
this O O
important O O
sequence O O
. O O

Additionally O O
, O O
Nef O O
inhibits O O
the O O
induction O O
of O O
HIV-1- O O
and O O
interleukin O O
2-directed O O
gene O O
expression O O
, O O
and O O
the O O
effect O O
on O O
HIV-1 O O
transcription O O
depends O O
on O O
an O O
intact O O
NF-kappa O O
B-binding O O
site O O
. O O

Cells O O
pretreated O O
with O O
dimaprit O O
showed O O
a O O
decrease O O
in O O
the O O
cAMP O O
response O O
to O O
subsequent O O
addition O O
of O O
H2 O O
agonists O O
, O O
whereas O O
the O O
cAMP O O
response O O
to O O
prostaglandin O O
E2 O O
remained O O
unaltered O O
. O O

Altogether O O
, O O
the O O
CD4 O O
gene O O
is O O
regulated O O
by O O
several O O
positive O O
and O O
negative O O
regulatory O O
mechanisms O O
which O O
come O O
into O O
play O O
in O O
a O O
developmentally O O
coordinated O O
manner O O
. O O

D-mib O O
Is O O
Required O O
to O O
Down-Regulate O O
Ser O O
at O O
the O O
Apical O O
Cortex O O

Contrary O O
to O O
previous O O
assumptions O O
, O O
we O O
observed O O
that O O
p65 O O
homodimers O O
can O O
interact O O
with O O
a O O
subset O O
of O O
DNA O O
sequences O O
not B-Negation B-Negation
recognized I-Negation I-Negation
by I-Negation I-Negation
p50 I-Negation I-Negation
homodimers I-Negation I-Negation
. O O

Constitutive O O
DNA O O
binding O O
activity O O
consisting O O
of O O
p50 O O
homodimers O O
was O O
detected O O
in O O
nuclear O O
extracts O O
from O O
both O O
cell O O
types O O
. O O

The O O
role O O
of O O
BSAP O O
( O O
Pax-5 O O
) O O
in O O
B-cell O O
development O O
. O O

In O O
contrast O O
, O O
expression O O
of O O
IL-4 O O
, O O
IL-10 O O
, O O
and O O
IFN-gamma O O
was O O
strongly O O
inhibited O O
in O O
the O O
transgenic O O
T O O
cells O O
. O O

The O O
NH2Cl-treated O O
neutrophils O O
showed O O
a O O
decrease O O
in O O
both O O
PKC O O
activity O O
and O O
PMA-induced O O
phosphorylation O O
of O O
a O O
47-kDa O O
protein O O
, O O
which O O
corresponds O O
to O O
the O O
cytosolic O O
factor O O
of O O
NADPH O O
oxidase O O
, O O
p47 O O
( O O
phox O O
) O O
. O O

Preincubation O O
of O O
endothelial O O
cells O O
with O O
endotoxin O O
[ O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
1 O O
microgram/ml O O
] O O
led O O
to O O
a O O
4-fold O O
increase O O
in O O
subsequent O O
adherence O O
of O O
polymorphonuclear O O
leukocytes O O
( O O
P O O
< O O
0.0001 O O
, O O
n O O
= O O
10 O O
) O O
to O O
endothelial O O
cells O O
, O O
an O O
increase O O
that O O
was O O
markedly O O
attenuated O O
when O O
endothelial O O
cells O O
were O O
treated O O
with O O
dexamethasone O O
( O O
IC50 O O
< O O
1 O O
nM O O
, O O
P O O
< O O
0.0001 O O
, O O
n O O
= O O
6 O O
or O O
7 O O
) O O
during O O
preincubation O O
with O O
LPS O O
. O O

We O O
report O O
the O O
identification O O
of O O
a O O
T O O
cell-specific O O
transcription O O
factor O O
, O O
TCF-1 O O
, O O
binding O O
to O O
this O O
element O O
. O O

Coordination O O
of O O
the O O
immune O O
response O O
to O O
injury O O
or O O
disease O O
in O O
the O O
brain O O
is O O
postulated O O
to O O
involve O O
bi-directional O O
discourse O O
between O O
the O O
immune O O
system O O
and O O
the O O
central O O
nervous O O
system O O
. O O

Perhaps O O
murine O O
thymocytes O O
are O O
denied O O
this O O
form O O
of O O
rescue O O
because O O
they O O
shut O O
off O O
IL-2R O O
beta O O
chain O O
expression O O
at O O
an O O
earlier O O
stage O O
or O O
because O O
they O O
may O O
be O O
uncommonly O O
Bcl-2 O O
deficient O O
( O O
cf O O
. O O

Treatment O O
of O O
the O O
differentiated O O
HL60 O O
cells O O
with O O
3-methylcholanthrene O O
, O O
a O O
ligand O O
of O O
AhR O O
, O O
induced O O
the O O
expression O O
of O O
the O O
P450IA1 O O
gene O O
. O O

Sequence O O
variation O O
in O O
the O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
region O O
of O O
HIV-1 O O
was O O
analyzed O O
in O O
viral O O
isolates O O
of O O
17 O O
infected O O
individuals O O
. O O

Conclusion O O

In O O
the O O
present O O
work O O
, O O
we O O
have O O
established O O
a O O
Drosophila O O
model O O
to O O
study O O
altered O O
levels O O
of O O
adenosine O O
and O O
deoxyadenosine O O
in O O
vivo O O
, O O
and O O
we O O
have O O
shown O O
that O O
loss O O
of O O
ADGF-A O O
function O O
causes O O
an O O
increase O O
of O O
these O O
nucleosides O O
in O O
larval O O
hemolymph O O
. O O

p45 O O
subunit O O
of O O
NF-E2 O O
contains O O
a O O
basic-leucine O O
zipper O O
domain O O
and O O
dimerizes O O
with O O
the O O
small O O
Maf O O
family O O
protein O O
to O O
form O O
functional O O
NF-E2 O O
complex O O
. O O

As O O
the O O
scores O O
of O O
the O O
predictors O O
increase O O
, O O
so O O
do O O
the O O
number O O
of O O
interactions O O
predicted O O
above O O
different O O
posterior O O
odds O O
ratio O O
thresholds O O
( O O
see O O
lower O O
portion O O
of O O
Table O O
3 O O
) O O
. O O

Activation O O
of O O
T O O
lymphocytes O O
by O O
Ags O O
or O O
cytokines O O
results O O
in O O
translocation O O
of O O
the O O
transcription O O
factors O O
NF-kappa O O
B O O
, O O
AP-1 O O
, O O
NFAT O O
, O O
and O O
STAT O O
from O O
the O O
cytoplasm O O
into O O
the O O
nucleus O O
. O O

Using O O
in O O
vitro O O
footprinting O O
and O O
gel O O
shift O O
assays O O
, O O
we O O
have O O
identified O O
four O O
distinct O O
binding O O
sites O O
for O O
nuclear O O
proteins O O
within O O
this O O
positive O O
regulatory O O
element O O
. O O

To O O
investigate O O
the O O
regulation O O
of O O
IL-13 O O
gene O O
expression O O
by O O
T O O
cells O O
, O O
we O O
isolated O O
and O O
sequenced O O
the O O
human O O
IL-13 O O
gene O O
, O O
analyzed O O
its O O
5'-flanking O O
region O O
for O O
potential O O
transcriptional O O
activation O O
elements O O
, O O
and O O
examined O O
its O O
expression O O
in O O
nontransformed O O
T-lineage O O
cell O O
populations O O
. O O

In O O
contrast O O
, O O
TGF-beta O O
had O O
only O O
minimal O O
effects O O
on O O
two O O
other O O
B O O
cell O O
membrane O O
proteins O O
, O O
HLA-DR O O
and O O
CD20 O O
. O O

Here O O
, O O
we O O
have O O
analyzed O O
the O O
mechanisms O O
involved O O
in O O
CTLA-4-mediated O O
inhibition O O
of O O
T O O
cell O O
activation O O
of O O
naive O O
CD4+ O O
T O O
cells O O
using O O
Ab O O
cross-linking O O
. O O

CONCLUSION O O
: O O
We O O
suggest O O
that O O
Oct1 O O
, O O
YY1 O O
, O O
and O O
octamer-like O O
factors O O
binding O O
to O O
the O O
-90/-79 O O
sequence O O
within O O
the O O
proximal O O
IL-5 O O
promoter O O
are O O
involved O O
in O O
suppression O O
of O O
IL-5 O O
transcription O O
in O O
T O O
cells O O
. O O

The O O
composite O O
motif O O
binds O O
a O O
multi-protein O O
hematopoietic-specific O O
transcription O O
factor O O
complex O O
which O O
includes O O
GATA-1 O O
, O O
SCL/tal-1 O O
, O O
E2A O O
, O O
Lmo2 O O
and O O
Ldb-1 O O
. O O

Expression O O
of O O
PILOT O O
, O O
a O O
putative O O
transcription O O
factor O O
, O O
requires O O
two O O
signals O O
and O O
is O O
cyclosporin O O
A O O
sensitive O O
in O O
T O O
cells O O
. O O

Using O O
homologous O O
recombination O O
, O O
both O O
EKLF O O
alleles O O
in O O
murine O O
embryonic O O
stem O O
( O O
ES O O
) O O
cells O O
were O O
inactivated O O
. O O

Reactive O O
oxygen O O
intermediate-dependent O O
NF-kappaB O O
activation O O
by O O
interleukin-1beta O O
requires O O
5-lipoxygenase O O
or O O
NADPH O O
oxidase O O
activity O O
. O O

The O O
last O O
two O O
columns O O
show O O
the O O
results O O
of O O
the O O
network O O
shuffling O O
experiments O O
. O O

Expression O O
of O O
wg-lacZ O O
in O O
the O O
hinge O O
region O O
( O O
arrowheads O O
in O O
[ O O
D O O
] O O
and O O
[ O O
E O O
] O O
) O O
and O O
the O O
accumulation O O
of O O
Cut O O
in O O
sensory O O
cells O O
( O O
small O O
arrows O O
in O O
[ O O
B O O
] O O
and O O
[ O O
C O O
] O O
) O O
and O O
muscle O O
precursor O O
cells O O
( O O
large O O
arrowheads O O
in O O
[ O O
B O O
] O O
and O O
[ O O
C O O
] O O
) O O
appeared O O
to O O
be O O
largely O O
unaffected O O
) O O
. O O

Neutralizing O O
mAbs O O
to O O
IL-10 O O
and O O
TNF-alpha O O
indicated O O
that O O
both O O
cytokines O O
were O O
essential O O
for O O
the O O
induction O O
and O O
were O O
required O O
to O O
generate O O
a O O
synergistic O O
increase O O
in O O
virus O O
expression O O
. O O

The O O
downstream O O
regulatory O O
region O O
contains O O
a O O
cyclic O O
AMP-responsive O O
element O O
( O O
CRE O O
) O O
. O O

Moreover O O
, O O
the O O
inhibitors O O
of O O
serine O O
proteases O O
, O O
N-alpha-tosyl-L-lysine O O
chloromethyl O O
ketone O O
and O O
N-alpha-tosyl-L-phenylalanine O O
chloromethyl O O
ketone O O
, O O
also O O
blocked O O
the O O
cytolytic O O
activity O O
of O O
NK O O
cells O O
against O O
the O O
sensitive O O
target O O
K562 O O
. O O

This O O
defect O O
in O O
maturation O O
resulted O O
in O O
a O O
transgene O O
dose-dependent O O
reduction O O
in O O
peripheral O O
T O O
lymphocytes O O
, O O
with O O
the O O
CD8 O O
lineage O O
being O O
more O O
severely O O
affected O O
. O O

Using O O
a O O
genetic O O
screen O O
in O O
yeast O O
, O O
we O O
have O O
isolated O O
B O O
cell-derived O O
cDNAs O O
encoding O O
Oct-binding O O
factor O O
1 O O
( O O
OBF-1 O O
) O O
, O O
a O O
novel O O
protein O O
that O O
specifically O O
associates O O
with O O
Oct-1 O O
and O O
Oct-2 O O
. O O

Nasal O O
NK- O O
and O O
T-cell O O
lymphomas O O
share O O
the O O
same O O
type O O
of O O
Epstein-Barr O O
virus O O
latency O O
as O O
nasopharyngeal O O
carcinoma O O
and O O
Hodgkin O O
's O O
disease O O
. O O

Nuclear O O
translocation O O
of O O
NF-kappaB O O
subunits O O
may O O
ultimately O O
increase O O
the O O
intracellular O O
pool O O
of O O
NF-kappaB/IkappaBalpha O O
by O O
an O O
autoregulatory O O
mechanism O O
. O O

Human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
-infected O O
T-cell O O
lines O O
constitutively O O
produce O O
high O O
levels O O
of O O
interleukin-1alpha O O
( O O
IL-1alpha O O
) O O
. O O

Our O O
studies O O
reveal O O
that O O
inactivation O O
of O O
the O O
v-abl O O
protein O O
tyrosine O O
kinase O O
triggers O O
high-frequency O O
rearrangement O O
of O O
kappa O O
and O O
lambda O O
light-chain O O
genes O O
. O O

Addition O O
of O O
r-hTBP-1 O O
to O O
U1 O O
cells O O
during O O
the O O
last O O
4 O O
h O O
of O O
a O O
24 O O
h O O
incubation O O
with O O
PMA O O
still O O
inhibited O O
p24 O O
antigen O O
production O O
by O O
15 O O
% O O
. O O

In O O
contrast O O
, O O
activation O O
in O O
THP-1 O O
cells O O
occurred O O
in O O
the O O
absence B-Negation B-Negation
of I-Negation I-Negation
vanadate I-Negation I-Negation
and O O
was O O
unaffected O O
by O O
catalase O O
. O O

In O O
the O O
examination O O
of O O
the O O
induction O O
of O O
autoimmunity O O
in O O
transgenic O O
mice O O
, O O
evidence O O
has O O
been O O
obtained O O
further O O
implicating O O
the O O
lymphokine O O
interferon-gamma O O
in O O
the O O
etiology O O
of O O
autoimmunity O O
. O O

Furthermore O O
, O O
methods O O
for O O
assessing O O
the O O
quality O O
of O O
high-throughput O O
experimental O O
results O O
are O O
in O O
high O O
demand O O
due O O
to O O
the O O
error O O
prone O O
nature O O
of O O
the O O
methods O O
used O O
. O O

In O O
scoring O O
a O O
motif O O
m O O
, O O
a O O
choice O O
must O O
therefore O O
be O O
made O O
as O O
to O O
whether O O
or O O
not O O
the O O
reverse O O
complement O O
mR O O
of O O
m O O
will O O
be O O
considered O O
to O O
be O O
the O O
same O O
motif O O
as O O
m O O
. O O

Here O O
we O O
show O O
that O O
phorbol O O
ester O O
treatment O O
also O O
abolishes O O
induction O O
of O O
chloramphenicol O O
acetyltransferase O O
activity O O
in O O
Ar-5 O O
cells O O
transfected O O
with O O
a O O
plasmid O O
containing O O
the O O
IL-2 O O
promoter O O
linked O O
to O O
this O O
reporter O O
gene O O
. O O

however O O
, O O
with O O
the O O
appropriate O O
activation O O
signal O O
HB24 O O
mRNA O O
was O O
induced O O
within O O
several O O
hours O O
even O O
in O O
the O O
presence O O
of O O
cycloheximide O O
. O O

When O O
expressed O O
in O O
Jurkat O O
T O O
cells O O
, O O
recombinant O O
NFAT1 O O
is O O
regulated O O
, O O
as O O
expected O O
, O O
by O O
the O O
calmodulin-dependent O O
phosphatase O O
calcineurin O O
, O O
and O O
its O O
function O O
is O O
inhibited O O
by O O
the O O
immunosuppressive O O
agent O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
. O O

The O O
adoR O O
mutants O O
are O O
fully O O
viable O O
. O O

Increased O O
monocyte O O
TF O O
expression O O
in O O
transplant O O
recipients O O
was O O
shown O O
to O O
be O O
adversely O O
affected O O
by O O
treatment O O
with O O
CsA O O
: O O
TF O O
induction O O
was O O
markedly O O
reduced O O
by O O
CsA O O
serum O O
concentrations O O
reaching O O
peak O O
CsA O O
drug O O
levels O O
. O O

The O O
mechanism O O
by O O
which O O
TGF-beta O O
inhibits O O
Ig O O
chain O O
synthesis O O
is O O
unclear O O
although O O
it O O
does O O
not B-Negation B-Negation
involve I-Negation I-Negation
inhibition I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
binding I-Negation I-Negation
of I-Negation I-Negation
NF-kappa I-Negation I-Negation
B I-Negation I-Negation
or I-Negation I-Negation
Oct-2 I-Negation I-Negation
to I-Negation I-Negation
their I-Negation I-Negation
respective I-Negation I-Negation
target I-Negation I-Negation
sequences I-Negation I-Negation
. O O

Sequence-specific O O
DNA O O
binding O O
of O O
the O O
B-cell-specific O O
coactivator O O
OCA-B O O
. O O

Some O O
mice O O
showed O O
marked O O
splenic O O
lymphocyte O O
depletion O O
. O O

The O O
mAb O O
failed B-Negation B-Negation
to I-Negation I-Negation
induce I-Negation I-Negation
NF-kappa I-Negation I-Negation
B/Rel I-Negation I-Negation
nuclear I-Negation I-Negation
activity I-Negation I-Negation
in I-Negation I-Negation
cells I-Negation I-Negation
incubated I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
presence I-Negation I-Negation
of I-Negation I-Negation
3,4-dichloroisocoumarin I-Negation I-Negation
, I-Negation I-Negation
an I-Negation I-Negation
inhibitor I-Negation I-Negation
of I-Negation I-Negation
I I-Negation I-Negation
kappa I-Negation I-Negation
B-alpha I-Negation I-Negation
degradation I-Negation I-Negation
. O O

The O O
primary O O
reservoir O O
of O O
infection O O
consists O O
of O O
latently O O
infected O O
B O O
lymphocytes O O
and O O
possibly O O
other O O
mononuclear O O
cells O O
. O O

Here O O
we O O
describe O O
the O O
functional O O
characterization O O
of O O
this O O
promoter O O
and O O
identification O O
of O O
the O O
factors O O
in O O
B O O
and O O
T O O
cells O O
that O O
regulate O O
its O O
activity O O
. O O

Overexpression O O
of O O
ADGF-A O O
in O O
animals O O
with O O
a O O
hypomorphic O O
cact O O
combination O O
( O O
cactE8/cactIIIG O O
) O O
increased O O
the O O
adult O O
survival O O
rate O O
almost O O
4-fold O O
( O O
Figure O O
8A O O
) O O
. O O

Multiple O O
TRAF3 O O
binding O O
sites O O
containing O O
a O O
PXQXT/S O O
core O O
sequence O O
can O O
be O O
identified O O
in O O
the O O
simian O O
EBV O O
LMP1s O O
by O O
an O O
in O O
vitro O O
binding O O
assay O O
. O O

The O O
cAMP-response O O
element O O
CRE O O
, O O
TGACGTCA O O
, O O
present O O
in O O
the O O
21 O O
base-pair O O
sequence O O
, O O
appears O O
to O O
be O O
essential O O
for O O
specific O O
protein-TRE-DNA O O
interactions O O
because O O
mutation O O
of O O
the O O
two O O
G O O
's O O
destroys O O
this O O
complex O O
. O O

Site-directed O O
mutagenesis O O
of O O
these O O
cis O O
elements O O
demonstrated O O
that O O
Cp O O
activity O O
is O O
highly O O
dependent O O
on O O
the O O
presence O O
of O O
a O O
properly O O
positioned O O
CCAAT O O
box O O
, O O
with O O
the O O
dependence O O
on O O
the O O
distal O O
CCAAT O O
box O O
apparent O O
only O O
when O O
the O O
proximal O O
CCAAT O O
box O O
was O O
deleted O O
or O O
mutated O O
. O O

Transfection O O
of O O
a O O
cDNA O O
containing O O
the O O
human O O
CIITA O O
coding O O
sequence O O
under O O
the O O
control O O
of O O
an O O
heterologous O O
promoter O O
restores O O
expression O O
of O O
human O O
MHC O O
class O O
II O O
genes O O
in O O
the O O
hybrids O O
and O O
is O O
responsible O O
for O O
de O O
novo O O
expression O O
of O O
mouse O O
MHC O O
class O O
II O O
genes O O
in O O
both O O
the O O
mouse O O
plasmacytoma O O
cell O O
line O O
and O O
the O O
hybrids O O
. O O

In O O
contrast O O
, O O
fixed O O
tissue O O
macrophages O O
express O O
detectable O O
HIV O O
proteins O O
, O O
indicating O O
permanent O O
virus O O
transcription O O
. O O

Using O O
sequential O O
deletion O O
mutants O O
of O O
the O O
human O O
fas O O
promoter O O
in O O
transient O O
transfection O O
assays O O
, O O
we O O
identified O O
a O O
47-bp O O
sequence O O
( O O
positions O O
-306 O O
to O O
-260 O O
relative O O
to O O
the O O
ATG O O
) O O
required O O
for O O
activation-driven O O
fas O O
upregulation O O
. O O

Thus O O
we O O
proposed O O
that O O
ETS1 O O
, O O
which O O
is O O
expressed O O
constitutively O O
in O O
Jurkat O O
cells O O
, O O
may O O
act O O
in O O
concert O O
with O O
PMA/ionomycin O O
inducible O O
factors O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
IL-10 O O
on O O
the O O
activation O O
of O O
HIV-1 O O
from O O
infected O O
monocytes O O
and O O
macrophages O O
. O O

However O O
, O O
none O B-Negation
of O I-Negation
these O I-Negation
proximal O I-Negation
regions O I-Negation
account O I-Negation
for O I-Negation
the O I-Negation
induction O I-Negation
of O I-Negation
IL-2R O I-Negation
alpha O I-Negation
transcription O I-Negation
by O I-Negation
IL-2 O I-Negation
. O O

NF-kappa O O
B O O
binding O O
activity O O
can O O
be O O
detected O O
for O O
several O O
hours O O
after O O
stimulation O O
. O O

These O O
data O O
suggest O O
that O O
, O O
in O O
addition O O
to O O
its O O
established O O
role O O
as O O
a O O
hormone-dependent O O
trans-activator O O
, O O
VDR O O
may O O
influence O O
gene O O
expression O O
by O O
ligand-independent O O
mechanisms O O
. O O

Pit-1 O O
is O O
a O O
pituitary-specific O O
transcription O O
factor O O
that O O
binds O O
to O O
and O O
transactivates O O
promoters O O
of O O
growth O O
hormone O O
and O O
prolactin O O
genes O O
. O O

5'-Rapid O O
amplification O O
of O O
cDNA O O
ends O O
( O O
5'-RACE O O
) O O
analysis O O
showed O O
that O O
transcription O O
initiation O O
occurred O O
at O O
several O O
closely O O
spaced O O
nearby O O
sites O O
originating O O
approximately O O
204 O O
bp O O
upstream O O
from O O
the O O
translation O O
start O O
site O O
. O O

A O O
list O O
of O O
all O O
combinations O O
of O O
iPfam O O
domains O O
( O O
the O O
domain O O
architecture O O
) O O
on O O
interacting O O
proteins O O
is O O
given O O
in O O
Additional O O
file O O
2 O O
. O O

Restriction O O
analysis O O
revealed O O
that O O
neutrophils O O
express O O
the O O
GH-N O O
gene O O
but O O
not B-Negation B-Negation
the I-Negation I-Negation
GH-V I-Negation I-Negation
gene I-Negation I-Negation
. O O

It O O
has O O
been O O
suggested O O
that O O
unstructured O O
regions O O
of O O
proteins O O
are O O
often O O
involved O O
in O O
binding O O
interactions O O
, O O
particularly O O
in O O
the O O
case O O
of O O
transient O O
interactions O O
77 O O
. O O

The O O
development O O
of O O
functionally O O
responsive O O
T O O
cells O O
. O O

These O O
results O O
suggest O O
that O O
blasts O O
in O O
M7 O O
and O O
TMD O O
may O O
correspond O O
to O O
progenitors O O
of O O
both O O
erythroid O O
and O O
megakaryocytic O O
lineages O O
. O O

This O O
underlines O O
that O O
a O O
few O O
promiscuous O O
iPfam O O
domain O O
pairs O O
are O O
responsible O O
for O O
the O O
majority O O
of O O
the O O
iPfam O O
coverage O O
. O O

The O O
overlaps O O
denote O O
co-observed O O
iPfam O O
domain O O
pairs O O
. O O

Coligation O O
of O O
CD28 O O
leads O O
to O O
synergistic O O
enhancement O O
of O O
IL-2 O O
secretion O O
. O O

Granulocyte-macrophage O O
colony-stimulating O O
factor O O
( O O
GM-CSF O O
) O O
induces O O
immediate O O
effects O O
in O O
monocytes O O
by O O
activation O O
of O O
the O O
Janus O O
kinase O O
( O O
JAK2 O O
) O O
and O O
STAT O O
transcription O O
factor O O
( O O
STAT5 O O
) O O
pathway O O
. O O

Immunohistochemical O O
techniques O O
were O O
used O O
to O O
demonstrate O O
that O O
SP140 O O
localized O O
to O O
the O O
NB O O
in O O
differentiated O O
HL60 O O
and O O
NB4 O O
cells O O
. O O

Some O O
of O O
these O O
proteins O O
( O O
referred O O
to O O
as O O
OTF-2 O O
) O O
are O O
lymphoid O O
specific O O
, O O
whereas O O
at O O
least O O
one O O
other O O
, O O
and O O
possibly O O
more O O
( O O
referred O O
to O O
as O O
OTF-1 O O
) O O
, O O
is O O
found O O
ubiquitously O O
in O O
all O O
cell O O
types O O
. O O

When O O
used O O
at O O
differentiation-inducing O O
concentrations O O
, O O
both O O
topoisomerase O O
inhibitors O O
caused O O
a O O
great O O
stimulation O O
of O O
AP-1 O O
binding O O
activity O O
, O O
with O O
maximum O O
value O O
at O O
hour O O
12 O O
in O O
etoposide-treated O O
cells O O
and O O
at O O
hour O O
48 O O
in O O
ICRF-193-treated O O
cells O O
. O O

These O O
studies O O
are O O
the O O
first O O
to O O
determine O O
the O O
structure O O
and O O
organization O O
of O O
the O O
5 O O
' O O
end O O
of O O
the O O
thromboxane O O
receptor O O
gene O O
and O O
demonstrate O O
that O O
thromboxane O O
receptor O O
gene O O
expression O O
can O O
be O O
regulated O O
by O O
activation O O
of O O
protein O O
kinase O O
C O O
via O O
induction O O
of O O
an O O
AP-2-like O O
nuclear O O
factor O O
binding O O
to O O
upstream O O
promoter O O
elements O O
. O O

MBP O O
also O O
induced O O
transient O O
increases O O
in O O
mRNA O O
for O O
macrophage O O
inflammatory O O
protein O O
( O O
MIP O O
) O O
-1alpha O O
and O O
MIP-1beta O O
, O O
but O O
did O O
not B-Negation B-Negation
stimulate I-Negation I-Negation
the I-Negation I-Negation
release I-Negation I-Negation
of I-Negation I-Negation
either I-Negation I-Negation
chemokine I-Negation I-Negation
. O O

In O O
addition O O
, O O
we O O
demonstrated O O
that O O
the O O
EBNA-1 O O
gene O O
in O O
infected O O
thymocytes O O
was O O
transcribed O O
from O O
the O O
Fp O O
promoter O O
, O O
rather B-Negation B-Negation
than I-Negation I-Negation
from I-Negation I-Negation
the I-Negation I-Negation
Cp/Wp I-Negation I-Negation
promoter I-Negation I-Negation
which I-Negation I-Negation
is I-Negation I-Negation
used I-Negation I-Negation
in I-Negation I-Negation
latently I-Negation I-Negation
infected I-Negation I-Negation
B I-Negation I-Negation
cells I-Negation I-Negation
. O O

This O O
probe O O
was O O
used O O
to O O
identify O O
a O O
rel-related O O
complementary O O
DNA O O
that O O
hybridized O O
to O O
a O O
2.6-kilobase O O
messenger O O
RNA O O
present O O
in O O
human O O
T O O
and O O
B O O
lymphocytes O O
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
analysis O O
suggested O O
that O O
AP-1 O O
and O O
NF-kappaB O O
are O O
among O O
the O O
possible O O
targets O O
of O O
GC O O
actions O O
on O O
TCR-stimulated O O
T O O
cells O O
. O O

Induction O O
of O O
nuclear O O
factor O O
kappa O O
B/Rel O O
nuclear O O
activity O O
in O O
human O O
peripheral O O
blood O O
T O O
lymphocytes O O
by O O
anti-HLA O O
class O O
I O O
monoclonal O O
antibodies O O
. O O

Monocytic O O
cell O O
lines O O
and O O
normal O O
peripheral O O
blood O O
monocytes O O
were O O
infected O O
with O O
HIV-1 O O
in O O
vitro O O
and O O
cultured O O
in O O
the O O
presence O O
or O O
absence B-Negation O
of I-Negation O
F I-Negation O
( I-Negation O
ab I-Negation O
' I-Negation O
) I-Negation O
2 I-Negation O
fragments I-Negation O
of I-Negation O
monoclonal I-Negation O
anti-CR1 I-Negation O
or I-Negation O
anti-CR3 I-Negation O
Abs I-Negation O
or I-Negation O
with I-Negation O
C3 I-Negation O
fragments I-Negation O
. O O

The O O
mechanism O O
by O O
which O O
eosinophil-specific O O
genes O O
encoding O O
primary O O
and O O
secondary O O
granule O O
proteins O O
( O O
e.g. O O
ECP O O
, O O
EDN O O
, O O
EPO O O
, O O
MBP O O
, O O
and O O
CLC O O
) O O
are O O
expressed O O
and O O
regulated O O
during O O
eosinophilopoiesis O O
is O O
also O O
unknown O O
. O O

Interferon O O
gamma O O
activated O O
strongly O O
c-fos O O
and O O
weakly O O
c-jun O O
and O O
AP1 O O
. O O

This O O
integrin-mediated O O
adhesion O O
controls O O
leukocyte O O
arrest O O
and O O
extravasation O O
during O O
the O O
onset O O
of O O
inflammatory O O
responses O O
. O O

For O O
each O O
pair O O
of O O
proteins O O
in O O
the O O
training O O
set O O
, O O
the O O
product O O
of O O
the O O
likelihood O O
ratios O O
from O O
all O O
other O O
modules O O
( O O
referred O O
to O O
as O O
the O O
preliminary O O
score O O
( O O
PS O O
) O O
in O O
Figure O O
1 O O
) O O
was O O
calculated O O
for O O
all O O
protein O O
pairs O O
neighboring O O
the O O
pair O O
( O O
i.e. O O
all O O
protein O O
pairs O O
which O O
involve O O
one O O
protein O O
from O O
the O O
initial O O
protein O O
pair O O
under O O
study O O
and O O
for O O
which O O
it O O
is O O
possible O O
to O O
calculate O O
such O O
a O O
score O O
) O O
. O O

In O O
this O O
report O O
we O O
demonstrate O O
that O O
interaction O O
with O O
thymic O O
epithelial O O
cells O O
( O O
TEC O O
) O O
induces O O
a O O
high-level O O
replication O O
of O O
the O O
T-tropic O O
primary O O
isolate O O
HIV-1 O O
( O O
B-LAIp O O
) O O
exclusively O O
in O O
the O O
mature O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
- O O
) O O
CD3 O O
( O O
+ O O
) O O
thymocytes O O
. O O

Monitoring O O
DPD O O
activity O O
may O O
be O O
important O O
in O O
the O O
management O O
of O O
patients O O
experiencing O O
severe O O
toxicity O O
secondary O O
to O O
FUra O O
chemotherapy O O
. O O

The O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
( O O
GM-CSF O O
) O O
gene O O
promoter O O
contains O O
a O O
consensus O O
sequence O O
for O O
the O O
polyomavirus O O
enhancer O O
binding-protein O O
2 O O
( O O
PEBP2 O O
) O O
transcription O O
factor O O
, O O
which O O
consists O O
of O O
alpha O O
and O O
beta O O
subunits O O
. O O

In O O
parallel O O
, O O
upregulation O O
of O O
the O O
lung O O
vascular O O
adhesion O O
molecule O O
, O O
intercellular O O
adhesion O O
molecule-1 O O
, O O
was O O
greatly O O
reduced O O
by O O
intrapulmonary O O
instillation O O
of O O
phosphonate-containing O O
liposomes O O
. O O

CIF O O
inhibited O O
induction O O
of O O
either O O
construct O O
as O O
did O O
cyclosporine O O
, O O
which O O
is O O
known O O
to O O
block O O
activation O O
of O O
the O O
NFAT O O
element O O
. O O

By O O
double-immunogold O O
labeling O O
of O O
PML O O
and O O
LYSP100 O O
, O O
some O O
LANDs O O
were O O
shown O O
to O O
contain O O
both O O
PML O O
and O O
LYSP100 O O
. O O

Indeed O O
, O O
most O O
mitochondria O O
released O O
all O O
their O O
cytochrome O O
c O O
within O O
a O O
one O O
minute O O
period O O
in O O
a O O
temperature-independent O O
manner O O
, O O
suggesting O O
that O O
an O O
enzymatic O O
transport O O
mechanism O O
is O O
probably O O
not O O
involved O O
. O O

Paradoxical O O
priming O O
effects O O
of O O
IL-10 O O
on O O
cytokine O O
production O O
. O O

NF-kappaB O O
activation O O
is O O
a O O
critical O O
regulator O O
of O O
human O O
granulocyte O O
apoptosis O O
in O O
vitro O O
. O O

Furthermore O O
, O O
a O O
TAL1 O O
mutant O O
not B-Negation B-Negation
binding I-Negation I-Negation
to I-Negation I-Negation
DNA I-Negation I-Negation
also O O
activated O O
the O O
transcription O O
of O O
RALDH2 O O
in O O
the O O
presence O O
of O O
LMO O O
and O O
GATA3 O O
. O O

Under O O
these O O
conditions O O
, O O
etoposide O O
produced O O
a O O
biphasic O O
activation O O
of O O
protein O O
kinase O O
C O O
, O O
which O O
consisted O O
in O O
an O O
early O O
transient O O
activation O O
( O O
from O O
hours O O
1 O O
to O O
6 O O
) O O
of O O
the O O
membrane-bound O O
enzyme O O
followed O O
by O O
a O O
later O O
activation O O
( O O
hour O O
48 O O
) O O
of O O
the O O
total O O
, O O
membrane-bound O O
and O O
cytosolic O O
enzyme O O
. O O

As O O
indicated O O
in O O
Table O O
1 O O
, O O
the O O
different O O
features O O
were O O
grouped O O
into O O
five O O
distinct O O
modules O O
: O O
Expression O O
( O O
E O O
) O O
, O O
Orthology O O
( O O
O O O
) O O
, O O
Combined O O
( O O
C O O
) O O
, O O
Disorder O O
( O O
D O O
) O O
and O O
Transitive O O
( O O
T O O
) O O
. O O

In O O
contrast O O
, O O
in O O
C57MG O O
fibroblast O O
cells O O
, O O
lithium O O
inactivates O O
GSK-3beta O O
and O O
induces O O
Tcf-controlled O O
transcription O O
. O O

The O O
TH1-to-TH2 O O
shift O O
may O O
be O O
responsible O O
for O O
the O O
stress-induced O O
susceptibility O O
of O O
the O O
organism O O
to O O
certain O O
infections O O
. O O

We O O
have O O
studied O O
the O O
regulation O O
of O O
sialoadhesin O O
expression O O
in O O
vitro O O
and O O
show O O
that O O
glucocorticoids O O
( O O
GC O O
) O O
induce O O
sialoadhesin O O
expression O O
on O O
freshly O O
isolated O O
rat O O
macrophages O O
and O O
the O O
rat O O
macrophage O O
cell O O
line O O
R2 O O
. O O

however O O
, O O
neither B-Negation B-Negation
LMP1 I-Negation I-Negation
nor I-Negation I-Negation
LMP2B I-Negation I-Negation
mRNA I-Negation I-Negation
was I-Negation I-Negation
detected I-Negation I-Negation
in I-Negation I-Negation
any I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
tumours I-Negation I-Negation
tested I-Negation I-Negation
. O O

The O O
regulation O O
of O O
NF-kappa O O
B O O
activation O O
following O O
the O O
triggering O O
of O O
HLA-DR O O
antigens O O
by O O
mAb O O
L243 O O
has O O
been O O
studied O O
at O O
various O O
times O O
in O O
Raji O O
cells O O
. O O

Both O O
phosphorylation O O
of O O
PECAM-1 O O
and O O
transendothelial O O
migration O O
of O O
monocytes O O
in O O
response O O
to O O
CoCl2 O O
were O O
inhibited O O
by O O
protein O O
kinase O O
inhibitor O O
( O O
GF109203X O O
) O O
and O O
augmented O O
by O O
protein O O
phosphatase O O
inhibitor O O
( O O
Calyculin O O
A O O
) O O
. O O

These O O
transcription O O
factors O O
are O O
post-transcriptionally O O
regulated O O
by O O
their O O
assembly O O
with O O
a O O
second O O
family O O
of O O
inhibitory O O
proteins O O
termed O O
I O O
kappa O O
B O O
that O O
serve O O
to O O
sequester O O
the O O
NF-kappa O O
B/Rel O O
complexes O O
in O O
the O O
cytoplasm O O
. O O

Neutrophil O O
accumulation O O
and O O
development O O
of O O
lung O O
injury O O
were O O
also O O
substantially O O
diminished O O
. O O

The O O
result O O
reported O O
here O O
is O O
in O O
agreement O O
, O O
but O O
it O O
is O O
not B-Negation B-Negation
conclusive I-Negation I-Negation
. O O

DNA-swap O O
experiments O O
using O O
chloramphenicol O O
acetyl-transferase O O
assay O O
demonstrated O O
that O O
androgen O O
can O O
suppress O O
the O O
transcriptional O O
activities O O
of O O
SV40 O O
early O O
promoter O O
via O O
the O O
interaction O O
between O O
this O O
TR2RE-SV40 O O
and O O
the O O
chimeric O O
receptor O O
AR/TR2/AR O O
with O O
the O O
DNA-binding O O
domain O O
of O O
the O O
TR2 O O
orphan O O
receptor O O
flanked O O
by O O
the O O
N-terminal O O
and O O
androgen-binding O O
domains O O
of O O
the O O
androgen O O
receptor O O
. O O

To O O
examine O O
whether O O
an O O
active O O
negative O O
regulatory O O
process O O
occurs O O
, O O
we O O
created O O
a O O
reporter O O
construct O O
containing O O
as O O
an O O
enhancer O O
four O O
copies O O
of O O
the O O
NF-AT O O
site O O
and O O
one O O
copy O O
of O O
the O O
octamer O O
site O O
( O O
4X O O
NF-AT-Oct O O
) O O
. O O

Mutations O O
and O O
deletions O O
of O O
both O O
sites O O
indicate O O
that O O
only O O
the O O
association O O
of O O
CCACC/Sp1 O O
and O O
GATA O O
binding O O
sites O O
can O O
drive O O
efficient O O
and O O
tissue-specific O O
expression O O
of O O
this O O
R-PK O O
minimal O O
promoter O O
. O O

Although O O
inhibition O O
of O O
IL-4-driven O O
germline O O
C O O
epsilon O O
transcription O O
by O O
NAC O O
was O O
not B-Negation B-Negation
sufficient I-Negation I-Negation
, O O
the O O
agent O O
remarkably O O
diminished O O
anti-CD40 O O
mAb-mediated O O
up-regulation O O
of O O
germline O O
C O O
epsilon O O
transcription O O
. O O

Both O O
the O O
Rhodes O O
dataset O O
and O O
our O O
LR400 O O
dataset O O
predict O O
interactions O O
involving O O
many O O
proteins O O
that O O
are O O
not B-Negation B-Negation
even I-Negation I-Negation
present I-Negation I-Negation
in I-Negation I-Negation
their I-Negation I-Negation
positive I-Negation I-Negation
training I-Negation I-Negation
set I-Negation I-Negation
( I-Negation O
the I-Negation O
HPRD I-Negation O
) I-Negation O
. O O

Algorithm O O

Transcription O O
specific O O
differences O O
visualized O O
by O O
fluorescence O O
in O O
situ O O
hybridization O O
pattern O O
on O O
interphase O O
nuclei O O
of O O
different O O
cell O O
types O O
. O O

Thus O O
, O O
the O O
DRA O O
promoter O O
discriminates O O
against O O
OTF-1 O O
activation O O
at O O
the O O
level O O
of O O
DNA O O
binding O O
in O O
the O O
glioblastoma O O
line O O
. O O

ATL-16T O O
cells O O
express O O
mRNA O O
of O O
three O O
GATA-binding O O
proteins O O
, O O
hGATA-2 O O
, O O
hGATA-3 O O
and O O
hGATA-4 O O
, O O
and O O
each O O
of O O
them O O
has O O
a O O
potential O O
to O O
bind O O
to O O
the O O
consensus O O
( O O
A/T O O
) O O
GATA O O
( O O
G/ O O
A O O
) O O
motif O O
. O O

The O O
requirement O O
for O O
TNF O O
is O O
further O O
confirmed O O
by O O
the O O
observation O O
that O O
the O O
inability O O
of O O
the O O
intermediate O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
- O O
) O O
CD3 O O
( O O
- O O
) O O
thymocytes O O
to O O
replicate O O
the O O
virus O O
is O O
associated O O
with O O
a O O
defect O O
in O O
TNF O O
production O O
during O O
their O O
interaction O O
with O O
TEC O O
and O O
correlates O O
with O O
the O O
absence B-Negation O
of I-Negation O
nuclear I-Negation O
NF-kappaB I-Negation O
activity I-Negation O
in I-Negation O
these I-Negation O
freshly I-Negation O
isolated I-Negation O
thymocytes I-Negation O
. O O

Whereas O O
anti-CD28 O O
together O O
with O O
PMA O O
increased O O
the O O
DNA O O
binding O O
and O O
trans-activation O O
activity O O
of O O
NF-kappa O O
B O O
, O O
PMA-induced O O
activation O O
of O O
AP-1 O O
was O O
significantly O O
suppressed O O
. O O

MIP1 O O
alpha O O
nuclear O O
protein O O
( O O
MNP O O
) O O
, O O
a O O
novel O O
transcription O O
factor O O
expressed O O
in O O
hematopoietic O O
cells O O
that O O
is O O
crucial O O
for O O
transcription O O
of O O
the O O
human O O
MIP-1 O O
alpha O O
gene O O
. O O

These O O
results O O
suggest O O
a O O
potential O O
role O O
of O O
PAF O O
in O O
HB-EGF O O
expression O O
and O O
provide O O
evidence O O
that O O
this O O
stimulation O O
may O O
occur O O
through O O
increased O O
kappa O O
B O O
binding O O
activity O O
. O O

Pyrrolidine O O
dithiocarbamate O O
( O O
PDTC O O
) O O
is O O
an O O
inhibitor O O
of O O
NF O O
kappaB O O
in O O
most O O
cells O O
; O O
however O O
, O O
we O O
show O O
that O O
PDTC O O
is O O
also O O
a O O
potent O O
scavenger O O
of O O
NO O O
through O O
formation O O
of O O
mononitrosyl O O
iron O O
complexes O O
with O O
PDTC O O
. O O

Our O O
data O O
are O O
most O O
consistent O O
with O O
a O O
model O O
in O O
which O O
recruitment O O
to O O
the O O
TCR O O
allows O O
ZAP-70 O O
autophosphorylation O O
and O O
binding O O
to O O
p56 O O
( O O
lck O O
) O O
, O O
which O O
in O O
turn O O
phosphorylates O O
Tyr-492 O O
and/or O O
Tyr-493 O O
with O O
consequent O O
up-regulation O O
of O O
the O O
ZAP-70 O O
kinase O O
activity O O
. O O

After O O
stimulation O O
, O O
neutrophils O O
separated O O
from O O
a O O
healthy O O
human O O
volunteer O O
were O O
added O O
with O O
or O O
without B-Negation B-Negation
anti-CD18 I-Negation I-Negation
antibody I-Negation I-Negation
. O O

The O O
relative O O
contribution O O
of O O
the O O
modules O O
to O O
the O O
prediction O O
of O O
interaction O O
was O O
investigated O O
in O O
order O O
to O O
gain O O
a O O
better O O
understanding O O
of O O
the O O
predictive O O
power O O
and O O
areas O O
of O O
highest O O
usefulness O O
of O O
the O O
different O O
modules O O
. O O

Furthermore O O
, O O
30 O O
% O O
of O O
IkappaBalpha O O
transfected O O
cells O O
were O O
apoptotic O O
after O O
8 O O
h O O
of O O
TNFalpha O O
treatment O O
. O O

Hence O O
, O O
three-step O O
filtering O O
procedures O O
were O O
applied O O
to O O
remove O O
the O O
false O O
positives O O
. O O

IAPs O O
( O O
inhibitors O O
of O O
apoptosis O O
) O O
have O O
been O O
shown O O
to O O
block O O
the O O
conversion O O
of O O
pro-caspases O O
into O O
active O O
enzymes O O
, O O
and O O
Reaper O O
, O O
Hid O O
, O O
Grim O O
, O O
and O O
Diablo/Smac O O
prevent O O
IAPs O O
from O O
carrying O O
out O O
this O O
protective O O
function O O
. O O

In O O
the O O
studies O O
described O O
in O O
this O O
report O O
, O O
we O O
demonstrated O O
a O O
physical O O
interaction O O
between O O
multiple O O
Ets O O
and O O
NF-kappaB/NFAT O O
proteins O O
both O O
in O O
vitro O O
and O O
in O O
activated O O
normal O O
human O O
T O O
cells O O
. O O

In O O
the O O
human O O
monocytic O O
cell O O
line O O
THP-1 O O
, O O
either O O
integrin-dependent O O
cell O O
adhesion O O
to O O
fibronectin O O
or O O
ligation O O
of O O
beta O O
1 O O
integrins O O
with O O
antibodies O O
causes O O
a O O
rapid O O
and O O
intense O O
tyrosine O O
phosphorylation O O
of O O
two O O
sets O O
of O O
proteins O O
of O O
about O O
65-75 O O
and O O
120-125 O O
kDa O O
. O O

Overexpression O O
of O O
TRAMP O O
leads O O
to O O
two O O
major O O
responses O O
, O O
NF-kappaB O O
activation O O
and O O
apoptosis O O
. O O

Raf-1 O O
activity O O
promotes O O
IL-2 O O
production O O
in O O
activated O O
T O O
lymphocytes O O
. O O

Costimulation O O
results O O
in O O
the O O
activation O O
of O O
a O O
signaling O O
pathway O O
that O O
leads O O
to O O
the O O
simultaneous O O
induction O O
of O O
the O O
two O O
transcription O O
factors O O
, O O
AP-1 O O
and O O
NF-kappa O O
B O O
. O O

In O O
parallel O O
with O O
such O O
differentiation O O
, O O
HIV O O
transcription O O
, O O
monitored O O
using O O
an O O
HIV O O
long O O
terminal O O
repeat O O
reporter O O
gene O O
construct O O
, O O
is O O
activated O O
in O O
such O O
cells O O
under O O
the O O
influence O O
of O O
enhanced O O
NF-kappa O O
B O O
expression O O
. O O

Tat O O
also O O
superactivates O O
the O O
HIV-1 O O
promoter O O
through O O
a O O
TAR-independent O O
mechanism O O
, O O
including O O
tumor O O
necrosis O O
factor O O
alpha-induced O O
and O O
protein O O
kinase O O
C O O
( O O
PKC O O
) O O
-dependent O O
activation O O
of O O
NF-kappa O O
B O O
, O O
and O O
inhibitors O O
of O O
Tat O O
and O O
NF-kappa O O
B O O
cooperatively O O
down-regulate O O
this O O
Tat-mediated O O
LTR O O
superactivation O O
. O O

CholecystokininB O O
receptor O O
from O O
human O O
Jurkat O O
lymphoblastic O O
T O O
cells O O
is O O
involved O O
in O O
activator O O
protein-1-responsive O O
gene O O
activation O O
. O O

Sialoadhesin O O
is O O
a O O
macrophage-restricted O O
member O O
of O O
the O O
Ig O O
superfamily O O
that O O
mediates O O
adhesion O O
with O O
lymphoid O O
and O O
myeloid O O
cells O O
. O O

On O O
these O O
datasets O O
, O O
SCOPE O O
's O O
average O O
accuracy O O
was O O
0.28 O O
, O O
0.29 O O
, O O
0.16 O O
, O O
and O O
0.08 O O
respectively O O
. O O

BOB.1/OBF.1 O O
was O O
phosphorylated O O
at O O
Ser184 O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
, O O
and O O
this O O
modification O O
was O O
required O O
for O O
inducible O O
activation O O
. O O

Mapping O O
of O O
the O O
transcriptional O O
repression O O
domain O O
of O O
the O O
lymphoid-specific O O
transcription O O
factor O O
oct-2A O O
. O O

A O O
major O O
obstacle O O
in O O
understanding O O
the O O
signaling O O
events O O
that O O
follow O O
CD28 O O
receptor O O
ligation O O
arises O O
from O O
the O O
fact O O
that O O
CD28 O O
acts O O
as O O
a O O
costimulus O O
to O O
TCR O O
engagement O O
, O O
making O O
it O O
difficult O O
to O O
assess O O
the O O
relative O O
contribution O O
of O O
CD28 O O
signals O O
as O O
distinct O O
from O O
those O O
of O O
the O O
TCR O O
. O O

In O O
human O O
leukocytes O O
, O O
the O O
peak O O
value O O
of O O
GR O O
was O O
found O O
to O O
parallel O O
that O O
of O O
plasma O O
cortisol O O
with O O
high O O
and O O
low O O
values O O
detected O O
at O O
04:00-08:00 O O
h O O
and O O
23:00-24:00 O O
h O O
, O O
respectively O O
. O O

Transient O O
transfection O O
assays O O
with O O
EGR-1 O O
promoter O O
fragments O O
linked O O
to O O
the O O
chloramphenicol O O
acetyltransferase O O
( O O
CAT O O
) O O
gene O O
demonstrated O O
that O O
PWM O O
induced O O
EGR-1 O O
transcription O O
is O O
conferred O O
by O O
the O O
CArG O O
motif O O
( O O
C O O
C O O
[ O O
AT O O
] O O
6GG O O
) O O
in O O
the O O
EGR-1 O O
promoter O O
. O O

Mutual O O
regulation O O
of O O
the O O
transcriptional O O
activator O O
NF-kappa O O
B O O
and O O
its O O
inhibitor O O
, O O
I O O
kappa O O
B-alpha O O
. O O

The O O
PML O O
gene O O
is O O
fused O O
to O O
the O O
retinoic O O
acid O O
receptor O O
alpha O O
gene O O
( O O
RAR O O
alpha O O
) O O
in O O
the O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
15 O O
; O O
17 O O
translocation O O
. O O

Some O O
patients O O
with O O
acquired O O
immunodeficiency O O
syndrome O O
( O O
AIDS O O
) O O
develop O O
glucocorticoid O O
resistance O O
characterized O O
by O O
low O O
receptor O O
affinity O O
( O O
Kd O O
) O O
for O O
glucocorticoids O O
in O O
mononuclear O O
, O O
cells O O
and O O
high O O
values O O
of O O
ACTH O O
and O O
cortisol O O
. O O

Furthermore O O
, O O
while O O
ligand-activated O O
c-erbA/TR O O
accelerated O O
differentiation O O
, O O
unliganded O O
c-erbA/TR O O
effectively O O
blocked O O
differentiation O O
and O O
supported O O
sustained O O
progenitor O O
growth O O
in O O
culture O O
. O O

As O O
evidenced O O
by O O
electro O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
and O O
the O O
use O O
of O O
a O O
NF-kappa O O
B O O
prototypic O O
probe O O
, O O
these O O
drugs O O
probably O O
exert O O
their O O
inhibitory O O
effects O O
by O O
interference O O
with O O
the O O
nuclear O O
translocation O O
of O O
NF-kappa O O
B/c-Rel O O
proteins O O
. O O

Here O O
, O O
we O O
describe O O
the O O
effect O O
of O O
383-bp O O
( O O
delta383 O O
) O O
and O O
99-bp O O
( O O
delta99 O O
) O O
sequences O O
containing O O
the O O
PYBF-binding O O
site O O
on O O
transcription O O
from O O
various O O
globin O O
and O O
non-globin O O
promoters O O
, O O
using O O
a O O
transient O O
assay O O
with O O
the O O
cat O O
reporter O O
gene O O
in O O
murine O O
erythroleukemia O O
( O O
MEL O O
) O O
cells O O
, O O
a O O
cell O O
line O O
with O O
abundant O O
PYBF O O
activity O O
. O O

We O O
show O O
that O O
the O O
inactivation O O
of O O
the O O
inhibition O O
was O O
dependent O O
on O O
the O O
activity O O
of O O
calcineurin O O
, O O
a O O
calcium-calmodulin-dependent O O
phosphatase O O
. O O

Analysis O O
of O O
DNA O O
binding O O
revealed O O
that O O
NF-kappa O O
B O O
activation O O
in O O
response O O
to O O
TNF O O
was O O
significantly O O
inhibited O O
under O O
these O O
conditions O O
. O O

GDSP O O
also O O
completely O O
inhibited O O
superoxide O O
formation O O
in O O
the O O
human O O
neutrophils O O
stimulated O O
by O O
N-formyl-methionine-leucine-phenyl-alanine O O
( O O
fMLP O O
) O O
or O O
12-O-tetradecanoylphorbol-13-acetate O O
( O O
TPA O O
) O O
. O O

Internal O O
labeling O O
with O O
[ O O
35S O O
] O O
methionine O O
and O O
immunoprecipitation O O
with O O
anti-IgM O O
, O O
anti-kappa O O
, O O
and O O
anti-lambda O O
antibodies O O
revealed O O
a O O
striking O O
reduction O O
in O O
kappa O O
L O O
chain O O
in O O
the O O
presence O O
of O O
TGF-beta O O
. O O

These O O
results O O
imply O O
that O O
Myc O O
promotes O O
activation-induced O O
apoptosis O O
by O O
obligatory O O
heterodimerization O O
with O O
Max O O
, O O
and O O
therefore O O
, O O
by O O
regulating O O
gene O O
transcription O O
. O O

Corroborating O O
the O O
results O O
of O O
previously O O
published O O
performance O O
comparisons O O
@ O O
14567 O O
@ O O
, O O
none B-Negation O
of I-Negation O
the I-Negation O
other I-Negation O
programs I-Negation O
showed I-Negation O
a I-Negation O
statistically I-Negation O
significant I-Negation O
difference I-Negation O
relative I-Negation O
to I-Negation O
the I-Negation O
other I-Negation O
nine I-Negation O
. O O

The O O
approximately O O
90-aa O O
N-terminus O O
of O O
the O O
latter O O
sequence O O
is O O
the O O
ring O O
finger O O
( O O
E O O
< O O
10-7 O O
, O O
multiple O O
BLASTP O O
matches O O
against O O
known O O
ring O O
fingers O O
in O O
GenBank O O
) O O
. O O

Because O O
we O O
have O O
no B-Negation B-Negation
a I-Negation I-Negation
priori I-Negation I-Negation
knowledge I-Negation I-Negation
about I-Negation I-Negation
the I-Negation I-Negation
23rd I-Negation I-Negation
amino I-Negation I-Negation
acid I-Negation I-Negation
, O O
cutoff O O
thresholds O O
for O O
the O O
filtering O O
procedures O O
were O O
determined O O
based O O
on O O
the O O
known O O
readthrough O O
proteins O O
. O O

Two O O
tandem O O
AP1 O O
binding O O
sites O O
with O O
dyad O O
symmetry O O
are O O
required O O
for O O
enhancer O O
activity O O
and O O
for O O
DNA-protein O O
complex O O
formation O O
with O O
members O O
of O O
the O O
c-fos/c-jun O O
family O O
. O O

This O O
silencer O O
is O O
inactive O O
in O O
the O O
most O O
immature O O
DN O O
thymocytes O O
, O O
which O O
probably O O
use O O
a O O
distinct O O
silencer O O
mechanism O O
to O O
down-regulate O O
CD4 O O
gene O O
expression O O
. O O

The O O
underlying O O
molecular O O
mechanism O O
for O O
Pb O O
's O O
complex O O
effects O O
on O O
the O O
immune O O
system O O
remain O O
obscure O O
. O O

These O O
observations O O
indicate O O
that O O
expression O O
of O O
Egr-1 O O
is O O
essential O O
for O O
and O O
restricts O O
differentiation O O
of O O
myeloblasts O O
along O O
the O O
macrophage O O
lineage O O
. O O

The O O
legend O O
under O O
the O O
sequence O O
show O O
the O O
names O O
of O O
transcription O O
factors O O
binding O O
to O O
matching O O
colored O O
binding O O
sites O O
. O O

Abnormality O O
of O O
Oct-1 O O
DNA O O
binding O O
in O O
T O O
cells O O
from O O
Sjogren O O
's O O
syndrome O O
patients O O
. O O

Taken O O
together O O
, O O
these O O
results O O
demonstrate O O
that O O
tolerance O O
to O O
LPS O O
is O O
determined O O
by O O
post-receptor O O
mechanisms O O
that O O
involve O O
an O O
altered O O
composition O O
of O O
the O O
NF-kappa O O
B O O
complex O O
. O O

6. O O
Partitioning O O
of O O
SMX-NHOH O O
into O O
red O O
blood O O
cells O O
was O O
significantly O O
( O O
P O O
< O O
0.05 O O
) O O
lower O O
than O O
with O O
the O O
hydroxylamine O O
of O O
dapsone O O
. O O

Finally O O
, O O
by O O
co-transfection O O
experiments O O
, O O
we O O
study O O
the O O
elements O O
involved O O
in O O
the O O
hGATA-1 O O
transactivation O O
of O O
the O O
R-PK O O
promoter O O
in O O
HeLa O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
importance O O
of O O
PI O O
3-kinase O O
in O O
TCR-directed O O
T-cell O O
activation O O
using O O
activated O O
or O O
inhibitory O O
versions O O
of O O
PI O O
3-kinase O O
. O O

iPfam O O

Nuclear O O
extracts O O
from O O
primary O O
human O O
T O O
lymphocytes O O
were O O
analyzed O O
by O O
electrophoretic O O
DNA O O
mobility O O
shift O O
assays O O
. O O

IL-2 O O
and O O
IL-7 O O
were O O
equivalent O O
in O O
their O O
ability O O
to O O
induce O O
tyrosine O O
phosphorylation O O
of O O
STAT5A O O
and O O
STAT5B O O
and O O
to O O
facilitate O O
binding O O
of O O
these O O
STATs O O
to O O
an O O
immobilized O O
GAS O O
element O O
. O O

Nevertheless O O
, O O
in O O
the O O
two O O
leukemia O O
cell O O
lines O O
transient O O
overexpression O O
of O O
p16 O O
reestablished O O
the O O
normal O O
regulation O O
of O O
thymidine O O
kinase O O
, O O
paralleled O O
by O O
an O O
increase O O
of O O
the O O
underphosphorylated O O
form O O
of O O
retinoblastoma O O
protein O O
and O O
decrease O O
of O O
free O O
E2F O O
bound O O
to O O
its O O
motif O O
in O O
the O O
thymidine O O
kinase O O
promoter O O
. O O

Inhibition O O
of O O
anti-CD3 O O
monoclonal O O
antibody-induced O O
T-cell O O
proliferation O O
by O O
dexamethasone O O
, O O
isoproterenol O O
, O O
or O O
prostaglandin O O
E2 O O
either O O
alone O O
or O O
in O O
combination O O
. O O

However O O
, O O
it O O
remains O O
unclear O O
how O O
this O O
viral O O
protein O O
induces O O
a O O
persistent O O
rather O O
than O O
transient O O
NF-kappaB O O
response O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrate O O
that O O
the O O
HIV-1 O O
DSE O O
can O O
mediate O O
the O O
transcriptional O O
synergy O O
elicited O O
by O O
the O O
combination O O
of O O
Ctx O O
and O O
TNFalpha O O
. O O

Receiver O O
operator O O
characteristic O O
( O O
ROC O O
) O O
curves O O
plot O O
the O O
true O O
positive O O
rate O O
versus O O
the O O
false O O
positive O O
rate O O
over O O
their O O
full O O
range O O
of O O
possible O O
values O O
. O O

Since O O
the O O
genome O O
annotation O O
of O O
M. O O
acetivorans O O
describes O O
this O O
protein O O
as O O
a O O
gene O O
containing O O
an O O
inframe O O
amber O O
codon O O
, O O
we O O
classified O O
it O O
as O O
a O O
`` O O
known O O
'' O O
candidate O O
, O O
although O O
it O O
is O O
still O O
unclear O O
whether O O
it O O
really O O
contains O O
pyrrolysine O O
. O O

In O O
this O O
study O O
, O O
we O O
show O O
that O O
HNF-3alpha O O
, O O
-3beta O O
, O O
-3gamma O O
, O O
-4gamma O O
, O O
and O O
-6 O O
are O O
expressed O O
in O O
pancreatic O O
beta-cells O O
. O O

These O O
observations O O
suggest O O
that O O
de O O
novo O O
EBV O O
infection O O
of O O
thymocytes O O
differs O O
from O O
infection O O
of O O
B O O
cells O O
. O O

Genomic O O
sequence O O
upstream O O
of O O
the O O
Fc O O
gamma O O
RIC O O
gene O O
was O O
cloned O O
and O O
subjected O O
to O O
primer O O
extension O O
analysis O O
, O O
which O O
demonstrated O O
a O O
single O O
transcription O O
initiation O O
site O O
without B-Negation B-Negation
a I-Negation I-Negation
TATA I-Negation I-Negation
box I-Negation I-Negation
. O O

These O O
results O O
suggest O O
that O O
induction O O
of O O
a O O
labile O O
inhibitory O O
factor O O
such O O
as O O
IkappaB O O
alpha O O
may O O
contribute O O
to O O
glucocorticoid-induced O O
apoptosis O O
. O O

Expression O O
of O O
D-mib O O
in O O
dorsal O O
cells O O
was O O
sufficient O O
to O O
rescue O O
growth O O
of O O
the O O
wing O O
pouch O O
and O O
of O O
the O O
expression O O
of O O
Cut O O
in O O
margin O O
cells O O
in O O
D-mib O O
mutant O O
discs O O
( O O
Figure O O
7A O O
) O O
. O O

Here O O
we O O
show O O
that O O
the O O
rate O O
of O O
constitutive O O
apoptosis O O
in O O
human O O
neutrophils O O
and O O
eosinophils O O
is O O
greatly O O
accelerated O O
in O O
both O O
a O O
rapid O O
and O O
concentration-dependent O O
manner O O
by O O
the O O
fungal O O
metabolite O O
gliotoxin O O
, O O
but O O
not B-Negation B-Negation
by I-Negation I-Negation
its I-Negation I-Negation
inactive I-Negation I-Negation
analog I-Negation I-Negation
methylthiogliotoxin I-Negation I-Negation
. O O

Regulation O O
of O O
programmed O O
cell O O
death O O

ISH O O
for O O
EBV-encoded O O
small O O
non-polyadenylated O O
RNAs O O
showed O O
that O O
all O O
cases O O
, O O
whether O O
NK O O
or O O
T O O
, O O
harboured O O
EBV O O
in O O
virtually O O
all O O
tumour O O
cells O O
. O O

To O O
ensure O O
that O O
a B-Negation O
conservation I-Negation O
profile I-Negation O
for I-Negation O
the I-Negation O
Transib I-Negation O
TPases I-Negation O
and I-Negation O
RAG1 I-Negation O
proteins I-Negation O
was I-Negation O
not I-Negation B-Negation
produced I-Negation I-Negation
by I-Negation I-Negation
a I-Negation I-Negation
systematic I-Negation I-Negation
error I-Negation I-Negation
, O O
we O O
employed O O
a O O
procedure O O
of O O
“ O O
step-wise O O
” O O
PSI-BLAST O O
iterations O O
. O O

Monoclonal O O
anti-endothelial O O
cell O O
antibodies O O
from O O
a O O
patient O O
with O O
Takayasu O O
arteritis O O
activate O O
endothelial O O
cells O O
from O O
large O O
vessels O O
. O O

Vaccination O O
with O O
synthetic O O
peptides O O
representing O O
cytotoxic O O
T O O
lymphocyte O O
( O O
CTL O O
) O O
epitopes O O
can O O
lead O O
to O O
a O O
protective O O
CTL-mediated O O
immunity O O
against O O
tumors O O
or O O
viruses O O
. O O

Treatment O O
of O O
PAEC O O
exposed O O
to O O
xenogeneic O O
serum O O
with O O
the O O
NF-kappa O O
B O O
inhibitors O O
pyrrolidinedithiocarbamate O O
( O O
PDTC O O
, O O
25 O O
microM O O
) O O
and O O
tosyl-phechloromethylketone O O
( O O
TPCK O O
, O O
25 O O
microM O O
) O O
significantly O O
( O O
P O O
< O O
0.01 O O
) O O
reduced O O
leukocyte O O
adhesion O O
in O O
respect O O
to O O
PAEC O O
treated O O
with O O
human O O
serum O O
alone O O
. O O

The O O
low O O
coverage O O
and O O
variable O O
quality O O
of O O
the O O
experimental O O
interaction O O
datasets O O
have O O
prompted O O
many O O
groups O O
to O O
investigate O O
computational O O
methods O O
to O O
predict O O
interactions O O
or O O
to O O
determine O O
the O O
most O O
likely O O
interactions O O
seen O O
in O O
the O O
high-throughput O O
datasets O O
. O O

These O O
data O O
suggest O O
that O O
E2 O O
is O O
one O O
of O O
the O O
activating O O
factors O O
for O O
NK/LGL O O
cells O O
. O O

Remarkably O O
, O O
the O O
hydra O O
RAG1L_NM O O
protein O O
turned O O
out O O
to O O
be O O
significantly O O
similar O O
to O O
the O O
Transib O O
TPase O O
( O O
26 O O
% O O
identity O O
; O O
E-value O O
is O O
approximately O O
equal O O
to O O
10-14 O O
in O O
a O O
BLASTX O O
search O O
against O O
GenBank O O
proteins O O
combined O O
with O O
the O O
Transib O O
TPase O O
sequences O O
) O O
. O O

T-lymphocytes O O
from O O
individuals O O
with O O
filarial O O
inflammatory O O
disease O O
have O O
increased O O
transendothelial O O
migration O O
in O O
vitro O O
. O O

The O O
activity O O
of O O
the O O
neur O O
gene O O
is O O
also O O
required O O
for O O
lateral O O
inhibition O O
during O O
neurogenesis O O
in O O
embryos O O
and O O
pupae O O
[ O O
4,45,61 O O
] O O
. O O

Mutation O O
of O O
a O O
20-base O O
pair O O
sequence O O
of O O
the O O
gamma-gene O O
5'-untranslated O O
region O O
( O O
UTR O O
) O O
led O O
to O O
derepression O O
of O O
beta-promoter O O
activity O O
. O O

However O O
, O O
apoptosis O O
was O O
much O O
higher O O
in O O
FTOC O O
infected O O
with O O
adenovirus O O
containing O O
mut-I O O
kappa O O
B O O
than O O
in O O
FTOC O O
infected O O
with O O
a O O
control O O
virus O O
. O O

Low O O
dose O O
dexamethasone O O
therapy O O
( O O
1-1.5 O O
mg/day O O
) O O
was O O
of O O
clinical O O
benefit O O
in O O
these O O
patients O O
. O O

Here O O
, O O
we O O
report O O
that O O
differentiated O O
B O O
cells O O
contain O O
a O O
novel O O
substoichiometric O O
TAF O O
of O O
105 O O
kDa O O
not B-Negation B-Negation
found I-Negation I-Negation
associated I-Negation I-Negation
with I-Negation I-Negation
TFIID I-Negation I-Negation
isolated I-Negation I-Negation
from I-Negation I-Negation
other I-Negation I-Negation
cell I-Negation I-Negation
types I-Negation I-Negation
. O O

Thus O O
, O O
Tax1 O O
was O O
suggested O O
to O O
replace O O
growth O O
signals O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
this O O
mechanism O O
. O O

We O O
examined O O
mRNA O O
levels O O
of O O
various O O
V-ATPase O O
subunits O O
during O O
differentiation O O
of O O
both O O
native O O
monocytes O O
and O O
the O O
cell O O
line O O
THP-1 O O
, O O
and O O
found O O
that O O
transcriptional O O
and O O
post-transcriptional O O
mechanisms O O
could O O
account O O
for O O
increases O O
in O O
cell O O
V-ATPase O O
content O O
. O O

An O O
unexpected O O
finding O O
was O O
that O O
the O O
Ig O O
levels O O
decreased O O
during O O
the O O
follow-up O O
period O O
. O O

Nuclear O O
run-on O O
analysis O O
revealed O O
that O O
the O O
rate O O
of O O
Fc O O
gamma O O
RI O O
transcription O O
was O O
increased O O
by O O
IFN-gamma O O
. O O

However O O
, O O
the B-Negation O
delay I-Negation O
in I-Negation O
development I-Negation O
and I-Negation O
block I-Negation O
of I-Negation O
pupariation I-Negation O
( I-Negation O
Figure I-Negation O
6B I-Negation O
) I-Negation O
, I-Negation O
as I-Negation O
well I-Negation O
as I-Negation O
the I-Negation O
pupal I-Negation O
body I-Negation O
shape I-Negation O
, I-Negation O
were I-Negation O
not I-Negation B-Negation
influenced I-Negation I-Negation
by I-Negation I-Negation
this I-Negation I-Negation
mutation I-Negation I-Negation
. O O

This O O
inhibition O O
prevented O O
the O O
degradation O O
of O O
the O O
NF-kappa O O
B O O
inhibitor O O
, O O
I O O
kappa O O
B O O
, O O
and O O
therefore O O
NF-kappa O O
B O O
was O O
retained O O
in O O
the O O
cytosol O O
. O O

Differential O O
regulation O O
of O O
proto-oncogenes O O
c-jun O O
and O O
c-fos O O
in O O
T O O
lymphocytes O O
activated O O
through O O
CD28 O O
. O O

Together O O
these O O
data O O
demonstrate O O
that O O
the O O
v-abl O O
protein O O
specifically O O
interferes O O
with O O
light-chain O O
gene O O
rearrangement O O
by O O
suppressing O O
at O O
least O O
two O O
pathways O O
essential O O
for O O
this O O
stage O O
of O O
B-cell O O
differentiation O O
and O O
suggest O O
that O O
tyrosine O O
phosphorylation O O
is O O
important O O
in O O
regulating O O
RAG O O
gene O O
expression O O
. O O

A O O
regulatory O O
element O O
in O O
the O O
human O O
interleukin O O
2 O O
gene O O
promoter O O
is O O
a O O
binding O O
site O O
for O O
the O O
zinc O O
finger O O
proteins O O
Sp1 O O
and O O
EGR-1 O O
. O O

The O O
gene O O
contains O O
a O O
CpG-rich O O
island O O
suggesting O O
expression O O
in O O
the O O
germ O O
line O O
. O O

Glycoprotein O O
( O O
GP O O
) O O
IX O O
is O O
a O O
subunit O O
of O O
the O O
von O O
Willebrand O O
receptor O O
, O O
GPIb-V-IX O O
, O O
which O O
mediates O O
adhesion O O
of O O
platelets O O
to O O
the O O
subendothelium O O
of O O
damaged O O
blood O O
vessels O O
. O O

However O O
, O O
like O O
NF O O
kappa O O
B O O
, O O
TCF-1 O O
activity O O
is O O
induced O O
by O O
phorbol O O
esters O O
and O O
other O O
T-cell O O
activators O O
. O O

These O O
observations O O
suggest O O
that O O
resynthesis O O
of O O
I O O
kappa O O
B O O
alpha O O
and O O
removal O O
of O O
the O O
stimulus O O
are O O
obligatory O O
steps O O
for O O
the O O
inactivation O O
of O O
nuclear O O
NF O O
kappa O O
B O O
. O O

The O O
activity O O
of O O
the O O
enhancer O O
is O O
almost O O
completely O O
dependent O O
on O O
the O O
integrity O O
of O O
a O O
dimeric O O
GATA-1 O O
binding O O
site O O
. O O

Retinoblastoma O O
protein O O
expression O O
leads O O
to O O
reduced O O
Oct-1 O O
DNA O O
binding O O
activity O O
and O O
enhances O O
interleukin-8 O O
expression O O
. O O

We O O
are O O
now O O
carrying O O
out O O
direct O O
tests O O
of O O
the O O
idea O O
that O O
the O O
differentiation O O
of O O
hemocytes O O
in O O
mutant O O
larvae O O
is O O
caused O O
by O O
elevated O O
adenosine O O
. O O

These O O
inhibitors O O
specifically O O
prevented O O
degradation O O
of O O
I O O
kappa O O
B O O
alpha O O
and O O
nuclear O O
translocation O O
of O O
c-Rel/p65 O O
heterodimers O O
. O O

-CDK2 O O
and O O
MCM4 O O
were O O
predicted O O
to O O
interact O O
at O O
a O O
posterior O O
odds O O
ratio O O
of O O
62 O O
. O O

Moreover O O
, O O
ACH-2 O O
cells O O
treated O O
with O O
HOCl O O
or O O
H2O2 O O
released O O
tumour O O
necrosis O O
factor-alpha O O
( O O
TNF-alpha O O
) O O
in O O
the O O
supernatants O O
. O O

Lymphocytes O O
are O O
particularly O O
susceptible O O
to O O
DNA O O
damage-induced O O
apoptosis O O
, O O
a O O
response O O
which O O
may O O
serve O O
as O O
a O O
form O O
of O O
'altruistic O O
suicide O O
' O O
to O O
counter O O
their O O
intrinsic O O
high O O
potential O O
for O O
mutation O O
and O O
clonal O O
expansion O O
. O O

As O O
the O O
expression O O
level O O
of O O
the O O
RP1 O O
gene O O
in O O
activated O O
T O O
cells O O
and O O
a O O
spectrum O O
of O O
tumor-derived O O
cell O O
lines O O
correlates O O
with O O
the O O
proliferative O O
status O O
of O O
the O O
cells O O
, O O
members O O
of O O
the O O
EB1-like O O
gene O O
family O O
may O O
not O O
only O O
be O O
involved O O
in O O
the O O
tumorigenesis O O
of O O
colorectal O O
cancers O O
but O O
may O O
also O O
play O O
a O O
role O O
in O O
the O O
proliferative O O
control O O
of O O
normal O O
cells O O
. O O

Adherence O O
to O O
either O O
fibronectin O O
or O O
collagen-coated O O
plastic O O
had O O
little O O
consistent O O
effect O O
on O O
PDGF O O
( O O
B O O
) O O
mRNA O O
accumulation O O
. O O

We O O
had O O
previously O O
shown O O
that O O
the O O
drug O O
undecylprodigiosin O O
( O O
UP O O
) O O
blocks O O
human O O
lymphocyte O O
proliferation O O
in O O
vitro O O
. O O

Regulation O O
of O O
Fas O O
ligand O O
expression O O
and O O
cell O O
death O O
by O O
apoptosis-linked O O
gene O O
4 O O
. O O

The O O
number O O
of O O
glucocorticoid O O
receptors O O
( O O
GCR O O
) O O
in O O
peripheral O O
leukocytes O O
was O O
determined O O
by O O
radioligand-binding O O
assay O O
in O O
extrinsic O O
and O O
intrinsic O O
asthmatics O O
. O O

Accordingly O O
, O O
we O O
selected O O
a O O
prior O O
odds O O
ratio O O
of O O
interaction O O
of O O
1/400 O O
which O O
is O O
similar O O
to O O
current O O
estimates O O
for O O
yeast O O
and O O
is O O
probably O O
still O O
quite O O
conservative O O
. O O

After O O
T O O
cell O O
activation O O
, O O
the O O
phosphorylation O O
of O O
Rb O O
results O O
in O O
the O O
release O O
of O O
Elf-1 O O
, O O
which O O
is O O
correlated O O
temporally O O
with O O
the O O
activation O O
of O O
Elf-1-mediated O O
transcription O O
. O O

Recently O O
, O O
we O O
have O O
reported O O
that O O
the O O
tumor O O
necrosis O O
factor O O
and O O
interleukin O O
1 O O
signaling O O
pathways O O
activate O O
two O O
kinases O O
, O O
IKK1 O O
and O O
IKK2 O O
. O O

RAG1 O O
aa O O
whose O O
replacements O O
resulted O O
in O O
previously O O
detected O O
defects O O
of O O
V O O
( O O
D O O
) O O
J O O
recombination O O
[ O O
31 O O
] O O
are O O
marked O O
by O O
color O O
rectangles O O
indicated O O
below O O
the O O
alignment O O
blocks O O
; O O
red O O
indicates O O
DNA O O
binding O O
defect O O
; O O
green O O
indicates O O
nicking O O
defect O O
; O O
cyan O O
indicates O O
hairpin O O
defect O O
; O O
blue O O
indicates O O
joining O O
mutants O O
; O O
yellow O O
indicates O O
catalytic O O
mutants O O
; O O
gray O O
indicates O O
joining/transposition O O
. O O

The O O
Eed-mediated O O
transcriptional O O
effects O O
are O O
likely O O
to O O
reflect O O
the O O
interaction O O
of O O
Eed O O
with O O
multiple O O
molecular O O
partners O O
, O O
including O O
K O O
protein O O
. O O

Constitutive O O
phosphorylation O O
of O O
Jak O O
kinases O O
may O O
facilitate O O
tumor O O
growth O O
in O O
both O O
HTLV-1 O O
infected O O
human O O
T O O
cells O O
and O O
the O O
transgenic O O
mouse O O
model O O
. O O

The O O
M-CSF O O
receptor O O
was O O
first O O
detectable O O
in O O
the O O
myeloid-committed O O
CD34+Thy-l-CD45RA+ O O
subset O O
. O O

LPS O O
stimulation O O
increased O O
the O O
binding O O
of O O
c-Jun-containing O O
complexes O O
. O O

Responses O O
to O O
these O O
EBV O O
antigens O O
by O O
synovial O O
lymphocytes O O
from O O
several O O
other O O
chronic O O
rheumatoid O O
arthritis O O
patients O O
were O O
readily O O
detectable O O
. O O

G28-5 O O
sFv O O
was O O
a O O
more O O
potent O O
agonist O O
than O O
G28-5 O O
IgG O O
and O O
was O O
able O O
to O O
stimulate O O
CD40 O O
responses O O
by O O
B O O
cells O O
and O O
monocytes O O
. O O

Our O O
data O O
demonstrate O O
a O O
major O O
role O O
of O O
the O O
GASd/EBSd O O
element O O
in O O
IL-2R O O
alpha O O
regulation O O
and O O
suggest O O
that O O
the O O
T-cell-specific O O
Elf-1 O O
factor O O
can O O
serve O O
as O O
a O O
transcriptional O O
repressor O O
. O O

Similar O O
inhibition O O
of O O
NFAT-1-mediated O O
gene O O
expression O O
was O O
observed O O
in O O
a O O
second O O
cell O O
line O O
, O O
which O O
is O O
stably O O
transfected O O
with O O
NFAT-1 O O
regulatory O O
elements O O
linked O O
to O O
the O O
reporter O O
gene O O
for O O
sCD8 O O
. O O

Thus O O
, O O
BOB.1/OBF.1 O O
is O O
a O O
transcriptional O O
coactivator O O
that O O
is O O
critically O O
regulated O O
by O O
posttranslational O O
modifications O O
to O O
mediate O O
cell O O
type-specific O O
gene O O
expression O O
. O O

The O O
conversion O O
of O O
the O O
TCEd O O
to O O
a O O
' O O
perfect O O
' O O
NF-kB O O
binding O O
site O O
leads O O
to O O
a O O
tighter O O
binding O O
of O O
NF-kB O O
to O O
TCEd O O
DNA O O
and O O
, O O
as O O
a O O
functional O O
consequence O O
, O O
to O O
the O O
activity O O
of O O
the O O
' O O
converted O O
' O O
TCEd O O
motifs O O
in O O
HeLa O O
cells O O
. O O

A O O
powerful O O
enhancer O O
has O O
been O O
mapped O O
to O O
an O O
18-bp O O
DNA O O
segment O O
located O O
11 O O
kb O O
5 O O
' O O
to O O
the O O
human O O
epsilon-globin O O
gene O O
within O O
the O O
dominant O O
control O O
or O O
locus-activating O O
region O O
. O O

In O O
this O O
study O O
we O O
demonstrate O O
that O O
a O O
subfragment O O
( O O
C26 O O
) O O
in O O
the O O
region O O
between O O
the O O
21-bp O O
elements O O
is O O
involved O O
in O O
trans-activation O O
by O O
p40tax O O
, O O
possibly O O
through O O
binding O O
to O O
an O O
NF-kappa O O
B-like O O
nuclear O O
factor O O
or O O
factors O O
. O O

Additionally O O
, O O
CoCl2 O O
caused O O
a O O
two- O O
to O O
threefold O O
increase O O
in O O
the O O
rate O O
of O O
transendothelial O O
migration O O
of O O
monocyte-like O O
HL-60 O O
cells O O
and O O
a O O
twentyfold O O
increase O O
in O O
phosphorylation O O
of O O
platelet O O
endothelial O O
cell O O
adhesion O O
molecules O O
( O O
PECAM-1 O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
corticosteroid O O
Type O O
I O O
and O O
Type O O
II O O
receptors O O
in O O
mononuclear O O
leukocytes O O
were O O
measured O O
in O O
10 O O
elderly O O
subjects O O
and O O
in O O
9 O O
young O O
adults O O
, O O
before O O
and O O
after O O
overnight O O
DST O O
( O O
1 O O
mg O O
) O O
. O O

Receptors O O
for O O
leukocyte O O
chemoattractants O O
, O O
including O O
chemokines O O
, O O
are O O
traditionally O O
considered O O
to O O
be O O
responsible O O
for O O
the O O
activation O O
of O O
special O O
leukocyte O O
functions O O
such O O
as O O
chemotaxis O O
, O O
degranulation O O
, O O
and O O
the O O
release O O
of O O
superoxide O O
anions O O
. O O

Deactivation O O
of O O
mononuclear O O
phagocytes O O
is O O
critical O O
to O O
limit O O
the O O
inflammatory O O
response O O
but O O
can O O
be O O
detrimental O O
in O O
the O O
face O O
of O O
progressive O O
infection O O
. O O

DNA O O
triplex O O
formation O O
selectively O O
inhibits O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
gene O O
expression O O
in O O
human O O
T O O
cells O O
. O O

Glucocorticoid O O
pharmacokinetics O O
, O O
glucocorticoid O O
receptor O O
characteristics O O
, O O
and O O
inhibition O O
of O O
peripheral O O
blood O O
T O O
cell O O
proliferation O O
by O O
glucocorticoids O O
in O O
vitro O O
. O O

The O O
Rex O O
protein O O
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
1 O O
is O O
required O O
for O O
the O O
nuclear O O
export O O
of O O
unspliced O O
viral O O
mRNA O O
and O O
, O O
therefore O O
, O O
for O O
virus O O
replication O O
. O O

Every O O
motif O O
finder O O
they O O
tested O O
was O O
found O O
to O O
be O O
sensitive O O
to O O
values O O
used O O
for O O
these O O
parameters O O
. O O

The O O
appearance O O
of O O
the O O
CMAT O O
binding O O
complex O O
was O O
inhibited O O
by O O
both O O
cyclosporin O O
A O O
and O O
rapamycin O O
. O O

This O O
dispersed O O
localization O O
of O O
a O O
group O O
of O O
functionally O O
related O O
gene O O
provides O O
insights O O
into O O
the O O
molecular O O
mechanism O O
of O O
human O O
genome O O
evolution O O
and O O
their O O
possible O O
involvement O O
in O O
human O O
diseases O O
. O O

Inhibitory O O
effect O O
of O O
growth O O
hormone O O
on O O
TNF-alpha O O
secretion O O
and O O
nuclear O O
factor-kappaB O O
translocation O O
in O O
lipopolysaccharide-stimulated O O
human O O
monocytes O O
. O O

However O O
, O O
this O O
appears O O
to O O
add O O
more O O
noise O O
to O O
the O O
prediction O O
without O B-Negation
increasing O I-Negation
the O I-Negation
accuracy O I-Negation
. O O

The O O
nuclear O O
factor-kappa O O
B O O
( O O
NF-kappaB O O
) O O
family O O
of O O
transcription O O
factors O O
regulates O O
genes O O
involved O O
in O O
inflammation O O
, O O
cell O O
proliferation O O
, O O
and O O
cell O O
differentiation O O
. O O

For O O
this O O
purpose O O
, O O
mice O O
were O O
immunized O O
with O O
a O O
fusion O O
protein O O
including O O
the O O
sequence O O
Thr729-Lys984 O O
of O O
hMR O O
. O O

The O O
requirement O O
for O O
AP1 O O
activation O O
suggested O O
a O O
role O O
for O O
the O O
mitogen-activated O O
protein O O
kinase O O
( O O
MAPK O O
) O O
signaling O O
pathway O O
in O O
regulating O O
alpha2 O O
integrin O O
gene O O
expression O O
. O O

Besides O O
binding O O
to O O
Apaf-1 O O
, O O
just O O
as O O
CED-9 O O
binds O O
and O O
thereby O O
regulates O O
CED-4 O O
activity O O
, O O
mammalian O O
Bcl-2 O O
family O O
members O O
have O O
been O O
proposed O O
to O O
regulate O O
mitochondrial O O
homeostasis O O
and O O
the O O
release O O
of O O
pro-apoptotic O O
factors O O
such O O
as O O
cytochrome O O
c O O
( O O
reviewed O O
in O O
[ O O
17 O O
] O O
) O O
. O O

However O O
, O O
a O O
TH-dependent O O
positive O O
effect O O
is O O
elicited O O
by O O
selective O O
interaction O O
of O O
the O O
THR O O
beta-PPAR O O
but O O
not B-Negation B-Negation
the I-Negation I-Negation
THR I-Negation I-Negation
alpha-PPAR I-Negation I-Negation
heterodimer I-Negation I-Negation
with I-Negation I-Negation
a I-Negation I-Negation
novel I-Negation I-Negation
TRE I-Negation I-Negation
( I-Negation I-Negation
DR+2 I-Negation I-Negation
) I-Negation I-Negation
. O O

Both O O
molecules O O
enhanced O O
LPS-induced O O
NF-kappaB O O
and O O
activating O O
protein-1 O O
binding O O
activity O O
. O O

Expression O O
of O O
Ah O O
receptor O O
( O O
TCDD O O
receptor O O
) O O
during O O
human O O
monocytic O O
differentiation O O
. O O

This O O
regulation O O
of O O
apoptosis O O
is O O
linked O O
to O O
Vpr O O
suppression O O
of O O
NF-kappa O O
B O O
activity O O
via O O
the O O
induction O O
of O O
I O O
kappa O O
B O O
, O O
an O O
inhibitor O O
of O O
NF-kappa O O
B O O
. O O

In O O
RAW264.7 O O
cells O O
, O O
the O O
binding O O
was O O
constitutive O O
, O O
however O O
, O O
in O O
bone O O
marrow-derived O O
macrophages O O
binding O O
activity O O
was O O
shown O O
to O O
be O O
interferon-gamma O O
inducible O O
. O O

Furthermore O O
, O O
the O O
substitution O O
of O O
this O O
GATA O O
binding O O
site O O
by O O
a O O
canonical O O
TFIID O O
binding O O
site O O
suppresses O O
the O O
promoter O O
activity O O
. O O

If O O
we O O
measure O O
purifying O O
selection O O
for O O
amino O O
acid O O
sequences O O
by O O
the O O
ratio O O
of O O
nonsynonymous O O
to O O
synonymous O O
substitution O O
rates O O
( O O
dN/dS O O
) O O
, O O
a O O
protein O O
with O O
a O O
stop-codon-encoded O O
amino O O
acid O O
will O O
indicate O O
the O O
sign O O
of O O
selection O O
, O O
while O O
CNS O O
will O O
not B-Negation B-Negation
. O O

Alpha-lipoic O O
acid O O
is O O
a O O
potent O O
inhibitor O O
of O O
NF-kappa O O
B O O
activation O O
in O O
human O O
T O O
cells O O
. O O

Moreover O O
, O O
the O O
NF-kappa O O
B O O
inhibitors O O
blocked O O
SP-A-dependent O O
increases O O
in O O
tumor O O
necrosis O O
factor-alpha O O
mRNA O O
levels O O
. O O

Alpha-tocopherol O O
treatment O O
of O O
the O O
mice O O
given O O
the O O
CCl4 O O
also O O
reduced O O
the O O
NF-kappa O O
B O O
binding O O
to O O
levels O O
approaching O O
those O O
found O O
in O O
normal O O
mice O O
. O O

NF-AT O O
DNA O O
binding O O
can O O
be O O
reconstituted O O
in O O
vitro O O
using O O
semi-purified O O
AP1 O O
proteins O O
mixed O O
with O O
cytosol O O
from O O
T O O
lymphocytes O O
. O O

Thapsigargin O O
( O O
TG O O
) O O
, O O
an O O
inhibitor O O
of O O
Ca O O
( O O
2+ O O
) O O
-ATPase O O
, O O
depletes O O
intracellular O O
Ca2+ O O
stores O O
and O O
induces O O
a O O
sustained O O
Ca2+ O O
influx O O
without B-Negation B-Negation
altering I-Negation I-Negation
phosphatidyl I-Negation I-Negation
inositol I-Negation I-Negation
levels I-Negation I-Negation
. O O

In O O
contrast O O
, O O
expression O O
of O O
the O O
activation-dependent O O
cell O O
surface O O
markers O O
CD25 O O
and O O
CD69 O O
was O O
within O O
normal O O
limits O O
. O O

We O O
propose O O
that O O
a O O
generally O O
permissive O O
enhancer/promoter O O
interaction O O
is O O
of O O
evolutionary O O
benefit O O
for O O
higher O O
eukaryotes O O
: O O
by O O
enhancer O O
shuffling O O
, O O
genes O O
could O O
be O O
easily O O
brought O O
under O O
a O O
new O O
type O O
of O O
inducibility/cell O O
type O O
specificity O O
. O O

Together O O
, O O
these O O
results O O
suggest O O
that O O
E2F O O
consists O O
of O O
multiple O O
, O O
biochemically O O
distinct O O
DNA-binding O O
proteins O O
which O O
function O O
at O O
different O O
points O O
in O O
the O O
cell O O
cycle O O
. O O

As O O
a O O
step O O
toward O O
elucidating O O
the O O
pathophysiological O O
background O O
of O O
the O O
so-called O O
glucose O O
toxicity O O
to O O
pancreatic O O
beta O O
cells O O
, O O
we O O
induced O O
glycation O O
in O O
HIT-T15 O O
cells O O
using O O
a O O
sugar O O
with O O
strong O O
deoxidizing O O
activity O O
, O O
D-ribose O O
, O O
and O O
examined O O
the O O
effects O O
on O O
insulin O O
gene O O
transcription O O
. O O

When O O
compared O O
with O O
normal O O
cells O O
, O O
the O O
activation O O
of O O
NF-kappa O O
B O O
activity O O
in O O
SLE O O
patients O O
was O O
significantly O O
decreased O O
in O O
SLE O O
, O O
but O O
not B-Negation B-Negation
in I-Negation I-Negation
RA I-Negation I-Negation
, O O
patients O O
. O O

Architecture O O
of O O
the O O
predictor O O
and O O
likelihoods O O
of O O
the O O
modules O O

In O O
vitro O O
, O O
the O O
ICAM-1 O O
kappa O O
B O O
site O O
appeared O O
to O O
bind O O
RelA O O
and O O
c-Rel O O
homodimers O O
as O O
well O O
as O O
heterodimers O O
with O O
NF-kappa O O
B1 O O
, O O
but O O
weakly O O
NF-kappa O O
B1 O O
homodimers O O
. O O

We O O
also O O
demonstrate O O
that O O
two O O
other O O
sites O O
contribute O O
to O O
promoter O O
activity O O
in O O
B O O
cells O O
; O O
an O O
Sp1 O O
binding O O
site O O
adjacent O O
to O O
the O O
octamer O O
site O O
, O O
and O O
the O O
PU.1 O O
autoregulatory O O
site O O
. O O

One O O
type O O
, O O
EA/S O O
, O O
is O O
located O O
in O O
the O O
upstream O O
promoter O O
region O O
, O O
and O O
the O O
other O O
, O O
E O O
( O O
gre O O
) O O
, O O
is O O
located O O
in O O
a O O
tandem O O
repeat O O
with O O
enhancer O O
properties O O
. O O

Effects O O
of O O
oxidative O O
stress O O
on O O
stimulation-dependent O O
signal O O
transduction O O
, O O
leading O O
to O O
IL-2 O O
expression O O
, O O
were O O
studied O O
. O O

Consistent O O
with O O
this O O
interpretation O O
, O O
Dl O O
and O O
Ser O O
have O O
been O O
proposed O O
to O O
act O O
redundantly O O
in O O
the O O
sensory O O
bristle O O
lineage O O
where O O
they O O
are O O
co-expressed O O
( O O
[ O O
11 O O
] O O
; O O
note O O
, O O
however O O
, O O
that O O
results O O
from O O
another O O
study O O
have O O
indicated O O
a O O
non-redundant O O
function O O
for O O
Dl O O
in O O
the O O
bristle O O
lineage O O
[ O O
12 O O
] O O
) O O
. O O

Analysis O O
of O O
CAT O O
activity O O
revealed O O
that O O
cipro O O
enhanced O O
IL-2 O O
gene O O
induction O O
. O O

Induction O O
of O O
apoptosis O O
in O O
lymphocytes O O
, O O
which O O
may O O
account O O
for O O
the O O
therapeutic O O
effects O O
of O O
glucocorticoids O O
in O O
various O O
diseases O O
including O O
leukemia O O
, O O
depends O O
on O O
the O O
glucocorticoid O O
receptor O O
. O O

Although O O
Fas O O
upregulation O O
is O O
central O O
to O O
the O O
preservation O O
of O O
immunologic O O
tolerance O O
, O O
little O O
is O O
known O O
about O O
the O O
molecular O O
machinery O O
underlying O O
this O O
process O O
. O O

Here O O
we O O
demonstrate O O
that O O
Bcl-3 O O
can O O
aid O O
kappa O O
B O O
site-dependent O O
transcription O O
in O O
vivo O O
by O O
counteracting O O
the O O
inhibitory O O
effects O O
of O O
p50/NF-kappa O O
B O O
homodimers O O
. O O

In O O
EMSAs O O
, O O
this O O
substitution O O
results O O
in O O
a O O
markedly O O
enhanced O O
affinity O O
for O O
sequence-specific O O
complexes O O
exhibiting O O
an O O
AP-1 O O
specificity O O
. O O

Tolerance O O
to O O
lipopolysaccharide O O
involves O O
mobilization O O
of O O
nuclear O O
factor O O
kappa O O
B O O
with O O
predominance O O
of O O
p50 O O
homodimers O O
. O O

For O O
example O O
, O O
the O O
Expression-Orthology O O
predictor O O
achieves O O
a O O
ROC50 O O
AUC O O
of O O
0.024 O O
and O O
predicts O O
5670 O O
interactions O O
at O O
a O O
posterior O O
odds O O
ratio O O
greater O O
than O O
1 O O
whereas O O
the O O
Expression-Orthology-Combined O O
predictor O O
achieves O O
a O O
ROC50 O O
AUC O O
of O O
0.044 O O
and O O
predicts O O
over O O
15000 O O
interactions O O
at O O
a O O
posterior O O
odds O O
ratio O O
above O O
1 O O
. O O

In O O
order O O
to O O
eliminate O O
pseudogenes O O
and O O
sequencing O O
errors O O
, O O
conservation O O
of O O
iORFs O O
and O O
their O O
inframe O O
stop O O
codons O O
was O O
examined O O
. O O

Each O O
count O O
was O O
repeated O O
five O O
to O O
ten O O
times O O
and O O
the O O
standard O O
error O O
is O O
shown O O
. O O

Specifically O O
the O O
altered O O
specificity O O
TBP O O
( O O
TATA O O
box O O
binding O O
protein O O
) O O
assay O O
has O O
been O O
used O O
to O O
analyze O O
the O O
response O O
of O O
the O O
CIITA O O
activation O O
domain O O
to O O
mutations O O
in O O
TBP O O
known O O
to O O
disrupt O O
its O O
interaction O O
with O O
its O O
associated O O
general O O
factors O O
. O O

Increased O O
activity O O
of O O
various O O
proteases O O
is O O
observed O O
in O O
both O O
human O O
and O O
experimental O O
pancreatitis O O
; O O
however O O
, O O
the O O
information O O
on O O
the O O
effects O O
of O O
specific O O
protease O O
inhibitors O O
on O O
the O O
disease O O
is O O
limited O O
. O O

In O O
contrast O O
, O O
GATA-2 O O
is O O
strongly O O
expressed O O
in O O
both O O
most O O
primitive O O
and O O
committed O O
progenitors O O
cells O O
, O O
whereas O O
GATA-3 O O
is O O
mostly O O
detected O O
in O O
most O O
primitive O O
ones O O
. O O

High O O
levels O O
of O O
Ser O O
in O O
dorsal O O
cells O O
activate O O
N O O
in O O
trans O O
in O O
ventral O O
cells O O
and O O
suppress O O
N O O
activation O O
in O O
cis O O
in O O
dorsal O O
cells O O
, O O
whereas O O
Fringe O O
modifies O O
N O O
in O O
dorsal O O
cells O O
such O O
that O O
dorsal O O
cells O O
located O O
at O O
the O O
D-V O O
boundary O O
respond O O
to O O
Dl O O
. O O

The O O
down-regulation O O
of O O
RANTES O O
expression O O
by O O
glucocorticoids O O
in O O
T O O
cells O O
may O O
directly O O
contribute O O
to O O
the O O
efficacy O O
of O O
these O O
agents O O
in O O
suppressing O O
cellular O O
infiltration O O
and O O
to O O
their O O
anti-inflammatory O O
properties O O
. O O

We O O
now O O
find O O
that O O
mutating O O
two O O
tyrosines O O
to O O
an O O
isoleucine O O
at O O
the O O
carboxyl O O
end O O
of O O
the O O
cytoplasmic O O
tail O O
cripples O O
the O O
ability O O
of O O
EBV O O
to O O
cause O O
lymphoblastoid O O
cell O O
outgrowth O O
, O O
thereby O O
marking O O
a O O
second O O
transformation O O
effector O O
site O O
, O O
TES2 O O
. O O

AM580 O O
, O O
a O O
stable O O
benzoic O O
derivative O O
of O O
retinoic O O
acid O O
, O O
has O O
powerful O O
and O O
selective O O
cyto-differentiating O O
effects O O
on O O
acute O O
promyelocytic O O
leukemia O O
cells O O
. O O

An O O
enhancer-blocking O O
element O O
( O O
BEAD-1 O O
, O O
for O O
blocking O O
element O O
alpha/delta O O
1 O O
) O O
was O O
localized O O
to O O
a O O
2.0-kb O O
region O O
3 O O
' O O
of O O
TCR O O
delta O O
gene O O
segments O O
and O O
5 O O
' O O
of O O
TCR O O
alpha O O
joining O O
gene O O
segments O O
within O O
this O O
locus O O
. O O

Our O O
data O O
suggests O O
that O O
CoCl2-induced O O
cellular O O
signals O O
directing O O
increased O O
expression O O
of O O
VCAM-1 O O
in O O
HUVEC O O
involve O O
downstream O O
activation O O
of O O
MAP O O
kinase O O
and O O
NF-kappaB O O
, O O
while O O
the O O
phosphorylation O O
of O O
PECAM-1 O O
occurs O O
as O O
a O O
result O O
of O O
activation O O
of O O
PKC O O
. O O

CLEO O O
defines O O
a O O
binding O O
site O O
for O O
protein O O
( O O
s O O
) O O
whose O O
optimum O O
binding O O
is O O
stimulated O O
by O O
PMA O O
and O O
A23187 O O
. O O

Steady-state B-Negation B-Negation
levels I-Negation I-Negation
of I-Negation I-Negation
1,25 I-Negation I-Negation
( I-Negation I-Negation
OH I-Negation I-Negation
) I-Negation I-Negation
2D3 I-Negation I-Negation
receptor I-Negation I-Negation
RNA I-Negation I-Negation
were I-Negation I-Negation
not I-Negation I-Negation
affected I-Negation I-Negation
by I-Negation I-Negation
terminal I-Negation I-Negation
differentiation I-Negation I-Negation
of I-Negation I-Negation
HL-60 I-Negation I-Negation
toward I-Negation I-Negation
either I-Negation I-Negation
granulocytes I-Negation I-Negation
or I-Negation I-Negation
macrophages I-Negation I-Negation
. O O

Understanding O O
the O O
monocyte-specific O O
function O O
of O O
the O O
peri-kappa O O
B O O
factor O O
may O O
ultimately O O
provide O O
insight O O
into O O
the O O
different O O
role O O
monocytes O O
and O O
T O O
cells O O
play O O
in O O
HIV O O
pathogenesis O O
. O O

CED-9 O O
and O O
EGL-1 O O
belong O O
to O O
a O O
large O O
family O O
of O O
proteins O O
related O O
to O O
the O O
mammalian O O
anti-apoptotic O O
protein O O
Bcl-2 O O
. O O

Unexpectedly O O
, O O
the O O
CD8+ O O
T-cell O O
subpopulation O O
failed B-Negation B-Negation
to I-Negation I-Negation
respond I-Negation I-Negation
. O O

It O O
has O O
previously O O
been O O
shown O O
that O O
transcripts O O
of O O
the O O
E2A O O
gene O O
can O O
be O O
detected O O
in O O
a O O
wide O O
range O O
of O O
cell O O
types O O
. O O

Expression O O
of O O
all O O
mammalian O O
genes O O
of O O
the O O
MCM O O
family O O
is O O
induced O O
by O O
growth O O
stimulation O O
, O O
unlike O O
yeast O O
, O O
and O O
the O O
mRNA O O
levels O O
peak O O
at O O
G1/S O O
boundary O O
. O O

These O O
results O O
indicate O O
that O O
Cu2+ O O
inhibits O O
the O O
release O O
of O O
NF O O
kappa O O
B O O
by O O
blockade O O
of O O
a O O
signal O O
leading O O
to O O
the O O
phosphorylation O O
of O O
I O O
kappa O O
B O O
alpha O O
. O O

Consistent O O
with O O
this O O
possibility O O
, O O
D-mib O O
is O O
uniformly O O
distributed O O
in O O
imaginal O O
discs O O
, O O
whereas O O
Neur O O
is O O
specifically O O
detected O O
in O O
sensory O O
cells O O
[ O O
52 O O
] O O
. O O

Inorganic O O
lead O O
activates O O
NF-kappa O O
B O O
in O O
primary O O
human O O
CD4+ O O
T O O
lymphocytes O O
. O O

Transcription O O
factor O O
NF-kappa O O
B O O
must O O
be O O
released O O
from O O
cytoplasmic O O
inhibitory O O
molecules O O
( O O
I O O
kappa O O
Bs O O
) O O
in O O
order O O
to O O
move O O
to O O
the O O
nucleus O O
and O O
to O O
activate O O
its O O
target O O
genes O O
. O O

One O O
possible O O
explanation O O
for O O
the O O
developmental O O
delay O O
and O O
failure O O
to O O
pupariate O O
is O O
that O O
the O O
adgf-a O O
mutation O O
affects O O
the O O
production O O
or O O
release O O
of O O
ecdysteroid O O
hormones O O
from O O
the O O
major O O
endocrine O O
organ O O
of O O
the O O
Drosophila O O
larva—the O O
ring O O
gland O O
. O O

Stimulation O O
was O O
significantly O O
higher O O
when O O
lysates O O
were O O
heated O O
at O O
100 O O
degrees O O
C O O
for O O
5 O O
min O O
but O O
was O O
reduced O O
by O O
treatment O O
with O O
lysozyme O O
or O O
protease O O
. O O

The O O
lymphoid O O
src O O
kinase O O
pp56 O O
( O O
lck O O
) O O
has O O
been O O
shown O O
to O O
be O O
essential O O
for O O
the O O
induction O O
of O O
different O O
T O O
lymphocyte O O
responses O O
, O O
including O O
CD4-mediated O O
enhancement O O
of O O
Ag-induced O O
T O O
cell O O
activation O O
, O O
early O O
T O O
cell O O
differentiation O O
, O O
induction O O
of O O
IL-2 O O
production O O
, O O
and O O
cytotoxicity O O
. O O

However O O
, O O
the O O
molecular O O
mechanism O O
of O O
Rb O O
rescue O O
of O O
the O O
class O O
II O O
genes O O
is O O
unknown O O
. O O

More O O
interestingly O O
, O O
transfection O O
experiments O O
with O O
CRE-CAT O O
plasmide O O
show O O
that O O
PGE2 O O
activates O O
the O O
transcription O O
of O O
a O O
CRE-containing O O
promoter O O
. O O

Any O O
performance O O
comparison O O
must O O
be O O
interpreted O O
with O O
caution O O
, O O
since O O
the O O
results O O
are O O
highly O O
dependent O O
on O O
the O O
dataset O O
used O O
, O O
the O O
conditions O O
of O O
the O O
testing O O
and O O
the O O
metrics O O
used O O
for O O
evaluation O O
. O O

The O O
nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NF-AT O O
) O O
3 O O
is O O
an O O
inducible O O
DNA-binding O O
protein O O
that O O
is O O
essential O O
for O O
transcriptional O O
induction O O
of O O
the O O
IL-2 O O
gene O O
during O O
T O O
cell O O
activation O O
. O O

Transitive O O
module O O
hypothesis O O
. O O

The O O
inducible O O
, O O
T O O
cell-specific O O
enhancers O O
of O O
murine O O
and O O
human O O
Interleukin O O
2 O O
( O O
Il-2 O O
) O O
genes O O
contain O O
the O O
kB-like O O
sequence O O
GGGATTTCACC O O
as O O
an O O
essential O O
cis-acting O O
enhancer O O
motif O O
. O O

Mutation O O
of O O
this O O
motif O O
almost O O
completely O O
, O O
and O O
specifically O O
, O O
abolished O O
the O O
binding O O
of O O
two O O
low-mobility O O
complexes O O
and O O
led O O
to O O
a O O
95 O O
% O O
decrease O O
of O O
constitutive O O
transcriptional O O
activation O O
of O O
a O O
reporter O O
construct O O
IL-1beta O O
( O O
-170/+108 O O
) O O
. O O

Further O O
, O O
CTLA-4 O O
engagement O O
inhibited O O
progression O O
through O O
the O O
cell O O
cycle O O
by O O
inhibiting O O
the O O
production O O
of O O
cyclin O O
D3 O O
, O O
cyclin-dependent O O
kinase O O
( O O
cdk O O
) O O
4 O O
, O O
and O O
cdk6 O O
when O O
the O O
T O O
cells O O
were O O
stimulated O O
with O O
anti-CD3/CD28 O O
and O O
with O O
anti-CD3 O O
alone O O
. O O

The O O
ADGF-A O O
fragment O O
was O O
then O O
cloned O O
into O O
the O O
pCaSpeR-hs O O
) O O
vector O O
cut O O
by O O
NotI/XbaI O O
to O O
obtain O O
the O O
HS-ADGF-A O O
construct O O
. O O

If O O
an O O
organism O O
has O O
many O O
readthrough O O
proteins O O
, O O
proteins O O
from O O
the O O
organism O O
will O O
frequently O O
appear O O
in O O
the O O
273 O O
clusters O O
. O O

The O O
product O O
of O O
the O O
likelihood O O
ratios O O
of O O
all O O
Group O O
A O O
modules O O
considered O O
in O O
a O O
given O O
prediction O O
is O O
referred O O
to O O
as O O
the O O
preliminary O O
score O O
( O O
PS O O
) O O
and O O
can O O
be O O
calculated O O
for O O
all O O
human O O
protein O O
pairs O O
. O O

These O O
domains O O
are O O
related O O
to O O
essential O O
cellular O O
functions O O
, O O
suggesting O O
that O O
many O O
domain O O
interactions O O
were O O
already O O
present O O
in O O
the O O
last O O
universal O O
common O O
ancestor O O
. O O

Expression O O
of O O
the O O
MAP O O
kinase-specific O O
phosphatase O O
, O O
MKP-1 O O
, O O
which O O
blocks O O
ERK O O
activation O O
, O O
inhibited O O
IL-2 O O
promoter O O
and O O
NF-AT-driven O O
transcription O O
stimulated O O
by O O
a O O
calcium O O
ionophore O O
and O O
PMA O O
, O O
and O O
in O O
addition O O
, O O
MKP-1 O O
neutralized O O
the O O
transcriptional O O
enhancement O O
caused O O
by O O
active O O
Raf-1 O O
and O O
MEK1 O O
expression O O
. O O

One O O
hundred O O
milligram O O
of O O
hydrocortisone O O
was O O
injected O O
intravenously O O
into O O
4 O O
normal O O
subjects O O
. O O

Adding O O
purified O O
NF-kappa O O
B O O
protein O O
to O O
nuclear O O
extracts O O
from O O
cells O O
with O O
restricted O O
expression O O
overcomes O O
this O O
lack B-Negation B-Negation
of I-Negation I-Negation
binding I-Negation I-Negation
. O O

The O O
potential O O
clinical O O
usefulness O O
of O O
these O O
CL O O
assays O O
was O O
suggested O O
by O O
the O O
ability O O
of O O
both O O
monocytes O O
and O O
IFN-U937 O O
cells O O
to O O
respond O O
to O O
red O O
cells O O
, O O
platelets O O
or O O
granulocytes O O
sensitized O O
with O O
sera O O
from O O
pregnant O O
women O O
whose O O
babies O O
had O O
either O O
haemolytic O O
disease O O
of O O
the O O
newborn O O
( O O
HDN O O
) O O
, O O
alloimmune O O
thrombocytopenia O O
or O O
alloimmune O O
neutropenia O O
respectively O O
. O O

Then O O
, O O
2Δl O O
= O O
2 O O
( O O
lfree O O
– O O
lfix O O
) O O
approximately O O
follows O O
the O O
χ2 O O
distribution O O
with O O
one O O
degree O O
of O O
freedom O O
. O O

We O O
note O O
, O O
however O O
, O O
that O O
no B-Negation B-Negation
clear I-Negation I-Negation
defects I-Negation I-Negation
in I-Negation I-Negation
Dl I-Negation I-Negation
subcellular I-Negation I-Negation
localization I-Negation I-Negation
and/or I-Negation I-Negation
trafficking I-Negation I-Negation
were I-Negation I-Negation
observed I-Negation I-Negation
in I-Negation I-Negation
D-mib I-Negation I-Negation
mutant I-Negation I-Negation
cells I-Negation I-Negation
. O O

This O O
observation O O
supports O O
a O O
model O O
, O O
in O O
which O O
promoter O O
selectivity O O
reflects O O
the O O
selectively O O
increased O O
antiproliferative O O
effect O O
of O O
VD O O
analogues O O
. O O

Regulation O O
of O O
the O O
beta-globin O O
locus O O
. O O

In O O
this O O
study O O
we O O
present O O
a O O
deletion O O
analysis O O
of O O
the O O
N-terminal O O
region O O
of O O
Oct-2a O O
to O O
determine O O
the O O
minimal O O
repression O O
domain O O
. O O

The O O
Wilms O O
' O O
tumor O O
suppressor O O
gene O O
( O O
WT1 O O
) O O
was O O
previously O O
identified O O
as O O
being O O
imprinted O O
, O O
with O O
frequent O O
maternal O O
expression O O
in O O
human O O
placentae O O
and O O
fetal O O
brains O O
. O O

Motif O O
orientation O O

NK O O
cell O O
activity O O
did O O
not B-Negation B-Negation
increase I-Negation I-Negation
in I-Negation I-Negation
patients I-Negation I-Negation
with I-Negation I-Negation
HER-2/neu I-Negation I-Negation
overexpression I-Negation I-Negation
. O O

From O O
these O O
data O O
, O O
and O O
taking O O
into O O
consideration O O
their O O
state O O
of O O
differentiation O O
and O O
relative O O
ease O O
of O O
culture O O
, O O
U-937 O O
was O O
chosen O O
over O O
HL-60 O O
and O O
THP-1 O O
as O O
the O O
cell O O
line O O
we O O
further O O
characterized O O
. O O

As O O
a O O
likely O O
consequence O O
of O O
these O O
events O O
, O O
thrombin O O
activated O O
the O O
nuclear O O
factor O O
NF-kB O O
. O O

By O O
building O O
on O O
components O O
that O O
efficiently O O
search O O
for O O
motifs O O
without B-Negation B-Negation
user-defined I-Negation I-Negation
parameters I-Negation I-Negation
, O O
SCOPE O O
requires O O
as O O
input O O
only O O
a O O
set O O
of O O
upstream O O
sequences O O
and O O
a O O
species O O
designation O O
, O O
making O O
it O O
a O O
practical O O
choice O O
for O O
non-expert O O
users O O
. O O

We O O
now O O
report O O
that O O
vaccination O O
with O O
a O O
CTL O O
epitope O O
derived O O
from O O
the O O
human O O
adenovirus O O
type O O
5 O O
E1A-region O O
( O O
Ad5E1A234-243 O O
) O O
, O O
which O O
can O O
serve O O
as O O
a O O
target O O
for O O
tumor-eradicating O O
CTL O O
, O O
enhances O O
rather B-Negation O
than I-Negation O
inhibits I-Negation O
the O O
growth O O
of O O
Ad5E1A-expressing O O
tumors O O
. O O

A O O
Sig O O
value O O
of O O
0 O O
implies O O
that O O
one O O
motif O O
of O O
that O O
significance O O
is O O
expected O O
by O O
chance O O
. O O

In O O
vertebrates O O
, O O
five O O
distinct O O
DNA O O
binding O O
subunits O O
are O O
currently O O
known O O
which O O
might O O
extensively O O
heterodimerize O O
, O O
thereby O O
forming O O
complexes O O
with O O
distinct O O
transcriptional O O
activity O O
, O O
DNA O O
sequence O O
specificity O O
, O O
and O O
cell O O
type- O O
and O O
cell O O
stage- O O
specific O O
distribution O O
. O O

We O O
tested O O
the O O
ability O O
of O O
human O O
TSP O O
1-chloramphenicol O O
acetyltransferase O O
constructs O O
to O O
respond O O
to O O
serum O O
in O O
stably O O
transfected O O
NIH-3T3 O O
cells O O
. O O

Initiator O O
caspases O O
usually O O
have O O
long O O
pro-domains O O
, O O
while O O
effector O O
caspases O O
have O O
short O O
pro-domains O O
. O O

Subsequent O O
studies O O
have O O
revealed O O
that O O
( O O
i O O
) O O
cytoplasmic O O
RelA O O
is O O
stably O O
associated O O
not O O
only O O
with O O
I O O
kappa O O
B O O
alpha O O
but O O
also O O
with O O
other O O
ankyrin O O
motif-rich O O
proteins O O
including O O
the O O
products O O
of O O
the O O
NF-kappa O O
B2 O O
( O O
p100 O O
) O O
and O O
NF-kappa O O
B1 O O
( O O
p105 O O
) O O
genes O O
; O O
( O O
ii O O
) O O
in O O
contrast O O
to O O
RelA-I O O
kappa O O
B O O
alpha O O
, O O
RelA-p100 B-Negation B-Negation
cytoplasmic I-Negation I-Negation
complexes I-Negation I-Negation
are I-Negation I-Negation
not I-Negation I-Negation
dissociated I-Negation I-Negation
following I-Negation I-Negation
tumor I-Negation I-Negation
necrosis I-Negation I-Negation
factor I-Negation I-Negation
alpha I-Negation I-Negation
activation I-Negation I-Negation
; O O
( O O
iii O O
) O O
p100 O O
functions O O
as O O
a O O
potent O O
inhibitor O O
of O O
RelA-mediated O O
transcription O O
in O O
vivo O O
; O O
( O O
iv O O
) O O
the O O
interaction O O
of O O
RelA O O
and O O
p100 O O
involves O O
the O O
conserved O O
Rel O O
homology O O
domain O O
of O O
both O O
proteins O O
but O O
not B-Negation B-Negation
the I-Negation I-Negation
nuclear I-Negation I-Negation
localization I-Negation I-Negation
signal I-Negation I-Negation
of I-Negation I-Negation
RelA I-Negation I-Negation
, O O
which O O
is O O
required O O
for O O
I O O
kappa O O
B O O
alpha O O
binding O O
; O O
( O O
v O O
) O O
p100 O O
inhibition O O
of O O
RelA O O
function O O
requires O O
the O O
C-terminal O O
ankyrin O O
motif O O
domain O O
, O O
which O O
mediates O O
cytoplasmic O O
retention O O
of O O
RelA O O
; O O
and O O
( O O
vi O O
) O O
as O O
observed O O
with O O
I O O
kappa O O
B O O
alpha O O
, O O
nuclear O O
RelA O O
stimulates O O
p100 O O
mRNA O O
and O O
protein O O
expression O O
. O O

Deletional O O
analysis O O
indicated O O
that O O
five O O
Sp1 O O
sites O O
mediated O O
basal O O
expression O O
in O O
uninduced O O
cells O O
. O O

Second O O
, O O
a O O
glutathione-S-transferase O O
( O O
GST O O
) O O
affinity-binding O O
assay O O
showed O O
that O O
the O O
interaction O O
of O O
holo-TFIIA O O
with O O
GST-Tax O O
was O O
20-fold O O
higher O O
than O O
that O O
observed O O
with O O
either O O
the O O
GST-Tax O O
M32 O O
activation O O
mutant O O
or O O
the O O
GST O O
control O O
. O O

Apparently O O
normal O O
at O O
birth O O
, O O
I O O
kappa O O
B O O
alpha-/- O O
mice O O
exhibit O O
severe O O
runting O O
, O O
skin O O
defects O O
, O O
and O O
extensive O O
granulopoiesis O O
postnatally O O
, O O
typically O O
dying O O
by O O
8 O O
days O O
. O O

For O O
this O O
analysis O O
, O O
solely O O
the O O
properties O O
of O O
physically O O
interacting O O
proteins O O
is O O
of O O
interest O O
. O O

It O O
is O O
becoming O O
increasingly O O
apparent O O
that O O
the O O
chronic O O
gut O O
inflammation O O
observed O O
in O O
the O O
idiopathic O O
inflammatory O O
bowel O O
diseases O O
( O O
e.g. O O
ulcerative O O
colitis O O
, O O
Crohn O O
's O O
disease O O
) O O
is O O
associated O O
with O O
enhanced O O
production O O
of O O
leukocyte-derived O O
oxidants O O
. O O

The O O
Ribophorin O O
I-EVI1 O O
fusion O O
in O O
particular O O
may O O
be O O
a O O
common O O
occurrence O O
in O O
t O O
( O O
3 O O
; O O
3 O O
) O O
. O O

Interaction O O
of O O
HTLV-I O O
Tax O O
with O O
the O O
human O O
proteasome O O
: O O
implications O O
for O O
NF-kappa O O
B O O
induction O O
. O O

In O O
contrast O O
, O O
when O O
HSF2-beta O O
is O O
expressed O O
at O O
levels O O
exceeding O O
those O O
of O O
endogenous O O
HSF2-alpha O O
, O O
the O O
hemin-induced O O
DNA O O
binding O O
activity O O
and O O
transcription O O
of O O
heat O O
shock O O
genes O O
are O O
repressed O O
, O O
whereas O O
overexpression O O
of O O
HSF2-alpha O O
results O O
in O O
an O O
enhanced O O
hemin O O
response O O
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
the O O
phenotype O O
of O O
mouse O O
transgenic O O
lines O O
obtained O O
by O O
inducing O O
tal-1 O O
protein O O
expression O O
in O O
lymphoid O O
tissues O O
using O O
the O O
LCK O O
promoter O O
. O O

Reactive O O
oxygen O O
intermediates O O
as O O
apparently O O
widely O O
used O O
messengers O O
in O O
the O O
activation O O
of O O
the O O
NF-kappa O O
B O O
transcription O O
factor O O
and O O
HIV-1 O O
. O O

Viral O O
transcription O O
, O O
as O O
measured O O
using O O
LTR-CAT O O
assays O O
, O O
was O O
only O O
slightly O O
enhanced O O
in O O
the O O
HIV-protease O O
expressing O O
cells O O
, O O
while O O
secretion B-Negation B-Negation
of I-Negation I-Negation
IL-2 I-Negation I-Negation
and I-Negation I-Negation
expression I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
IL-2 I-Negation I-Negation
receptor I-Negation I-Negation
were I-Negation I-Negation
not I-Negation I-Negation
affected I-Negation I-Negation
. O O

Fibroblast O O
growth O O
factor-1 O O
( O O
FGF-1 O O
) O O
enhances O O
IL-2 O O
production O O
and O O
nuclear O O
translocation O O
of O O
NF-kappaB O O
in O O
FGF O O
receptor-bearing O O
Jurkat O O
T O O
cells O O
. O O

There O O
is O O
increasing O O
evidence O O
that O O
IFN-alpha O O
has O O
an O O
important O O
role O O
in O O
T-cell O O
biology O O
. O O

Implications O O
for O O
immunity O O
and O O
vaccine O O
design O O
. O O

However O O
, O O
stimulation O O
with O O
MBP O O
did O O
not B-Negation B-Negation
produce I-Negation I-Negation
an I-Negation I-Negation
increase I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
binding I-Negation I-Negation
activity I-Negation I-Negation
of I-Negation I-Negation
nuclear I-Negation I-Negation
factor I-Negation I-Negation
( I-Negation I-Negation
NF I-Negation I-Negation
) I-Negation I-Negation
-kappaB I-Negation I-Negation
or I-Negation I-Negation
activator I-Negation I-Negation
protein-1 I-Negation I-Negation
. O O

Nuclei O O
from O O
GATA-1- O O
mutant O O
embryonic O O
stem O O
cells O O
can O O
still O O
be O O
reprogrammed O O
to O O
express O O
their O O
globin O O
genes O O
in O O
erythroid O O
heterokaryons O O
, O O
indicating O O
that O O
de O O
novo O O
induction O O
of O O
GATA-1 O O
is O O
not O O
required O O
for O O
globin O O
gene O O
activation O O
following O O
cell O O
fusion O O
. O O

Mouse O O
interleukin-2 O O
receptor O O
alpha O O
gene O O
expression O O
. O O

The O O
field O O
of O O
motif O O
finding O O
is O O
saturated O O
with O O
a O O
large O O
number O O
of O O
algorithms O O
representing O O
myriad O O
search O O
strategies O O
, O O
objective O O
functions O O
and O O
motif O O
models O O
. O O

The O O
Drosophila O O
dosage O O
compensation O O
complex O O

Altogether O O
, O O
the O O
data O O
provide O O
the O O
evidence O O
that O O
both O O
pathways O O
complement O O
each O O
other O O
in O O
regulating O O
gene O O
expression O O
and O O
, O O
conversely O O
, O O
downregulate O O
the O O
TcR O O
transduction O O
mechanisms O O
. O O

We O O
propose O O
from O O
these O O
results O O
that O O
the O O
source O O
of O O
the O O
fused O O
fragment O O
encompassing O O
both O O
ends O O
of O O
EBV O O
DNA O O
is O O
a O O
concatenated O O
linear O O
EBV O O
DNA O O
molecule O O
, O O
and O O
that O O
such O O
a O O
concatenated O O
molecule O O
most O O
likely O O
represents O O
a O O
replicative O O
form O O
of O O
EBV O O
DNA O O
in O O
productively O O
infected O O
cells O O
. O O

Consistent O O
with O O
its O O
Rel/NF-kappaB-dependent O O
induction O O
, O O
Jagged1 O O
was O O
found O O
to O O
be O O
highly O O
expressed O O
in O O
splenic O O
B O O
cells O O
where O O
c-Rel O O
is O O
expressed O O
constitutively O O
. O O

Interestingly O O
, O O
it O O
was O O
shown O O
that O O
NF-kappa O O
B-mediated O O
gene O O
transcription O O
, O O
both O O
in O O
the O O
context O O
of O O
the O O
IL-6 O O
promoter O O
as O O
well O O
as O O
on O O
its O O
own O O
, O O
was O O
dependent O O
on O O
both O O
serine O O
kinase O O
activity O O
and O O
interaction O O
with O O
c-Jun O O
protein O O
. O O

These O O
results O O
indicate O O
that O O
the O O
regulation O O
of O O
NF-kappa O O
B O O
activation O O
during O O
T O O
cell O O
activation O O
by O O
TcR/CD3 O O
signals O O
is O O
biphasic O O
: O O
TcR/CD3 O O
triggers O O
its O O
immediate O O
translocation O O
, O O
which O O
is O O
transient O O
if O O
no O B-Negation
TNF-alpha O I-Negation
is O I-Negation
present O I-Negation
. O O

Because O O
monocytes O O
play O O
a O O
pivotal O O
role O O
in O O
the O O
pathophysiology O O
of O O
intravascular O O
coagulation O O
activation O O
through O O
their O O
ability O O
to O O
synthesize O O
tissue O O
factor O O
( O O
TF O O
) O O
, O O
we O O
asked O O
( O O
1 O O
) O O
whether O O
monocyte O O
TF O O
activation O O
occurs O O
in O O
cardiac O O
transplant O O
recipients O O
and O O
( O O
2 O O
) O O
whether O O
monocyte O O
TF O O
expression O O
is O O
affected O O
by O O
treatment O O
with O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
. O O

After O O
tyrosine O O
phosphorylation O O
by O O
src O O
and O O
possibly O O
syk O O
protein O O
tyrosine O O
kinases O O
SIT O O
recruits O O
the O O
SH2 O O
domain-containing O O
tyrosine O O
phosphatase O O
SHP2 O O
via O O
an O O
immunoreceptor O O
tyrosine-based O O
inhibition O O
motif O O
. O O

The O O
Disorder O O
module O O
offers O O
the O O
advantage O O
of O O
increasing O O
the O O
coverage O O
of O O
the O O
prediction O O
as O O
a O O
disorder O O
score O O
is O O
calculated O O
for O O
all O O
protein O O
pairs O O
. O O

The O O
algorithm O O
was O O
constructed O O
with O O
the O O
aim O O
of O O
identifying O O
segments O O
in O O
Ag O O
which O O
are O O
resistant O O
to O O
proteolytic O O
degradation O O
by O O
the O O
enzymes O O
cathepsin O O
B O O
, O O
L O O
, O O
and O O
D O O
. O O

The O O
CTL O O
specifically O O
recognized O O
the O O
succinimide-containing O O
peptide O O
showing O O
only O O
weak O O
cross-reactivity O O
at O O
high O O
concentrations O O
of O O
the O O
parent O O
peptide O O
containing O O
unmodified O O
asparagine O O
. O O

This O O
is O O
the O O
third O O
patient O O
with O O
severe O O
FUra O O
toxicity O O
secondary O O
to O O
an O O
alteration O O
in O O
pyrimidine O O
catabolism O O
and O O
the O O
second O O
from O O
our O O
clinic O O
population O O
suggesting O O
that O O
the O O
frequency O O
of O O
this O O
genetic O O
defect O O
may O O
be O O
greater O O
than O O
previously O O
thought O O
. O O

θS O O
The O O
number O O
of O O
observed O O
interactions O O
in O O
species O O
S O O
that O O
contain O O
an O O
iPfam O O
domain O O
pair O O

We O O
observed O O
no B-Negation B-Negation
change I-Negation I-Negation
in I-Negation I-Negation
membrane I-Negation I-Negation
structural I-Negation I-Negation
order I-Negation I-Negation
with I-Negation I-Negation
RU I-Negation I-Negation
486 I-Negation I-Negation
up I-Negation I-Negation
to I-Negation I-Negation
a I-Negation I-Negation
concentration I-Negation I-Negation
of I-Negation I-Negation
10 I-Negation I-Negation
( I-Negation I-Negation
-4 I-Negation I-Negation
) I-Negation I-Negation
M I-Negation I-Negation
. O O

Consequently O O
, O O
cytosolic O O
activation O O
, O O
nuclear O O
translocation O O
and O O
DNA-binding O O
of O O
nuclear O O
factor-kappaB O O
were O O
decreased O O
. O O

Using O O
this O O
assay O O
system O O
, O O
we O O
have O O
evaluated O O
the O O
contributions O O
of O O
ligand O O
binding O O
and O O
heat O O
activation O O
to O O
DNA O O
binding O O
by O O
these O O
glucocorticoid O O
receptors O O
. O O

In O O
vivo O O
genomic O O
DMS O O
footprinting O O
revealed O O
upstream O O
of O O
the O O
major O O
transcription O O
initiation O O
sites O O
, O O
the O O
presence O O
of O O
at O O
least O O
three O O
protein O O
binding O O
sites O O
, O O
two O O
of O O
which O O
were O O
constitutively O O
occupied O O
. O O

ADGF-A O O
Genetically O O
Interacts O O
with O O
Toll O O
Signaling O O
Pathway O O

SHP2-interacting O O
transmembrane O O
adaptor O O
protein O O
( O O
SIT O O
) O O
, O O
a O O
novel O O
disulfide-linked O O
dimer O O
regulating O O
human O O
T O O
cell O O
activation O O
. O O

Thus O O
, O O
motif O O
finders O O
designed O O
for O O
one O O
class O O
of O O
motifs O O
will O O
win O O
on O O
regulons O O
containing O O
those O O
motifs O O
, O O
but O O
will O O
perform O O
poorly O O
on O O
other O O
regulons O O
, O O
while O O
more O O
general O O
motif O O
finders O O
will O O
tend O O
to O O
have O O
more O O
consistently O O
mediocre O O
performance O O
. O O

We O O
have O O
recently O O
identified O O
and O O
cloned O O
a O O
human O O
transcription O O
factor O O
, O O
TCF-1 O O
, O O
that O O
binds O O
to O O
a O O
functional O O
element O O
in O O
the O O
T O O
lymphocyte-specific O O
enhancer O O
of O O
CD3-epsilon O O
. O O

Similar O O
selective O O
effects O O
on O O
NF-kappaB O O
transcription O O
are O O
seen O O
with O O
the O O
unrelated O O
antioxidants O O
, O O
N-acetylcysteine O O
( O O
NAC O O
) O O
and O O
vitamin O O
C O O
. O O

Conclusion O O

A O O
wide O O
range O O
of O O
databases O O
were O O
used O O
to O O
cover O O
as O O
many O O
distinct O O
experimental O O
data O O
sets O O
as O O
possible O O
. O O

This O O
is O O
in O O
contrast O O
to O O
the O O
infection O O
in O O
B O O
cells O O
where O O
the O O
genome O O
can O O
circularize O O
within O O
24 O O
hr O O
of O O
infection O O
. O O

It O O
has O O
been O O
shown O O
to O O
possess O O
anti-inflammatory O O
activity O O
in O O
a O O
variety O O
of O O
animal O O
models O O
and O O
more O O
recently O O
to O O
inhibit O O
IL-2 O O
induced O O
signal O O
transduction O O
. O O

The O O
main O O
feature O O
of O O
cellular O O
senescence O O
in O O
vitro O O
is O O
cessation O O
of O O
cell O O
proliferation O O
. O O

The O O
true O O
positive O O
rate O O
( O O
TPR O O
) O O
versus O O
false O O
positive O O
rate O O
( O O
FPR O O
) O O
is O O
plotted O O
for O O
different O O
values O O
of O O
the O O
posterior O O
odds O O
ratio O O
estimated O O
for O O
the O O
dataset O O
by O O
five-fold O O
cross-validation O O
. O O

Regulation O O
of O O
the O O
transcription O O
factor O O
NF-kappaB O O
involves O O
proteasome-mediated O O
processing O O
of O O
the O O
NF-kappaB1 O O
p105 O O
precursor O O
protein O O
, O O
which O O
generates O O
the O O
p50 O O
subunit O O
of O O
NF-kappaB O O
. O O

For O O
a O O
detailed O O
calculation O O
of O O
the O O
likelihoods O O
see O O
Additional O O
File O O
4 O O
. O O

In O O
contrast O O
, O O
a O O
mutant O O
of O O
Tax O O
that O O
selectively O O
fails O B-Negation
to O I-Negation
activate O I-Negation
nuclear O I-Negation
NF-kappa O I-Negation
B O I-Negation
expression O I-Negation
does O O
not B-Negation B-Negation
associate I-Negation I-Negation
with I-Negation I-Negation
p100 I-Negation I-Negation
. O O

CD2 O O
, O O
but O O
not B-Negation B-Negation
CD3 I-Negation I-Negation
, O O
cross-linking O O
increased O O
cAMP O O
detected O O
by O O
competitive O O
enzyme-linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
approximately O O
fourfold O O
. O O

Regulation O O
of O O
NF-kappa O O
B O O
, O O
AP-1 O O
, O O
NFAT O O
, O O
and O O
STAT1 O O
nuclear O O
import O O
in O O
T O O
lymphocytes O O
by O O
noninvasive O O
delivery O O
of O O
peptide O O
carrying O O
the O O
nuclear O O
localization O O
sequence O O
of O O
NF-kappa O O
B O O
p50 O O
. O O

When O O
mouse O O
MPC11 O O
plasmacytoma O O
cells O O
, O O
in O O
which O O
the O O
IgH O O
3 O O
' O O
enhancer O O
is O O
active O O
, O O
are O O
fused O O
with O O
fibroblasts O O
, O O
Ig O O
expression O O
is O O
extinguished O O
at O O
the O O
level O O
of O O
transcription O O
. O O

These O O
data O O
support O O
the O O
view O O
of O O
an O O
impaired O O
ligand-induced O O
plasticity O O
of O O
glucocorticoid O O
receptor O O
regulation O O
rather O O
than O O
the O O
hypothesis O O
of O O
decreased O O
glucocorticoid O O
receptor O O
numbers O O
during O O
depression O O
. O O

All O O
other O O
molecules O O
studied O O
were O O
found O O
to O O
be O O
expressed O O
at O O
this O O
stage O O
of O O
differentiation O O
. O O

On O O
the O O
other O O
hand O O
, O O
interleukin O O
2 O O
( O O
IL-2 O O
) O O
-induced O O
signals O O
are O O
blocked O O
by O O
rapamycin O O
but O O
not B-Negation B-Negation
by I-Negation I-Negation
FK506 I-Negation I-Negation
. O O

Invariably O O
, O O
the O O
BCL-6 O O
coding O O
region O O
is O O
intact O O
, O O
but O O
its O O
5 O O
' O O
untranslated O O
region O O
is O O
replaced O O
with O O
sequences O O
from O O
the O O
translocation O O
partner O O
. O O

We O O
estimated O O
false O O
positive O O
rates O O
for O O
each O O
of O O
the O O
datasets O O
by O O
comparing O O
them O O
two O O
by O O
two O O
to O O
one O O
of O O
the O O
reference O O
datasets O O
, O O
thus O O
generating O O
4 O O
to O O
6 O O
different O O
estimates O O
of O O
false O O
positive O O
rates O O
for O O
each O O
computational O O
dataset O O
, O O
as O O
shown O O
in O O
Figure O O
6A O O
( B-Negation O
the I-Negation O
two I-Negation O
Lehner I-Negation O
datasets I-Negation O
were I-Negation O
not I-Negation B-Negation
compared I-Negation I-Negation
to I-Negation I-Negation
each I-Negation I-Negation
other I-Negation I-Negation
, O O
which O O
is O O
why O O
they O O
have O O
fewer O O
FPR O O
estimates O O
) O O
. O O

Further O O
evidence O O
that O O
at O O
least O O
roX2 O O
RNA O O
is O O
an O O
integral O O
part O O
of O O
the O O
DCC O O
comes O O
from O O
independent O O
immunoprecipitation O O
experiments O O
from O O
all O O
three O O
groups O O
[ O O
1,2,3 O O
] O O
using O O
extracts O O
from O O
Drosophila O O
S2 O O
cells O O
that O O
express O O
all O O
the O O
MSLs O O
and O O
roX2 O O
RNA O O
. O O

Coexpression O O
of O O
both O O
proteins O O
activated O O
transcription O O
of O O
the O O
-137 O O
to O O
-64 O O
element O O
in O O
COS-7 O O
cells O O
. O O

Finally O O
, O O
both O O
PU.1 O O
and O O
Spi-B O O
function O O
as O O
transcriptional O O
activators O O
of O O
the O O
immunoglobulin O O
light-chain O O
enhancer O O
E O O
lambda O O
2.4 O O
when O O
coexpressed O O
with O O
Pip O O
( O O
PU.1-interaction O O
partner O O
) O O
in O O
NIH-3T3 O O
cells O O
. O O

Using O O
information O O
from O O
the O O
genome O O
project O O
, O O
C. O O
elegans O O
was O O
shown O O
to O O
contain O O
several O O
potential O O
caspases O O
in O O
addition O O
to O O
CED-3 O O
, O O
but O O
none B-Negation B-Negation
of I-Negation I-Negation
these I-Negation I-Negation
has I-Negation I-Negation
been I-Negation I-Negation
shown I-Negation I-Negation
to I-Negation I-Negation
function I-Negation I-Negation
in I-Negation I-Negation
programmed I-Negation I-Negation
cell I-Negation I-Negation
death I-Negation I-Negation
[ O O
9 O O
] O O
. O O

Mycobacterium O O
tuberculosis O O
mannose-capped O O
lipoarabinomannan O O
can O O
induce O O
NF-kappaB-dependent O O
activation O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
long O O
terminal O O
repeat O O
in O O
T O O
cells O O
. O O

The O O
signaling O O
events O O
that O O
link O O
FGF O O
receptor-1 O O
engagement O O
and O O
NF-kappaB O O
activation O O
in O O
Jurkat O O
are O O
probably O O
distinct O O
from O O
the O O
CD28 O O
costimulation O O
pathway O O
, O O
since O O
FGF-1-induced O O
Rel/kappaB O O
binding O O
proteins O O
do O O
not B-Negation B-Negation
contain I-Negation I-Negation
significant I-Negation I-Negation
levels I-Negation I-Negation
of I-Negation I-Negation
c-Rel I-Negation I-Negation
and O O
are O O
not B-Negation B-Negation
identical I-Negation I-Negation
with I-Negation I-Negation
the I-Negation I-Negation
CD28 I-Negation I-Negation
response I-Negation I-Negation
complex I-Negation I-Negation
. O O

These O O
results O O
show O O
that O O
, O O
in O O
the O O
vast O O
majority O O
of O O
patients O O
presented O O
here O O
, O O
the O O
failure B-Negation B-Negation
to I-Negation I-Negation
detect I-Negation I-Negation
loss I-Negation I-Negation
of I-Negation I-Negation
heterozygosity I-Negation I-Negation
can I-Negation I-Negation
not I-Negation I-Negation
be I-Negation I-Negation
attributed I-Negation I-Negation
to I-Negation I-Negation
the I-Negation I-Negation
presence I-Negation I-Negation
of I-Negation I-Negation
normal I-Negation I-Negation
polyclonal I-Negation I-Negation
granulocytes I-Negation I-Negation
. O O

B O O
lymphocytes O O
and O O
macrophages O O
express O O
closely O O
related O O
immunoglobulin O O
G O O
( O O
IgG O O
) O O
Fc O O
receptors O O
( O O
Fc O O
gamma O O
RII O O
) O O
that O O
differ O O
only O O
in O O
the O O
structures O O
of O O
their O O
cytoplasmic O O
domains O O
. O O

The O O
posttranscriptional O O
effect O O
of O O
antioxidants O O
on O O
TF O O
expression O O
data O O
suggests O O
a O O
novel O O
mechanism O O
whereby O O
these O O
agents O O
might O O
modulate O O
monocyte/macrophage O O
activation O O
. O O

Specific O O
antibodies O O
directed O O
against O O
the O O
individual O O
STAT O O
proteins O O
were O O
used O O
in O O
supershift O O
experiments O O
. O O

Since O O
this O O
is O O
the O O
first O O
report O O
on O O
IL-10 O O
induced O O
signal O O
transduction O O
, O O
these O O
data O O
may O O
help O O
to O O
identify O O
the O O
intracellular O O
mechanisms O O
by O O
which O O
IL-10 O O
stimulates O O
human O O
B-cells O O
. O O

These O O
bHLH O O
antagonists O O
are O O
induced O O
during O O
a O O
mitogenic O O
signalling O O
response O O
, O O
and O O
they O O
function O O
by O O
sequestering O O
their O O
bHLH O O
targets O O
in O O
inactive O O
heterodimers O O
that O O
are B-Negation O
unable I-Negation B-Negation
to I-Negation I-Negation
bind I-Negation I-Negation
to I-Negation I-Negation
specific I-Negation I-Negation
gene I-Negation I-Negation
regulatory I-Negation I-Negation
( I-Negation I-Negation
E I-Negation I-Negation
box I-Negation I-Negation
) I-Negation I-Negation
sequences I-Negation I-Negation
. O O

In O O
the O O
present O O
study O O
, O O
we O O
have O O
characterized O O
the O O
transcriptional O O
induction O O
of O O
p40 O O
by O O
CD40 O O
ligation O O
in O O
a O O
human O O
B O O
lymphoblastoid O O
cell O O
line O O
, O O
Daudi O O
, O O
and O O
a O O
human O O
acute O O
monocytic O O
leukemia O O
cell O O
line O O
, O O
THP-1 O O
. O O

DeltaSpi-B O O
product O O
was O O
not B-Negation B-Negation
able I-Negation I-Negation
to I-Negation I-Negation
bind I-Negation I-Negation
DNA I-Negation I-Negation
and O O
was O O
recovered O O
in O O
cytoplasmic O O
cellular O O
extracts O O
. O O

To O O
elucidate O O
the O O
role O O
of O O
retinoic O O
acid O O
( O O
RA O O
) O O
in O O
anti-CD40 O O
+ O O
interleukin-4 O O
( O O
IL-4 O O
) O O
-mediated O O
B-cell O O
activation O O
, O O
the O O
effect O O
of O O
10 O O
( O O
-12 O O
) O O
to O O
10 O O
( O O
-6 O O
) O O
mol/L O O
RA O O
was O O
studied O O
in O O
anti-CD40 O O
( O O
1 O O
microgram/mL O O
) O O
+ O O
IL-4 O O
( O O
5 O O
ng/mL O O
) O O
-mediated O O
proliferation O O
and O O
Ig O O
synthesis O O
by O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
and O O
B O O
cells O O
in O O
healthy O O
donors O O
. O O

TINUR O O
belongs O O
to O O
the O O
NGFI-B/nur77 O O
family O O
of O O
the O O
steroid O O
receptor O O
superfamily O O
and O O
is O O
an O O
orphan O O
receptor O O
. O O

We O O
provide O O
all O O
our O O
predictions O O
ranked O O
according O O
to O O
the O O
posterior O O
odds O O
ratio O O
of O O
interaction O O
in O O
Additional O O
File O O
3 O O
. O O

To O O
determine O O
whether O O
enhancer O O
elements O O
in O O
addition O O
to O O
the O O
highly O O
conserved O O
octamer O O
( O O
OCTA O O
) O O
-nucleotide O O
motif O O
are O O
important O O
for O O
lymphoid-specific O O
expression O O
of O O
the O O
immunoglobulin O O
heavy-chain O O
( O O
IgH O O
) O O
gene O O
, O O
we O O
have O O
investigated O O
the O O
effect O O
of O O
mutating O O
the O O
binding O O
site O O
for O O
a O O
putative O O
additional O O
lymphoid-specific O O
transcription O O
factor O O
, O O
designated O O
NF-microB O O
, O O
in O O
the O O
murine O O
IgH O O
enhancer O O
. O O

A O O
novel O O
DNA O O
sequence O O
element O O
termed O O
the O O
J O O
element O O
involved O O
in O O
the O O
regulated O O
expression O O
of O O
class O O
II O O
major O O
histocompatibility O O
complex O O
genes O O
was O O
recently O O
described O O
. O O

Constitutively O O
active O O
MAPKK-1 O O
fully O O
activates O O
ERK-2 O O
and O O
the O O
transcription O O
factor O O
Elk-1 O O
, O O
but O O
does O O
not B-Negation B-Negation
substitute I-Negation I-Negation
for I-Negation I-Negation
activated I-Negation I-Negation
p21ras I-Negation I-Negation
and I-Negation I-Negation
synergize I-Negation I-Negation
with I-Negation I-Negation
calcium/calcineurin I-Negation I-Negation
signals I-Negation I-Negation
to I-Negation I-Negation
induce I-Negation I-Negation
NFAT I-Negation I-Negation
. O O

Constitutive O O
expression O O
c-fos O O
, O O
c-jun O O
, O O
and O O
NF O O
kappa O O
B O O
mRNA O O
is O O
in O O
nucleated O O
fetal O O
blood O O
cells O O
and O O
up-regulation O O
of O O
c-fos O O
and O O
c-jun O O
with O O
anti-CD3 O O
stimulation O O
. O O

The O O
low O O
confidence O O
bins O O
were O O
filled O O
by O O
human O O
protein O O
pairs O O
that O O
have O O
interacting O O
orthologs O O
according O O
to O O
InParanoid O O
but O O
neither B-Negation B-Negation
achieves I-Negation I-Negation
a I-Negation I-Negation
score I-Negation I-Negation
of I-Negation I-Negation
1 I-Negation I-Negation
( O O
i.e. O O
neither O B-Negation
is O I-Negation
the O I-Negation
best O I-Negation
match O I-Negation
for O I-Negation
the O I-Negation
two O I-Negation
human O I-Negation
proteins O I-Negation
under O I-Negation
consideration O I-Negation
) O I-Negation
. O O

Because O O
erythrocytes O O
are O O
anucleated O O
, O O
these O O
results O O
are O O
discussed O O
as O O
evidence O O
for O O
biochemical O O
changes O O
by O O
TCDD O O
without B-Negation B-Negation
requiring I-Negation I-Negation
the I-Negation I-Negation
activation I-Negation I-Negation
of I-Negation I-Negation
gene I-Negation I-Negation
products I-Negation I-Negation
. O O

In O O
contrast O O
, O O
Egr-1 O O
expression O O
is O O
abrogated O O
in O O
group O O
I O O
Burkitt O O
tumor O O
cells O O
, O O
irrespective O O
of O O
the O O
EBV O O
genome O O
carrying O O
status O O
. O O

Life-table O O
analysis O O
( O O
Mantel-Cox O O
) O O
was O O
used O O
to O O
assess O O
the O O
probability O O
of O O
disease-free O O
survival O O
( O O
DFS O O
) O O
and O O
overall O O
survival O O
( O O
OS O O
) O O
. O O

This O O
loss O O
of O O
activity O O
was O O
shown O O
to O O
correlate O O
with O O
deletion O O
of O O
two O O
CCAAT O O
boxes O O
, O O
a O O
proximal O O
CCAAT O O
box O O
located O O
at O O
bp O O
-61 O O
to O O
-65 O O
and O O
a O O
distal O O
CCAAT O O
box O O
located O O
at O O
bp O O
-253 O O
to O O
-257 O O
, O O
upstream O O
of O O
Cp O O
. O O

Positive O O
and O O
negative O O
regulation O O
of O O
IL-2 O O
gene O O
expression O O
: O O
role O O
of O O
multiple O O
regulatory O O
sites O O
. O O

We O O
then O O
investigated O O
if O O
HCMV O O
binding O O
also O O
resulted O O
in O O
the O O
translation O O
and O O
secretion O O
of O O
cytokines O O
. O O

In O O
this O O
report O O
, O O
we O O
demonstrate O O
that O O
the O O
PB1 O O
element O O
alone O O
confers O O
inducibility O O
on O O
a O O
heterologous O O
promoter O O
following O O
transfection O O
into O O
human O O
Jurkat O O
T O O
cells O O
. O O

We O O
have O O
previously O O
shown O O
that O O
c-Jun O O
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
rat O O
prolactin O O
( O O
rPRL O O
) O O
promoter O O
activity O O
induced O O
by O O
either O O
oncogenic O O
Ras O O
or O O
phorbol O O
esters O O
. O O

A O O
TATA-like O O
motif O O
was O O
identified O O
immediately O O
upstream O O
of O O
the O O
transcriptional O O
start O O
site O O
. O O

Tax1 O O
, O O
a O O
transcriptional O O
trans-activator O O
of O O
the O O
Human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
, O O
induces O O
the O O
expression O O
of O O
many O O
cellular O O
genes O O
through O O
interaction O O
with O O
at O O
least O O
three O O
distinct O O
cellular O O
transcription O O
factors O O
; O O
CREB/ATF O O
, O O
NF-kappaB O O
, O O
and O O
SRF O O
. O O

In O O
this O O
study O O
, O O
we O O
characterize O O
an O O
essential O O
upstream O O
IL-2 O O
response O O
element O O
that O O
contains O O
both O O
consensus O O
and O O
non-consensus O O
GAS O O
motifs O O
, O O
two O O
putative O O
Ets O O
binding O O
sites O O
( O O
EBS O O
) O O
, O O
one O O
of O O
which O O
overlaps O O
the O O
consensus O O
GAS O O
motif O O
, O O
and O O
a O O
GATA O O
motif O O
, O O
which O O
overlaps O O
the O O
non-consensus O O
GAS O O
motif O O
. O O

To O O
enhance O O
sensitivity O O
of O O
the O O
filters O O
, O O
the O O
whole O O
length O O
of O O
an O O
iORF O O
was O O
used O O
as O O
a O O
BLAST O O
query O O
instead B-Negation O
of I-Negation O
the I-Negation O
partial I-Negation O
sequence I-Negation O
, O O
and O O
the O O
size O O
of O O
the O O
BLAST O O
database O O
was O O
increased O O
from O O
the O O
191 O O
nonredundant O O
genomes O O
to O O
the O O
328 O O
complete O O
genomes O O
in O O
GenomeNet O O
and O O
246 O O
draft O O
genome O O
sequences O O
downloaded O O
from O O
GenBank O O
in O O
May O O
2006 O O
. O O

Glucocorticoid O O
receptors O O
in O O
normal O O
leukocytes O O
: O O
effects O O
of O O
age O O
, O O
gender O O
, O O
season O O
, O O
and O O
plasma O O
cortisol O O
concentrations O O
. O O

Subsequently O O
, O O
I O O
kappa O O
B-alpha O O
mRNA O O
and O O
protein O O
levels O O
are O O
quickly O O
induced O O
by O O
the O O
activated O O
NF-kappa O O
B O O
. O O

Interleukin O O
10 O O
induced O O
c-fos O O
expression O O
in O O
human O O
B O O
cells O O
by O O
activation O O
of O O
divergent O O
protein O O
kinases O O
. O O

The O O
fraction O O
of O O
experimental O O
interactions O O
that O O
contain O O
at O O
least O O
one O O
iPfam O O
domain O O
pair O O
is O O
referred O O
to O O
as O O
the O O
iPfam O O
coverage O O
. O O

Further O O
studies O O
will O O
have O O
to O O
prove O O
if O O
Urapidil O O
is O O
suited O O
for O O
prepartal O O
treatment O O
of O O
PIH O O
as O O
well O O
. O O

The O O
Fc O O
epsilon O O
RI-gamma O O
chains O O
are O O
expressed O O
in O O
a O O
variety O O
of O O
hematopoietic O O
cells O O
where O O
they O O
play O O
a O O
critical O O
role O O
in O O
signal O O
transduction O O
. O O

Activation O O
of O O
the O O
signal O O
transducer O O
and O O
transcription O O
( O O
STAT O O
) O O
signaling O O
pathway O O
in O O
a O O
primary O O
T O O
cell O O
response O O
. O O

To O O
investigate O O
the O O
mechanisms O O
of O O
transcriptional O O
activation O O
of O O
interleukin-1beta O O
( O O
IL-1beta O O
) O O
in O O
non-monocytic O O
cells O O
, O O
we O O
constructed O O
a O O
series O O
of O O
reporter O O
plasmids O O
with O O
the O O
bacterial O O
chloramphenicol O O
acetyltransferase O O
gene O O
linked O O
to O O
various O O
parts O O
of O O
the O O
human O O
IL-1beta O O
promoter O O
and O O
performed O O
transient O O
transfection O O
experiments O O
. O O

A O O
principal O O
objective O O
of O O
the O O
present O O
study O O
was O O
to O O
identify O O
more O O
precisely O O
similarities O O
and O O
divergences O O
among O O
lipopolysaccharide O O
( O O
LPS O O
) O O
- O O
and O O
lipoprotein-lipopeptide-induced O O
immune O O
cell O O
signaling O O
events O O
. O O

These O O
results O O
were O O
consistent O O
with O O
the O O
relationship O O
between O O
the O O
Sig O O
score O O
and O O
performance O O
on O O
synthetic O O
datasets O O
( O O
Figure O O
2 O O
) O O
. O O

Human O O
immunodeficiency O O
virus O O
type O O
1 O O
Nef O O
protein O O
inhibits O O
NF-kappa O O
B O O
induction O O
in O O
human O O
T O O
cells O O
. O O

could O O
new O O
regulatory O O
pathways O O
evolve O O
by O O
enhancer O O
shuffling O O
? O O

Sodium O O
dodecyl O O
sulfate-polyacrylamide O O
gel O O
electrophoresis O O
showed O O
significant O O
aldosterone O O
binding O O
at O O
a O O
molecular O O
weight O O
of O O
approximately O O
50000 O O
Dalton O O
which O O
was O O
absent O B-Negation
with O I-Negation
1 O I-Negation
microM O I-Negation
cold O I-Negation
aldosterone O I-Negation
, O O
but O O
not B-Negation B-Negation
cortisol I-Negation I-Negation
in O I-Negation
the O I-Negation
binding O I-Negation
media O I-Negation
. O O

The O O
Combined O O
module O O
provides O O
positive O O
evidence O O
for O O
the O O
highest O O
number O O
of O O
interactions O O
of O O
the O O
LR400 O O
dataset O O
. O O

Transcription O O
factor O O
activation O O
and O O
gene O O
transcription O O
were O O
studied O O
by O O
gel-shift O O
assays O O
and O O
Northern O O
blot O O
analysis O O
, O O
respectively O O
. O O

The O O
promoter O O
activity O O
from O O
HIV O O
long O O
terminal O O
repeat O O
was O O
greatly O O
augmented O O
by O O
co-transfecting O O
the O O
Trx-expressing O O
plasmid O O
, O O
whose O O
effect O O
was O O
dependent O O
on O O
the O O
NF O O
kappa O O
B-binding O O
sites O O
. O O

In O O
the O O
absence B-Negation B-Negation
of I-Negation I-Negation
a I-Negation I-Negation
cloned I-Negation I-Negation
MIBP1 I-Negation I-Negation
gene I-Negation I-Negation
for I-Negation I-Negation
further I-Negation I-Negation
studies I-Negation I-Negation
, O O
we O O
hypothesize O O
that O O
RFX1 O O
acts O O
with O O
MIBP1 O O
to O O
negatively O O
regulate O O
the O O
core O O
promoter O O
activity O O
through O O
the O O
NRE O O
gamma O O
site O O
. O O

At O O
low O O
GSSG O O
levels O O
, O O
T O O
cells O O
can B-Negation B-Negation
not I-Negation I-Negation
optimally I-Negation I-Negation
activate I-Negation I-Negation
the I-Negation I-Negation
immunologically I-Negation I-Negation
important I-Negation I-Negation
transcription I-Negation I-Negation
factor I-Negation I-Negation
NF I-Negation I-Negation
kappa I-Negation I-Negation
B I-Negation I-Negation
, O O
whereas O O
high O O
GSSG O O
levels O O
inhibit O O
the O O
DNA O O
binding O O
activity O O
of O O
NF O O
kappa O O
B O O
. O O

These O O
results O O
demonstrate O O
the O O
existence O O
of O O
a O O
triple O O
autoregulatory O O
loop O O
in O O
monocytes O O
and O O
macrophages O O
involving O O
HIV O O
, O O
p105 O O
and O O
p50 O O
, O O
and O O
MAD3 O O
, O O
with O O
the O O
end O O
result O O
of O O
persistent O O
NF-kappa O O
B O O
activation O O
and O O
viral O O
persistence O O
. O O

One O O
possibility O O
is O O
that O O
adenosine O O
acts O O
as O O
a O O
downstream O O
effector O O
of O O
ecdysone-regulated O O
prepupal O O
changes O O
, O O
and O O
that O O
the O O
increase O O
in O O
adenosine O O
concentration O O
is O O
mediated O O
by O O
ecdysone-induced O O
down-regulation O O
of O O
ADGF-A O O
expression O O
. O O

In O O
an O O
effort O O
to O O
further O O
elucidate O O
the O O
biological O O
effects O O
of O O
A O O
beta O O
towards O O
microglia O O
, O O
we O O
investigated O O
the O O
ability O O
of O O
A O O
beta O O
peptides O O
to O O
activate O O
nuclear O O
factor O O
( O O
NF O O
) O O
-kappa O O
B O O
in O O
the O O
N9 O O
murine O O
microglial O O
cell O O
line O O
. O O

Analogously O O
, O O
the O O
15-bp O O
insertion O O
sites O O
were O O
composed O O
of O O
two O O
4-bp O O
and O O
3-bp O O
flanking O O
fragments O O
. O O

It O O
is O O
interesting O O
that O O
IL-11 O O
did O O
not B-Negation B-Negation
affect I-Negation I-Negation
BAL I-Negation I-Negation
fluid I-Negation I-Negation
content I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
CXC I-Negation I-Negation
chemokines I-Negation I-Negation
, I-Negation I-Negation
macrophage I-Negation I-Negation
inflammatory I-Negation I-Negation
protein-2 I-Negation I-Negation
( I-Negation I-Negation
MIP-2 I-Negation I-Negation
) I-Negation I-Negation
and I-Negation I-Negation
cytokine-inducible I-Negation I-Negation
neutrophil I-Negation I-Negation
chemoattractant I-Negation I-Negation
( I-Negation I-Negation
CINC I-Negation I-Negation
) I-Negation I-Negation
; O O
the O O
presence O O
of O O
IL-11 O O
did O O
not B-Negation B-Negation
affect I-Negation I-Negation
these I-Negation I-Negation
chemokines I-Negation I-Negation
. O O

Therefore O O
, O O
costimulation O O
by O O
alpha O O
4 O O
beta O O
1 O O
ligands O O
was O O
not B-Negation B-Negation
due I-Negation I-Negation
to I-Negation I-Negation
stabilization I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
interaction I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
cells I-Negation I-Negation
with I-Negation I-Negation
its I-Negation I-Negation
substrate I-Negation I-Negation
. O O

Tumor O O
samples O O
, O O
obtained O O
from O O
129 O O
patients O O
who O O
underwent O O
surgery O O
between O O
January O O
1987 O O
and O O
December O O
1988 O O
, O O
were O O
processed O O
for O O
staining O O
by O O
an O O
immunohistochemical O O
procedure O O
( O O
avidin-biotin O O
complex O O
) O O
. O O

Functional O O
DC O O
characteristics O O
include O O
fluid O O
phase O O
macromolecule O O
uptake O O
( O O
FITC-dextran O O
) O O
and O O
activation O O
of O O
resting O O
T O O
cells O O
. O O

We O O
produced O O
a O O
loss-of-function O O
mutation O O
in O O
the O O
ADGF-A O O
gene O O
, O O
which O O
produces O O
a O O
product O O
( O O
ADGF-A O O
) O O
with O O
ADA O O
activity O O
. O O

These O O
results O O
support O O
the O O
feasibility O O
and O O
usefulness O O
of O O
this O O
systematic O O
approach O O
to O O
studying O O
variation O O
in O O
gene O O
expression O O
patterns O O
in O O
human O O
cancers O O
as O O
a O O
means O O
to O O
dissect O O
and O O
classify O O
solid O O
tumors O O
. O O

In O O
the O O
mouse O O
Th2 O O
D10 O O
cells O O
and O O
in O O
the O O
human O O
Th2 O O
clones O O
, O O
POS-1 O O
( O O
designated O O
POS-1b O O
) O O
contains O O
NF-IL6beta O O
, O O
Jun O O
, O O
and O O
NF-ATc/p O O
. O O

The O O
STP-C488 O O
P10 O O
-- O O
> O O
R O O
mutant O O
was O O
also O O
defective O O
in O O
Rat-1 O O
fibroblast O O
transformation O O
, O O
and O O
fibroblast O O
cell O O
transformation O O
was O O
blocked O O
by O O
a O O
TRAF2 O O
dominant-negative O O
mutant O O
. O O

Two O O
to O O
4 O O
h O O
following O O
LPS O O
addition O O
to O O
endothelial O O
cells O O
, O O
when O O
NF-kappa O O
B O O
was O O
already O O
activated O O
, O O
addition O O
of O O
rBPI21 O O
resulted O O
in O O
marked O O
reduction O O
of O O
NF-kappa O O
B O O
detectable O O
at O O
4 O O
or O O
6 O O
h O O
. O O

Yet O O
, O O
little O O
is O O
known O O
as O O
to O O
how O O
the O O
RA O O
and O O
VitD3 O O
receptor O O
network O O
operates O O
in O O
hematopoietic O O
cells O O
, O O
and O O
whether O O
receptor O O
interactions O O
can O O
explain O O
the O O
interplay O O
between O O
the O O
RA- O O
and O O
VitD3-signaling O O
pathways O O
during O O
differentiation O O
. O O

By O O
assaying O O
CAT O O
enzyme O O
activity O O
across O O
a O O
24-h O O
PRL O O
induction O O
time O O
course O O
, O O
we O O
were O O
able O O
to O O
assign O O
G1 O O
vs. O O
S O O
phase O O
PRL O O
responses O O
of O O
the O O
IRF-1 O O
gene O O
to O O
different O O
regions O O
of O O
the O O
IRF-1 O O
5'-flanking O O
and O O
promoter O O
DNA O O
. O O

Glucocorticoid O O
receptor O O
in O O
patients O O
with O O
lupus O O
nephritis O O
: O O
relationship O O
between O O
receptor O O
levels O O
in O O
mononuclear O O
leukocytes O O
and O O
effect O O
of O O
glucocorticoid O O
therapy O O
. O O

The O O
J O O
delta O O
1 O O
segment O O
was O O
correctly O O
spliced O O
to O O
C O O
delta O O
; O O
in O O
addition O O
the O O
four O O
C O O
delta O O
exons O O
were O O
found O O
to O O
be O O
already O O
assembled O O
. O O

The O O
motifs O O
reported O O
by O O
SCOPE O O
overlap O O
to O O
a O O
large O O
extent O O
with O O
the O O
published O O
cis-regulatory O O
elements O O
( O O
as O O
discussed O O
in O O
Additional O O
file O O
1 O O
, O O
section O O
S3 O O
, O O
a O O
difference O O
of O O
one O O
base O O
pair O O
length O O
between O O
the O O
reported O O
motif O O
and O O
the O O
published O O
cis-regulatory O O
element O O
results O O
in O O
an O O
expected O O
accuracy O O
of O O
about O O
0.25 O O
) O O
. O O

Mean O O
and O O
standard O O
deviations O O
of O O
the O O
randomisation O O
experiments O O
are O O
shown O O
in O O
Table O O
1 O O
. O O

Changes O O
in O O
these O O
signaling O O
molecules O O
during O O
cytokine O O
treatment O O
were O O
also O O
investigated O O
. O O

In O O
Jurkat O O
T-cells O O
, O O
PG490 O O
inhibits O O
PMA/Iono-stimulated O O
IL-2 O O
transcription O O
. O O

IL-10 O O
inhibition O O
of O O
IFN-gamma-induced O O
ICAM-1 O O
expression O O
was O O
apparent O O
as O O
early O O
as O O
3 O O
hours O O
and O O
was O O
blocked O O
by O O
an O O
anti-IL-10 O O
antibody O O
but O O
not B-Negation B-Negation
by I-Negation I-Negation
an I-Negation I-Negation
isotype-matched I-Negation I-Negation
control I-Negation I-Negation
antibody I-Negation I-Negation
. O O

Involvement O O
of O O
intracellular O O
Ca2+ O O
in O O
oxidant-induced O O
NF-kappa O O
B O O
activation O O
. O O

Although O O
the O O
determination O O
of O O
interactions O O
by O O
small-scale O O
laboratory O O
techniques O O
is O O
impractical O O
for O O
a O O
complete O O
proteome O O
on O O
the O O
grounds O O
of O O
cost O O
and O O
time O O
, O O
several O O
experimental O O
techniques O O
now O O
exist O O
to O O
determine O O
protein-protein O O
interactions O O
in O O
a O O
high-throughput O O
manner O O
1 O O
. O O

The O O
c-Jun O O
delta-domain O O
inhibits O O
neuroendocrine O O
promoter O O
activity O O
in O O
a O O
DNA O O
sequence- O O
and O O
pituitary-specific O O
manner O O
. O O

Second O O
is O O
a O O
controlled O O
phase O O
of O O
TCR O O
gene O O
rearrangement O O
. O O

This O O
analysis O O
identified O O
one O O
such O O
element O O
repeated O O
four O O
times O O
within O O
the O O
CD11b O O
promoter O O
. O O

Because O O
there O O
were O O
no B-Negation B-Negation
known I-Negation I-Negation
TPases I-Negation I-Negation
similar I-Negation I-Negation
to I-Negation I-Negation
RAG1 I-Negation I-Negation
, O O
it O O
could O O
be O O
argued O O
that O O
RAG1 O O
independently O O
developed O O
some O O
TPase-like O O
properties O O
, O O
rather O O
than O O
deriving O O
them O O
from O O
a O O
TE-encoded O O
TPase O O
[ O O
24 O O
] O O
. O O

Impaired O O
myelopoiesis O O
in O O
vivo O O
was O O
shown O O
by O O
stressing O O
these O O
mice O O
with O O
sublethal O O
irradiation O O
. O O

Despite O O
this O O
, O O
37714 O O
gene-gene O O
interactions O O
were O O
recovered O O
from O O
the O O
Rhodes O O
dataset O O
and O O
6132 O O
interactions O O
from O O
the O O
Ramani O O
dataset O O
as O O
well O O
as O O
64306 O O
and O O
10454 O O
interactions O O
from O O
the O O
Lehner O O
full O O
and O O
core O O
datasets O O
respectively O O
. O O

Moreover O O
, O O
when O O
introduced O O
into O O
murine O O
pro-B O O
lymphocytes O O
, O O
the O O
oncogenic O O
E2A-HLF O O
fusion O O
protein O O
reversed O O
both O O
interleukin-3-dependent O O
and O O
p53-mediated O O
apoptosis O O
. O O

MATERIAL O O
AND O O
METHODS O O
: O O
In O O
the O O
present O O
study O O
, O O
we O O
analyzed O O
the O O
effects O O
of O O
CyA O O
, O O
aspirin O O
, O O
and O O
indomethacin O O
on O O
T O O
cell O O
proliferation O O
using O O
a O O
proliferation O O
assay O O
. O O

The B-Negation B-Negation
extent I-Negation I-Negation
to I-Negation I-Negation
which I-Negation I-Negation
peptides I-Negation I-Negation
containing I-Negation I-Negation
chemically I-Negation I-Negation
and I-Negation I-Negation
post-translationally I-Negation I-Negation
modified I-Negation I-Negation
amino I-Negation I-Negation
acid I-Negation I-Negation
side I-Negation I-Negation
chains I-Negation I-Negation
are I-Negation I-Negation
recognized I-Negation I-Negation
by I-Negation I-Negation
primed I-Negation I-Negation
CTL I-Negation I-Negation
has I-Negation I-Negation
not I-Negation I-Negation
been I-Negation I-Negation
clearly I-Negation I-Negation
defined I-Negation I-Negation
. O O

Our O O
results O O
demonstrate O O
that O O
IL-10 O O
can O O
inhibit O O
the O O
induction O O
of O O
NF-kappa O O
B/Rel O O
nuclear O O
activity O O
in O O
CD3-stimulated O O
T O O
lymphocytes O O
. O O

Both O O
overexpressed O O
p65 O O
and O O
coexpressed O O
p50 O O
are O O
cytoplasmic O O
, O O
whereas O O
p65 O O
delta O O
is O O
partly O O
nuclear O O
, O O
indicating O O
that O O
the O O
I O O
kappa O O
B O O
induced O O
by O O
p65 O O
can O O
maintain O O
NF-kappa O O
B O O
in O O
the O O
cytoplasm O O
. O O

While O O
the O O
activation O O
of O O
the O O
IL-2 O O
promoter O O
and O O
an O O
NFAT-driven O O
minimal O O
promoter O O
by O O
Tpl-2 O O
was O O
fully O O
blocked O O
by O O
the O O
dominant O O
negative O O
mutant O O
NFAT O O
delta418 O O
, O O
it O O
was O O
only O O
partially O O
blocked O O
by O O
the O O
calcineurin O O
inhibitor O O
cyclosporin O O
A O O
suggesting O O
that O O
the O O
Tpl-2-mediated O O
NFAT O O
activation O O
is O O
under O O
the O O
control O O
of O O
a O O
combination O O
of O O
calcineurin-dependent O O
and O O
independent O O
pathways O O
. O O

Each O O
binding O O
site O O
contributes O O
to O O
the O O
overall O O
activity O O
of O O
the O O
enhancer O O
, O O
however O O
no B-Negation B-Negation
single I-Negation I-Negation
element I-Negation I-Negation
seems O I-Negation
absolutely O I-Negation
required O I-Negation
for O I-Negation
activity O I-Negation
. O O

By O O
using O O
a O O
DNA O O
sequence O O
selected O O
for O O
its O O
ability O O
to O O
bind O O
recombinant O O
BCL-6 O O
in O O
vitro O O
, O O
we O O
show O O
here O O
that O O
BCL-6 O O
is O O
present O O
in O O
DNA-binding O O
complexes O O
in O O
nuclear O O
extracts O O
from O O
various O O
B-cell O O
lines O O
. O O

In O O
addition O O
, O O
BMT O O
exhibited O O
antiviral O O
activity O O
against O O
SIVmac251 O O
. O O

Therefore O O
, O O
it O O
is O O
important O O
not B-Negation O
to I-Negation O
assume I-Negation O
non-readthrough I-Negation O
homologs I-Negation O
for I-Negation O
exploring I-Negation O
novel I-Negation O
candidates I-Negation O
. O O

In O O
conclusion O O
an O O
increased O O
transcription O O
efficiency O O
of O O
a O O
cell O O
type O O
specific O O
gene O O
is O O
accompanied O O
by O O
a O O
higher O O
hybridization O O
accessibility O O
in O O
the O O
corresponding O O
cell O O
nuclei O O
. O O

Finally O O
, O O
two O O
other O O
domains O O
, O O
located O O
at O O
positions O O
-460 O O
and O O
-510 O O
, O O
interact O O
with O O
proteins O O
that O O
are O O
only O O
present O O
in O O
megakaryocytic O O
cells O O
. O O

ETS1 O O
, O O
NFkappaB O O
and O O
AP1 O O
synergistically O O
transactivate O O
the O O
human O O
GM-CSF O O
promoter O O
. O O

For O O
expression O O
of O O
ADGF-A O O
using O O
the O O
HS-ADGF-A O O
construct O O
, O O
flies O O
were O O
heat O O
shocked O O
as O O
late O O
embryos/early O O
first O O
instars O O
at O O
37 O O
°C O O
for O O
30 O O
min O O
. O O

B O O
cells O O
and O O
epithelial O O
cells O O
have O O
a O O
pivotal O O
role O O
in O O
the O O
life O O
cycle O O
of O O
the O O
virus O O
. O O

Fourth O O
, O O
hAT- O O
and O O
RAG1/2-mediated O O
transpositions O O
differ O O
dramatically O O
in O O
terms O O
of O O
the O O
GC O O
content O O
of O O
their O O
target O O
sites O O
: O O
Unlike O O
Transib O O
transposons O O
and O O
RAG1 O O
transpositions O O
occurring O O
in O O
GC-rich O O
DNA O O
, O O
hAT O O
transposons O O
tend O O
to O O
be O O
integrated O O
into O O
AT-rich O O
regions O O
( O O
Table O O
S2 O O
) O O
. O O

Association O O
with O O
the O O
precursors O O
is O O
sufficient O O
for O O
cytoplasmic O O
retention O O
of O O
either O O
p65 O O
or O O
c-Rel O O
, O O
both O O
of O O
which O O
are O O
otherwise O O
nuclear O O
. O O

Together O O
, O O
these O O
results O O
suggest O O
that O O
NF-kappa O O
B O O
plays O O
an O O
important O O
role O O
in O O
long-term O O
activation O O
of O O
human O O
primary O O
T-lymphocytes O O
via O O
CD2 O O
+ O O
CD28 O O
. O O

Further O O
studies O O
indicated O O
that O O
inhibition O O
of O O
GTP-cyclohydrolase O O
I O O
( O O
an O O
enzyme O O
involved O O
in O O
de O O
novo O O
synthesis O O
of O O
an O O
important O O
cofactor O O
for O O
NOS O O
activity O O
, O O
tetrahydrobiopterin O O
) O O
prevented O O
the O O
generation O O
of O O
NO O O
in O O
A/R-tolerant O O
cells O O
. O O

In O O
vivo O O
, O O
anergy O O
has O O
mainly O O
been O O
studied O O
at O O
the O O
cellular O O
level O O
. O O

Initial O O
experiments O O
indicated O O
that O O
a O O
50 O O
% O O
decrease O O
in O O
VDR O O
levels O O
was O O
associated O O
with O O
a O O
2-fold O O
increase O O
in O O
cell O O
proliferation O O
and O O
a O O
similar O O
rise O O
in O O
c-myc O O
mRNA O O
expression O O
. O O

The O O
kinetics O O
of O O
induced O O
differentiation O O
are O O
consistent O O
with O O
a O O
G1 O O
specific O O
cellular O O
response O O
to O O
initiate O O
the O O
metabolic O O
cascade O O
culminating O O
in O O
cell O O
differentiation O O
. O O

The O O
AML1 O O
and O O
CBF O O
beta O O
genes O O
that O O
encode O O
CBF O O
each O O
have O O
the O O
ability O O
to O O
influence O O
cell O O
growth O O
and O O
differentiation O O
and O O
have O O
been O O
implicated O O
as O O
proto-oncogenes O O
in O O
acute O O
myeloid O O
leukemia O O
. O O

Because O O
of O O
their O O
role O O
in O O
cell O O
adhesion O O
, O O
PTPase O O
may O O
provide O O
a O O
novel O O
target O O
of O O
drug O O
development O O
for O O
treatment O O
of O O
inflammation O O
, O O
atherogenesis O O
, O O
and O O
tumor O O
metastasis O O
. O O

Although O O
CD40 O O
ligand O O
( O O
CD40L O O
) O O
triggers O O
a O O
shift O O
from O O
dephosphorylated O O
to O O
phosphorylated O O
pRB O O
and O O
proliferation O O
of O O
B O O
cells O O
, O O
the O O
addition O O
of O O
exogenous O O
IL-6 O O
to O O
CD40L-treated O O
B O O
cells O O
does O O
not B-Negation B-Negation
alter I-Negation I-Negation
either I-Negation I-Negation
pRB I-Negation I-Negation
or I-Negation I-Negation
proliferation I-Negation I-Negation
, O O
as O O
observed O O
in O O
MM O O
cells O O
. O O

Although O O
the O O
-20 O O
GATA O O
binding O O
site O O
( O O
AGATAA O O
) O O
is O O
also O O
a O O
potential O O
TFIID O O
binding O O
site O O
, O O
it O O
does O O
not B-Negation B-Negation
bind I-Negation I-Negation
TFIID I-Negation I-Negation
. O O

This O O
decrease O O
was O O
observed O O
at O O
2 O O
hr O O
, O O
reached O O
a O O
nadir O O
at O O
4 O O
hr O O
, O O
and O O
returned O O
to O O
baseline O O
levels O O
at O O
24 O O
hr O O
. O O

These O O
RNAs O O
, O O
Xist O O
( O O
X-inactive O O
specific O O
transcript O O
) O O
in O O
mammals O O
, O O
and O O
roX1 O O
and O O
roX2 O O
( O O
RNA O O
on O O
the O O
X O O
) O O
in O O
Drosophila O O
, O O
are O O
structurally O O
unrelated O O
, O O
yet O O
they O O
share O O
the O O
intriguing O O
property O O
of O O
remaining O O
tightly O O
associated O O
with O O
the O O
X O O
chromosome O O
. O O

Previously O O
, O O
a O O
nuclear O O
factor O O
, O O
IRF-1 O O
( O O
interferon O O
regulatory O O
factor O O
1 O O
) O O
, O O
which O O
binds O O
to O O
type O O
I O O
IFN O O
and O O
some O O
IFN-inducible O O
gene O O
promoters O O
, O O
was O O
identified O O
and O O
cloned O O
. O O

In O O
contrast O O
to O O
the O O
purely O O
enhancer-dependent O O
effect O O
of O O
cytokines O O
such O O
as O O
TNF O O
on O O
the O O
activity O O
of O O
the O O
HIV O O
regulatory O O
region O O
( O O
LTR O O
) O O
, O O
we O O
observed O O
that O O
okadaic O O
acid O O
( O O
OKA O O
) O O
activates O O
HIV O O
transcription O O
through O O
both O O
the O O
enhancer O O
, O O
responding O O
to O O
the O O
factor O O
NF-kappa O O
B O O
, O O
and O O
the O O
promoter O O
domain O O
of O O
the O O
LTR O O
. O O

If O O
an O O
iORF O O
codes O O
a O O
readthrough O O
protein O O
, O O
BLAST O O
hits O O
from O O
other O O
organisms O O
will O O
cover O O
the O O
inframe O O
stop O O
codon O O
. O O

The O O
fact O O
that O O
BCL-6 O O
rearrangements O O
identify O O
biologically O O
and O O
clinically O O
distinct O O
subsets O O
of O O
DLCL O O
suggests O O
that O O
these O O
lesions O O
may O O
be O O
useful O O
as O O
markers O O
in O O
selection O O
of O O
differential O O
therapeutic O O
strategies O O
based O O
on O O
different O O
risk O O
groups O O
. O O

however O O
, O O
proliferation O O
was O O
only O O
partially O O
inhibited O O
by O O
neutralizing O O
anti-IL-6 O O
monoclonal O O
antibody O O
( O O
MoAb O O
) O O
. O O

Mutations O O
affecting O O
the O O
5 O O
' O O
guanine O O
residues O O
of O O
the O O
kappa O O
B O O
site O O
were O O
unable B-Negation B-Negation
to I-Negation I-Negation
compete I-Negation I-Negation
for I-Negation I-Negation
these I-Negation I-Negation
NF-kappa I-Negation I-Negation
B-related I-Negation I-Negation
proteins I-Negation I-Negation
. O O

LAM O O
and O O
LPS O O
were O O
potent O O
inducers O O
of O O
IL-6 O O
gene O O
expression O O
in O O
peripheral O O
blood O O
monocytes O O
. O O

4 O O
patients O O
were O O
receiving O O
dopamine O O
, O O
which O O
did O O
not B-Negation B-Negation
affect I-Negation I-Negation
the I-Negation I-Negation
GR I-Negation I-Negation
count I-Negation I-Negation
. O O

The O O
NB4 O O
cell O O
line O O
, O O
which O O
is O O
derived O O
from O O
the O O
bone O O
marrow O O
of O O
a O O
patient O O
with O O
APL O O
during O O
relapse O O
, O O
can O O
be O O
used O O
as O O
a O O
model O O
system O O
to O O
study O O
the O O
growth O O
and O O
differentiation O O
of O O
APL O O
cells O O
. O O

We O O
report O O
the O O
effect O O
of O O
E3330 O O
on O O
transcriptional O O
activation O O
of O O
tumor O O
necrosis O O
factor O O
( O O
TNF O O
) O O
-alpha O O
gene O O
and O O
on O O
nuclear O O
factor O O
( O O
NF O O
) O O
-kappa O O
B O O
activation O O
. O O

In O O
this O O
report O O
, O O
we O O
show O O
that O O
exposure O O
of O O
cells O O
to O O
hypoxia O O
( O O
0.02 O O
% O O
O2 O O
) O O
results O O
in O O
I O O
kappa O O
B O O
alpha O O
degradation O O
, O O
increased O O
NF-kappa O O
B O O
DNA O O
binding O O
activity O O
, O O
and O O
transactivation O O
of O O
a O O
reporter O O
gene O O
construct O O
containing O O
two O O
NF-kappa O O
B O O
DNA O O
binding O O
sites O O
. O O

T3SO4 O O
had O O
no B-Negation B-Negation
thyromimetic I-Negation I-Negation
effect I-Negation I-Negation
on O I-Negation
the O I-Negation
activity O I-Negation
of O I-Negation
Ca O I-Negation
( O I-Negation
2+ O I-Negation
) O I-Negation
-ATPase O I-Negation
in O I-Negation
human O I-Negation
erythrocyte O I-Negation
membranes O I-Negation
at O O
doses O O
up O O
to O O
10,000 O O
times O O
the O O
maximally O O
effective O O
dose O O
of O O
T3 O O
( O O
10 O O
( O O
-10 O O
) O O
mol/L O O
) O O
. O O

Interestingly O O
, O O
enhanced O O
expression O O
of O O
Spi-1 O O
and O O
Fli-1 O O
genes O O
already O O
was O O
detected O O
in O O
the O O
Ter O O
119 O O
positive O O
cell O O
population O O
of O O
transgenic O O
mice O O
spleen O O
in O O
vivo O O
. O O

The O O
Group O O
A O O
modules O O
( O O
shown O O
in O O
panel O O
A O O
) O O
are O O
trained O O
in O O
parallel O O
. O O

Induction O O
of O O
TF O O
mRNA O O
expression O O
by O O
LPS O O
tended O O
to O O
be O O
partially O O
reduced O O
by O O
the O O
lysophospholipid O O
. O O

The O O
involvement O O
of O O
a O O
CD28 O O
response O O
element O O
in O O
the O O
induction O O
of O O
IL-8 O O
expression O O
in O O
activated O O
T O O
cells O O
may O O
provide O O
new O O
insights O O
into O O
the O O
pathogenesis O O
and O O
persistence O O
of O O
immune O O
disorders O O
characterized O O
by O O
increased O O
levels O O
of O O
IL-8 O O
, O O
such O O
as O O
psoriasis O O
and O O
rheumatoid O O
arthritis O O
. O O

The O O
cell O O
type-specific O O
regulation O O
of O O
the O O
CD34 O O
promoter O O
by O O
MZF-1 O O
suggests O O
the O O
presence O O
of O O
tissue-specific O O
regulators/adapters O O
or O O
differential O O
MZF-1 O O
modifications O O
that O O
determine O O
MZF-1 O O
transcriptional O O
regulatory O O
function O O
. O O

From O O
these O O
observations O O
we O O
conclude O O
that O O
free O O
thiols O O
in O O
the O O
IL-1RI O O
complex O O
are O O
essential O O
for O O
the O O
activation O O
of O O
the O O
IL-1RI-associated O O
protein O O
kinase O O
and O O
that O O
this O O
process O O
is O O
mandatory O O
for O O
IL-1 O O
signaling O O
leading O O
to O O
NF-kappa O O
B O O
activation O O
. O O

The O O
role O O
of O O
jun O O
and O O
fos O O
gene O O
family O O
members O O
in O O
12-O-tetradecanoylphorbol-13-acetate O O
induced O O
hemopoietic O O
differentiation O O
. O O

In O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
NF O O
kappa O O
B O O
binds O O
to O O
both O O
conserved O O
sites O O
in O O
the O O
HIV-1 O O
transcriptional O O
enhancer O O
and O O
only O O
to O O
the O O
single O O
conserved O O
site O O
in O O
the O O
HIV-2 O O
transcriptional O O
enhancer O O
. O O

In O O
this O O
study O O
, O O
we O O
demonstrate O O
that O O
nuclear O O
factor O O
( O O
NF O O
) O O
-kappa O O
B O O
and O O
NF-kappa O O
B-like O O
transcription O O
factors O O
are O O
activated O O
after O O
cross-linking O O
CD40 O O
on O O
resting O O
human O O
tonsillar O O
B O O
cells O O
and O O
on O O
B O O
cell O O
lines O O
. O O

Genetically O O
, O O
this O O
Drosophila O O
Bcl-2 O O
family O O
member O O
appears O O
to O O
function O O
upstream O O
of O O
, O O
or O O
in O O
parallel O O
to O O
, O O
the O O
Drosophila O O
ced-4/apaf-1 O O
homolog O O
and O O
downstream O O
of O O
, O O
or O O
in O O
parallel O O
to O O
, O O
the O O
Drosophila O O
regulators O O
of O O
apoptosis O O
, O O
reaper O O
, O O
hid O O
, O O
and O O
grim O O
[ O O
22 O O
] O O
. O O

Inhibition O O
of O O
phorbol O O
ester-induced O O
monocytic O O
differentiation O O
by O O
dexamethasone O O
is O O
associated O O
with O O
down-regulation O O
of O O
c-fos O O
and O O
c-jun O O
( O O
AP-1 O O
) O O
. O O

We O O
derive O O
a O O
Spearman O O
correlation O O
coefficient O O
of O O
0.50 O O
for O O
the O O
frequencies O O
of O O
all O O
524 O O
iPfam O O
domain O O
pairs O O
that O O
are O O
conserved O O
between O O
S. O O
cerevisiae O O
and O O
H. O O
sapiens O O
. O O

Increased O O
IkappaB O O
expression O O
and O O
diminished O O
nuclear O O
NF-kappaB O O
in O O
human O O
mononuclear O O
cells O O
following O O
hydrocortisone O O
injection O O
. O O

An O O
allosteric O O
drug O O
, O O
o O O
, O O
o'-bismyristoyl O O
thiamine O O
disulfide O O
, O O
suppresses O O
HIV-1 O O
replication O O
through O O
prevention O O
of O O
nuclear O O
translocation O O
of O O
both O O
HIV-1 O O
Tat O O
and O O
NF-kappa O O
B O O
. O O

We O O
have O O
examined O O
the O O
effects O O
of O O
RA O O
on O O
normal O O
hematopoiesis O O
by O O
using O O
early O O
hematopoietic O O
progenitor O O
cells O O
( O O
HPC O O
) O O
stringently O O
purified O O
from O O
adult O O
peripheral O O
blood O O
. O O

A O O
human O O
IL-5 O O
promoter/enhancer O O
luciferase O O
gene O O
construct O O
transfected O O
into O O
IL-5-producing O O
T O O
cell O O
clones O O
was O O
clearly O O
transcribed O O
after O O
stimulation O O
, O O
indicating O O
that O O
the O O
515 O O
base O O
pair O O
IL-5 O O
gene O O
segment O O
upstream O O
of O O
the O O
coding O O
region O O
was O O
sufficient O O
to O O
respond O O
to O O
activating O O
signals O O
in O O
human O O
helper O O
T O O
cells O O
. O O

SCOPE O O
's O O
high O O
accuracy O O
was O O
a O O
reflection O O
of O O
both O O
high O O
PPV O O
and O O
high O O
sensitivity O O
( O O
Figure O O
6a O O
; O O
see O O
Methods O O
for O O
a O O
precise O O
definition O O
) O O
. O O

Surprisingly O O
, O O
we O O
find O O
also O O
that O O
the B-Negation O
interaction I-Negation O
between I-Negation O
SLP-76 I-Negation O
and I-Negation O
Vav I-Negation O
is I-Negation O
not I-Negation B-Negation
required I-Negation I-Negation
for I-Negation I-Negation
their I-Negation I-Negation
cooperation I-Negation I-Negation
in I-Negation I-Negation
augmenting I-Negation I-Negation
IL-2 I-Negation I-Negation
promoter I-Negation I-Negation
activity I-Negation I-Negation
, O O
as O O
the O O
two O O
molecules O O
appear O O
to O O
function O O
in O O
different O O
signaling O O
pathways O O
upstream O O
of O O
IL-2 O O
gene O O
expression O O
. O O

We O O
demonstrate O O
that O O
mRNAs O O
for O O
all O O
three O O
of O O
these O O
regulatory O O
factors O O
are O O
expressed O O
in O O
fetal O O
blood O O
cells O O
by O O
the O O
27th O O
week O O
of O O
gestation O O
and O O
in O O
term O O
cord O O
bloods O O
. O O

Resistance O O
to O O
tumor O O
necrosis O O
factor O O
induced O O
apoptosis O O
in O O
vitro O O
correlates O O
with O O
high O O
metastatic O O
capacity O O
of O O
cells O O
in O O
vivo O O
. O O

The O O
NFAT-controlled O O
luciferase O O
gene O O
system O O
distinguishes O O
CIF O O
from O O
other O O
T O O
cell O O
inhibitory O O
activities O O
present O O
in O O
colostrum O O
, O O
in O O
particular O O
, O O
TGF O O
beta O O
1 O O
and O O
TGF O O
beta O O
2 O O
and O O
the O O
glucocorticoids O O
. O O

Involvement O O
of O O
Rel O O
, O O
Fos O O
, O O
and O O
Jun O O
proteins O O
in O O
binding O O
activity O O
to O O
the O O
IL-2 O O
promoter O O
CD28 O O
response O O
element/AP-1 O O
sequence O O
in O O
human O O
T O O
cells O O
. O O

p50.c-rel O O
heterodimers O O
were O O
also O O
detected O O
bound O O
to O O
this O O
sequence O O
at O O
early O O
time O O
points O O
( O O
7-16 O O
h O O
; O O
early O O
) O O
, O O
and O O
both O O
remained O O
active O O
at O O
later O O
time O O
points O O
( O O
40 O O
h O O
; O O
late O O
) O O
after O O
activation O O
. O O

These O O
latter O O
two O O
proteins O O
require O O
all O O
the O O
other O O
MSL O O
proteins O O
to O O
be O O
present O O
to O O
enable O O
them O O
to O O
associate O O
with O O
the O O
X O O
chromosome O O
. O O

Of O O
these O O
, O O
Diap1 O O
has O O
been O O
most O O
extensively O O
characterized O O
; O O
it O O
can O O
block O O
cell O O
death O O
caused O O
by O O
the O O
ectopic O O
expression O O
of O O
reaper O O
, O O
hid O O
, O O
and O O
grim O O
( O O
reviewed O O
in O O
[ O O
26 O O
] O O
) O O
. O O

Since O O
internal O O
sites O O
of O O
oxidant O O
production O O
have O O
been O O
shown O O
to O O
play O O
a O O
key O O
role O O
in O O
the O O
cytokine-stimulated O O
activation O O
of O O
NF-kappa O O
B O O
, O O
and O O
since O O
tyrosine O O
kinase O O
and O O
phosphatase O O
activities O O
are O O
known O O
to O O
be O O
altered O O
by O O
oxidants O O
, O O
these O O
findings O O
suggest O O
that O O
intracellular O O
redox O O
status O O
controls O O
NF-kappa O O
B O O
activation O O
by O O
regulating O O
tyrosine O O
phosphorylation O O
event O O
( O O
s O O
) O O
within O O
the O O
common O O
step O O
of O O
the O O
NF-kappa O O
B O O
signal O O
transduction O O
pathway O O
. O O

Therefore O O
, O O
two O O
different O O
negative O O
regulatory O O
pathways O O
are O O
involved O O
in O O
c-myc O O
regulation O O
: O O
one O O
which O O
is O O
independent O O
and O O
one O O
which O O
depends O O
on O O
de O O
novo O O
protein O O
synthesis O O
. O O

Similarly O O
, O O
iORFs O O
were O O
compared O O
with O O
RNA O O
genes O O
using O O
BLASTN O O
, O O
and O O
those O O
matched O O
with O O
the O O
RNAs O O
were O O
removed O O
. O O

This O O
effect O O
is O O
blocked O O
by O O
anti-VCAM O O
antibodies O O
. O O

Exogenous O O
ETS1 O O
, O O
but O O
not B-Negation B-Negation
ELF1 I-Negation I-Negation
, O O
can O O
transactivate O O
GM-CSF O O
, O O
through O O
the O O
GM5 O O
site O O
, O O
in O O
a O O
PMA/ionomycin O O
dependent O O
manner O O
. O O

As O O
assessed O O
with O O
mutagenized O O
promoters O O
, O O
the O O
most O O
important O O
IL-2 O O
cis-regulatory O O
elements O O
in O O
normal O O
T O O
cells O O
are O O
the O O
proximal O O
AP-1 O O
site O O
and O O
the O O
NF- O O
kappaB O O
site O O
. O O

Interestingly O O
, O O
phase O O
1 O O
adhesion O O
was O O
inversely O O
correlated O O
with O O
GSH O O
levels O O
but O O
not B-Negation B-Negation
with I-Negation I-Negation
the I-Negation I-Negation
GSSG/GSH I-Negation I-Negation
ratio I-Negation I-Negation
, O O
whereas O O
phase O O
2 O O
neutrophil O O
adhesion O O
was O O
positively O O
correlated O O
with O O
GSSG/GSH O O
ratio O O
but O O
not B-Negation B-Negation
with I-Negation I-Negation
GSH I-Negation I-Negation
levels I-Negation I-Negation
. O O

Gel O O
shift O O
analysis O O
revealed O O
that O O
oxidative O O
suppression O O
of O O
NF-AT O O
represented O O
inhibition O O
in O O
the O O
early O O
generation O O
of O O
NFAT O O
complexes O O
rather B-Negation O
than I-Negation O
the I-Negation O
binding I-Negation O
of I-Negation O
preformed I-Negation O
NF-AT I-Negation O
complexes I-Negation O
. O O

( O O
1 O O
) O O
GenBank O O
accession O O
number O O
U47019 O O
; O O
( O O
2 O O
) O O
Repbase O O
Update O O
, O O
the O O
angrep.ref O O
section O O
; O O
( O O
3 O O
) O O
GenBank O O
X04705 O O
; O O
( O O
4 O O
) O O
Repbase O O
Update O O
, O O
the O O
drorep.ref O O
section O O
; O O
( O O
5 O O
) O O
Repbase O O
Update O O
, O O
spurep.ref O O
; O O
( O O
6 O O
) O O
Repbase O O
Updates O O
, O O
the O O
zebrep.ref O O
section O O
. O O

Prediction O O
of O O
putative O O
exons O O
and O O
introns O O
encoded O O
by O O
the O O
Transib O O
consensus O O
sequences O O
was O O
done O O
with O O
FGENESH O O
[ O O
33 O O
] O O
( O O
at O O
http O O
: O O
//www.softberry.com O O
) O O
. O O

The O O
molecular O O
mechanisms O O
underlying O O
the O O
IL-7 O O
effect O O
involve O O
the O O
upregulation O O
of O O
the O O
DNA O O
binding O O
activity O O
of O O
NFAT O O
( O O
60 O O
% O O
) O O
and O O
AP-1 O O
( O O
120 O O
% O O
) O O
, O O
without B-Negation B-Negation
affecting I-Negation I-Negation
the I-Negation I-Negation
activities I-Negation I-Negation
of I-Negation I-Negation
NFkappaB I-Negation I-Negation
and I-Negation I-Negation
CD28RC I-Negation I-Negation
, O O
which O O
was O O
confirmed O O
by O O
transfection O O
assays O O
. O O

We O O
generated O O
permanent O O
clones O O
of O O
the O O
murine O O
T O O
cell O O
line O O
EL4 O O
6.1 O O
overexpressing O O
human O O
( O O
h O O
) O O
IRAK O O
to O O
evaluate O O
the O O
role O O
of O O
this O O
kinase O O
in O O
IL-1 O O
signaling O O
. O O

All O O
sequence O O
motifs O O
within O O
the O O
functional O O
core O O
of O O
HS-40 O O
, O O
as O O
mapped O O
by O O
transient O O
expression O O
analysis O O
, O O
appeared O O
to O O
bind O O
a O O
nuclear O O
factor O O
( O O
s O O
) O O
in O O
living O O
K562 O O
cells O O
but O O
not O B-Negation
in O I-Negation
nonerythroid O I-Negation
cells O I-Negation
. O O

Like O O
other O O
enhancers O O
, O O
the O O
Ig O O
heavy O O
chain O O
enhancer O O
contains O O
several O O
short O O
sequence O O
motifs O O
that O O
bind O O
specific O O
transcription O O
factors O O
. O O

Molecular O O
mechanisms O O
of O O
steroid O O
action O O
: O O
a O O
novel O O
type O O
of O O
cross-talk O O
between O O
glucocorticoids O O
and O O
NF-kappa O O
B O O
transcription O O
factors O O
. O O

Transcription O O
factor O O
binding O O
sites O O
downstream O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
transcription O O
start O O
site O O
are O O
important O O
for O O
virus O O
infectivity O O
. O O

These O O
data O O
suggest O O
that O O
while O O
GATA-1 O O
can O O
transactivate O O
the O O
EpoR O O
promoter O O
, O O
the O O
level O O
of O O
hEpoR O O
gene O O
expression O O
does O O
not O B-Negation
depend O I-Negation
on O I-Negation
GATA-1 O I-Negation
alone O I-Negation
. O O

Multiple O O
TcR O O
delta O O
transcripts O O
deriving O O
from O O
an O O
unrearranged O O
TcR O O
delta O O
gene O O
were O O
detected O O
in O O
both O O
polyclonal O O
and O O
clonal O O
CD3-CD16+ O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
lines O O
. O O

Function O O
of O O
NF-kappa O O
B/Rel O O
binding O O
sites O O
in O O
the O O
major O O
histocompatibility O O
complex O O
class O O
II O O
invariant O O
chain O O
promoter O O
is O O
dependent O O
on O O
cell-specific O O
binding O O
of O O
different O O
NF-kappa O O
B/Rel O O
subunits O O
. O O

To O O
test O O
the O O
hypothesis O O
that O O
cortivazol O O
acts O O
in O O
dex-resistant O O
cells O O
by O O
making O O
use O O
of O O
the O O
residual O O
GR O O
found O O
there O O
, O O
wild-type O O
and O O
dex-resistant O O
clones O O
were O O
treated O O
with O O
various O O
concentrations O O
of O O
cortivazol O O
and O O
induction O O
of O O
GR O O
mRNA O O
was O O
studied O O
. O O

alpha-Tocopheryl O O
succinate O O
inhibits O O
monocytic O O
cell O O
adhesion O O
to O O
endothelial O O
cells O O
by O O
suppressing O O
NF-kappa O O
B O O
mobilization O O
. O O

Phorbol O O
esters O O
are O O
required O O
to O O
induce O O
AIM/CD69 O O
cell-surface O O
expression O O
as O O
well O O
as O O
for O O
triggering O O
the O O
proliferation O O
of O O
T O O
cells O O
in O O
conjunction O O
with O O
anti-AIM O O
mAb O O
. O O

The O O
ubiquitous O O
octamer-binding O O
protein O O
( O O
s O O
) O O
is O O
sufficient O O
for O O
transcription O O
of O O
immunoglobulin O O
genes O O
. O O

To O O
make O O
clear O O
the O O
roles O O
of O O
RA O O
and O O
RAR O O
alpha O O
in O O
the O O
normal O O
hematopoiesis O O
, O O
I O O
have O O
introduced O O
the O O
construct O O
of O O
human O O
RAR O O
alpha O O
( O O
hRAR O O
alpha O O
) O O
into O O
murine O O
bone O O
marrow O O
cells O O
with O O
retroviral O O
vector O O
, O O
and O O
selected O O
infected O O
cells O O
with O O
drug O O
resistant O O
marker O O
( O O
Neo O O
( O O
r O O
) O O
) O O
cultured O O
on O O
the O O
stroma O O
cell O O
line O O
( O O
PA6-neo O O
) O O
, O O
and O O
analyzed O O
the O O
behavior O O
of O O
infected O O
cells O O
. O O

CD40 O O
expression O O
was O O
confirmed O O
in O O
7 O O
human O O
MM O O
cell O O
lines O O
established O O
from O O
immunogenic O O
primary O O
tumors O O
or O O
metastases O O
, O O
whereas O O
11 O O
cell O O
lines O O
established O O
from O O
advanced O O
stages O O
were O O
CD40 O O
negative O O
. O O

Taken O O
together O O
these O O
results O O
demonstrate O O
that O O
the O O
IK O O
protein O O
plays O O
a O O
key O O
role O O
in O O
the O O
constitutive O O
expression O O
of O O
MHC O O
class O O
II O O
antigens O O
and O O
that O O
inhibition O O
induced O O
by O O
IK O O
is O O
upstream O O
of O O
CIITA O O
in O O
this O O
regulatory O O
pathway O O
. O O

We O O
and O O
others O O
have O O
shown O O
that O O
EBV O O
can O O
also O O
infect O O
a O O
subset O O
of O O
thymocytes O O
. O O

Currently O O
it O O
is O O
accepted O O
the O O
existence O O
of O O
a O O
cytoplasmic O O
and/or O O
nuclear O O
receptor O O
, O O
without B-Negation B-Negation
explaining I-Negation I-Negation
satisfactorily I-Negation I-Negation
how I-Negation I-Negation
the I-Negation I-Negation
hormones I-Negation I-Negation
come I-Negation I-Negation
to I-Negation I-Negation
the I-Negation I-Negation
nucleus I-Negation I-Negation
. O O

Stepwise O O
deletions O O
into O O
the O O
proximal O O
promoter O O
also O O
revealed O O
that O O
the O O
CBF O O
site O O
, O O
but O O
not B-Negation B-Negation
the I-Negation I-Negation
YY-1 I-Negation I-Negation
site I-Negation I-Negation
, O O
was O O
required O O
for O O
efficient O O
induction O O
of O O
transcriptional O O
activation O O
. O O

Domain O O
pairs O O
that O O
cluster O O
to O O
the O O
left O O
of O O
the O O
plot O O
can O O
be O O
called O O
specific O O
domain O O
pairs O O
, O O
as O O
they O O
only O O
occur O O
in O O
very O O
few O O
covered O O
experimental O O
interactions O O
. O O

We O O
have O O
previously O O
shown O O
that O O
treatment O O
of O O
Jurkat O O
T O O
cells O O
with O O
phytohemaglutinin O O
( O O
PHA O O
) O O
and O O
the O O
phorbol O O
ester O O
, O O
PMA O O
, O O
activated O O
transcription O O
initiation O O
from O O
the O O
IL-3 O O
gene O O
. O O

A O O
wide O O
spectrum O O
of O O
levels O O
of O O
HIV-1 O O
expression O O
have O O
been O O
demonstrated O O
in O O
various O O
cells O O
, O O
both O O
in O O
cell O O
culture O O
and O O
in O O
vivo O O
. O O

In O O
addition O O
, O O
we O O
supplemented O O
one O O
group O O
of O O
individuals O O
with O O
a O O
daily O O
oral O O
replacement O O
dose O O
of O O
T3 O O
to O O
isolate O O
the O O
influence O O
of O O
serum O O
thyroxine O O
( O O
T4 O O
) O O
and O O
thyrotropin O O
( O O
TSH O O
) O O
levels O O
on O O
receptor O O
kinetics O O
. O O

Every O O
enhancer O O
works O O
with O O
every O O
promoter O O
for O O
all O O
the O O
combinations O O
tested O O
: O O

Multiple O O
Alignment O O
of O O
the O O
RAG1 O O
Core O O
and O O
RAG1 O O
Core–Like O O
Proteins O O
Encoded O O
by O O
the O O
Sea O O
Urchin O O
and O O
Lancelet O O
Genomes O O

Expression O O
of O O
luciferase O O
in O O
these O O
cells O O
was O O
induced O O
by O O
phorbol O O
myristate O O
acetate O O
plus O O
a O O
calcium O O
ionophore O O
. O O

( O O
b O O
) O O
Readthrough O O
genes O O
can O O
be O O
distinguished O O
from O O
two O O
adjacent O O
genes O O
based O O
on O O
the O O
results O O
of O O
BLAST O O
searches O O
. O O

The O O
Drosophila O O
homolog O O
is O O
more O O
similar O O
to O O
Apaf-1 O O
than O O
to O O
CED-4 O O
: O O
it O O
has O O
the O O
WD O O
repeats O O
found O O
in O O
Apaf-1 O O
, O O
which O O
potentially O O
function O O
in O O
binding O O
regulatory O O
proteins O O
such O O
as O O
cytochrome O O
c O O
. O O

SDS-PAGE O O
analysis O O
of O O
the O O
receptor O O
protein O O
has O O
shown O O
a O O
molecular O O
weight O O
of O O
approximately O O
50 O O
kD O O
. O O

We O O
also O O
found O O
a O O
third O O
protein O O
on O O
contig O O
768 O O
that O O
contains O O
unique O O
motifs O O
in O O
its O O
N-terminal O O
regions O O
that O O
best O O
match O O
the O O
homologous O O
regions O O
of O O
RAG1 O O
. O O

The O O
previously O O
defined O O
minimal O O
enhancer O O
containing O O
the O O
muA O O
, O O
muE3 O O
, O O
and O O
muB O O
sites O O
is O O
transactivated O O
by O O
a O O
combination O O
of O O
the O O
ETS-domain O O
proteins O O
PU.1 O O
and O O
Ets-1 O O
in O O
nonlymphoid O O
cells O O
. O O

Similarly O O
, O O
when O O
two O O
proteins O O
show O O
clear O O
sequence O O
similarity O O
to O O
proteins O O
that O O
exist O O
in O O
a O O
complex O O
for O O
which O O
the O O
three-dimensional O O
structure O O
is O O
known O O
, O O
detailed O O
predictions O O
of O O
the O O
atomic-level O O
interactions O O
may O O
be O O
made O O
. O O

Binding O O
of O O
125I-labeled O O
aldosterone O O
to O O
plasma O O
membranes O O
of O O
HML O O
shares O O
important O O
features O O
with O O
these O O
functional O O
data O O
. O O

Radiolabeled O O
hormone/receptor O O
complexes O O
of O O
nuclei O O
isolated O O
from O O
cells O O
exposed O O
for O O
3 O O
h O O
to O O
radiolabeled O O
hormone O O
-- O O
in O O
contrast O O
to O O
identical O O
experiments O O
with O O
intact O O
cells O O
-- O O
did O O
not B-Negation B-Negation
disappear I-Negation I-Negation
from I-Negation I-Negation
the I-Negation I-Negation
nuclear I-Negation I-Negation
compartment I-Negation I-Negation
upon I-Negation I-Negation
incubation I-Negation I-Negation
of I-Negation I-Negation
nuclei I-Negation I-Negation
with I-Negation I-Negation
identical I-Negation I-Negation
concentrations I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
unlabeled I-Negation I-Negation
compound I-Negation I-Negation
. O O

One O O
gene O O
, O O
two O O
transcripts O O
: O O
isolation O O
of O O
an O O
alternative O O
transcript O O
encoding O O
for O O
the O O
autoantigen O O
La/SS-B O O
from O O
a O O
cDNA O O
library O O
of O O
a O O
patient O O
with O O
primary O O
Sjogrens O O
' O O
syndrome O O
. O O

Low-density O O
lipoprotein O O
( O O
LDL O O
) O O
is O O
a O O
well-established O O
risk O O
factor O O
for O O
atherosclerosis O O
. O O

Our O O
studies O O
provide O O
an O O
explanation O O
for O O
a O O
previous O O
observation O O
that O O
TCRG O O
mRNA O O
levels O O
, O O
but O O
not B-Negation B-Negation
mRNA I-Negation I-Negation
levels I-Negation I-Negation
for I-Negation I-Negation
T I-Negation I-Negation
cell I-Negation I-Negation
receptor I-Negation I-Negation
alpha I-Negation I-Negation
and I-Negation I-Negation
-beta I-Negation I-Negation
, O O
are O O
increased O O
by O O
ionomycin O O
treatment O O
. O O

By O O
using O O
70Z/3-derived O O
pre-B-cell O O
lines O O
either O O
lacking O B-Negation
or O I-Negation
expressing O I-Negation
human O I-Negation
CD14 O I-Negation
( O I-Negation
the O I-Negation
LPS O I-Negation
receptor O I-Negation
) O I-Negation
, O O
it O O
was O O
observed O O
that O O
expression O O
of O O
human O O
CD14 O O
imparted O O
responsiveness O O
to O O
LPS O O
but O O
not B-Negation B-Negation
to I-Negation I-Negation
OspA I-Negation I-Negation
or I-Negation I-Negation
spirochetal I-Negation I-Negation
lipopeptides I-Negation I-Negation
( O O
assessed O O
by O O
induction O O
of O O
NF-kappa O O
B O O
and O O
expression O O
of O O
surface O O
immunoglobulin O O
M O O
) O O
. O O

From O O
491 O O
complexes O O
described O O
by O O
Gavin O O
et O O
al. O O
, O O
157 O O
contained O O
at O O
least O O
one O O
pair O O
of O O
proteins O O
with O O
an O O
iPfam O O
domain O O
pair O O
( O O
31.9 O O
% O O
) O O
. O O

Analysis O O
of O O
the O O
inactive O O
X O O
specific O O
methylation O O
at O O
the O O
androgen O O
receptor O O
gene O O
showed O O
unbalanced O O
inactivation O O
in O O
the O O
twins O O
' O O
fibroblasts O O
and O O
in O O
opposite O O
directions O O
. O O

Human O O
umbilical O O
vein O O
ECs O O
were O O
pretreated O O
with O O
alpha-tcp O O
before O O
stimulation O O
with O O
known O O
agonists O O
of O O
monocyte O O
adhesion O O
: O O
IL-1 O O
( O O
10 O O
ng/ml O O
) O O
, O O
LPS O O
( O O
10 O O
ng/ml O O
) O O
, O O
thrombin O O
( O O
30 O O
U/ml O O
) O O
, O O
or O O
PMA O O
( O O
10 O O
nM O O
) O O
. O O

However O O
, O O
the O O
Ets O O
protein O O
( O O
s O O
) O O
that O O
regulated O O
GPIX O O
promoter O O
expression O O
was O O
unknown O O
. O O

This O O
protein O O
is O O
distinct O O
from O O
other O O
members O O
of O O
the O O
steroid/thyroid O O
hormone O O
receptor O O
family O O
including O O
the O O
COUP O O
protein O O
which O O
has O O
a O O
closely O O
related O O
DNA O O
binding O O
specificity O O
. O O

TCR O O
engagement O O
stimulates O O
the O O
activation O O
of O O
the O O
protein O O
kinase O O
Raf-1 O O
. O O

Three O O
molecular O O
clones O O
of O O
HIV-1 O O
, O O
derived O O
from O O
a O O
single O O
isolate O O
( O O
AL1 O O
) O O
, O O
exhibited O O
distinct O O
replicative O O
and O O
cytopathic O O
properties O O
during O O
propagation O O
in O O
a O O
human O O
T O O
cell O O
line O O
. O O

Furthermore O O
, O O
CAT O O
assays O O
using O O
mutated O O
HIV O O
long O O
terminal O O
repeat-CAT O O
constructs O O
and O O
gel O O
shift O O
assays O O
demonstrate O O
that O O
this O O
activation O O
is O O
dependent O O
on O O
the O O
NF-kappa O O
B O O
enhancer O O
. O O

To O O
study O O
transcriptional O O
regulation O O
in O O
normal O O
human O O
T O O
cells O O
, O O
we O O
have O O
optimized O O
conditions O O
for O O
transient O O
transfection O O
. O O

Moreover O O
, O O
mRNA B-Negation B-Negation
for I-Negation I-Negation
IL-2 I-Negation I-Negation
and I-Negation I-Negation
IFN-gamma I-Negation I-Negation
could I-Negation I-Negation
not I-Negation I-Negation
be I-Negation I-Negation
detected I-Negation I-Negation
. O O

Furthermore O O
, O O
nuclear O O
extracts O O
from O O
Ipr O O
CD4-8- O O
T O O
cells O O
display O O
high O O
levels O O
of O O
a O O
novel O O
specific O O
binding O O
activity O O
at O O
the O O
NF-AT O O
site O O
, O O
which O O
is O O
present O O
at O O
much O O
lower O O
levels O O
in O O
freshly O O
isolated O O
normal O O
T O O
lymphocytes O O
. O O

Stop O O
codon O O
usage O O

The O O
unique O O
characteristics O O
of O O
this O O
new O O
pathway O O
for O O
steroid O O
action O O
include O O
its O O
rapid O O
time O O
course O O
, O O
10,000-fold O O
selectivity O O
for O O
aldosterone O O
over O O
cortisol O O
and O O
the O O
ineffectiveness O O
of O O
spironolactones O O
, O O
classical O O
mineralocorticoid O O
antagonists O O
, O O
as O O
antagonists O O
of O O
the O O
response O O
. O O

PEBP2 O O
alpha O O
B O O
is O O
the O O
murine O O
counterpart O O
of O O
human O O
AML1 O O
, O O
which O O
is O O
located O O
at O O
the O O
breakpoints O O
of O O
the O O
8 O O
; O O
21 O O
and O O
3 O O
; O O
21 O O
chromosome O O
translocations O O
associated O O
with O O
acute O O
myeloid O O
leukemia O O
. O O

High O O
doses O O
of O O
sodium O O
salicylate O O
suppressed O O
NF-kappa O O
B O O
p65 O O
mRNA O O
accumulation O O
, O O
resulting O O
in O O
suppression O O
of O O
total O O
NF-kappa O O
B O O
, O O
p50 O O
on O O
tissue O O
oligonucleotide O O
had O O
no B-Negation B-Negation
effects I-Negation I-Negation
on I-Negation I-Negation
lipopolysaccharide-induced I-Negation I-Negation
NF-kappa I-Negation I-Negation
B I-Negation I-Negation
activation I-Negation I-Negation
. O O

A O O
mammalian O O
histone O O
deacetylase O O
related O O
to O O
the O O
yeast O O
transcriptional O O
regulator O O
Rpd3p O O
[ O O
see O O
comments O O
] O O

Clinical O O
deterioration O O
in O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
infection O O
is O O
associated O O
with O O
increased O O
levels O O
of O O
viral O O
replication O O
and O O
burden O O
in O O
the O O
peripheral O O
blood O O
and O O
lymphoid O O
organs O O
. O O

Three-step O O
filtering O O
of O O
the O O
candidate O O
clusters O O

CTLA-4-Mediated O O
inhibition O O
of O O
early O O
events O O
of O O
T O O
cell O O
proliferation O O
. O O

The O O
mechanism O O
of O O
PG490 O O
inhibition O O
of O O
cytokine O O
gene O O
expression O O
differs O O
from O O
cyclosporin O O
A O O
and O O
involves O O
nuclear O O
inhibition O O
of O O
transcriptional O O
activation O O
of O O
NF-kappaB O O
and O O
the O O
purine-box O O
regulator O O
operating O O
at O O
the O O
ARRE/NF-AT O O
site O O
at O O
a O O
step O O
after O O
specific O O
DNA O O
binding O O
. O O

As O O
suggested O O
in O O
18 O O
, O O
by O O
making O O
more O O
such O O
datasets O O
available O O
, O O
it O O
will O O
be O O
possible O O
to O O
increase O O
our O O
coverage O O
of O O
the O O
interaction O O
space O O
and O O
determine O O
the O O
most O O
likely O O
human O O
interactions O O
. O O

We O O
have O O
examined O O
the O O
effect O O
of O O
cytokines O O
on O O
IL-2 O O
deprivation-induced O O
apoptosis O O
of O O
human O O
antigen-specific O O
T O O
helper O O
clones O O
with O O
different O O
cytokine O O
production O O
profiles O O
. O O

The O O
table O O
shows O O
that O O
hAT O O
transposons O O
are O O
inserted O O
preferentially O O
into O O
GC-rich O O
sites O O
. O O

The O O
nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
regulates O O
cytokine O O
gene O O
expression O O
in O O
T O O
cells O O
through O O
cis-acting O O
elements O O
located O O
in O O
the O O
promoters O O
of O O
several O O
cytokine O O
genes O O
. O O

The O O
molecular O O
mechanisms O O
regulating O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
persistence O O
in O O
a O O
major O O
cell O O
reservoir O O
such O O
as O O
the O O
macrophage O O
remain O O
unknown O O
. O O

To O O
illustrate O O
the O O
characteristic O O
5-bp O O
TSDs O O
, O O
we O O
show O O
copies O O
of O O
Transib O O
transposons O O
with O O
intact O O
5 O O
? O O
and O O
3 O O
? O O
TIRs O O
from O O
diverse O O
families O O
of O O
Transib O O
transposons O O
present O O
in O O
the O O
D. O O
melanogaster O O
, O O
D. O O
pseudoobscura O O
, O O
A. O O
gambiae O O
, O O
and O O
S. O O
purpuratus O O
genomes O O
( O O
Figure O O
S4 O O
) O O
. O O

To O O
examine O O
the O O
molecular O O
basis O O
of O O
constitutive O O
NF-kappaB O O
DNA-binding O O
activity O O
in O O
HIV1-infected O O
cells O O
, O O
we O O
analyzed O O
the O O
phosphorylation O O
and O O
turnover O O
of O O
IkappaBalpha O O
protein O O
, O O
the O O
activity O O
of O O
the O O
double-stranded O O
RNA-dependent O O
protein O O
kinase O O
( O O
PKR O O
) O O
and O O
the O O
intracellular O O
levels O O
of O O
NF-kappaB O O
subunits O O
in O O
the O O
PLB-985 O O
and O O
U937 O O
myeloid O O
cell O O
models O O
. O O

We O O
have O O
demonstrated O O
that O O
lipoarabinomannan O O
( O O
LAM O O
) O O
from O O
the O O
mycobacterial O O
cell O O
wall O O
, O O
which O O
was O O
virtually O O
devoid O O
of O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
stimulated O O
mononuclear O O
phagocytes O O
to O O
release O O
IL-6 O O
in O O
a O O
dose-response O O
manner O O
. O O

TPO O O
induced O O
tyrosine O O
phosphorylation O O
of O O
the O O
TPO O O
receptor O O
but O O
not B-Negation B-Negation
the I-Negation I-Negation
erythropoietin I-Negation I-Negation
( I-Negation I-Negation
EPO I-Negation I-Negation
) I-Negation I-Negation
receptor I-Negation I-Negation
. O O

A O O
proximal O O
region O O
between O O
-46 O O
and O O
-80 O O
was O O
identified O O
as O O
the O O
minimum O O
sequence O O
for O O
the O O
basal O O
and O O
inducible O O
expression O O
of O O
the O O
IL-9 O O
gene O O
in O O
C5MJ2 O O
cells O O
. O O

We O O
investigated O O
the O O
upstream O O
regulatory O O
elements O O
of O O
the O O
human O O
IL-4 O O
promoter O O
. O O

The O O
Ets O O
protein O O
Spi-B O O
is O O
expressed O O
exclusively O O
in O O
B O O
cells O O
and O O
T O O
cells O O
during O O
development O O
. O O

The O O
PSSM O O
is O O
a O O
weight O O
matrix O O
indicating O O
the O O
relative O O
occurrence O O
of O O
each O O
of O O
the O O
20 O O
aa O O
at O O
each O O
position O O
in O O
the O O
alignment O O
. O O

The O O
two O O
nuclear O O
proteins O O
NF-kappa O O
B O O
( O O
consisting O O
of O O
subunits O O
p50 O O
andp65 O O
) O O
and O O
the O O
DNA-binding O O
subunit O O
of O O
NF-kappa O O
B O O
( O O
p50 O O
) O O
by O O
itself O O
, O O
also O O
called O O
KBF1 O O
, O O
are O O
constitutively O O
expressed O O
and O O
localized O O
in O O
the O O
nucleus O O
of O O
the O O
human O O
T-cell O O
line O O
IARC O O
301.5 O O
. O O

Tumor-derived O O
soluble O O
products O O
from O O
cultured O O
RCC O O
explants O O
inhibit O O
NFkappaB O O
activity O O
in O O
T O O
cells O O
from O O
healthy O O
volunteers O O
, O O
despite O O
a O O
normal O O
level O O
of O O
stimulus-induced O O
IkappaBalpha O O
degradation O O
in O O
these O O
cells O O
. O O

In O O
freshly O O
isolated O O
cells O O
, O O
both O O
FOS O O
and O O
FOSB O O
mRNAs O O
increase O O
dramatically O O
in O O
response O O
to O O
the O O
protein O O
synthesis O O
inhibitor O O
cycloheximide O O
. O O

They O O
may O O
also O O
prove O O
useful O O
in O O
the O O
identification O O
of O O
new O O
, O O
ubiquitous O O
cellular O O
transcription O O
factors O O
. O O

Furthermore O O
, O O
we O O
evaluated O O
the O O
mineralocorticoid O O
receptor O O
( O O
MR O O
) O O
count O O
in O O
mononuclear O O
leukocytes O O
in O O
the O O
2 O O
groups O O
. O O

All O O
RSSs O O
can O O
be O O
divided O O
into O O
two O O
groups O O
, O O
referred O O
to O O
as O O
RSS12 O O
and O O
RSS23 O O
, O O
and O O
consist O O
of O O
conserved O O
heptamer O O
and O O
nonamer O O
sequences O O
separated O O
by O O
a O O
variable O O
spacer O O
either O O
12 O O
± O O
1 O O
( O O
RSS12 O O
) O O
or O O
23 O O
± O O
1 O O
( O O
RSS23 O O
) O O
bp O O
long O O
[ O O
4–7 O O
] O O
. O O

Purified O O
quiescent O O
human O O
blood O O
T O O
lymphocytes O O
were O O
subjected O O
to O O
: O O
( O O
i O O
) O O
acute O O
exposure O O
to O O
hydrogen O O
peroxide O O
; O O
( O O
ii O O
) O O
chronic O O
exposure O O
to O O
hydrogen O O
peroxide O O
; O O
and O O
( O O
iii O O
) O O
acute O O
exposure O O
to O O
ionizing O O
radiation O O
. O O

The O O
role O O
of O O
p95vav O O
in O O
TCR-mediated O O
signaling O O
processes O O
is O O
unclear O O
. O O

Levels O O
of O O
bcl-2 O O
mRNA O O
and O O
protein O O
increase O O
with O O
cross-linking O O
of O O
surface O O
immunoglobulin O O
. O O

A O O
second O O
peak O O
was O O
observed O O
at O O
a O O
later O O
time O O
point O O
following O O
LPS O O
stimulation O O
, O O
which O O
consisted O O
of O O
both O O
IKK-alpha O O
and O O
-beta O O
activity O O
. O O

Multiple O O
cellular O O
DNA-binding O O
transcription O O
factors O O
are O O
required O O
by O O
HIV O O
type O O
1 O O
for O O
RNA O O
synthesis O O
. O O

These O O
data O O
suggest O O
that O O
Rho O O
potentiates O O
AP-1 O O
transcription O O
during O O
T-cell O O
activation O O
. O O

ras O O
protein O O
activity O O
is O O
essential O O
for O O
T-cell O O
antigen O O
receptor O O
signal O O
transduction O O
. O O

Differential O O
regulation O O
of O O
IL-6 O O
gene O O
transcription O O
and O O
expression O O
by O O
IL-4 O O
and O O
IL-10 O O
in O O
human O O
monocytic O O
cell O O
lines O O
. O O

Interferon-alpha O O
activates O O
multiple O O
STAT O O
proteins O O
and O O
upregulates O O
proliferation-associated O O
IL-2Ralpha O O
, O O
c-myc O O
, O O
and O O
pim-1 O O
genes O O
in O O
human O O
T O O
cells O O
. O O

Intriguingly O O
, O O
the O O
transcription O O
of O O
the O O
Drosophila O O
CED-4/Apaf-1 O O
homolog O O
is O O
upregulated O O
in O O
response O O
to O O
both O O
X-ray O O
and O O
ultraviolet O O
irradiation O O
, O O
suggesting O O
that O O
death-inducing O O
stimuli O O
can O O
feed O O
into O O
the O O
cell O O
death O O
pathway O O
at O O
this O O
step O O
[ O O
16 O O
] O O
. O O

Two O O
examples O O
extracted O O
from O O
the O O
NCBI O O
BLASTP O O
output O O
illustrate O O
similarity O O
between O O
the O O
approximately O O
60-aa O O
C-terminal O O
portions O O
of O O
the O O
Transib2_AG O O
TPase O O
( O O
which O O
we O O
used O O
as O O
a O O
query O O
in O O
a O O
BLASTP O O
search O O
against O O
all O O
GenBank O O
proteins O O
) O O
and O O
the O O
RAG1 O O
core O O
. O O

It O O
was O O
found O O
that O O
lipopolysaccharide O O
induced O O
strongly O O
both O O
c-fos O O
and O O
c-jun O O
expression O O
as O O
well O O
as O O
AP1 O O
formation O O
. O O

Transient O O
tranfection O O
of O O
a O O
promyelocyte O O
cell O O
line O O
( O O
NB4 O O
) O O
with O O
a O O
C/EBP-epsilon O O
expression O O
plasmid O O
increased O O
cell O O
growth O O
by O O
sevenfold O O
, O O
while O O
antisense O O
C/EBP-epsilon O O
caused O O
a O O
fivefold O O
decrease O O
in O O
clonal O O
growth O O
of O O
these O O
cells O O
. O O

The O O
results O O
demonstrate O O
that O O
okadaic O O
acid O O
treatment O O
is O O
associated O O
with O O
induction O O
of O O
a O O
differentiated O O
monocyte O O
phenotype O O
characterized O O
by O O
: O O
( O O
a O O
) O O
growth O O
arrest O O
; O O
( O O
b O O
) O O
increases O O
in O O
Mac-1 O O
cell O O
surface O O
antigen O O
expression O O
; O O
( O O
c O O
) O O
down-regulation O O
of O O
c-myc O O
transcripts O O
; O O
and O O
( O O
d O O
) O O
induction O O
of O O
tumor O O
necrosis O O
factor O O
gene O O
expression O O
. O O

We O O
showed O O
that O O
both O O
IL-10 O O
and O O
IL-4 O O
inhibit O O
LPS-induced O O
IL-6 O O
mRNA O O
and O O
protein O O
expression O O
by O O
inhibiting O O
the O O
transcription O O
rate O O
of O O
the O O
IL-6 O O
gene O O
. O O

The O O
Pan O O
gene O O
encodes O O
at O O
least O O
two O O
distinct O O
transcripts O O
, O O
Pan-1 O O
and O O
Pan-2 O O
( O O
also O O
known O O
as O O
E47 O O
and O O
E12 O O
, O O
respectively O O
) O O
, O O
by O O
the O O
mechanism O O
of O O
alternative O O
RNA O O
splicing O O
. O O

Functional O O
synergy O O
between O O
Raf O O
and O O
calcineurin O O
. O O

By O O
using O O
immunohistochemistry O O
with O O
antibodies O O
against O O
proteins O O
encoded O O
by O O
a O O
particular O O
gene O O
in O O
a O O
cluster O O
, O O
the O O
identity O O
of O O
the O O
cell O O
type O O
within O O
the O O
tumor O O
specimen O O
that O O
contributed O O
the O O
observed O O
gene O O
expression O O
pattern O O
could O O
be O O
determined O O
. O O

To O O
analyze O O
the O O
mechanisms O O
that O O
lead O O
to O O
the O O
expression O O
of O O
IL-1alpha O O
in O O
HTLV-I-infected O O
cell O O
lines O O
, O O
we O O
studied O O
regulatory O O
regions O O
of O O
the O O
human O O
IL-1alpha O O
promoter O O
involved O O
in O O
activation O O
of O O
the O O
IL-1alpha O O
gene O O
. O O

A O O
number O O
of O O
the O O
ETS O O
family O O
of O O
transcription O O
factors O O
are O O
expressed O O
in O O
T O O
cells O O
, O O
including O O
ETS1 O O
and O O
ELF1 O O
. O O

Abnormal O O
activation O O
of O O
NFkappaB O O
is O O
also O O
present O O
in O O
> O O
50 O O
% O O
of O O
patients O O
and O O
may O O
also O O
revert O O
to O O
normal O O
during O O
IL-2/IFN O O
alpha-based O O
treatment O O
. O O

Furthermore O O
, O O
NF-kappaB O O
transcriptional O O
factor O O
of O O
aggregated O O
cells O O
had O O
approximately O O
40-fold O O
higher O O
activity O O
than O O
that O O
of O O
parental O O
cells O O
. O O

Inhibition O O
of O O
NO O O
synthase O O
( O O
NOS O O
) O O
during O O
the O O
second O O
A/R O O
challenge O O
prevents O O
the O O
development O O
of O O
A/R O O
tolerance O O
with O O
respect O O
to O O
PMN O O
adhesion O O
. O O

Preincubation O O
of O O
cells O O
with O O
1,25- O O
( O O
OH O O
) O O
2D3 O O
augmented O O
IL-1 O O
beta O O
mRNA O O
levels O O
only O O
in O O
U-937 O O
and O O
HL-60 O O
cells O O
. O O

As O O
described O O
in O O
other O O
systems O O
, O O
fragmentation O O
required O O
ongoing O O
protein O O
synthesis O O
. O O

As O O
a O O
functional O O
correlate O O
of O O
this O O
finding O O
, O O
transient O O
co-transfection O O
of O O
HIV-1 O O
LTR O O
reporter O O
constructs O O
in O O
a O O
different O O
T O O
cell O O
line O O
demonstrated O O
that O O
v-src O O
activated O O
this O O
promoter O O
in O O
a O O
kappa O O
B-dependent O O
manner O O
. O O

M2 O O
leukemic O O
blast O O
cells O O
behave O O
differently O O
because O O
they O O
undergo O O
monocytic O O
differentiation O O
with O O
both O O
the O O
differentiation O O
inducers O O
. O O

Proximal O O
signal O O
transduction O O
events O O
and O O
immediate O O
early O O
gene O O
transcription O O
were O O
unaffected O O
. O O

A O O
murine O O
monoclonal O O
antibody O O
raised O O
to O O
an O O
unidentified O O
estrogen O O
receptor-related O O
29-kDa O O
protein O O
selectively O O
recognized O O
these O O
proteins O O
as O O
well O O
as O O
a O O
more O O
basic O O
, O O
unphosphorylated O O
27-kDa O O
protein O O
. O O

Comparison O O
of O O
these O O
sequences O O
to O O
those O O
required O O
to O O
mediate O O
virus O O
or O O
lipopolysaccharide O O
( O O
LPS O O
) O O
induction O O
of O O
the O O
gene O O
reveal O O
significant O O
differences O O
, O O
and O O
thus O O
, O O
the O O
sequence O O
requirements O O
for O O
PMA O O
induction O O
are O O
distinct O O
from O O
those O O
that O O
mediate O O
induction O O
by O O
virus O O
or O O
LPS O O
. O O

To O O
understand O O
the O O
diminished O O
T O O
cell O O
response O O
to O O
activation O O
signals O O
, O O
we O O
measured O O
nucleoprotein O O
DNA-binding O O
activities O O
regulating O O
gene O O
expression O O
during O O
T O O
cell O O
activation O O
using O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

The O O
recent O O
definition O O
of O O
a O O
consensus O O
DNA O O
binding O O
sequence O O
for O O
the O O
Ets O O
family O O
of O O
transcription O O
factors O O
has O O
allowed O O
the O O
identification O O
of O O
potential O O
Ets O O
binding O O
sites O O
in O O
the O O
promoters O O
and O O
enhancers O O
of O O
many O O
inducible O O
T-cell O O
genes O O
. O O

BM O O
were O O
exposed O O
to O O
Chrysotile O O
B O O
and O O
soot O O
particle O O
FR O O
101 O O
in O O
a O O
concentration O O
of O O
100 O O
microg/10 O O
( O O
6 O O
) O O
cells O O
. O O

Contribution O O
of O O
the O O
modules O O
. O O

We O O
demonstrate O O
that O O
upon O O
stimulation O O
by O O
lipopolysaccharide O O
, O O
Taxol O O
, O O
phorbol O O
myristate O O
acetate O O
, O O
interleukin-1 O O
, O O
or O O
double-stranded O O
RNA O O
, O O
I B-Negation B-Negation
kappaB I-Negation I-Negation
alpha I-Negation I-Negation
is I-Negation I-Negation
not I-Negation I-Negation
degraded I-Negation I-Negation
, O O
as O O
a O O
result O O
of O O
an O O
absence B-Negation B-Negation
of I-Negation I-Negation
induced I-Negation I-Negation
phosphorylation I-Negation I-Negation
on I-Negation I-Negation
serines I-Negation I-Negation
32 I-Negation I-Negation
and I-Negation I-Negation
36 I-Negation I-Negation
. O O

We O O
have O O
located O O
the O O
major O O
positive O O
regulatory O O
region O O
for O O
control O O
of O O
bcl-2 O O
expression O O
in O O
B O O
cells O O
in O O
the O O
5'-flanking O O
region O O
. O O

The O O
HLK O O
ensemble O O
method O O
4 O O
successfully O O
exploits O O
the O O
first O O
key O O
observation O O
above O O
. O O

To O O
define O O
the O O
regions O O
of O O
the O O
gene O O
required O O
for O O
transcription O O
activation O O
, O O
we O O
generated O O
a O O
series O O
of O O
reporter O O
constructs O O
containing O O
different O O
regions O O
of O O
the O O
IL-3 O O
gene O O
5 O O
' O O
and O O
3 O O
' O O
flanking O O
sequences O O
. O O

Mutations O O
in O O
this O O
site O O
which O O
eliminate O O
PU.1 O O
binding O O
decrease O O
M-CSF O O
receptor O O
promoter O O
activity O O
significantly O O
in O O
macrophage O O
cell O O
lines O O
only O O
. O O

Two O O
of O O
these O O
were O O
not B-Negation B-Negation
cell I-Negation I-Negation
type I-Negation I-Negation
specific I-Negation I-Negation
, O O
but O O
the O O
third O O
was O O
detected O O
only O O
in O O
EBNA2 O O
positive O O
cell O O
extracts O O
. O O

Using O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
at O O
least O O
six O O
novel O O
octamer O O
binding O O
proteins O O
were O O
detected O O
in O O
nuclear O O
extracts O O
of O O
cultured O O
mouse O O
astrocytes O O
. O O

Finally O O
, O O
potential O O
targets O O
of O O
regulation O O
by O O
the O O
zinc-finger O O
transcription O O
factor O O
encoded O O
by O O
egr-1 O O
include O O
the O O
interleukin-2 O O
, O O
CD44 O O
, O O
ICAM-1 O O
, O O
and O O
tumor O O
necrosis O O
factor O O
genes O O
. O O

The O O
SCL O O
protein O O
displays O O
cell-specific O O
heterogeneity O O
in O O
size O O
. O O

This O O
novel O O
enzyme O O
is O O
distinct O O
from O O
E6-AP O O
, O O
the O O
p53-conjugating O O
ligase O O
, O O
and O O
from O O
E3 O O
alpha O O
, O O
the O O
`` O O
N-end O O
rule O O
'' O O
ligase O O
. O O

Since O O
the O O
DSE O O
and O O
TRE O O
sites O O
can B-Negation B-Negation
not I-Negation I-Negation
bind I-Negation I-Negation
CREB/ATF I-Negation I-Negation
homodimers I-Negation I-Negation
, O O
we O O
propose O O
a O O
mechanism O O
in O O
which O O
the O O
HIV-1 O O
DSE O O
bind O O
heterodimers O O
composed O O
of O O
both O O
AP-1 O O
and O O
CREB/ATF O O
proteins O O
. O O

The O O
5'-positive O O
regulatory O O
unit O O
, O O
consisting O O
of O O
the O O
promoter O O
and O O
the O O
5 O O
' O O
enhancer O O
, O O
is O O
already O O
active O O
at O O
the O O
CD4-CD8-double-negative O O
( O O
DN O O
) O O
stage O O
of O O
development O O
. O O

Despite O O
stimulation O O
with O O
LPS O O
, O O
disruption O O
of O O
the O O
NF-kappaB O O
signaling O O
pathway O O
in O O
precursor O O
B O O
cells O O
led O O
to O O
the O O
loss O O
of O O
inducible O O
Oct-2 O O
DNA O O
binding O O
activity O O
in O O
vitro O O
and O O
the O O
suppression O O
of O O
Oct-2-directed O O
transcription O O
in O O
vivo O O
. O O

Whereas O O
the O O
NF-kappaB O O
binding O O
activity O O
in O O
Tax-expressing O O
T-cell O O
lines O O
consisted O O
mostly O O
of O O
p50/c-Rel O O
, O O
fresh O O
ATL O O
samples O O
contained O O
p50/p50 O O
and O O
p50/p65 O O
heterodimers O O
. O O

Activation O O
of O O
primary O O
human O O
T-lymphocytes O O
through O O
CD2 O O
plus O O
CD28 O O
adhesion O O
molecules O O
induces O O
long-term O O
nuclear O O
expression O O
of O O
NF-kappa O O
B O O
. O O

Because O O
oleic O O
acid O O
is O O
implicated O O
in O O
the O O
antiatherogenic O O
effects O O
attributed O O
to O O
the O O
Mediterranean O O
diet O O
, O O
we O O
investigated O O
whether O O
this O O
fatty O O
acid O O
can O O
modulate O O
endothelial O O
activation O O
, O O
ie O O
, O O
the O O
concerted O O
expression O O
of O O
gene O O
products O O
involved O O
in O O
leukocyte O O
recruitment O O
and O O
early O O
atherogenesis O O
. O O

Average O O
and O O
standard O O
error O O
of O O
sensitivity O O
and O O
PPV O O
for O O
the O O
component O O
algorithms O O
of O O
SCOPE O O
on O O
all O O
78 O O
regulons O O
. O O

The O O
only O O
line O O
showing O O
significant O O
( O O
but O O
not B-Negation B-Negation
complete I-Negation I-Negation
) I-Negation I-Negation
rescue O I-Negation
of O I-Negation
adgf-a O I-Negation
survival O I-Negation
without B-Negation I-Negation
expression I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
lymph I-Negation I-Negation
glands I-Negation I-Negation
was O O
GawB5015 O O
( O O
see O O
Figure O O
2 O O
) O O
, O O
which O O
expresses O O
the O O
Gal4 O O
driver O O
very O O
strongly O O
and O O
specifically O O
in O O
the O O
ring O O
gland O O
and O O
salivary O O
glands O O
( O O
as O O
well O O
as O O
very O O
weak O O
and O O
spotty O O
expression O O
in O O
imaginal O O
discs O O
[ O O
unpublished O O
data O O
] O O
) O O
. O O

In O O
ductal O O
carcinomas O O
, O O
chromosome O O
1 O O
alterations O O
increased O O
with O O
histologic O O
grade O O
, O O
DNA O O
aneuploidy O O
, O O
loss O O
of O O
bcl-2 O O
and O O
high O O
c-erb O O
B-2 O O
expression O O
. O O

Surfactant O O
suppresses O O
NF-kappa O O
B O O
activation O O
in O O
human O O
monocytic O O
cells O O
. O O

Although O O
NF-AT B-Negation B-Negation
has I-Negation I-Negation
not I-Negation I-Negation
been I-Negation I-Negation
cloned I-Negation I-Negation
or I-Negation I-Negation
purified I-Negation I-Negation
, O O
there O O
is O O
evidence O O
that O O
it O O
is O O
a O O
major O O
target O O
for O O
immunosuppression O O
by O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
and O O
FK506 O O
( O O
refs O O
2-7 O O
) O O
. O O

Both O O
signal O O
cascades O O
contribute O O
to O O
the O O
induction O O
of O O
the O O
interleukin O O
2 O O
( O O
IL-2 O O
) O O
gene O O
during O O
T-cell O O
activation O O
. O O

Communication O O
between O O
resident O O
tissue O O
fibroblasts O O
and O O
T O O
cells O O
is O O
necessary O O
for O O
normal O O
wound O O
healing O O
, O O
and O O
can O O
be O O
pathologic O O
, O O
resulting O O
in O O
tissue O O
fibrosis O O
. O O

In O O
each O O
case O O
the O O
allele O O
loss O O
was O O
caused O O
by O O
an O O
interstitial O O
deletion O O
because O O
heterozygosity O O
at O O
distal O O
markers O O
was O O
retained O O
and O O
because O O
quantitative O O
Southern O O
blotting O O
demonstrated O O
hemizygosity O O
. O O

Leukotriene O O
B4 O O
stimulates O O
c-fos O O
and O O
c-jun O O
gene O O
transcription O O
and O O
AP-1 O O
binding O O
activity O O
in O O
human O O
monocytes O O
. O O

Two O O
cis-acting O O
elements O O
GM-kappa O O
B/GC-box O O
and O O
CLE0 O O
, O O
of O O
the O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
( O O
GM-CSF O O
) O O
gene O O
are O O
required O O
for O O
maximal O O
induction O O
in O O
Jurkat O O
T O O
cells O O
by O O
costimulation O O
with O O
phorbol-12-myristate O O
acetate O O
( O O
PMA O O
) O O
and O O
Ca2+ O O
ionophore O O
( O O
A23187 O O
) O O
. O O

Again O O
, O O
as O O
in O O
the O O
case O O
of O O
the O O
sea O O
urchin O O
sequences O O
, O O
the O O
lancelet O O
RAG1 O O
core–like O O
elements O O
show O O
no B-Negation B-Negation
hallmarks I-Negation I-Negation
of I-Negation I-Negation
transposons I-Negation I-Negation
( B-Negation I-Negation
data I-Negation I-Negation
not I-Negation I-Negation
shown I-Negation I-Negation
) I-Negation I-Negation
. O O

However O O
, O O
this O O
condition O O
is O O
not B-Negation B-Negation
sufficient I-Negation I-Negation
, O O
since O O
two O O
major O O
problems O O
remain O O
: O O
: O O
pseudogenes O O
and O O
two O O
adjacent O O
genes O O
. O O

Using O O
this O O
system O O
, O O
we O O
observed O O
that O O
CD28 O O
stimulation O O
by O O
B7-transfected O O
CHO O O
cells O O
induced O O
a O O
proliferative O O
response O O
in O O
T O O
cells O O
that O B-Negation
was O I-Negation
not B-Negation I-Negation
accompanied I-Negation I-Negation
by I-Negation I-Negation
measurable I-Negation I-Negation
IL-2 I-Negation I-Negation
production I-Negation I-Negation
. O O

PDTC O O
strongly O O
inhibited O O
low O O
shear-induced O O
activation O O
of O O
NF-kappaB O O
, O O
expression O O
of O O
VCAM-1 O O
, O O
and O O
EC-Mn O O
adhesion O O
. O O

In O O
summary O O
, O O
we O O
derived O O
an O O
experimental O O
system O O
that O O
allows O O
us O O
to O O
dissect O O
the O O
function O O
of O O
GATA-1 O O
in O O
red O O
cell O O
development O O
at O O
a O O
genetic O O
level O O
. O O

Recent O O
studies O O
have O O
shown O O
that O O
the O O
non-steroidal O O
anti-inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
activate O O
heat O O
shock O O
transcription O O
factor O O
( O O
HSF1 O O
) O O
from O O
a O O
latent O O
cytoplasmic O O
form O O
to O O
a O O
nuclear O O
, O O
DNA O O
binding O O
state O O
. O O

Role O O
of O O
AP-1- O O
and O O
octamer-binding O O
proteins O O
in O O
control O O
of O O
IL3 O O
gene O O
expression O O
. O O

Many O O
effects O O
of O O
lipopolysaccharide O O
( O O
LPS O O
) O O
on O O
gene O O
expression O O
, O O
including O O
that O O
of O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
, O O
in O O
monocytic O O
cells O O
are O O
mediated O O
by O O
activation O O
of O O
kappa O O
B O O
DNA-binding O O
proteins O O
. O O

Irrespective O O
of O O
the O O
etiology O O
, O O
many O O
kidney O O
diseases O O
result O O
in O O
inflammation O O
and O O
fibrosis O O
of O O
the O O
tubulointerstitium O O
, O O
with O O
the O O
subsequent O O
loss O O
of O O
renal O O
function O O
. O O

The O O
effects O O
of O O
TNF-alpha O O
on O O
gene O O
expression O O
were O O
examined O O
by O O
transient O O
expression O O
assays O O
using O O
reporter O O
chloramphenicol O O
acetyltransferase O O
plasmids O O
linked O O
to O O
regulatory O O
elements O O
from O O
the O O
HIV O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
and O O
the O O
beta O O
interferon O O
promoter O O
. O O

Adherence-dependent O O
increase O O
in O O
human O O
monocyte O O
PDGF O O
( O O
B O O
) O O
mRNA O O
is O O
associated O O
with O O
increases O O
in O O
c-fos O O
, O O
c-jun O O
, O O
and O O
EGR2 O O
mRNA O O
. O O

Vitamin O O
D O O
receptor O O
expression O O
in O O
human O O
lymphocytes O O
. O O

Interestingly O O
, O O
alteration O O
of O O
either O O
the O O
microB O O
or O O
E3 O O
site O O
in O O
a O O
70-base-pair O O
fragment O O
of O O
the O O
IgH O O
enhancer O O
that O O
lacks B-Negation B-Negation
the I-Negation I-Negation
binding I-Negation I-Negation
site I-Negation I-Negation
for I-Negation I-Negation
OCTA I-Negation I-Negation
abolished O I-Negation
enhancer O I-Negation
activity O I-Negation
in O I-Negation
lymphoid O I-Negation
cells O I-Negation
completely O I-Negation
. O O

Suppression O O
of O O
NF-kappaB O O
activation O O
in O O
normal O O
T O O
cells O O
by O O
supernatant O O
fluid O O
from O O
human O O
renal O O
cell O O
carcinomas O O
. O O

Afternoon O O
ACTH O O
and O O
cortisol O O
concentrations O O
did O O
not B-Negation B-Negation
differ I-Negation I-Negation
significantly I-Negation I-Negation
between I-Negation I-Negation
the I-Negation I-Negation
three I-Negation I-Negation
groups I-Negation I-Negation
. O O

These O O
findings O O
are O O
consistent O O
with O O
a O O
model O O
for O O
Rex-mediated O O
trans-activation O O
in O O
which O O
Rex-viral O O
mRNA O O
complexes O O
are O O
targeted O O
for O O
nuclear O O
export O O
by O O
the O O
direct O O
action O O
of O O
the O O
activation O O
domain O O
. O O

Cross-linking O O
of O O
CD44 O O
on O O
rheumatoid O O
synovial O O
cells O O
up-regulates O O
VCAM-1 O O
. O O

The O O
TCR-mediated O O
activation O O
of O O
NF-kappaB O O
was O O
also O O
dependent O O
on O O
a O O
Ca2+ O O
influx O O
, O O
because O O
the O O
Ca2+ O O
channel O O
blocker O O
, O O
SK O O
& O O
F O O
96365 O O
, O O
as O O
well O O
as O O
other O O
agents O O
that O O
prevented O O
the O O
Ca2+ O O
influx O O
, O O
inhibited O O
NF-kappaB O O
activation O O
. O O

This O O
decrease O O
was O O
seen O O
in O O
patients O O
who O O
responded O O
to O O
the O O
therapy O O
as O O
well O O
as O O
in O O
those O O
who O O
did O O
not B-Negation B-Negation
. O O

The O O
results O O
showed O O
that O O
the O O
average O O
number O O
of O O
GCR O O
in O O
asthmatics O O
was O O
significantly O O
lower O O
than O O
that O O
in O O
healthy O O
subjects O O
( O O
P O O
< O O
0.01 O O
) O O
, O O
and O O
there O O
was O O
a O O
linear O O
correlation O O
between O O
the O O
number O O
of O O
GCR O O
and O O
the O O
course O O
of O O
asthma O O
. O O

The O O
ecd1 O O
flies O O
( O O
Bloomington O O
stock O O
BL-218 O O
) O O
served O O
as O O
a O O
control O O
for O O
the O O
functional O O
20E O O
diet O O
[ O O
31 O O
] O O
: O O
flies O O
were O O
raised O O
at O O
22 O O
°C O O
( O O
permissive O O
temperature O O
for O O
the O O
temperature-sensitive O O
ecd1 O O
mutation O O
) O O
and O O
transferred O O
to O O
vials O O
with O O
control O O
or O O
20E-containing O O
diet O O
and O O
raised O O
at O O
29 O O
°C O O
( O O
restrictive O O
temperature O O
) O O
. O O

However O O
, O O
it B-Negation B-Negation
was I-Negation I-Negation
not I-Negation I-Negation
detected I-Negation I-Negation
in I-Negation I-Negation
lymphoid I-Negation I-Negation
cells I-Negation I-Negation
MOLT4 I-Negation I-Negation
( I-Negation I-Negation
T I-Negation I-Negation
cell I-Negation I-Negation
) I-Negation I-Negation
and I-Negation I-Negation
BALL1 I-Negation I-Negation
( I-Negation I-Negation
B I-Negation I-Negation
cell I-Negation I-Negation
) I-Negation I-Negation
, I-Negation I-Negation
nor I-Negation I-Negation
in I-Negation I-Negation
K562 I-Negation I-Negation
erythroblasts I-Negation I-Negation
. O O

Thus O O
, O O
our O O
data O O
establish O O
that O O
ATF/CREB O O
factors O O
functionally O O
modulate O O
histone O O
H4 O O
gene O O
transcription O O
at O O
distal O O
and O O
proximal O O
promoter O O
elements O O
. O O

Transactivation O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
promoter O O
by O O
human O O
herpesvirus O O
6 O O
( O O
HHV-6 O O
) O O
strains O O
GS O O
and O O
Z-29 O O
in O O
primary O O
human O O
T O O
lymphocytes O O
and O O
identification O O
of O O
transactivating O O
HHV-6 O O
( O O
GS O O
) O O
gene O O
fragments O O
. O O

First O O
, O O
only O O
iORFs O O
longer O O
than O O
80 O O
codons O O
were O O
extracted O O
. O O

This O O
pie O O
chart O O
shows O O
how O O
many O O
iPfam O O
domain O O
pairs O O
were O O
found O O
in O O
PDB O O
structures O O
from O O
each O O
species O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
demonstrated O O
no B-Negation B-Negation
difference I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
pattern I-Negation I-Negation
of I-Negation I-Negation
TNF-stimulated I-Negation I-Negation
nuclear I-Negation I-Negation
factor-kappaB I-Negation I-Negation
activation I-Negation I-Negation
between I-Negation I-Negation
HUVECs I-Negation I-Negation
and I-Negation I-Negation
HUAECs I-Negation I-Negation
. O O

Thus O O
, O O
reduced O O
levels O O
of O O
PKC-induced O O
nuclear O O
NF-kB O O
activity O O
in O O
two O O
T O O
cell O O
subclones O O
did O O
not B-Negation B-Negation
affect I-Negation I-Negation
their I-Negation I-Negation
normal I-Negation I-Negation
cell I-Negation I-Negation
growth I-Negation I-Negation
, O O
but O O
correlated O O
with O O
a O O
pronounced O O
reduction O O
in O O
their O O
susceptibility O O
to O O
HIV-1 O O
infection O O
. O O

These O O
results O O
suggest O O
that O O
, O O
while O O
lipopolysaccharide-induced O O
expression O O
of O O
inflammatory O O
mediators O O
requires O O
tyrosine O O
kinase O O
activity O O
, O O
tyrosine O O
kinase O O
activity O O
is O O
not O B-Negation
obligatory O I-Negation
for O I-Negation
lipopolysaccharide O I-Negation
signal O I-Negation
transduction O I-Negation
. O O

It O O
is O O
identical O O
to O O
the O O
Spi-1 O O
oncogene O O
, O O
which O O
is O O
implicated O O
in O O
spleen O O
focus-forming O O
virus-induced O O
murine O O
erythroleukemias O O
. O O

Unfortunately O O
, O O
no B-Negation B-Negation
roX2 I-Negation I-Negation
mutations I-Negation I-Negation
have I-Negation I-Negation
been I-Negation I-Negation
recovered I-Negation I-Negation
yet O O
; O O
they O O
would O O
be O O
important O O
tools O O
for O O
validating O O
the O O
significance O O
of O O
the O O
roX O O
RNAs O O
in O O
vivo O O
. O O

We O O
have O O
investigated O O
the O O
molecular O O
and O O
biochemical O O
basis O O
for O O
activation O O
of O O
interleukin O O
3 O O
( O O
IL3 O O
) O O
gene O O
expression O O
in O O
primary O O
human O O
T O O
lymphocytes O O
following O O
CD3 O O
and O O
CD2 O O
receptor O O
stimulation O O
or O O
activation O O
by O O
phytohemagglutinin O O
plus O O
phorbol O O
12-myristate O O
13-acetate O O
. O O

It O O
suggested O O
that O O
increase O O
of O O
ER O O
levels O O
play O O
an O O
important O O
role O O
in O O
the O O
pathogenesis O O
of O O
gynecomastia O O
. O O

A O O
reporter O O
construct O O
containing O O
the O O
5'-flanking O O
region O O
of O O
the O O
mouse O O
TNF-alpha O O
gene O O
displayed O O
weak O O
activity O O
when O O
transfected O O
into O O
RAW264.7 O O
macrophage-like O O
cells O O
. O O

A O O
protein O O
Dpro_2 O O
contains O O
yet O O
another O O
inframe O O
stop O O
codon O O
( O O
TAG O O
) O O
at O O
the O O
column O O
189 O O
. O O

However O O
, O O
a B-Negation B-Negation
role I-Negation I-Negation
for I-Negation I-Negation
NF-kappaB I-Negation I-Negation
in I-Negation I-Negation
human I-Negation I-Negation
CD34 I-Negation I-Negation
( I-Negation I-Negation
+ I-Negation I-Negation
) I-Negation I-Negation
bone I-Negation I-Negation
marrow I-Negation I-Negation
cells I-Negation I-Negation
has I-Negation I-Negation
not I-Negation I-Negation
been I-Negation I-Negation
described I-Negation I-Negation
. O O

Forced O O
expression O O
of O O
SOCS-1 O O
in O O
a O O
macrophage O O
cell O O
line O O
, O O
RAW264 O O
, O O
markedly O O
suppressed O O
trans-activation O O
of O O
an O O
IL-4-inducible O O
reporter O O
as O O
well O O
as O O
IL-6- O O
and O O
IFN-gamma-induced O O
reporter O O
gene O O
activity O O
. O O

The O O
cell O O
lines O O
exhibit O O
a O O
low O O
level O O
of O O
constitutive O O
TNF O O
mRNA O O
expression O O
. O O

Here O O
it O O
is O O
shown O O
that O O
microbial O O
lipoproteins O O
are O O
potent O O
stimulators O O
of O O
IL-12 O O
production O O
by O O
human O O
macrophages O O
, O O
and O O
that O O
induction O O
is O O
mediated O O
by O O
Toll-like O O
receptors O O
( O O
TLRs O O
) O O
. O O

Interleukin-1 O O
and O O
interleukin-2 O O
control O O
transcription O O
via O O
distinct O O
cis-acting O O
elements O O
. O O

We O O
show O O
that O O
an O O
inducible O O
protein O O
complex O O
( O O
Band O O
A O O
) O O
binds O O
to O O
SRE O O
DNA O O
within O O
10 O O
min O O
after O O
mitogenic O O
stimulation O O
of O O
human O O
PBL-T O O
, O O
and O O
becomes O O
nondetectable O O
by O O
60 O O
min O O
. O O

ADGF-A O O
Is O O
Involved O O
in O O
Hemocyte O O
Differentiation O O
in O O
the O O
Lymph O O
Glands O O

In O O
this O O
study O O
, O O
we O O
cloned O O
two O O
cDNAs O O
encoding O O
proteins O O
which O O
bind O O
to O O
an O O
oligonucleotide O O
in O O
silencer O O
I O O
containing O O
a O O
BP1 O O
binding O O
site O O
. O O

Hormones O O
such O O
as O O
1 O O
alpha O O
, O O
25-dihydroxy O O
vitamin O O
D3 O O
( O O
D3 O O
) O O
, O O
all-trans O O
retinoic O O
acid O O
, O O
and O O
9-cis O O
retinoic O O
acid O O
stimulate O O
differentiation O O
of O O
myeloid O O
progenitor O O
cells O O
via O O
their O O
interaction O O
with O O
specific O O
hormone O O
receptors O O
. O O

Selection O O
of O O
optimal O O
kappa O O
B/Rel O O
DNA-binding O O
motifs O O
: O O
interaction O O
of O O
both O O
subunits O O
of O O
NF-kappa O O
B O O
with O O
DNA O O
is O O
required O O
for O O
transcriptional O O
activation O O
. O O

These B-Negation B-Negation
differences I-Negation I-Negation
in I-Negation I-Negation
gene I-Negation I-Negation
expression I-Negation I-Negation
have I-Negation I-Negation
not I-Negation I-Negation
been I-Negation I-Negation
molecularly I-Negation I-Negation
defined I-Negation I-Negation
. O O

These O O
data O O
suggest O O
a O O
model O O
in O O
which O O
CD30 O O
limits O O
its O O
own O O
ability O O
to O O
transduce O O
cell O O
survival O O
signals O O
through O O
signal-coupled O O
depletion O O
of O O
TRAF2 O O
. O O

Thus O O
, O O
ceramide O O
is O O
not B-Negation B-Negation
a I-Negation I-Negation
positive I-Negation I-Negation
signal I-Negation I-Negation
for I-Negation I-Negation
ERK I-Negation I-Negation
activation I-Negation I-Negation
in I-Negation I-Negation
T-cell I-Negation I-Negation
lines I-Negation I-Negation
. O O

Both O O
are O O
located O O
in O O
the O O
particulate O O
fraction O O
following O O
platelet O O
activation O O
and O O
are O O
also O O
able O O
to O O
bind O O
to O O
a O O
GST-construct O O
containing O O
the O O
SH2 O O
and O O
SH3 O O
domains O O
of O O
phospholipase O O
C O O
gamma O O
1 O O
. O O

In O O
a O O
3 O O
day O O
intervention O O
study O O
in O O
which O O
600 O O
mg O O
of O O
the O O
antioxidant O O
thioctic O O
acid O O
( O O
alpha-lipoic O O
acid O O
) O O
per O O
day O O
were O O
given O O
to O O
nine O O
patients O O
with O O
diabetic O O
nephropathy O O
oxidative O O
stress O O
in O O
plasma O O
samples O O
was O O
decreased O O
by O O
48 O O
% O O
and O O
NF-kappaB O O
binding O O
activity O O
in O O
ex O O
vivo O O
isolated O O
peripheral O O
blood O O
mononuclear O O
cells O O
by O O
38 O O
% O O
. O O

For O O
the O O
1.2 O O
% O O
of O O
proteins O O
in O O
H. O O
sapiens O O
and O O
6.4 O O
% O O
in O O
S. O O
cerevisiae O O
which O O
have O O
a O O
degree O O
higher O O
than O O
50 O O
, O O
the O O
correlation O O
gradually O O
diminishes O O
. O O

As O O
p65 O O
complexes O O
are O O
transcriptionally O O
active O O
in O O
comparison O O
to O O
the O O
p50 O O
homodimer O O
, O O
this O O
novel O O
finding O O
may O O
provide O O
insight O O
on O O
the O O
origin O O
of O O
abnormal O O
cytokine O O
or O O
other O O
gene O O
transcription O O
in O O
SLE O O
patients O O
. O O

Average O O
and O O
standard O O
error O O
of O O
sensitivity O O
and O O
PPV O O
for O O
the O O
component O O
algorithms O O
of O O
SCOPE O O
on O O
all O O
78 O O
regulons O O

The O O
initial O O
infection O O
with O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
in O O
most O O
individuals O O
usually O O
results O O
in O O
the O O
establishment O O
of O O
a O O
latent O O
or O O
chronic O O
infection O O
before O O
eventual O O
progression O O
toward O O
acquired O O
immunodeficiency O O
syndrome O O
. O O

The O O
method O O
described O O
here O O
can O O
be O O
used O O
in O O
future O O
studies O O
to O O
explore O O
novel O O
readthrough O O
events O O
from O O
complete O O
genomes O O
, O O
which O O
are O O
rapidly O O
growing O O
. O O

Because O O
monocytes O O
and O O
macrophages O O
are O O
important O O
mediators O O
of O O
Th1-type O O
responses O O
, O O
such O O
as O O
delayed-type O O
hypersensitivity O O
, O O
we O O
sought O O
to O O
determine O O
if O O
IL-10 O O
could O O
directly O O
mediate O O
inhibition O O
of O O
IFNgamma- O O
and O O
IFNalpha-induced O O
gene O O
expression O O
in O O
these O O
cells O O
. O O

The O O
increase O O
in O O
mRNA O O
accumulation O O
was O O
at O O
least O O
partly O O
due O O
to O O
an O O
increase O O
in O O
the O O
transcription O O
rates O O
of O O
the O O
respective O O
genes O O
and O O
was O O
accompanied O O
by O O
a O O
strong O O
induction O O
of O O
nuclear O O
factor-kappa O O
B O O
and O O
activator O O
protein-1 O O
transcription O O
factor O O
expression O O
. O O

The O O
myeloid O O
integrin O O
CD11b O O
is O O
expressed O O
selectively O O
on O O
the O O
surface O O
of O O
mature O O
macrophages O O
, O O
monocytes O O
, O O
neutrophils O O
, O O
and O O
natural O O
killer O O
cells O O
. O O

These O O
data O O
demonstrate O O
that O O
PBMC O O
differentially O O
regulate O O
basal O O
HTLV-I O O
transcription O O
compared O O
with O O
Jurkat O O
T O O
cells O O
, O O
and O O
this O O
differential O O
regulation O O
is O O
due O O
, O O
in O O
part O O
to O O
differential O O
phosphorylation O O
and O O
binding O O
of O O
CREB/ATF-1 O O
to O O
TRE-1 O O
in O O
the O O
HTLV-I O O
promoter O O
. O O

The O O
Ca O O
( O O
2+ O O
) O O
-dependent O O
factor O O
NF-ATp O O
plays O O
a O O
key O O
role O O
in O O
the O O
inducible O O
transcription O O
of O O
both O O
these O O
lymphokine O O
genes O O
. O O

Specific O O
nuclear O O
translocation O O
of O O
[ O O
3H O O
] O O
calcitriol/VDR O O
was O O
found O O
to O O
be O O
time O O
dependent O O
reaching O O
a O O
maximum O O
of O O
approximately O O
2100 O O
binding O O
sites/nucleus O O
after O O
3 O O
h O O
of O O
incubation O O
in O O
HL60 O O
cells O O
, O O
whereas O O
a O O
maximum O O
of O O
approximately O O
310 O O
binding O O
sites/nucleus O O
was O O
found O O
after O O
3 O O
h O O
in O O
PBL O O
. O O

The O O
mitogen-induced O O
increase O O
of O O
c-Fos O O
and O O
c-Jun O O
immunoreactivity O O
was O O
inhibited O O
by O O
H-7 O O
, O O
a O O
kinase O O
inhibitor O O
with O O
relatively O O
high O O
specificity O O
for O O
PKC O O
, O O
and O O
less O O
efficiently O O
by O O
H-8 O O
, O O
a O O
structurally O O
related O O
kinase O O
inhibitor O O
less O O
active O O
on O O
PKC O O
, O O
but O O
more O O
active O O
on O O
cyclic O O
nucleotide-dependent O O
kinases O O
. O O

The O O
octamer O O
sequence O O
ATGCAAAT O O
is O O
present O O
in O O
the O O
promoter O O
and O O
the O O
enhancer O O
of O O
Ig O O
genes O O
, O O
and O O
plays O O
an O O
important O O
role O O
in O O
its O O
tissue-specific O O
expression O O
. O O

In O O
both O O
cell O O
types O O
, O O
the O O
cytokine O O
that O O
inhibits O O
the O O
induction O O
of O O
IkappaBalpha O O
by O O
DEX O O
, O O
also O O
rescues O O
these O O
cells O O
from O O
DEX-induced O O
apoptosis O O
, O O
although O O
the O O
rescue O O
cytokine O O
is O O
different O O
in O O
Th1 O O
and O O
Th2 O O
cells O O
. O O

Pretreatment O O
with O O
actinomycin O O
D O O
and O O
cycloheximide O O
or O O
with O O
competing O O
ds-oligonucleotides O O
that O O
contained O O
nuclear O O
factor-kappaB O O
or O O
activator O O
protein-1 O O
cognate O O
DNA O O
sequences O O
significantly O O
attenuated O O
the O O
phase O O
2 O O
response O O
, O O
which O O
implicated O O
a O O
role O O
for O O
de O O
novo O O
protein O O
synthesis O O
. O O

BCL-6 O O
, O O
a O O
POZ/zinc-finger O O
protein O O
, O O
is O O
a O O
sequence-specific O O
transcriptional O O
repressor O O
. O O

Consequently O O
, O O
these O O
results O O
suggest O O
that O O
physiologically O O
relevant O O
concentrations O O
of O O
ethanol O O
may O O
affect O O
production O O
of O O
inflammatory O O
cytokines O O
, O O
such O O
as O O
tumor O O
necrosis O O
factor-alpha O O
, O O
interleukin-1 O O
beta O O
, O O
and O O
interleukin-6 O O
by O O
disrupting O O
NF-kappa O O
B O O
signaling O O
in O O
monocytes O O
. O O

First O O
, O O
lethality O O
of O O
homozygous O O
D-mib1 O O
pupae O O
is O O
associated O O
with O O
the O O
insertion O O
of O O
a O O
P-element O O
into O O
the O O
5 O O
? O O
UTR O O
of O O
the O O
D-mib O O
gene O O
. O O

Deletion O O
constructs O O
containing O O
as O O
little O O
as O O
72 O O
bp O O
of O O
5 O O
' O O
-flanking O O
sequence O O
of O O
the O O
collagenase O O
promoter O O
were O O
sufficient O O
for O O
LPS- O O
or O O
zymosan-mediated O O
transcriptional O O
induction O O
, O O
whereas O O
phorbol O O
inducibility O O
exhibited O O
an O O
absolute O O
requirement O O
for O O
upstream O O
elements O O
including O O
the O O
polyoma O O
enhancer O O
A-binding O O
protein-3 O O
site O O
( O O
-83 O O
to O O
-91 O O
) O O
and O O
TTCA O O
sequence O O
( O O
-102 O O
to O O
-105 O O
) O O
in O O
both O O
monocytic O O
cells O O
and O O
fibroblasts O O
. O O

( O O
A O O
) O O
Larvae O O
of O O
different O O
genotypes O O
were O O
collected O O
after O O
L2/L3 O O
molt O O
, O O
and O O
the O O
number O O
of O O
puparia O O
was O O
counted O O
at O O
different O O
time O O
points O O
( O O
x-axis O O
: O O
hours O O
after O O
egg O O
laying O O
) O O
. O O

However O O
, O O
latent O O
, O O
transformation-associated O O
viral O O
genes O O
demonstrate O O
marked O O
sequence O O
divergence O O
among O O
species O O
despite O O
the O O
conserved O O
functions O O
. O O

The O O
results O O
indicate O O
that O O
DNA O O
methylation O O
, O O
chromatin O O
structure O O
, O O
and O O
transactivation O O
at O O
an O O
Sp1 O O
site O O
contribute O O
to O O
the O O
highly O O
restricted O O
expression O O
of O O
this O O
myelomonocytic O O
lineage O O
specific O O
gene O O
. O O

As O O
judged O O
by O O
supershifting O O
the O O
DNA-protein O O
complexes O O
with O O
Abs O O
recognizing O O
specific O O
components O O
of O O
the O O
NF-kappa O O
B/Rel O O
protein O O
family O O
, O O
the O O
p50/p65 O O
( O O
Rel O O
A O O
) O O
heterodimeric O O
form O O
of O O
NF-kappa O O
B O O
is O O
primarily O O
affected O O
. O O

It O O
is O O
a O O
potent O O
transcriptional O O
activator O O
of O O
many O O
viral O O
and O O
cellular O O
promoters O O
. O O

A O O
2-bp O O
mutation O O
within O O
the O O
CBF O O
site O O
resulted O O
in O O
a O O
2-3-fold O O
decrease O O
in O O
the O O
activities O O
of O O
both O O
a O O
69-bp O O
proximal O O
promoter O O
fragment O O
and O O
a O O
627-bp O O
full-length O O
promoter O O
fragment O O
. O O

Using O O
Tax O O
mutants O O
that O O
fail B-Negation B-Negation
to I-Negation I-Negation
activate I-Negation I-Negation
either I-Negation I-Negation
ATF- I-Negation I-Negation
or I-Negation I-Negation
NF-kappaB-dependent I-Negation I-Negation
promoters I-Negation I-Negation
and I-Negation I-Negation
different I-Negation I-Negation
5 I-Negation I-Negation
' I-Negation I-Negation
truncation I-Negation I-Negation
mutants I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
E2F-1 I-Negation I-Negation
promoter I-Negation I-Negation
, O O
we O O
show O O
that O O
the O O
Tax-dependent O O
transcriptional O O
control O O
of O O
the O O
E2F1 O O
gene O O
involves O O
, O O
at O O
least O O
in O O
part O O
, O O
the O O
ATF O O
binding O O
site O O
located O O
in O O
the O O
E2F-1 O O
promoter O O
. O O

The O O
apparent O O
high O O
frequency O O
of O O
IL-12-nonresponsive O O
Th O O
cells O O
within O O
the O O
allergen-specific O O
populations O O
in O O
atopic O O
patients O O
predicts O O
a O O
limited O O
skewing O O
potential O O
of O O
IL-12 O O
in O O
the O O
case O O
of O O
established O O
Th2 O O
responses O O
, O O
but O O
only O O
affecting O O
newly O O
recruited O O
naive O O
Th O O
cells O O
. O O

This O O
deletion O O
represents O O
a O O
null O O
allele O O
of O O
D-mib O O
and O O
was O O
named O O
D-mib2 O O
. O O

BioGRID O O
for O O
example O O
contains O O
a O O
large O O
manually O O
curated O O
set O O
of O O
protein O O
interactions O O
for O O
S. O O
cerevisiae O O
19 O O
. O O

These O O
results O O
demonstrate O O
that O O
Rb O O
interacts O O
specifically O O
with O O
a O O
lineage-restricted O O
Ets O O
transcription O O
factor O O
. O O

Two O O
subclones O O
were O O
found O O
to O O
have O O
an O O
abnormal O O
response O O
to O O
the O O
protein O O
kinase O O
C O O
( O O
PKC O O
) O O
activator O O
PMA O O
. O O

Detailed O O
structural O O
analysis O O
of O O
the O O
first O O
12 O O
cDNAs O O
( O O
HZF O O
1-10 O O
) O O
and O O
a O O
partial O O
characterization O O
of O O
HZF O O
11-42 O O
revealed O O
that O O
a O O
common O O
feature O O
of O O
human O O
Kruppel-related O O
zinc O O
finger O O
proteins O O
is O O
the O O
presence O O
of O O
tandem O O
arrays O O
of O O
zinc O O
fingers O O
ranging O O
in O O
number O O
from O O
3 O O
to O O
over O O
20 O O
that O O
are O O
preferentially O O
located O O
in O O
the O O
carboxy-terminal O O
regions O O
of O O
the O O
proteins O O
. O O

The O O
expression O O
of O O
the O O
gene O O
encoding O O
the O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
( O O
GM-CSF O O
) O O
is O O
induced O O
upon O O
activation O O
of O O
T O O
cells O O
with O O
phytohemagglutinin O O
and O O
active O O
phorbolester O O
and O O
upon O O
expression O O
of O O
tax1 O O
, O O
a O O
transactivating O O
protein O O
of O O
the O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
. O O

Our O O
results O O
indicate O O
that O O
the O O
stoichiometry O O
of O O
directly O O
interacting O O
but O O
opposing O O
transcription O O
factors O O
may O O
be O O
a O O
crucial O O
determinant O O
governing O O
processes O O
of O O
normal O O
differentiation O O
and O O
malignant O O
transformation O O
. O O

PtdIns O O
binding O O
to O O
mCD14 O O
can O O
be O O
blocked O O
by O O
anti-CD14 O O
monoclonal O O
antibodies O O
that O O
inhibit O O
LPS-mCD14 O O
binding O O
, O O
and O O
PtdIns O O
can O O
inhibit O O
both O O
LPS-mCD14 O O
binding O O
and O O
LPS-induced O O
responses O O
in O O
monocytes O O
. O O

In O O
fact O O
, O O
we O O
find O O
the O O
most O O
frequent O O
iPfam O O
domain O O
pairs O O
to O O
be O O
recognition O O
domains O O
in O O
signal O O
transduction O O
. O O

Minimizing O O
energy O O
studies O O
of O O
BMT O O
structure O O
reveal O O
that O O
a O O
trans-disulfide O O
of O O
thiamine O O
( O O
holo O O
drug O O
) O O
disulfide O O
( O O
TDS O O
, O O
protodrug O O
) O O
is O O
allosterically O O
transited O O
to O O
the O O
reactive O O
twisted O O
disulfide O O
of O O
BMT O O
( O O
allo O O
drug O O
) O O
by O O
o O O
, O O
o'-bismyristoyl O O
esterification O O
of O O
TDS O O
. O O

Along O O
the O O
x-axis O O
( O O
which O O
is O O
shared O O
with O O
[ O O
B O O
] O O
) O O
, O O
the O O
rescue O O
experiments O O
are O O
shown O O
( O O
marked O O
by O O
the O O
Gal4 O O
driver O O
used O O
for O O
expression O O
of O O
ADGF-A O O
except O O
for O O
first O O
three O O
sets O O
of O O
bars—the O O
first O O
set O O
presents O O
only O O
an O O
adgf-a O O
mutant O O
, O O
the O O
second O O
an O O
adgf-a O O
mutant O O
carrying O O
HS-ADGF-A O O
construct O O
without B-Negation B-Negation
heat I-Negation I-Negation
shock I-Negation I-Negation
, O O
and O O
the O O
third O O
with O O
heat O O
shock O O
) O O
and O O
the O O
y-axis O O
represents O O
percentage O O
of O O
pupae O O
and O O
adult O O
flies O O
out O O
of O O
the O O
total O O
number O O
of O O
transferred O O
first-instar O O
larvae O O
of O O
particular O O
genotype O O
. O O

This O O
method O O
could O O
be O O
quite O O
useful O O
to O O
detect O O
not O O
only O O
CAG O O
repeats O O
in O O
SBMA O O
but O O
also O O
other O O
polymorphic O O
dinucleotide O O
and O O
trinucleotide O O
repeats O O
. O O

The O O
likelihood O O
ratios O O
of O O
interaction O O
are O O
evaluated O O
for O O
each O O
module O O
by O O
considering O O
the O O
relative O O
proportions O O
of O O
positive O O
and O O
negative O O
training O O
examples O O
that O O
have O O
a O O
specific O O
state O O
( O O
i.e. O O
that O O
fall O O
in O O
a O O
particular O O
bin O O
of O O
a O O
module O O
) O O
. O O

In O O
contrast O O
, O O
p65 O O
delta O O
, O O
a O O
naturally O O
occurring O O
splice O O
variant O O
, O O
fails O B-Negation
to O I-Negation
markedly O I-Negation
augment O I-Negation
I O I-Negation
kappa O I-Negation
B O I-Negation
protein O I-Negation
levels O I-Negation
. O O

Because O O
antioxidants O O
have O O
been O O
considered O O
to O O
be O O
of O O
antiatherosclerotic O O
potential O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
alpha-tocopherol O O
( O O
TCP O O
) O O
and O O
its O O
acetate O O
and O O
succinate O O
esters O O
on O O
monocyte O O
adhesion O O
to O O
cytokine-stimulated O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
( O O
HUVEC O O
) O O
. O O

However O O
, O O
the O O
transcription O O
and O O
synthesis O O
of O O
interleukin O O
2 O O
and O O
other O O
delayed O O
early O O
cytokines O O
were O O
markedly O O
attenuated O O
by O O
BCL-2 O O
. O O

In O O
vitro O O
studies O O
using O O
pure O O
recombinant O O
p21ras O O
demonstrate O O
that O O
the O O
activation O O
is O O
direct O O
and O O
reversible O O
. O O

the O O
former O O
seems O O
to O O
be O O
related O O
to O O
the O O
50 O O
kD O O
polypeptide O O
of O O
NF-kB O O
. O O

The O O
promoter O O
of O O
the O O
human O O
major O O
histocompatibility O O
complex O O
class O O
II-associated O O
invariant-chain O O
gene O O
( O O
Ii O O
) O O
contains O O
two O O
NF-kappa O O
B/Rel O O
binding O O
sites O O
located O O
at O O
-109 O O
to O O
-118 O O
( O O
Ii O O
kappa O O
B-1 O O
) O O
and O O
-163 O O
to O O
-172 O O
( O O
Ii O O
kappa O O
B-2 O O
) O O
from O O
the O O
transcription O O
start O O
site O O
. O O

Kinetics O O
of O O
nuclear O O
translocation O O
and O O
turnover O O
of O O
the O O
vitamin O O
D O O
receptor O O
in O O
human O O
HL60 O O
leukemia O O
cells O O
and O O
peripheral O O
blood O O
lymphocytes O O
-- O O
coincident O O
rise O O
of O O
DNA-relaxing O O
activity O O
in O O
nuclear O O
extracts O O
. O O

The O O
signal O O
cascade O O
transducing O O
this O O
effect O O
is O O
not O O
yet O O
clear O O
. O O

Molecular O O
dissection O O
of O O
the O O
B-cell-specific O O
transcription O O
coactivator O O
OCA-B O O
has O O
revealed O O
distinct O O
regions O O
important O O
, O O
respectively O O
, O O
for O O
recruitment O O
to O O
immunoglobulin O O
promoters O O
through O O
interaction O O
with O O
octamer-bound O O
Oct-1 O O
and O O
for O O
subsequent O O
coactivator O O
function O O
. O O

High O O
affinity O O
receptors O O
( O O
VDR O O
) O O
for O O
1,25-dihydroxycholecalciferol O O
( O O
calcitriol O O
) O O
are O O
expressed O O
in O O
HL60 O O
human O O
leukemia O O
cells O O
and O O
in O O
low O O
numbers O O
in O O
peripheral O O
blood O O
lymphocytes O O
( O O
PBL O O
) O O
. O O

However O O
, O O
in O O
contrast O O
to O O
GATA-1 O O
, O O
SCL O O
is O O
expressed O O
in O O
the O O
developing O O
brain O O
. O O

The O O
peroxisome-proliferator O O
activated O O
receptor O O
gamma O O
( O O
PPARgamma O O
) O O
, O O
a O O
member O O
of O O
the O O
nuclear O O
receptor O O
superfamily O O
of O O
ligand O O
activated O O
transcription O O
factors O O
, O O
plays O O
a O O
key O O
role O O
in O O
the O O
anti-diabetic O O
actions O O
of O O
the O O
thiazolidinediones O O
( O O
TZDs O O
) O O
. O O

Comparison O O
of O O
tumor O O
specimen O O
from O O
MM O O
precursor O O
lesions O O
, O O
primary O O
tumors O O
, O O
and O O
metastases O O
revealed O O
that O O
CD40 O O
surface O O
expression O O
is O O
down-regulated O O
during O O
tumor O O
progression O O
. O O

Peripheral O O
blood O O
lymphocytes O O
from O O
9/19 O O
SS O O
patients O O
were O O
found O O
to O O
be O O
defective O O
in O O
their O O
ability O O
to O O
bind O O
an O O
october O O
sequence O O
( O O
Oct-1 O O
) O O
. O O

Seven O O
of O O
15 O O
fibroblast O O
lines O O
were O O
heterozygous O O
for O O
polymorphic O O
alleles O O
, O O
and O O
the O O
expression O O
patterns O O
were O O
variable O O
, O O
i.e. O O
, O O
equal O O
, O O
unequal O O
or O O
monoallelic O O
paternal O O
expression O O
in O O
three O O
, O O
two O O
and O O
two O O
cases O O
, O O
respectively O O
. O O

Our O O
results O O
indicate O O
distinct O O
effects O O
of O O
B7 O O
and O O
LFA-3 O O
costimulation O O
on O O
the O O
activity O O
of O O
AP-1 O O
and O O
NF-kappa O O
B O O
. O O

We O O
demonstrate O O
that O O
a O O
fusion O O
protein O O
composed O O
of O O
a O O
C-terminal O O
Hsp70 O O
peptide O O
and O O
the O O
p50 O O
subunit O O
of O O
NF-kappaB O O
was O O
directed O O
into O O
the O O
nucleus O O
of O O
cells O O
, O O
could O O
bind O O
DNA O O
specifically O O
, O O
and O O
activated O O
Igkappa O O
expression O O
and O O
TNFalpha O O
production O O
. O O

To O O
explore O O
these O O
I O O
kappa O O
B O O
alpha-dependent O O
mechanisms O O
for O O
NF-kappa O O
B O O
induction O O
, O O
we O O
identified O O
novel O O
mutants O O
of O O
I O O
kappa O O
B O O
alpha O O
that O O
uncouple O O
its O O
inhibitory O O
and O O
signal-transducing O O
functions O O
in O O
human O O
T O O
lymphocytes O O
. O O

CD40 O O
activation O O
of O O
B O O
cells O O
is O O
strongly O O
influenced O O
by O O
the O O
presence O O
of O O
cytokines O O
. O O

Trans-activation O O
of O O
the O O
TP1 O O
promoter O O
and O O
of O O
the O O
BamHI O O
C O O
promoter O O
has O O
already O O
been O O
investigated O O
in O O
detail O O
and O O
appears O O
to O O
be O O
mediated O O
via O O
protein-protein O O
interactions O O
and O O
not O O
by O O
direct O O
binding O O
of O O
EBNA-2 O O
type O O
A O O
( O O
of O O
EBV O O
type O O
1 O O
) O O
to O O
the O O
DNA O O
. O O

The O O
activity O O
of O O
A-MYB O O
in O O
B O O
and O O
not B-Negation O
T I-Negation O
cells I-Negation O
was O O
observed O O
when O O
either O O
an O O
artificial O O
construct O O
or O O
the O O
c-MYC O O
promoter O O
was O O
used O O
as O O
a O O
reporter O O
. O O

TCF-1 O O
mRNA O O
was O O
expressed O O
uniquely O O
in O O
T O O
lymphocytes O O
. O O

The O O
ZEBRA O O
protein O O
from O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
activates O O
a O O
switch O O
from O O
the O O
latent O O
to O O
the O O
lytic O O
expression O O
program O O
of O O
the O O
virus O O
. O O

Earlier O O
studies O O
on O O
the O O
IL-2 O O
gene O O
expression O O
showed O O
that O O
overexpression O O
of O O
calcineurin O O
( O O
CN O O
) O O
, O O
a O O
Ca2+/calmodulin-dependent O O
protein O O
phosphatase O O
, O O
can O O
stimulate O O
transcription O O
from O O
the O O
IL-2 O O
promoter O O
through O O
the O O
NF-AT-binding O O
site O O
. O O

We O O
analyzed O O
expression O O
of O O
AP-1 O O
, O O
NF-kappa O O
B O O
, O O
NF-AT O O
, O O
and O O
octamer O O
binding O O
transcription O O
factors O O
, O O
which O O
are O O
known O O
to O O
be O O
involved O O
in O O
the O O
regulation O O
of O O
IL-2 O O
gene O O
promoter O O
activity O O
. O O

Dexamethasone O O
inhibited O O
LPS-induced O O
bioactive O O
IL-12 O O
production O O
in O O
a O O
dose-dependent O O
fashion O O
and O O
at O O
physiologically O O
relevant O O
concentrations O O
; O O

Recently O O
, O O
a O O
computational O O
study O O
addressed O O
this O O
question O O
and O O
reported O O
that O O
no B-Negation B-Negation
tRNA I-Negation I-Negation
gene I-Negation I-Negation
for I-Negation I-Negation
unknown I-Negation I-Negation
amino I-Negation I-Negation
acid I-Negation I-Negation
was I-Negation I-Negation
found I-Negation I-Negation
in I-Negation I-Negation
genome I-Negation I-Negation
sequences I-Negation I-Negation
available I-Negation I-Negation
. O O

CsA O O
and O O
FK506 O O
are O O
powerful O O
suppressors O O
of O O
the O O
immune O O
system O O
, O O
most O O
notably O O
of O O
T O O
cells O O
. O O

Transcriptional O O
regulation O O
of O O
the O O
beta-casein O O
gene O O
by O O
cytokines O O
: O O
cross-talk O O
between O O
STAT5 O O
and O O
other O O
signaling O O
molecules O O
. O O

The O O
primDCC O O
might O O
then O O
be O O
reinforced O O
by O O
the O O
addition O O
of O O
the O O
remaining O O
two O O
proteins O O
, O O
MSL3 O O
and O O
MOF O O
, O O
one O O
or O O
both O O
of O O
which O O
might O O
recognize O O
other O O
motifs O O
within O O
the O O
roX2 O O
RNA O O
, O O
to O O
form O O
the O O
mature O O
complex O O
( O O
matDCC O O
) O O
. O O

Pharmacological O O
modification O O
of O O
cytokine O O
dysregulation O O
, O O
therefore O O
, O O
has O O
been O O
suggested O O
as O O
a O O
therapeutic O O
modality O O
for O O
HIV-1 O O
infection O O
. O O

Tyloxapol O O
also O O
reduces O O
the O O
viscosity O O
of O O
CF O O
sputum O O
( O O
from O O
463 O O
± O O
133 O O
to O O
128 O O
± O O
52 O O
centipoise O O
) O O
. O O

Enzymatic O O
assay O O
of O O
alpha-galactosidase O O
in O O
blood O O
leucocytes O O
, O O
skin O O
fibroblasts O O
, O O
Epstein-Barr O O
virus O O
transformed O O
lymphoid O O
cell O O
lines O O
, O O
and O O
hair O O
follicles O O
of O O
the O O
twins O O
and O O
their O O
parents O O
confirmed O O
the O O
heterozygous O O
status O O
of O O
the O O
twins O O
and O O
indicated O O
that O O
Fabry O O
disease O O
had O O
occurred O O
as O O
a O O
result O O
of O O
a O O
de O O
novo O O
mutation O O
. O O

Together O O
these O O
results O O
demonstrate O O
that O O
T O O
cell O O
expression O O
of O O
IL-3 O O
is O O
not B-Negation O
specified I-Negation O
by I-Negation O
the I-Negation O
activity I-Negation O
of I-Negation O
a I-Negation O
single I-Negation O
tissue-specific I-Negation O
element I-Negation O
, O O
but O O
instead O O
involves O O
multiple O O
interacting O O
elements O O
that O O
provide O O
both O O
specific O O
positive O O
regulation O O
in O O
T O O
cells O O
and O O
specific O O
negative O O
regulation O O
in O O
fibroblasts O O
. O O

Double-stranded O O
GIRE O O
sequence O O
, O O
but O O
not B-Negation B-Negation
a I-Negation I-Negation
scrambled I-Negation I-Negation
sequence I-Negation I-Negation
, O O
was O O
specifically O O
bound O O
by O O
nuclear O O
proteins O O
from O O
IFN-gamma O O
treated O O
U937 O O
cells O O
. O O

NLS O O
peptide-mediated O O
disruption O O
of O O
the O O
nuclear O O
import O O
of O O
these O O
transcription O O
factors O O
results O O
in O O
inhibition O O
of O O
I O O
kappa O O
B O O
alpha O O
and O O
IL-2 O O
gene O O
expression O O
, O O
processes O O
dependent O O
on O O
NF-kappa O O
B O O
or O O
the O O
combination O O
of O O
NF-kappa O O
B O O
, O O
AP-1 O O
, O O
and O O
NFAT O O
. O O

Not O O
only O O
functional O O
but O O
also O O
specific O O
binding O O
interactions O O
between O O
CIITA O O
and O O
CBP O O
were O O
demonstrated O O
. O O

All O O
NK O O
clones O O
and O O
cell O O
lines O O
studied O O
were O O
found O O
to O O
express O O
hGATA-3-specific O O
mRNA O O
, O O
suggesting O O
that O O
hGATA-3 O O
may O O
be O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
unrearranged O O
TcR O O
delta O O
gene O O
expression O O
in O O
NK O O
cells O O
. O O

This O O
chronic O O
inflammatory O O
reaction O O
results O O
from O O
a O O
sequence O O
of O O
events O O
that O O
begins O O
with O O
the O O
trapping O O
of O O
low O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
in O O
the O O
subendothelial O O
space O O
of O O
the O O
artery O O
wall O O
. O O

Exposure O O
to O O
NSAIDs O O
had O O
a O O
complex O O
effect O O
on O O
HSP O O
gene O O
expression O O
and O O
while O O
sulindac O O
activated O O
the O O
stress O O
responsive O O
HSP70B O O
promoter O O
, O O
sodium O O
salicylate O O
did O O
not B-Negation B-Negation
. O O

Both O O
pathways O O
were O O
fully O O
blocked O O
by O O
Bcl-2 O O
or O O
Bcl-X O O
( O O
L O O
) O O
. O O

The O O
gp160-mediated O O
activation O O
of O O
NF-kappa O O
B O O
in O O
CD4 O O
positive O O
T O O
cells O O
may O O
be O O
involved O O
in O O
biological O O
effects O O
, O O
e.g. O O
, O O
enhanced O O
HIV O O
replication O O
, O O
hypergammaglobulinemia O O
, O O
increased O O
cytokine O O
secretion O O
, O O
hypercellularity O O
in O O
bone O O
marrow O O
and O O
apoptosis O O
. O O

The O O
glucocorticoid-induced O O
reduction O O
of O O
IL-12 O O
production O O
was O O
antagonized O O
by O O
RU O O
486 O O
, O O
a O O
glucocorticoid-receptor O O
antagonist O O
, O O
suggesting O O
that O O
it O O
was O O
mediated O O
by O O
the O O
glucocorticoid O O
receptor O O
. O O

This O O
shift O O
is O O
apparently O O
not O O
caused O O
by O O
a O O
recruitment O O
phenomenon O O
, O O
because O O
in O O
FCS+ O O
culture O O
, O O
the O B-Negation
total O I-Negation
number O I-Negation
of O I-Negation
colonies O I-Negation
is O I-Negation
not O I-Negation
significantly O I-Negation
modified O I-Negation
by O I-Negation
RA O I-Negation
addition O I-Negation
. O O

PG490 O O
( O O
triptolide O O
) O O
is O O
a O O
diterpene O O
triepoxide O O
with O O
potent O O
immunosuppressive O O
and O O
antiinflammatory O O
properties O O
. O O

The O O
mechanism O O
of O O
action O O
of O O
DM O O
on O O
IL-2R O O
alpha O O
transcription O O
was O O
examined O O
by O O
determining O O
the O O
mRNA O O
levels O O
of O O
the O O
p50 O O
subunit O O
of O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF-kappa O O
B O O
) O O
, O O
a O O
transcription O O
factor O O
that O O
stimulates O O
IL-2R O O
alpha O O
gene O O
expression O O
. O O

Little O O
was O O
known O O
, O O
however O O
, O O
about O O
the O O
specific O O
role O O
of O O
the O O
roX O O
RNAs O O
during O O
the O O
formation O O
of O O
the O O
DCC O O
. O O

On O O
this O O
dataset O O
, O O
SCOPE O O
had O O
the O O
highest O O
score O O
by O O
both O O
criteria O O
( O O
Figure O O
5a O O
) O O
. O O

The O O
number O O
of O O
estrogen O O
receptors O O
( O O
ER O O
) O O
in O O
human O O
peripheral O O
leucocytes O O
in O O
12 O O
women O O
with O O
menopausal O O
type O O
II O O
diabetes O O
was O O
measured O O
with O O
radio-ligand O O
binding O O
method O O
. O O

Using O O
a O O
conservative O O
threshold O O
, O O
our O O
most O O
accurate O O
predictor O O
identifies O O
37606 O O
human O O
interactions O O
, O O
32892 O O
( O O
80 O O
% O O
) O O
of O O
which O O
are O O
not B-Negation B-Negation
present I-Negation I-Negation
in I-Negation I-Negation
other I-Negation I-Negation
publicly I-Negation I-Negation
available I-Negation I-Negation
large I-Negation I-Negation
human I-Negation I-Negation
interaction I-Negation I-Negation
datasets I-Negation I-Negation
, O O
thus O O
substantially O O
increasing O O
the O O
coverage O O
of O O
the O O
human O O
interaction O O
map O O
. O O

The O O
first O O
alteration O O
involves O O
the O O
constitutive O O
expression O O
of O O
substantial O O
kappa O O
B-binding O O
activity O O
in O O
nuclear O O
extracts O O
, O O
which O O
was O O
observed O O
in O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

In O O
contrast O O
, O O
AP-1 O O
from O O
PHA-activated O O
cells O O
contains O O
c-Jun O O
and O O
low O O
levels O O
of O O
c-Fos O O
. O O

Chronic O O
HIV-1 O O
infection O O
of O O
myeloid O O
cells O O
leads O O
to O O
constitutive O O
NF-kappa O O
B O O
DNA-binding O O
activity O O
and O O
provides O O
an O O
intranuclear O O
environment O O
capable O O
of O O
perpetuating O O
HIV-1 O O
replication O O
. O O

The O O
induction O O
of O O
this O O
promoter O O
was O O
confirmed O O
in O O
COS7 O O
cells O O
. O O

NF-kappa O O
B O O
controls O O
expression O O
of O O
inhibitor O O
I O O
kappa O O
B O O
alpha O O
: O O
evidence O O
for O O
an O O
inducible O O
autoregulatory O O
pathway O O
. O O

We O O
used O O
phenolic O O
, O O
lipid-soluble O O
, O O
chain-breaking O O
antioxidants O O
( O O
butylated O O
hydroxyanisole O O
( O O
BHA O O
) O O
, O O
nordihydroquairetic O O
acid O O
, O O
or O O
alpha-tocopherol O O
( O O
vitamin O O
E O O
) O O
to O O
show O O
that O O
peroxyl O O
radical O O
scavenging O O
in O O
unstimulated O O
and O O
PMA- O O
or O O
TNF-stimulated O O
cells O O
blocks O O
the O O
functions O O
depending O O
on O O
NF-kappa O O
B O O
activation O O
. O O

Despite O O
this O O
, O O
there O O
are O O
still O O
significant O O
gaps O O
in O O
our O O
understanding O O
of O O
this O O
process O O
and O O
its O O
consequences O O
. O O

Datasets O O

The O O
comprehensive O O
study O O
of O O
such O O
interactions O O
on O O
a O O
genome-wide O O
scale O O
will O O
lead O O
to O O
a O O
clearer O O
understanding O O
of O O
diverse O O
cellular O O
processes O O
and O O
of O O
the O O
molecular O O
mechanisms O O
of O O
disease O O
. O O

In O O
the O O
cell O O
types O O
tested O O
, O O
the O O
LS O O
mutations O O
indicated O O
an O O
apparent O O
requirement O O
not O O
only O O
for O O
the O O
intact O O
NF-kappa O O
B O O
and O O
SP1-binding O O
sites O O
but O O
also O O
for O O
several O O
regions O O
between O O
-201 O O
and O O
-130 O O
not O O
previously O O
associated O O
with O O
viral O O
infectivity O O
. O O

Our O O
test O O
set O O
of O O
78 O O
regulons O O
was O O
selected O O
in O O
a O O
blinded O O
manner O O
( O O
for O O
details O O
, O O
see O O
Additional O O
file O O
1 O O
, O O
section O O
S3 O O
) O O
, O O
thus O O
these O O
results O O
suggest O O
the O O
generalizability O O
of O O
SCOPE O O
's O O
use O O
of O O
domain O O
knowledge O O
on O O
biologically O O
relevant O O
datasets O O
from O O
these O O
species O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
we O O
determined O O
that O O
the O O
pattern O O
of O O
band O O
migration O O
differed O O
between O O
the O O
two O O
cell O O
types O O
. O O

Identification O O
and O O
characterization O O
of O O
a O O
leukocyte-specific O O
component O O
of O O
the O O
nuclear O O
body O O
. O O

Several O O
criteria O O
indicated O O
that O O
the O O
defect O O
in O O
this O O
cell O O
line O O
influences O O
the O O
activity O O
of O O
an O O
isotype-specific O O
transcription O O
factor O O
. O O

Our O O
report O O
expands O O
current O O
knowledge O O
of O O
the O O
radiation-induced O O
signaling O O
cascade O O
by O O
clarifying O O
the O O
chronological O O
sequence O O
of O O
biochemical O O
events O O
that O O
follow O O
irradiation O O
. O O

CD40 O O
, O O
but O O
not B-Negation B-Negation
lipopolysaccharide I-Negation I-Negation
and I-Negation I-Negation
anti-IgM I-Negation I-Negation
stimulation I-Negation I-Negation
of I-Negation I-Negation
primary I-Negation I-Negation
B I-Negation I-Negation
lymphocytes I-Negation I-Negation
, O O
leads O O
to O O
a O O
persistent O O
nuclear O O
accumulation O O
of O O
RelB O O
. O O

We O O
hypothesize O O
that O O
this O O
110-kDa O O
protein O O
may O O
be O O
a O O
functionally O O
important O O
B O O
cell-specific O O
co-activator O O
of O O
A-MYB O O
. O O

Akthar O O
et O O
al. O O
[ O O
2 O O
] O O
then O O
tested O O
the O O
putative O O
RNA-binding O O
property O O
of O O
MOF O O
directly O O
using O O
electromobility O O
shift O O
assays O O
. O O

The O O
x-axis O O
shows O O
the O O
genotypes O O
and O O
is O O
shared O O
with O O
( O O
B O O
) O O
. O O

Binding O O
of O O
the O O
65-kDa O O
plus O O
50-kDa O O
heterodimer O O
to O O
the O O
HIV-1 O O
enhancer O O
can O O
be O O
negatively O O
regulated O O
in O O
monocytes O O
, O O
providing O O
one O O
mechanism O O
restricting O O
HIV-1 O O
gene O O
expression O O
. O O

The O O
MZF-1 O O
protein O O
contains O O
13 O O
C2H2 O O
zinc O O
fingers O O
arranged O O
in O O
bipartite O O
DNA O O
binding O O
domains O O
containing O O
zinc O O
fingers O O
through O O
4 O O
and O O
, O O
in O O
the O O
carboxy-terminus O O
, O O
5 O O
through O O
13 O O
. O O

Our O O
results O O
are O O
consistent O O
with O O
the O O
view O O
that O O
the O O
DNA-binding O O
activity O O
LEF1/BCF1 O O
is O O
a O O
homodimer O O
of O O
E2A O O
proteins O O
; O O

Furthermore O O
, O O
it O O
is O O
highly O O
expressed O O
in O O
Burkitt O O
's O O
lymphoma O O
cells O O
and O O
may O O
participate O O
in O O
the O O
pathogenesis O O
of O O
this O O
disease O O
. O O

TPA O O
induction O O
inhibits O O
the O O
binding O O
of O O
the O O
lineage O O
limited O O
transcription O O
factor O O
NF-E2 O O
to O O
this O O
transcriptional O O
control O O
element O O
. O O

All O O
factors O O
are O O
induced O O
in O O
the O O
nuclei O O
of O O
T O O
cells O O
upon O O
activation O O
with O O
mitogens O O
but O O
not B-Negation B-Negation
with I-Negation I-Negation
exogenous I-Negation I-Negation
IL-2 I-Negation I-Negation
growth I-Negation I-Negation
factor I-Negation I-Negation
. O O

However O O
, O O
a O O
unique O O
DNA-protein O O
complex O O
was O O
detected O O
when O O
the O O
promoter O O
central O O
21 O O
bp O O
repeat O O
was O O
reacted O O
with O O
nuclear O O
extracts O O
derived O O
from O O
either O O
the O O
U-373 O O
MG O O
glioblastoma O O
cell O O
line O O
or O O
the O O
THP-1 O O
mature O O
monocytic O O
cell O O
line O O
. O O

Formation O O
of O O
the O O
NFAT-1 O O
transcriptional O O
complex O O
on O O
the O O
IL-2 O O
promoter O O
is O O
essential O O
for O O
IL-2 O O
transcription O O
. O O

The O O
peri-kappa O O
B O O
site O O
mediates O O
human O O
immunodeficiency O O
virus O O
type O O
2 O O
enhancer O O
activation O O
in O O
monocytes O O
but O O
not B-Negation B-Negation
in I-Negation I-Negation
T I-Negation I-Negation
cells I-Negation I-Negation
. O O

The O O
data O O
also O O
demonstrate O O
that O O
special O O
precautions O O
must O O
be O O
taken O O
when O O
making O O
extracts O O
from O O
myelo-monocytic O O
cells O O
. O O

In O O
particular O O
, O O
gene O O
pairs O O
within O O
an O O
operon O O
are O O
problematic O O
because O O
their O O
gene O O
arrangement O O
is O O
often O O
conserved O O
. O O

A O O
flowchart O O
of O O
the O O
prediction O O
procedure O O
. O O

A O O
switch O O
from O O
human O O
fetal O O
( O O
gamma O O
) O O
-to O O
adult O O
( O O
beta O O
) O O
- O O
globin O O
expression O O
occurs O O
within O O
erythroid O O
precursor O O
cells O O
of O O
the O O
adult O O
lineage O O
. O O

The O O
primary O O
tumors O O
in O O
Group O O
C O O
had O O
a O O
normal O O
profile O O
of O O
p16 O O
, O O
p15 O O
and O O
CDK4 O O
at O O
presentation O O
. O O

We O O
have O O
recently O O
shown O O
that O O
both O O
phosphorylation O O
processes O O
require O O
T-cell O O
costimulation O O
. O O

We O O
show O O
here O O
that O O
DTCs O O
inhibited O O
both O O
interleukin O O
2 O O
( O O
IL-2 O O
) O O
synthesis O O
and O O
membrane O O
expression O O
of O O
antigens O O
which O O
are O O
induced O O
during O O
T-cell O O
activation O O
. O O

Expression O O
of O O
LAZ3/BCL6 O O
in O O
follicular O O
center O O
( O O
FC O O
) O O
B O O
cells O O
of O O
reactive O O
lymph O O
nodes O O
and O O
FC-derived O O
non-Hodgkin O O
lymphomas O O
. O O

The O O
signaling O O
events O O
mediating O O
this O O
effect O O
appeared O O
to O O
involve O O
the O O
release O O
of O O
H2O2 O O
, O O
since O O
LTB4 O O
failed B-Negation B-Negation
to I-Negation I-Negation
induce I-Negation I-Negation
NF-chi I-Negation I-Negation
B I-Negation I-Negation
or I-Negation I-Negation
NF-IL6 I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
presence I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
scavenger I-Negation I-Negation
of I-Negation I-Negation
H2O2 I-Negation I-Negation
, I-Negation I-Negation
N-acetyl-L-cysteine I-Negation I-Negation
. O O

Monochloramine O O
derivatives O O
are O O
long O O
lived O O
physiological O O
oxidants O O
produced O O
by O O
neutrophils O O
during O O
the O O
respiratory O O
burst O O
. O O

I O O
kappa O O
B O O
proteins O O
inhibit O O
DNA O O
binding O O
and O O
prevent O O
nuclear O O
uptake O O
of O O
NF-kappa O O
B O O
complexes O O
. O O

The O O
levels O O
of O O
secreted O O
IL-1beta O O
, O O
TNF-alpha O O
, O O
and O O
IL-6 O O
during O O
24 O O
h O O
of O O
stimulation O O
were O O
comparable O O
to O O
those O O
induced O O
by O O
Escherichia O O
coli O O
lipopolysaccharide O O
at O O
1 O O
microg/ml O O
. O O

Lavage O O
T-lymphocytes O O
from O O
patients O O
with O O
tuberculosis O O
or O O
with O O
sarcoidosis O O
, O O
but O O
not B-Negation B-Negation
those I-Negation I-Negation
from I-Negation I-Negation
normal I-Negation I-Negation
control I-Negation I-Negation
subjects I-Negation I-Negation
, O O
expressed O O
1,25 O O
( O O
OH O O
) O O
2D3 O O
receptors O O
as O O
demonstrated O O
by O O
binding O O
of O O
[ O O
3H O O
] O O
1,25 O O
( O O
OH O O
) O O
2D3 O O
, O O
which O O
was O O
inhibited O O
by O O
the O O
presence O O
of O O
excess O O
unlabeled O O
1,25 O O
( O O
OH O O
) O O
2D3 O O
, O O
but O O
not B-Negation B-Negation
by I-Negation I-Negation
the I-Negation I-Negation
presence I-Negation I-Negation
of I-Negation I-Negation
unlabeled I-Negation I-Negation
25 I-Negation I-Negation
( I-Negation I-Negation
OH I-Negation I-Negation
) I-Negation I-Negation
D3 I-Negation I-Negation
( I-Negation O
receptor-positive I-Negation O
lymphocytes I-Negation O
: O O
sarcoidosis O O
, O O
20 O O
± O O
12 O O
% O O
; O O
tuberculosis O O
, O O
31 O O
± O O
17 O O
% O O
) O O
. O O

The O O
CLE0 O O
sequence O O
interacts O O
with O O
factors O O
, O O
related O O
to O O
a O O
PMA-induced O O
AP-1 O O
and O O
a O O
PMA/A23187-induced O O
NF-AT O O
. O O

Although O O
these O O
cells O O
share O O
other O O
characteristics O O
with O O
plasmatocytes O O
, O O
they B-Negation O
are I-Negation O
normally I-Negation O
not I-Negation B-Negation
seen I-Negation I-Negation
in I-Negation I-Negation
circulation I-Negation I-Negation
until O O
they O O
are O O
released O O
from O O
the O O
lymph O O
glands O O
at O O
the O O
onset O O
of O O
metamorphosis O O
under O O
the O O
regulation O O
of O O
ecdysone O O
to O O
serve O O
as O O
phagocytes O O
for O O
histolysing O O
tissues O O
during O O
metamorphosis—thus O O
, O O
they O O
are O O
referred O O
to O O
as O O
pupal O O
macrophages O O
[ O O
19 O O
] O O
. O O

Finally O O
, O O
phorbol O O
12-myristate O O
13-acetate O O
increased O O
the O O
activity O O
of O O
both O O
the O O
core O O
and O O
the O O
969-bp O O
promoter O O
fragments O O
, O O
and O O
this O O
increase O O
was O O
abrogated O O
by O O
mutations O O
at O O
the O O
CRE O O
site O O
. O O

We O O
also O O
identified O O
a O O
potent O O
inhibitory O O
sequence O O
within O O
its O O
N-terminal O O
domain O O
. O O

PU.1 O O
mRNA O O
expression O O
and O O
PU.1 O O
DNA O O
binding O O
activity O O
, O O
as O O
measured O O
by O O
Northern O O
blot O O
analysis O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
respectively O O
, O O
were O O
evident O O
in O O
cell O O
lines O O
representing O O
pro-B O O
, O O
pre-B O O
, O O
and O O
mature O O
B O O
cells O O
. O O

The O O
cumulative O O
distribution O O
of O O
accuracy O O
shows O O
that O O
SCOPE O O
had O O
the O O
most O O
high-scoring O O
motifs O O
at O O
every O O
level O O
( O O
Figure O O
5b O O
) O O
. O O

The O O
first O O
large-scale O O
prediction O O
of O O
the O O
human O O
interactome O O
map O O
involved O O
transferring O O
interactions O O
from O O
model O O
organisms O O
36 O O
. O O

The O O
matrix O O
elements O O
were O O
subsequently O O
normalized O O
to O O
the O O
number O O
of O O
alignments O O
N O O
. O O

Nonpituitary O O
human O O
prolactin O O
gene O O
transcription O O
is O O
independent O O
of O O
Pit-1 O O
and O O
differentially O O
controlled O O
in O O
lymphocytes O O
and O O
in O O
endometrial O O
stroma O O
. O O

Ca2+-modulating O O
cyclophilin O O
ligand O O
( O O
CAML O O
) O O
was O O
originally O O
described O O
as O O
a O O
cyclophilin O O
B-binding O O
protein O O
whose O O
overexpression O O
in O O
T O O
cells O O
causes O O
a O O
rise O O
in O O
intracellular O O
calcium O O
, O O
thus O O
activating O O
transcription O O
factors O O
responsible O O
for O O
the O O
early O O
immune O O
response O O
. O O

A O O
brief O O
survey O O
of O O
the O O
per-regulon O O
results O O
of O O
these O O
performance O O
comparisons O O
yields O O
two O O
key O O
observations O O
: O O
( O O
1 O O
) O O
there O O
are O O
many O O
regulons O O
for O O
which O O
a O O
large O O
number O O
of O O
programs O O
find O O
a O O
small O O
portion O O
of O O
the O O
binding O O
sites O O
( O O
though O O
not O O
necessarily O O
the O O
same O O
portion O O
) O O
; O O
and O O
( O O
2 O O
) O O
every O O
program O O
has O O
a O O
respectable O O
number O O
of O O
`` O O
wins O O
'' O O
( O O
i.e. O O
every O O
program O O
is O O
the O O
best O O
existing O O
program O O
on O O
some O O
handful O O
of O O
regulons O O
145678 O O
. O O

We O O
used O O
our O O
monoclonal O O
model O O
of O O
germinal O O
center O O
maturation O O
, O O
CL-01 O O
B O O
cells O O
, O O
to O O
investigate O O
the O O
role O O
of O O
CD30 O O
in O O
human O O
B O O
cell O O
differentiation O O
. O O

The O O
above O O
negative O O
result O O
could O O
be O O
explained O O
if O O
the O O
filtering O O
process O O
, O O
which O O
is O O
the O O
final O O
step O O
of O O
the O O
prediction O O
method O O
( O O
Figure O O
2 O O
) O O
, O O
was O O
too O O
strict O O
. O O

The O O
IL-10 O O
gene O O
polymorphism O O
was O O
a O O
C-to-A O O
exchange O O
571 O O
base O O
pairs O O
upstream O O
from O O
the O O
translation O O
start O O
site O O
and O O
was O O
present O O
between O O
consensus O O
binding O O
sequences O O
for O O
Sp1 O O
and O O
elevated O O
total O O
serum O O
. O O

Plasma O O
cortisol O O
concentration O O
and O O
blood O O
leukocyte O O
content O O
of O O
glucocorticoid O O
receptors O O
( O O
GCR O O
) O O
were O O
assayed O O
in O O
20 O O
patients O O
with O O
deficiency O O
syndromes O O
, O O
10 O O
cold O O
in O O
property O O
( O O
deficiency-cold O O
) O O
, O O
the O O
other O O
10 O O
hot O O
in O O
property O O
( O O
deficiency-heat O O
) O O
, O O
and O O
also O O
in O O
10 O O
healthy O O
individuals O O
as O O
normal O O
control O O
for O O
the O O
purpose O O
of O O
investigating O O
the O O
nature O O
of O O
cold O O
and O O
heat O O
syndromes O O
. O O

The O O
development O O
of O O
resistance O O
to O O
host O O
defense O O
mechanisms O O
such O O
as O O
tumor O O
necrosis O O
factor O O
( O O
TNF O O
) O O
- O O
and O O
Fas-mediated O O
apoptosis O O
of O O
transformed O O
or O O
virus-infected O O
cells O O
may O O
be O O
a O O
critical O O
component O O
in O O
the O O
development O O
of O O
disease O O
. O O

Resolution O O
of O O
whole O O
cell O O
extract O O
through O O
two O O
chromatographic O O
steps O O
yields O O
a O O
single O O
protein O O
fraction O O
requiring O O
only O O
the O O
addition O O
of O O
TFIID O O
for O O
the O O
initiation O O
of O O
transcription O O
at O O
RNA O O
polymerase O O
II O O
promoters O O
. O O

Moreover O O
, O O
M-CSF-induced O O
expression O O
of O O
the O O
fos-related O O
gene O O
, O O
fra-1 O O
, O O
was O O
delayed O O
compared O O
to O O
that O O
for O O
both O O
c-fos O O
and O O
fos-B O O
. O O

Interstitial O O
collagenase O O
( O O
MMP-1 O O
) O O
, O O
a O O
metalloproteinase O O
produced O O
by O O
resident O O
and O O
inflammatory O O
cells O O
during O O
connective O O
tissue O O
turnover O O
, O O
cleaves O O
type O O
I O O
collagen O O
fibrils O O
. O O

TNF-alpha O O
, O O
IL-1 O O
beta O O
and O O
phorbol O O
myristate O O
acetate O O
( O O
PMA O O
) O O
treatment O O
increased O O
AP-1 O O
and O O
NF O O
kappa O O
B O O
DNA O O
binding O O
by O O
up O O
to O O
200 O O
% O O
but O O
decreased O O
CREB O O
binding O O
( O O
38 O O
% O O
) O O
over O O
a O O
60-min O O
time O O
course O O
. O O

To O O
determine O O
whether O O
oxidative O O
stress O O
dependent O O
NF-kappaB O O
activation O O
is O O
evident O O
in O O
patients O O
with O O
diabetic O O
nephropathy O O
we O O
used O O
an O O
Electrophoretic O O
Mobility O O
Shift O O
Assay O O
based O O
semiquantitative O O
detection O O
system O O
which O O
enabled O O
us O O
to O O
determine O O
NF-kappaB O O
activation O O
in O O
ex O O
vivo O O
isolated O O
peripheral O O
blood O O
mononuclear O O
cells O O
. O O

The O O
probability O O
of O O
seeing O O
m O O
at O O
least O O
C O O
( O O
m O O
) O O
times O O
in O O
the O O
regulon O O
can O O
be O O
approximated O O
by O O
the O O
Poisson O O
distribution O O
: O O
p O O
( O O
m O O
) O O
= O O
∑k≥C O O
( O O
m O O
) O O
[ O O
( O O
λke-λ O O
) O O
/k O O
! O O
] O O
where O O
λ O O
is O O
the O O
expectation O O
of O O
C O O
( O O
m O O
) O O
with O O
respect O O
to O O
the O O
null O O
motif O O
distribution O O
and O O
the O O
number O O
of O O
positions O O
in O O
the O O
regulon O O
. O O

Its O O
expression O O
is O O
restricted O O
to O O
a O O
few O O
cell O O
types O O
, O O
including O O
monocyte/macrophages O O
. O O

In O O
the O O
control O O
group O O
, O O
dexamethasone O O
produced O O
a O O
significant O O
depression O O
of O O
Type O O
I O O
receptors O O
( O O
from O O
267 O O
± O O
72 O O
to O O
169 O O
± O O
71 O O
receptors O O
per O O
cell O O
) O O
, O O
which O O
can O O
be O O
interpreted O O
as O O
a O O
primary O O
involvement O O
of O O
Type O O
I O O
receptors O O
in O O
the O O
response O O
to O O
dexamethasone O O
; O O

Rescue O O
of O O
the O O
adgf-a O O
Mutant O O
Phenotype O O
by O O
Expression O O
of O O
ADGF-A O O
in O O
Different O O
Tissues O O

In O O
EBV-transformed O O
B O O
clones O O
, O O
the O O
chi O O
B O O
site O O
exerted O O
the O O
strongest O O
inducible O O
activity O O
; O O
the O O
NF-AT O O
binding O O
sites O O
showed O O
either O O
no O O
or O O
only O O
weak O O
activity O O
compared O O
to O O
Jurkat O O
T O O
cells O O
. O O

Background O O

The O O
T O O
cell O O
activation O O
factor O O
NF-ATc O O
positively O O
regulates O O
HIV-1 O O
replication O O
and O O
gene O O
expression O O
in O O
T O O
cells O O
. O O

For O O
example O O
, O O
kappa O O
B-related O O
sequences O O
have O O
been O O
shown O O
to O O
be O O
important O O
for O O
the O O
transcription O O
of O O
a O O
few O O
inducible O O
genes O O
, O O
such O O
as O O
the O O
interleukin O O
2 O O
receptor O O
alpha-chain O O
gene O O
and O O
the O O
beta-interferon O O
gene O O
. O O

Thus O O
, O O
DR3 O O
likely O O
plays O O
a O O
role O O
in O O
regulating O O
lymphocyte O O
homeostasis O O
. O O

Similar O O
downregulation O O
of O O
BCL-6 O O
mRNA O O
was O O
seen O O
in O O
human O O
B O O
cells O O
stimulated O O
with O O
Staphylococcus O O
aureus O O
plus O O
interleukin-2 O O
or O O
anti-IgM O O
antibodies O O
and O O
in O O
human O O
T O O
lymphocytes O O
stimulated O O
with O O
phytohemagglutinin O O
. O O

Regulation O O
of O O
gene O O
expression O O
at O O
early O O
stages O O
of O O
B-cell O O
and O O
T-cell O O
differentiation O O
. O O

Interleukin O O
2 O O
( O O
IL-2 O O
) O O
is O O
an O O
important O O
lymphokine O O
required O O
in O O
the O O
process O O
of O O
T O O
cell O O
activation O O
, O O
proliferation O O
, O O
clonal O O
expansion O O
and O O
differentiation O O
. O O

Autoregulation O O
of O O
the O O
NF-kappa O O
B O O
transactivator O O
RelA O O
( O O
p65 O O
) O O
by O O
multiple O O
cytoplasmic O O
inhibitors O O
containing O O
ankyrin O O
motifs O O
. O O

These O O
findings O O
suggest O O
that O O
dexamethasone O O
down-regulates O O
TPA-induced O O
transcription O O
of O O
the O O
c-jun O O
gene O O
during O O
monocytic O O
differentiation O O
by O O
inhibiting O O
activation O O
of O O
the O O
AP-1 O O
site O O
. O O

It O O
is O O
directly O O
implicated O O
in O O
the O O
emergence O O
of O O
the O O
age-related O O
immune O O
deficiency O O
. O O

Since O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
replication O O
is O O
known O O
to O O
be O O
favored O O
under O O
oxidative O O
stress O O
conditions O O
, O O
ex O O
vivo O O
experiments O O
using O O
uninfected O O
PBMCs O O
, O O
primary O O
monocytes O O
or O O
a O O
latently O O
infected O O
promonocytic O O
U1 O O
cell O O
line O O
show O O
that O O
HIV-1 O O
replication O O
and O O
reactivation O O
, O O
monitored O O
by O O
p24 O O
antigen O O
measurement O O
, O O
are O O
inhibited O O
by O O
PAO O O
in O O
a O O
time- O O
and O O
concentration-dependent O O
manner O O
. O O

Synergism O O
between O O
two O O
distinct O O
elements O O
of O O
the O O
HTLV-I O O
enhancer O O
during O O
activation O O
by O O
the O O
trans-activator O O
of O O
HTLV-I O O
. O O

Tat O O
, O O
a O O
potent O O
activator O O
of O O
HIV-1 O O
gene O O
expression O O
, O O
serves O O
to O O
greatly O O
increase O O
the O O
rate O O
of O O
transcription O O
directed O O
by O O
the O O
viral O O
promoter O O
. O O

Although O O
a O O
role O O
of O O
p16 O O
in O O
this O O
regulation O O
has O O
been O O
presumed O O
, O O
there O O
is O O
no O O
proof O O
so O O
far O O
that O O
loss O O
of O O
this O O
tumor O O
suppressor O O
gene O O
really O O
affects O O
E2F-mediated O O
regulations O O
. O O

We O O
have O O
shown O O
that O O
the O O
D-mib O O
gene O O
regulates O O
wing O O
margin O O
formation O O
, O O
leg O O
segmentation O O
, O O
and O O
vein O O
formation O O
, O O
whereas O O
none B-Negation O
of I-Negation O
these I-Negation O
three I-Negation O
processes I-Negation O
depend I-Negation O
on I-Negation O
neur I-Negation O
gene I-Negation O
activity I-Negation O
( O O
[ O O
45,60 O O
] O O
; O O
this O O
study O O
) O O
. O O

The O O
nature O O
of O O
the O O
nuclear O O
factor O O
( O O
s O O
) O O
that O O
control O O
TNF-alpha O O
gene O O
transcription O O
in O O
humans O O
remains O O
obscure O O
, O O
although O O
NF-kappaB O O
has O O
been O O
suggested O O
. O O

The O O
nuclear O O
pool O O
of O O
I O O
( O O
kappa O O
) O O
B O O
( O O
alpha O O
) O O
showed O O
a O O
higher O O
stability O O
than O O
cytosolic O O
I O O
( O O
kappa O O
) O O
B O O
( O O
alpha O O
) O O
and O O
was O O
partially O O
independent O O
of O O
the O O
resynthesis O O
of O O
the O O
protein O O
. O O

Splitting O O
the O O
HS2 O O
enhancer O O
between O O
two O O
tandem O O
Ap1 O O
sites O O
abolishes O O
the O O
synthesis O O
of O O
a O O
group O O
of O O
long O O
enhancer O O
transcripts O O
and O O
results O O
in O O
loss O O
of O O
enhancer O O
function O O
and O O
transcriptional O O
silencing O O
of O O
the O O
cis-linked O O
CAT O O
gene O O
. O O

After O O
stimulation O O
, O O
two O O
new O O
kappa O O
B-specific O O
complexes O O
were O O
identified O O
as O O
NF-kappa O O
B O O
p50-p65 O O
heterodimer O O
and O O
putative O O
c-Rel O O
homodimer O O
or O O
c-Rel-p65 O O
heterodimer O O
. O O

Jurkat O O
cells O O
were O O
transfected O O
with O O
plasmids O O
containing O O
either O O
the O O
intact O O
IL-2 O O
promoter O O
or O O
its O O
AP-1 O O
, O O
NF-AT O O
, O O
and O O
NF-kB O O
motifs O O
. O O

The O O
5'-UTR O O
contains O O
binding O O
sites O O
for O O
the O O
transcription O O
factors O O
AP-1 O O
, O O
NF-kappaB O O
, O O
NF-AT O O
, O O
IRF O O
, O O
and O O
Sp1 O O
. O O

p65 O O
, O O
p50 O O
, O O
and O O
c-Rel O O
activities O O
were O O
found O O
in O O
both O O
CD4- O O
and O O
CD8-positive O O
thymocytes O O
. O O

Immunoblot O O
analysis O O
identified O O
Fli-1 O O
protein O O
in O O
lysates O O
derived O O
from O O
platelets O O
. O O

The O O
rates O O
estimated O O
for O O
the O O
Rhodes O O
and O O
Lehner O O
datasets O O
are O O
similar O O
to O O
previous O O
estimates O O
18 O O
. O O

We O O
determined O O
that O O
the O O
protein-binding O O
region O O
on O O
the O O
LMP O O
promoter O O
was O O
within O O
a O O
42 O O
bp O O
fragment O O
encompassing O O
nucleotides O O
-135 O O
to O O
-176 O O
relative O O
to O O
the O O
LMP O O
transcriptional O O
start O O
site O O
. O O

In O O
addition O O
to O O
finding O O
hLH-2 O O
expression O O
in O O
all O O
cases O O
of O O
CML O O
, O O
expression O O
was O O
observed O O
in O O
lymphoid O O
malignancies O O
and O O
myeloid O O
cell O O
lines O O
, O O
but O O
not B-Negation B-Negation
in I-Negation I-Negation
primary I-Negation I-Negation
cases I-Negation I-Negation
of I-Negation I-Negation
acute I-Negation I-Negation
myelogenous I-Negation I-Negation
leukaemia I-Negation I-Negation
. O O

Various O O
modes O O
of O O
basic O O
helix-loop-helix O O
protein-mediated O O
regulation O O
of O O
murine O O
leukemia O O
virus O O
transcription O O
in O O
lymphoid O O
cell O O
lines O O
. O O

This O O
study O O
suggests O O
a O O
therapeutic O O
approach O O
against O O
AIDS O O
by O O
application O O
of O O
two O O
drugs O O
, O O
one O O
against O O
a O O
cellular O O
and O O
the O O
other O O
a O O
viral O O
target O O
, O O
which O O
may O O
provide O O
an O O
approach O O
to O O
the O O
problem O O
of O O
frequent O O
emergence O O
of O O
resistant O O
variants O O
to O O
combinations O O
of O O
drugs O O
that O O
target O O
only O O
HIV O O
genes O O
. O O

However O O
, O O
for O O
IL-4 O O
this O O
was O O
accompanied O O
with O O
a O O
reduction O O
of O O
AP-1 O O
and O O
NF-IL6 O O
binding O O
activity O O
whereas O O
IL-10 O O
only O O
inhibited O O
AP-1 O O
binding O O
activity O O
. O O

Adenosine O O
and O O
deoxyadenosine O O
concentrations O O
measurement O O

Whereas O O
TPCK O O
inhibits O O
phosphorylation O O
of O O
I O O
kappa O O
B O O
and O O
, O O
consequently O O
, O O
activation O O
of O O
NF-kappa O O
B O O
, O O
it O O
markedly O O
enhances O O
the O O
activity O O
of O O
JNK O O
, O O
the O O
MAP O O
kinase-related O O
kinase O O
that O O
phosphorylates O O
the O O
transactivation O O
domain O O
of O O
c-Jun O O
. O O

Transfection O O
of O O
an O O
expression O O
vector O O
containing O O
ORF2 O O
but O O
not B-Negation B-Negation
full I-Negation I-Negation
length I-Negation I-Negation
cDNA I-Negation I-Negation
was O O
able O O
to O O
transform O O
NIH3T3 O O
cells O O
and O O
induce O O
tumors O O
in O O
nude O O
mice O O
. O O

IkappaBalpha O O
was O O
degraded O O
normally O O
following O O
stimulation O O
in O O
both O O
normal O O
controls O O
and O O
T O O
cells O O
from O O
RCC O O
patients O O
. O O

Transactivation O O
of O O
PTHrP O O
by O O
Tax O O
was O O
seen O O
in O O
T O O
cells O O
but O O
not B-Negation B-Negation
in I-Negation I-Negation
B-cell I-Negation I-Negation
lines I-Negation I-Negation
or I-Negation I-Negation
fibroblasts I-Negation I-Negation
. O O

Electron O O
microscopy O O
revealed O O
a O O
marked O O
increase O O
in O O
granules O O
resembling O O
those O O
specific O O
for O O
eosinophils O O
. O O

Specific O O
nuclear O O
translocation O O
of O O
[ O O
3H O O
] O O
calcitriol/VDR O O
was O O
examined O O
after O O
exposure O O
of O O
whole O O
cells O O
to O O
10 O O
( O O
-9 O O
) O O
M/l O O
calcitriol O O
in O O
the O O
presence O O
and O O
absence O O
of O O
a O O
500-fold O O
excess O O
of O O
unlabeled O O
ligand O O
and O O
subsequent O O
isolation O O
of O O
nuclei O O
. O O

Among O O
the O O
20 O O
selected O O
oligonucleotides O O
, O O
two O O
potent O O
15-mer O O
AS O O
oligonucleotides O O
( O O
C-JUN O O
AS O O
oligonucleotides O O
) O O
exhibited O O
significant O O
inhibition O O
of O O
cell O O
growth O O
in O O
a O O
dose-dependent O O
manner O O
between O O
2 O O
and O O
10 O O
microM O O
. O O

these O O
cells O O
can O O
respond O O
to O O
IFN-gamma O O
and O O
express O O
beta-chain O O
. O O

CD15 O O
cross-linking O O
also O O
concomitantly O O
increased O O
interleukin-1 O O
beta O O
( O O
IL-1 O O
beta O O
) O O
mRNA O O
, O O
while O O
no B-Negation B-Negation
apparent I-Negation I-Negation
change I-Negation I-Negation
was I-Negation I-Negation
observed I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
levels I-Negation I-Negation
of I-Negation I-Negation
beta-actin I-Negation I-Negation
mRNA I-Negation I-Negation
, O O
indicating O O
specificity O O
. O O

MLE O O
might O O
be O O
removed O O
in O O
vitro O O
( O O
for O O
example O O
, O O
by O O
elevated O O
ionic O O
strength O O
) O O
without O B-Negation
destroying O I-Negation
the O I-Negation
entire O I-Negation
complex O I-Negation
, O O
because O O
of O O
the O O
stabilizing O O
presence O O
of O O
MOF-MSL3 O O
. O O

We O O
have O O
shown O O
previously O O
that O O
EBNA2 O O
transactivates O O
the O O
promoters O O
of O O
the O O
latent O O
membrane O O
antigens O O
LMP O O
, O O
TP1 O O
and O O
TP2 O O
. O O

Dose-dependence O O
studies O O
using O O
histamine O O
and O O
dimaprit O O
showed O O
that O O
the O O
EC50 O O
values O O
for O O
cAMP O O
production O O
and O O
c-fos O O
increase O O
were O O
similar O O
, O O
suggesting O O
that O O
cAMP O O
might O O
be O O
involved O O
in O O
c-fos O O
induction O O
via O O
H2 O O
receptors O O
. O O

A O O
73 O O
kDa O O
protein O O
was O O
identified O O
by O O
this O O
analysis O O
: O O

Differentiation O O
of O O
T-helper O O
lymphocytes O O
: O O
selective O O
regulation O O
by O O
members O O
of O O
the O O
STAT O O
family O O
of O O
transcription O O
factors O O
. O O

BASELINE O O
's O O
average O O
score O O
never O O
exceeded O O
that O O
of O O
SCOPE O O
( O O
p O O
< O O
8.25 O O
× O O
10-6 O O
) O O
. O O

Levels B-Negation B-Negation
of I-Negation I-Negation
RNA I-Negation I-Negation
coding I-Negation I-Negation
for I-Negation I-Negation
the I-Negation I-Negation
receptor I-Negation I-Negation
were I-Negation I-Negation
not I-Negation I-Negation
modulated I-Negation I-Negation
by I-Negation I-Negation
exposure I-Negation I-Negation
to I-Negation I-Negation
high I-Negation I-Negation
levels I-Negation I-Negation
of I-Negation I-Negation
ligand I-Negation I-Negation
. O O

Treatment O O
of O O
HL-60 O O
cells O O
with O O
both O O
TPA O O
and O O
cycloheximide O O
had O O
no B-Negation B-Negation
effect I-Negation I-Negation
on I-Negation I-Negation
the I-Negation I-Negation
rates I-Negation I-Negation
of I-Negation I-Negation
c-jun I-Negation I-Negation
transcription I-Negation I-Negation
. O O

PTK O O
inhibition O O
with O O
Gen O O
attenuated O O
both O O
LPS-induced O O
NF-kappaB O O
DNA O O
binding O O
and O O
TNF-alpha O O
production O O
in O O
human O O
monocytes O O
. O O

In O O
the O O
T3+ O O
group O O
, O O
serum O O
total O O
thyroxine O O
( O O
TT4 O O
) O O
, O O
free O O
T4 O O
( O O
FT4 O O
) O O
, O O
and O O
TSH O O
were O O
approx O O
50 O O
% O O
lower O O
than O O
both O O
basal O O
and O O
T3-values O O
. O O

Both O O
compounds O O
inhibited O O
the O O
mixed O O
lymphocyte O O
reaction O O
, O O
and O O
this O O
inhibition O O
was O O
reversed O O
by O O
exogenous O O
IL-2 O O
. O O

In O O
contrast O O
, O O
a O O
cysteine O O
protease O O
inhibitor O O
that O O
also O O
blocks O O
apoptosis O O
had O O
no B-Negation B-Negation
substantial I-Negation I-Negation
affect I-Negation I-Negation
upon I-Negation I-Negation
cytokine I-Negation I-Negation
production I-Negation I-Negation
. O O

In O O
this O O
study O O
, O O
we O O
report O O
that O O
both O O
Exosurf O O
and O O
Survanta O O
suppress O O
TNF O O
mRNA O O
and O O
secretion O O
( O O
85 O O
± O O
4 O O
% O O
mean O O
percent O O
inhibition O O
± O O
SEM O O
by O O
Exosurf O O
; O O
71 O O
± O O
6 O O
% O O
by O O
Survanta O O
) O O
by O O
endotoxin-stimulated O O
THP-1 O O
, O O
a O O
human O O
monocytic O O
cell O O
line O O
. O O

Analysis O O
of O O
myeloid-associated O O
genes O O
in O O
human O O
hematopoietic O O
progenitor O O
cells O O
. O O

High O O
conservation O O
of O O
residues O O
near O O
the O O
inframe O O
stop O O
codon O O
also O O
suggests O O
the O O
importance O O
of O O
this O O
region O O
. O O

By O O
using O O
Jurkat O O
and O O
primary O O
human O O
T O O
lymphocytes O O
, O O
we O O
demonstrate O O
that O O
the O O
simultaneous O O
activation O O
of O O
two O O
second O O
messengers O O
of O O
the O O
TCR-initiated O O
signal O O
transduction O O
, O O
protein O O
kinase O O
C O O
( O O
PKC O O
) O O
and O O
calcineurin O O
, O O
results O O
in O O
the O O
synergistic O O
activation O O
of O O
the O O
IkappaBalpha O O
kinase O O
( O O
IKK O O
) O O
complex O O
but O O
not B-Negation B-Negation
of I-Negation I-Negation
another I-Negation I-Negation
putative I-Negation I-Negation
IkappaBalpha I-Negation I-Negation
kinase I-Negation I-Negation
, I-Negation I-Negation
p90 I-Negation I-Negation
( I-Negation I-Negation
rsk I-Negation I-Negation
) I-Negation I-Negation
. O O

Nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
and O O
AP-1 O O
are O O
insufficient O O
for O O
IL-2 O O
promoter O O
activation O O
: O O
requirement O O
for O O
CD28 O O
up-regulation O O
of O O
RE/AP O O
. O O

Cooperation O O
of O O
binding O O
sites O O
for O O
STAT6 O O
and O O
NF O O
kappa O O
B/rel O O
in O O
the O O
IL-4-induced O O
up-regulation O O
of O O
the O O
human O O
IgE O O
germline O O
promoter O O
. O O

Jak3 O O
is O O
associated O O
with O O
CD40 O O
and O O
is O O
critical O O
for O O
CD40 O O
induction O O
of O O
gene O O
expression O O
in O O
B O O
cells O O
. O O

Together O O
, O O
these O O
studies O O
demonstrate O O
that O O
the O O
processing O O
and O O
inducible O O
degradation O O
of O O
p105 O O
are O O
differentially O O
regulated O O
. O O

The O O
cDNA O O
library O O
was O O
screened O O
with O O
the O O
patients O O
own O O
autoimmune O O
serum O O
being O O
monospecific O O
for O O
the O O
nuclear O O
autoantigen O O
La/SS-B O O
. O O

Columns O O
4–6 O O
report O O
the O O
Ei-values O O
for O O
best O O
matches O O
between O O
RAG1s O O
and O O
a O O
Transib-derived O O
PSSM O O
after O O
adding O O
7 O O
, O O
13 O O
, O O
and O O
18 O O
Transib O O
TPases O O
to O O
the O O
GenBank O O
set O O
, O O
respectively O O
. O O

Furthermore O O
, O O
inhibition O O
can O O
be O O
blocked O O
by O O
actinomycin O O
D O O
, O O
indicating O O
a O O
requirement O O
for O O
de O O
novo O O
transcription O O
. O O

Maximal O O
increase O O
in O O
IL-2 O O
transcription O O
was O O
recorded O O
with O O
CHO-DR/B7/LFA-3 O O
, O O
suggesting O O
a O O
cooperative O O
effect O O
of O O
B7 O O
and O O
LFA-3 O O
at O O
the O O
transcriptional O O
level O O
. O O

gamma-Interferon O O
expression O O
was O O
only O O
detectable O O
in O O
1 O O
Hashimoto O O
's O O
goiter O O
. O O

The O O
molecular O O
mechanisms O O
of O O
the O O
effects O O
of O O
IL-4 O O
and O O
IL-13 O O
on O O
HIV O O
infection O O
in O O
human O O
monocytes O O
as O O
they O O
matured O O
into O O
monocyte-derived O O
macrophages O O
over O O
7 O O
days O O
were O O
investigated O O
using O O
HIV-1 O O
( O O
BaL O O
) O O
, O O
and O O
low O O
passage O O
clinical O O
strains O O
. O O

5 O O
. O O
Finally O O
, O O
the O O
addition O O
of O O
anti-CD28 O O
mAb O O
to O O
anti-CD3 O O
mAb-stimulated O O
T O O
cells O O
overcame O O
much O O
of O O
the O O
suppression O O
of O O
proliferation O O
induced O O
by O O
PGE2 O O
or O O
ISO O O
but O O
less O O
so O O
than O O
that O O
induced O O
by O O
DEX O O
. O O

Characterization O O
of O O
the O O
NF-kappa O O
B1 O O
promoter O O
identified O O
an O O
Egr-1 O O
site O O
which O O
was O O
found O O
to O O
be O O
essential O O
for O O
both O O
the O O
PMA/PHA-mediated O O
induction O O
as O O
well O O
as O O
the O O
synergistic O O
activation O O
observed O O
after O O
the O O
expression O O
of O O
the O O
RelA O O
subunit O O
of O O
NF-kappa O O
B O O
and O O
Egr-1 O O
. O O

We O O
feel O O
that O O
these O O
experiments O O
are O O
vital O O
to O O
understanding O O
the O O
function O O
of O O
GATA-1 O O
during O O
erythroid O O
ontogeny O O
. O O

ALD-induced O O
calcium O O
mobilization O O
and O O
PKC O O
activation O O
are O O
independent O O
of O O
tyrosine O O
protein O O
kinase O O
activity O O
as O O
shown O O
by O O
the O O
lack B-Negation B-Negation
of I-Negation I-Negation
effect I-Negation I-Negation
of I-Negation I-Negation
herbimycin I-Negation I-Negation
, I-Negation I-Negation
a I-Negation I-Negation
tyrosine-protein I-Negation I-Negation
kinase-specific I-Negation I-Negation
inhibitor I-Negation I-Negation
. O O

We O O
previously O O
detected O O
a O O
tissue-specific O O
promoter O O
preceding O O
the O O
exon O O
encoding O O
the O O
N O O
terminus O O
of O O
the O O
pp52 O O
leukocyte O O
protein O O
. O O

Although O O
the O O
low O O
overall O O
iPfam O O
coverage O O
hampers O O
the O O
interpretation O O
of O O
our O O
results O O
, O O
it O O
looks O O
as O O
if O O
there O O
has O O
been O O
a O O
diversification O O
of O O
domain O O
interactions O O
from O O
E. O O
coli O O
to O O
H. O O
sapiens O O
. O O

We O O
previously O O
identified O O
and O O
analyzed O O
a O O
45-nucleotide O O
sequence O O
( O O
downstream O O
regulatory O O
element O O
1 O O
[ O O
DRE O O
1 O O
] O O
) O O
, O O
+195 O O
to O O
+240 O O
, O O
at O O
the O O
boundary O O
of O O
the O O
R/U5 O O
region O O
of O O
the O O
long O O
terminal O O
repeat O O
which O O
is O O
required O O
for O O
HTLV-I O O
basal O O
transcription O O
. O O

By O O
contrast O O
, O O
T O O
cells O O
from O O
elderly O O
subjects O O
with O O
normal O O
levels O O
of O O
IL-2 O O
production O O
exhibited O O
normal O O
activation O O
of O O
AP-1 O O
and O O
NF-AT O O
. O O

In O O
addition O O
, O O
BLPs O O
stimulated O O
nuclear O O
factor-kappaB O O
, O O
a O O
transcriptional O O
activator O O
of O O
multiple O O
host O O
defense O O
genes O O
, O O
and O O
activated O O
the O O
respiratory O O
burst O O
through O O
hTLR2 O O
. O O

This O O
effect O O
is O O
largely O O
independent O O
of O O
the O O
CD2 O O
: O O
lymphocyte O O
function-associated O O
Ag-3 O O
pathway O O
. O O

To O O
clarify O O
the O O
role O O
of O O
mammalian O O
runt O O
products O O
in O O
normal O O
and O O
leukemic O O
hematopoiesis O O
, O O
we O O
have O O
studied O O
their O O
pattern O O
of O O
expression O O
in O O
mouse O O
hematopoietic O O
tissues O O
in O O
the O O
adult O O
and O O
during O O
ontogeny O O
using O O
an O O
anti-runt O O
box O O
antiserum O O
. O O

Second O O
, O O
TRE-DNA O O
binding O O
proteins O O
sedimented O O
through O O
a O O
glycerol O O
density O O
gradient O O
at O O
rates O O
corresponding O O
to O O
proteins O O
of O O
native O O
molecular O O
weights O O
of O O
35 O O
to O O
50 O O
kD O O
and O O
110 O O
kD O O
. O O

Furthermore O O
, O O
the O O
hemin-induced O O
accumulation O O
of O O
globin O O
, O O
known O O
as O O
a O O
marker O O
of O O
erythroid O O
differentiation O O
, O O
is O O
decreased O O
in O O
cells O O
overexpressing O O
HSF2-beta O O
. O O

Coexpression O O
of O O
both O O
PEBP2betaMYH11 O O
and O O
activated O O
NRAS O O
induced O O
a O O
more O O
severe O O
phenotype O O
characterized O O
by O O
abnormal O O
nuclear O O
morphology O O
indicative O O
of O O
granulocytic O O
dysplasia O O
. O O

The O O
data O O
obtained O O
demonstrate O O
that O O
phorbol O O
dibutyrate/calcium O O
ionophore O O
A23187 O O
( O O
PDBu/iono O O
) O O
combination O O
induced O O
a O O
clearly O O
higher O O
nuclear O O
translocation O O
of O O
NF-kappa O O
B O O
in O O
neonatal O O
than O O
adult O O
T O O
cells O O
. O O

Phenotypic O O
DC O O
characteristics O O
of O O
KG1 O O
dendritic-like O O
cells O O
include O O
morphology O O
( O O
loosely O O
adherent O O
cells O O
with O O
long O O
neurite O O
processes O O
) O O
, O O
MHC O O
I+/MHC O O
IIbright/CD83+/CD86+/CD14- O O
surface O O
Ag O O
expression O O
, O O
and O O
RelB O O
and O O
DC-CK1 O O
gene O O
expression O O
. O O

Our O O
data O O
demonstrate O O
that O O
those O O
cell O O
lines O O
lacking B-Negation O
capability I-Negation O
to I-Negation O
form I-Negation O
metastatic I-Negation O
tumors I-Negation O
in I-Negation O
vivo I-Negation O
are O O
susceptible O O
to O O
TNF O O
induced O O
apoptosis O O
in O O
vitro O O
. O O

Identification O O
and O O
cloning O O
of O O
TCF-1 O O
, O O
a O O
T O O
lymphocyte-specific O O
transcription O O
factor O O
containing O O
a O O
sequence-specific O O
HMG O O
box O O
. O O

Stat3gamma O O
is O O
derived O O
from O O
Stat3alpha O O
by O O
limited O O
proteolysis O O
and O O
lacks B-Negation B-Negation
the I-Negation I-Negation
carboxyl-terminal I-Negation I-Negation
portion I-Negation I-Negation
of I-Negation I-Negation
Stat3alpha I-Negation I-Negation
. O O

The O O
effects O O
of O O
phorbol O O
ester O O
on O O
MNDA O O
mRNA O O
appeared O O
to O O
be O O
associated O O
with O O
induced O O
differentiation O O
since O O
inhibiting O O
cell O O
proliferation O O
did O O
not B-Negation B-Negation
alter I-Negation I-Negation
the I-Negation I-Negation
level I-Negation I-Negation
of I-Negation I-Negation
MNDA I-Negation I-Negation
mRNA I-Negation I-Negation
and O I-Negation
cell B-Negation I-Negation
cycle I-Negation I-Negation
variation I-Negation I-Negation
in I-Negation I-Negation
MNDA I-Negation I-Negation
mRNA I-Negation I-Negation
levels I-Negation I-Negation
were I-Negation I-Negation
not I-Negation I-Negation
observed I-Negation I-Negation
. O O

Some O O
subsets O O
of O O
quite O O
high O O
posterior O O
odds O O
have O O
much O O
smaller O O
overlaps O O
with O O
the O O
training O O
set O O
. O O

The O O
process O O
of O O
apoptosis O O
is O O
used O O
to O O
eliminate O O
unwanted O O
cells O O
from O O
a O O
wide O O
variety O O
of O O
organisms O O
. O O

We O O
have O O
previously O O
shown O O
that O O
protein O O
kinase O O
C O O
( O O
PKC O O
) O O
activation O O
( O O
with O O
phorbol O O
ester O O
( O O
PMA O O
) O O
alone O O
) O O
specifically O O
induces O O
differentiation O O
of O O
primary O O
human O O
CD34+ O O
hemopoietic O O
progenitor O O
cells O O
( O O
HPC O O
) O O
to O O
mature O O
DC O O
. O O

1 O O
alpha,25- O O
( O O
OH O O
) O O
2D3 O O
inhibited O O
CD23 O O
expression O O
in O O
U937 O O
cells O O
, O O
yet O O
failed B-Negation B-Negation
to I-Negation I-Negation
modulate I-Negation I-Negation
CD23 I-Negation I-Negation
expression I-Negation I-Negation
in I-Negation I-Negation
B I-Negation I-Negation
cells I-Negation I-Negation
. O O

Diminished O O
NF-kappaB O O
activity O O
has O O
been O O
shown O O
to O O
occur O O
in O O
T O O
cells O O
with O O
aging O O
, O O
suggesting O O
that O O
impaired O O
activation O O
of O O
NF-kappaB O O
might O O
occur O O
during O O
cellular O O
senescence O O
. O O

In O O
addition O O
, O O
we O O
show O O
that O O
PNU156804 O O
does O O
not B-Negation B-Negation
block I-Negation I-Negation
significantly I-Negation I-Negation
the I-Negation I-Negation
induction I-Negation I-Negation
of I-Negation I-Negation
either I-Negation I-Negation
IL-2 I-Negation I-Negation
or I-Negation I-Negation
IL-2R I-Negation I-Negation
alpha- I-Negation I-Negation
and I-Negation I-Negation
gamma-chains I-Negation I-Negation
but O O
inhibits O O
IL-2-dependent O O
T O O
cell O O
proliferation O O
. O O

CTL O O
recognition O O
of O O
an O O
altered O O
peptide O O
associated O O
with O O
asparagine O O
bond O O
rearrangement O O
. O O

Furthermore O O
, O O
p65 O O
was O O
detected O O
in O O
the O O
nuclei O O
of O O
some O O
lymphocytes O O
. O O

Neither B-Negation B-Negation
of I-Negation I-Negation
the I-Negation I-Negation
two I-Negation I-Negation
toxins I-Negation I-Negation
affected I-Negation I-Negation
kappaB I-Negation I-Negation
binding I-Negation I-Negation
activity I-Negation I-Negation
induced I-Negation I-Negation
by I-Negation I-Negation
TNFalpha I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
same I-Negation I-Negation
cells I-Negation I-Negation
. O O

In O O
B7.1-positive O O
B O O
cells O O
, O O
this O O
element O O
bound O O
several O O
members O O
of O O
the O O
NF-kappaB O O
family O O
, O O
transcription O O
factors O O
already O O
implicated O O
in O O
signal O O
transduction O O
pathways O O
relevant O O
to O O
B7.1 O O
expression O O
. O O

Activated O O
Rac-1 O O
could O O
mimic O O
activated O O
p21ras O O
to O O
induce O O
AP-1 O O
but O O
not O B-Negation
to O I-Negation
induce O I-Negation
NFAT O I-Negation
. O O

The O O
I O O
kappa O O
B O O
gamma O O
isoforms O O
also O O
display O O
differences O O
in O O
specificity O O
and O O
affinity O O
for O O
Rel/NF-kappa O O
B O O
proteins O O
. O O

Interferons O O
induce O O
normal O O
and O O
aberrant O O
retinoic-acid O O
receptors O O
type O O
alpha O O
in O O
acute O O
promyelocytic O O
leukemia O O
cells O O
: O O

Secondly O O
, O O
the O O
described O O
modularity O O
of O O
known O O
S. O O
cerevisiae O O
complexes O O
lends O O
support O O
to O O
the O O
assumption O O
that O O
the O O
underlying O O
iPfam O O
domain O O
pairs O O
are O O
modular O O
. O O

Thus O O
, O O
IL-10 O O
inhibits O O
IFN-gamma-induced O O
ICAM-1 O O
expression O O
in O O
monocytes O O
primarily O O
at O O
the O O
level O O
of O O
gene O O
transcription O O
. O O

Our O O
data O O
also O O
demonstrate O O
that O O
NAC O O
increases O O
the O O
GSH-to-GSSG O O
ratio O O
within O O
the O O
EC O O
suggesting O O
one O O
possible O O
mechanism O O
through O O
which O O
this O O
antioxidant O O
inhibits O O
agonist-induced O O
monocyte O O
adhesion O O
to O O
EC O O
. O O

Lack B-Negation B-Negation
of I-Negation I-Negation
T-cell-mediated I-Negation I-Negation
recognition I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
fusion I-Negation I-Negation
region I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
pml/RAR-alpha I-Negation I-Negation
hybrid I-Negation I-Negation
protein I-Negation I-Negation
by I-Negation I-Negation
lymphocytes I-Negation I-Negation
of I-Negation I-Negation
acute I-Negation I-Negation
promyelocytic I-Negation I-Negation
leukemia I-Negation I-Negation
patients I-Negation I-Negation
. O O

Using O O
in O O
vivo O O
genomic O O
footprinting O O
we O O
identified O O
interactions O O
in O O
B-cell O O
lines O O
at O O
the O O
octamer O O
site O O
and O O
the O O
Y O O
, O O
X1 O O
, O O
and O O
X2 O O
boxes O O
. O O

The O O
adgf-a O O
Mutant O O
Phenotype O O
Is O O
Rescued O O
by O O
Expression O O
of O O
ADGF-A O O
in O O
the O O
Lymph O O
Glands O O

Modulation O O
of O O
endogenous O O
IL-1 O O
beta O O
and O O
IL-1 O O
receptor O O
antagonist O O
results O O
in O O
opposing O O
effects O O
on O O
HIV O O
expression O O
in O O
chronically O O
infected O O
monocytic O O
cells O O
. O O

The O O
C/EBP O O
motif O O
is O O
bound O O
by O O
Ig/EBP-1 O O
in O O
pre-B O O
cell O O
and O O
T O O
cell O O
extracts O O
, O O
but O O
is O O
replaced O O
by O O
nuclear O O
factor-IL-6beta O O
or O O
a O O
nuclear O O
factor-IL-6beta-Ig/EBP-1 O O
heterodimer O O
in O O
plasmacytoma O O
cell O O
extracts O O
. O O

Here O O
, O O
Stanley O O
Korsmeyer O O
provides O O
a O O
brief O O
overview O O
of O O
bcl-2 O O
, O O
concentrating O O
on O O
its O O
roles O O
in O O
B- O O
and O O
T-cell O O
development O O
and O O
in O O
oncogenesis O O
. O O

The O O
c-jun O O
mRNA O O
, O O
which O O
is O O
constitutively O O
expressed O O
in O O
human O O
peripheral-blood O O
monocytes O O
at O O
relatively O O
high O O
levels O O
, O O
was O O
also O O
slightly O O
augmented O O
by O O
LTB4 O O
, O O
although O O
to O O
a O O
much O O
lower O O
extent O O
than O O
c-fos O O
. O O

Neur O O
and O O
D-mib O O
were O O
shown O O
to O O
similarly O O
promote O O
down-regulation O O
of O O
Ser O O
from O O
the O O
cell O O
surface O O
when O O
overexpressed O O
( O O
E. O O
C. O O
Lai O O
, O O
F. O O
Roegiers O O
, O O
X. O O
Qin O O
, O O
R. O O
Le O O
Borgne O O
, O O
F. O O
Schweisguth O O
, O O
et O O
al. O O
, O O
unpublished O O
data O O
) O O
. O O

On O O
the O O
y-axis O O
, O O
we O O
show O O
the O O
average O O
number O O
of O O
iPfam O O
domain O O
pairs O O
in O O
edges O O
adjacent O O
to O O
proteins O O
of O O
degree O O
x O O
. O O

Protein O O
kinase O O
C O O
( O O
PKC O O
) O O
depletion O O
generated O O
by O O
a O O
long-term O O
phorbol O O
12 O O
myristate O O
13-acetate O O
treatment O O
had O O
weak O O
effects O O
on O O
proliferation O O
. O O

Although O O
GM-CSF O O
receptor O O
is O O
devoid O O
of O O
tyrosine O O
kinase O O
enzymatic O O
activity O O
, O O
GM-CSF-induced O O
peripheral O O
blood O O
polymorphonuclear O O
leukocytes O O
( O O
PMN O O
) O O
functional O O
activation O O
is O O
mediated O O
by O O
the O O
phosphorylation O O
of O O
a O O
large O O
number O O
of O O
intracellular O O
signaling O O
molecules O O
. O O

The O O
purpose O O
of O O
this O O
review O O
is O O
to O O
analyze O O
and O O
concilliate O O
the O O
reported O O
data O O
on O O
the O O
mechanism O O
of O O
action O O
of O O
estrogens O O
. O O

In O O
group O O
I O O
BL O O
cells O O
, O O
containing O O
low O O
levels O O
of O O
NF-kappaB O O
, O O
only O O
RBP O O
binding O O
was O O
observed O O
in O O
EMSAs O O
, O O
whereas O O
NF-kappaB O O
binding O O
could O O
be O O
demonstrated O O
in O O
EBV-transformed O O
B O O
cell O O
lines O O
containing O O
high O O
levels O O
of O O
activated O O
NF-kappaB O O
. O O

Direct O O
interaction O O
of O O
hematopoietic O O
transcription O O
factors O O
PU.1 O O
and O O
GATA-1 O O
: O O
functional O O
antagonism O O
in O O
erythroid O O
cells O O
. O O

Interferon-gamma O O
( O O
IFN-gamma O O
) O O
, O O
also O O
known O O
as O O
type O O
II O O
interferon O O
, O O
is O O
an O O
important O O
immunoregulatory O O
gene O O
that O O
has O O
multiple O O
effects O O
on O O
the O O
development O O
, O O
maturation O O
, O O
and O O
function O O
of O O
the O O
immune O O
system O O
. O O

Here O O
, O O
we O O
show O O
that O O
overexpression O O
of O O
p95vav O O
alone O O
in O O
Jurkat O O
T O O
cells O O
leads O O
to O O
activation O O
of O O
the O O
nuclear O O
factors O O
, O O
including O O
NFAT O O
, O O
involved O O
in O O
interleukin-2 O O
expression O O
. O O

This O O
is O O
practically O O
indispensable O O
for O O
objective O O
classification O O
of O O
candidates O O
, O O
but O O
there O O
is O O
no O O
guarantee O O
that O O
unknown O O
proteins O O
with O O
the O O
23rd O O
amino O O
acid O O
will O O
score O O
higher O O
than O O
the O O
thresholds O O
. O O

Antisense O O
cDNA O O
to O O
clone O O
18 O O
inhibited O O
the O O
expression O O
of O O
a O O
reporter O O
construct O O
containing O O
the O O
DPA O O
promoter O O
, O O
indicating O O
its O O
functional O O
importance O O
in O O
the O O
expression O O
of O O
this O O
class O O
II O O
gene O O
. O O

However O O
, O O
while O O
IL2 O O
expression O O
requires O O
the O O
contribution O O
of O O
Ca O O
( O O
2+ O O
) O O
- O O
and O O
protein O O
kinase O O
C-dependent O O
signals O O
, O O
we O O
report O O
that O O
activation O O
of O O
human O O
IL4 O O
transcription O O
through O O
the O O
Ca O O
( O O
2+ O O
) O O
-dependent O O
pathway O O
is O O
diminished O O
by O O
protein O O
kinase O O
C O O
stimulation O O
in O O
Jurkat O O
T O O
cells O O
. O O

All O O
TCC O O
expressed O O
equal O O
levels O O
of O O
the O O
low-affinity O O
IL-12R O O
beta1 O O
subunit O O
. O O

This O O
potent O O
interleukin O O
2 O O
( O O
IL-2 O O
) O O
-dependent O O
activation O O
does O O
not B-Negation B-Negation
require I-Negation I-Negation
monocytes I-Negation I-Negation
or I-Negation I-Negation
accessory I-Negation I-Negation
cells I-Negation I-Negation
. O O

This O O
inhibition O O
, O O
which O O
occurred O O
with O O
a O O
parallel O O
activation O O
of O O
c-Jun O O
transactivating O O
functions O O
and O O
expression O O
, O O
was O O
reflected O O
by O O
transfection O O
experiments O O
at O O
the O O
IL-2 O O
promoter O O
level O O
, O O
and O O
involved O O
not O O
only O O
the O O
inhibition O O
of O O
NF-kappaB-driven O O
reporter O O
activation O O
but O O
also O O
that O O
of O O
nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
. O O

It O O
is O O
present O O
in O O
an O O
active O O
form O O
in O O
both O O
B O O
cells O O
and O O
non-B O O
cells O O
, O O
where O O
it O O
can O O
mediate O O
transcriptional O O
activation O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Indomethacin O O
blocked O O
PGE2 O O
release O O
, O O
but O O
had O O
no B-Negation B-Negation
influence I-Negation I-Negation
on I-Negation I-Negation
the I-Negation I-Negation
observed I-Negation I-Negation
effects I-Negation I-Negation
of I-Negation I-Negation
C3a I-Negation I-Negation
, O O
suggesting O O
that O O
the O O
effects O O
of O O
C3a O O
on O O
IL-6 O O
production O O
are O O
independent O O
of O O
PGE2 O O
formation O O
by O O
monocytes O O
. O O

Replication O O
of O O
human O O
immunodeficiency O O
virus-1 O O
in O O
primary O O
human O O
T O O
cells O O
is O O
dependent O O
on O O
the O O
autocrine O O
secretion O O
of O O
tumor O O
necrosis O O
factor O O
through O O
the O O
control O O
of O O
nuclear O O
factor-kappa O O
B O O
activation O O
. O O

During O O
wing O O
development O O
, O O
expression O O
of O O
D-mib O O
in O O
dorsal O O
cells O O
appears O O
to O O
be O O
necessary O O
and O O
sufficient O O
for O O
wing O O
margin O O
specification O O
, O O
indicating O O
that O O
D-mib O O
also O O
regulates O O
Ser O O
signaling O O
. O O

Nevertheless O O
, O O
based O O
on O O
the O O
orientations O O
and O O
relative O O
positions O O
of O O
these O O
transposons O O
, O O
none B-Negation O
of I-Negation O
them I-Negation O
appears O O
to O O
be O O
associated O O
with O O
the O O
RAG1-like O O
sequences O O
( O O
see O O
Figure O O
5 O O
) O O
. O O

These O O
mechanisms O O
include O O
the O O
assembly O O
of O O
higher O O
order O O
nucleoprotein O O
complexes O O
and O O
other O O
protein-protein O O
interactions O O
that O O
enhance O O
the O O
functional O O
specificity O O
of O O
transcriptional O O
regulators O O
in O O
lymphocytes O O
. O O

A O O
diverged O O
homeobox O O
gene O O
, O O
HB24 O O
, O O
which O O
is O O
known O O
to O O
be O O
induced O O
following O O
lymphocyte O O
activation O O
, O O
was O O
introduced O O
into O O
Jurkat O O
T O O
cells O O
under O O
the O O
control O O
of O O
a O O
constitutive O O
promoter O O
. O O

Our O O
data O O
suggest O O
that O O
CD30 O O
critically O O
regulates O O
the O O
CD40-mediated O O
differentiation O O
of O O
non-antigen-selected O O
human O O
B O O
cells O O
. O O

CTLA-4 O O
engagement O O
by O O
mAbs O O
inhibits O O
, O O
while O O
CD28 O O
enhances O O
, O O
IL-2 O O
production O O
and O O
proliferation O O
upon O O
T O O
cell O O
activation O O
. O O

The O O
ability O O
of O O
RFX1 O O
to O O
transactivate O O
the O O
core O O
promoter O O
raises O O
the O O
possibility O O
that O O
RFX1 O O
may O O
play O O
a O O
dual O O
role O O
in O O
regulating O O
HBV O O
gene O O
expression O O
. O O

1 O O
. O O
Blood O O
cell O O
receptors O O
in O O
volunteers O O
with O O
moderately O O
increased O O
body O O
burdens O O
. O O

A O O
major O O
transcription O O
initiation O O
site O O
was O O
located O O
in O O
three O O
human O O
tissues O O
approximately O O
560 O O
bp O O
upstream O O
from O O
the O O
translation O O
initiation O O
codon O O
and O O
380 O O
bp O O
upstream O O
from O O
any O O
previously O O
identified O O
transcription O O
initiation O O
site O O
. O O

NF-kappaB O O
activity O O
is O O
tightly O O
correlated O O
with O O
the O O
transcriptional O O
activity O O
of O O
a O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
of O O
HIV-1 O O
transfected O O
in O O
thymocytes O O
. O O

Furthermore O O
, O O
expression O O
of O O
physiological O O
levels O O
of O O
Bcl-x O O
protected O O
B O O
cells O O
from O O
Fas-mediated O O
apoptosis O O
in O O
the O O
absence B-Negation B-Negation
of I-Negation I-Negation
NF-kappaB I-Negation I-Negation
signaling I-Negation I-Negation
. O O

But O O
on O O
reporter O O
genes O O
with O O
nonoptimal O O
binding O O
sites O O
, O O
their O O
transcriptional O O
properties O O
diverged O O
and O O
E2A-HLF O O
competitively O O
inhibited O O
activation O O
by O O
wild-type O O
PAR O O
proteins O O
. O O

Secreted O O
TNF-alpha O O
mediated O O
the O O
enhancement O O
of O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF-kappa O O
B O O
) O O
and O O
activator O O
protein-1 O O
( O O
AP-1 O O
) O O
binding O O
activity O O
; O O
in O O
fact O O
, O O
the O O
triggering O O
of O O
HLA-DR O O
antigens O O
in O O
the O O
presence O O
of O O
antihuman O O
TNF-alpha-neutralizing O O
antibodies O O
did O O
not B-Negation B-Negation
upregulate I-Negation I-Negation
NF-kappa I-Negation I-Negation
B I-Negation I-Negation
and I-Negation I-Negation
AP-1 I-Negation I-Negation
. O O

This O O
intracellular O O
signaling O O
complex O O
potently O O
stimulates O O
kappa O O
B-directed O O
transcription O O
from O O
either O O
the O O
HIV-1 O O
LTR O O
or O O
the O O
IL-2R O O
alpha O O
promoter O O
via O O
the O O
strong O O
transactivation O O
domain O O
present O O
in O O
p65 O O
. O O

LPS O O
stimulation O O
transiently O O
enhanced O O
the O O
I O O
kappa O O
B O O
alpha-bound O O
kinase O O
activity O O
in O O
THP-1 O O
cells O O
. O O

BCL-2-deficient O O
T O O
cells O O
demonstrate O O
accelerated O O
cell O O
cycle O O
progression O O
and O O
increased O O
apoptosis O O
following O O
activation O O
. O O

In O O
this O O
article O O
, O O
transcriptional O O
regulation O O
of O O
the O O
archetypal O O
T-cell-specific O O
gene O O
, O O
alpha O O
TCR O O
, O O
is O O
discussed O O
. O O

Increased O O
natural O O
killer O O
cell O O
activity O O
correlates O O
with O O
low O O
or O O
negative O O
expression O O
of O O
the O O
HER-2/neu O O
oncogene O O
in O O
patients O O
with O O
breast O O
cancer O O
. O O

We O O
found O O
, O O
however O O
, O O
that O O
PI O O
3-kinase O O
profoundly O O
influenced O O
the O O
transactivation O O
capacity O O
of O O
'nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
' O O
( O O
NF-AT O O
) O O
elicited O O
by O O
the O O
TCR O O
: O O
expression O O
of O O
an O O
activated O O
form O O
of O O
PI O O
3-kinase O O
inhibited O O
TCR-mediated O O
NF-AT O O
responses O O
, O O
whereas O O
expression O O
of O O
a O O
dominant O O
negative O O
mutant O O
of O O
PI O O
3-kinase O O
potently O O
enhanced O O
TCR-controlled O O
NF-AT O O
induction O O
. O O

The O O
results O O
of O O
the O O
three O O
algorithms O O
are O O
merged O O
and O O
sorted O O
. O O

However O O
, O O
the O O
ALD O O
stimulus O O
is O O
not B-Negation B-Negation
capable I-Negation I-Negation
of I-Negation I-Negation
causing I-Negation I-Negation
complete I-Negation I-Negation
T I-Negation I-Negation
cell I-Negation I-Negation
activation I-Negation I-Negation
. O O

NFATx1 O O
, O O
which O O
is O O
preferentially O O
expressed O O
in O O
the O O
thymus O O
and O O
peripheral O O
blood O O
leukocytes O O
, O O
is O O
one O O
of O O
four O O
members O O
of O O
the O O
NFAT O O
family O O
of O O
transcription O O
factors O O
. O O

Studies O O
of O O
the O O
function O O
of O O
SCL O O
suggest O O
it O O
is O O
also O O
important O O
in O O
proliferation O O
and O O
self-renewal O O
events O O
in O O
erythroid O O
cells O O
. O O

Control O O
of O O
NF-kappa O O
B O O
activity O O
by O O
the O O
I O O
kappa O O
B O O
beta O O
inhibitor O O
. O O

The O O
increase O O
in O O
SCL O O
protein O O
levels O O
in O O
early O O
erythroid O O
precursors O O
stimulated O O
with O O
Steel O O
factor O O
suggests O O
one O O
mechanism O O
through O O
which O O
Steel O O
factor O O
may O O
enhance O O
normal O O
erythroid O O
proliferation O O
. O O

In O O
fact O O
, O O
cellular O O
NF-kappa O O
B O O
activity O O
was O O
phosphorylation-dependent O O
and O O
the O O
DNA O O
binding O O
activity O O
of O O
p65-containing O O
NF-kappa O O
B O O
was O O
enhanced O O
by O O
phosphorylation O O
in O O
vitro O O
. O O

The O O
results O O
were O O
compared O O
to O O
those O O
obtained O O
with O O
the O O
parental O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
( O O
GM-CSF O O
) O O
-dependent O O
cell O O
line O O
, O O
UT-7 O O
, O O
which O O
has O O
a O O
predominantly O O
megakaryoblastic O O
phenotype O O
and O O
is O O
unable B-Negation B-Negation
to I-Negation I-Negation
proliferate I-Negation I-Negation
continuously I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
presence I-Negation I-Negation
of I-Negation I-Negation
Epo I-Negation I-Negation
. O O

We O O
show O O
that O O
inhibition O O
is O O
not B-Negation B-Negation
due I-Negation I-Negation
to I-Negation I-Negation
a I-Negation I-Negation
direct I-Negation I-Negation
modification I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
active I-Negation I-Negation
NF-kappaB I-Negation I-Negation
heterodimer I-Negation I-Negation
. O O

Stimulation O O
of O O
the O O
cAMP O O
signal O O
transduction O O
pathway O O
, O O
which O O
skews O O
cytokine O O
production O O
toward O O
a O O
Th2 O O
pattern O O
, O O
resulted O O
in O O
the O O
preferential O O
suppression O O
of O O
Stat1 O O
activity O O
. O O

Improvement O O
in O O
urinary O O
protein O O
excretion O O
and O O
in O O
disease O O
activity O O
, O O
which O O
was O O
scored O O
according O O
to O O
the O O
SLE O O
Disease O O
Activity O O
Index O O
system O O
of O O
the O O
University O O
of O O
Toronto O O
, O O
closely O O
related O O
to O O
the O O
glucocorticoid O O
receptor O O
concentrations O O
in O O
MNL O O
isolated O O
from O O
the O O
corresponding O O
patients O O
. O O

Abstract O O

WIN O O
61058 O O
and O O
WIN O O
53071 O O
were O O
identified O O
as O O
microM O O
inhibitors O O
. O O

We O O
have O O
demonstrated O O
that O O
native O O
envelope O O
glycoproteins O O
of O O
HIV-1 O O
, O O
gp160 O O
can O O
induce O O
activation O O
of O O
the O O
transcription O O
factor O O
, O O
NF-kappa O O
B O O
. O O

Furthermore O O
, O O
Elf-1 O O
interacts O O
specifically O O
with O O
the O O
E74 O O
target O O
sequence O O
and O O
can O O
stimulate O O
transcription O O
driven O O
by O O
the O O
E74 O O
site O O
independent O O
of O O
mitogenic O O
signaling O O
. O O

The O O
B3 O O
factor O O
was O O
only O O
slightly O O
evident O O
in O O
nuclei O O
of O O
uninfected O O
cells O O
but O O
was O O
readily O O
detectable O O
in O O
nuclei O O
of O O
infected O O
monocytes O O
. O O

Before O O
this O O
time O O
, O O
programmed O O
cell O O
death O O
was O O
defined O O
by O O
a O O
set O O
of O O
specific O O
morphological O O
characteristics O O
, O O
including O O
chromatin O O
condensation O O
, O O
nuclear O O
shrinkage O O
and O O
blebbing O O
of O O
the O O
plasma O O
membrane O O
that O O
could O O
be O O
observed O O
in O O
dying O O
cells O O
; O O
the O O
term O O
apoptosis O O
was O O
coined O O
to O O
distinguish O O
this O O
type O O
of O O
cell O O
death O O
from O O
necrotic O O
deaths O O
resulting O O
from O O
injury O O
[ O O
3,4 O O
] O O
. O O

We O O
developed O O
unicellular O O
culture O O
systems O O
for O O
unilineage O O
differentiation O O
of O O
purified O O
hematopoietic O O
progenitor O O
cells O O
followed O O
by O O
daughter O O
cell O O
analysis O O
at O O
cellular O O
and O O
molecular O O
level O O
. O O

We O O
demonstrate O O
that O O
CD4 O O
triggering O O
delivers O O
signals O O
capable O O
of O O
activating O O
the O O
NF-AT O O
transcription O O
factor O O
which O O
is O O
required O O
for O O
interleukin-2 O O
gene O O
expression O O
. O O

ML-9-induced O O
differentiation O O
was O O
also O O
reversible O O
when O O
the O O
cells O O
were O O
cultured O O
with O O
cultured O O
with O O
ML-9 O O
plus O O
an O O
anti-cancer O O
drug O O
such O O
as O O
1-beta-D-arabino-furanosylcytosine O O
or O O
daunomycin O O
. O O

No B-Negation B-Negation
significant I-Negation I-Negation
difference I-Negation I-Negation
was I-Negation I-Negation
detected I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
activation I-Negation I-Negation
of I-Negation I-Negation
MAPK I-Negation I-Negation
kinase-1 I-Negation I-Negation
that I-Negation I-Negation
is I-Negation I-Negation
induced I-Negation I-Negation
by I-Negation I-Negation
bufalin I-Negation I-Negation
in I-Negation I-Negation
wild-type I-Negation I-Negation
or I-Negation I-Negation
Bcl-2-overexpressed I-Negation I-Negation
U937 I-Negation I-Negation
cells I-Negation I-Negation
; O O
however O O
, O O
the O O
activation O O
of O O
MAPK O O
by O O
bufalin O O
was O O
significantly O O
attenuated O O
in O O
the O O
cells O O
overexpressing O O
Bcl-2 O O
. O O

Extracellular-regulated O O
kinase O O
1/2 O O
, O O
Jun O O
N-terminal O O
kinase O O
, O O
and O O
c-Jun O O
are O O
involved O O
in O O
NF-kappa O O
B-dependent O O
IL-6 O O
expression O O
in O O
human O O
monocytes O O
. O O

The O O
same O O
is O O
true O O
for O O
nuclear O O
extracts O O
taken O O
from O O
the O O
murine O O
P388D1 O O
macrophage O O
cell O O
line O O
when O O
tested O O
with O O
the O O
-516 O O
motif O O
of O O
the O O
murine O O
TNF O O
promoter O O
( O O
GGGGGCTTTCCC O O
) O O
. O O

Finally O O
, O O
chromosomal O O
localization O O
using O O
fluorescence O O
in O O
situ O O
hybridization O O
revealed O O
that O O
LITAF O O
mapped O O
to O O
chromosome O O
16p12-16p13.3 O O
. O O

Even O O
in O O
H. O O
sapiens O O
, O O
where O O
we O O
suspect O O
a O O
positive O O
bias O O
due O O
to O O
the O O
overrepresentation O O
of O O
disease-related O O
proteins O O
in O O
both O O
the O O
PDB O O
and O O
protein O O
interaction O O
databases O O
, O O
81 O O
% O O
of O O
protein O O
interactions O O
do O O
not B-Negation B-Negation
contain I-Negation I-Negation
an I-Negation I-Negation
iPfam I-Negation I-Negation
domain I-Negation I-Negation
pair I-Negation I-Negation
. O O

High-level O O
NF-kappaB O O
activation O O
also O O
appears O O
to O O
be O O
a O O
critical O O
component O O
of O O
long-term O O
outgrowth O O
. O O

Platelet-activating O O
factor O O
( O O
PAF O O
) O O
positively O O
auto-regulates O O
the O O
expression O O
of O O
human O O
PAF O O
receptor O O
transcript O O
1 O O
( O O
leukocyte-type O O
) O O
through O O
NF-kappa O O
B O O
. O O

GR O O
was O O
determined O O
by O O
whole O O
cell O O
assay O O
with O O
3H-Dex O O
. O O

Human O O
immunodeficiency O O
virus-type O O
1 O O
( O O
HIV-1 O O
) O O
infection O O
is O O
characterized O O
by O O
a O O
chronic O O
state O O
of O O
immune O O
hyperactivation O O
in O O
patients O O
. O O

Thus O O
, O O
the O O
dioxin O O
receptor O O
system O O
provides O O
a O O
complex O O
and O O
interesting O O
model O O
of O O
the O O
regulation O O
of O O
transcription O O
factors O O
by O O
hsp90 O O
. O O

DZA O O
inhibits O O
the O O
transcriptional O O
activity O O
of O O
NF-kappaB O O
through O O
the O O
hindrance O O
of O O
p65 O O
( O O
Rel-A O O
) O O
phosphorylation O O
without B-Negation B-Negation
reduction I-Negation I-Negation
of I-Negation I-Negation
its I-Negation I-Negation
nuclear I-Negation I-Negation
translocation I-Negation I-Negation
and I-Negation I-Negation
DNA I-Negation I-Negation
binding I-Negation I-Negation
activity I-Negation I-Negation
. O O

The O O
close O O
homology O O
of O O
the O O
basic O O
region/leucine O O
zipper O O
( O O
bZIP O O
) O O
DNA-binding O O
and O O
dimerization O O
domain O O
of O O
HLF O O
to O O
that O O
of O O
the O O
CES-2 O O
cell-death O O
specification O O
protein O O
of O O
Caenorhabditis O O
elegans O O
suggests O O
a O O
model O O
of O O
leukaemogenesis O O
in O O
which O O
E2A-HLF O O
blocks O O
an O O
early O O
step O O
within O O
an O O
evolutionarily O O
conserved O O
cell-death O O
pathway O O
. O O

They O O
are O O
particularly O O
abundant O O
in O O
lymphoid O O
tissues O O
and O O
are O O
thought O O
to O O
be O O
critical O O
for O O
the O O
transcription O O
of O O
genes O O
involved O O
in O O
immune O O
and O O
inflammatory O O
responses O O
. O O

Switching O O
is O O
hampered O O
by O O
CD30 O O
coengagement O O
, O O
possibly O O
through O O
interference O O
with O O
the O O
CD40-mediated O O
NF-kappaB-dependent O O
transcriptional O O
activation O O
of O O
downstream O O
C O O
( O O
H O O
) O O
genes O O
. O O

We O O
report O O
here O O
a O O
simple O O
and O O
rapid O O
strategy O O
to O O
detect O O
the O O
precise O O
number O O
of O O
the O O
CAGs O O
. O O

Analyses O O
of O O
nuclear O O
extracts O O
by O O
electrophoretic O O
DNA O O
mobility O O
shift O O
assays O O
showed O O
that O O
decreased O O
IL-2 O O
production O O
by O O
stimulated O O
T O O
cells O O
of O O
elderly O O
individuals O O
was O O
closely O O
associated O O
with O O
impairments O O
in O O
the O O
activation O O
of O O
both O O
AP-1 O O
and O O
NF-AT O O
. O O

D-mib O O
Regulates O O
Dl O O
Signaling O O

Our O O
laboratory O O
has O O
shown O O
that O O
RA O O
can O O
enhance O O
in O O
vitro O O
polyclonal O O
B O O
cell O O
immunoglobulin O O
( O O
Ig O O
) O O
response O O
. O O

Six O O
proteins O O
are O O
essential O O
for O O
this O O
process O O
and O O
they O O
associate O O
with O O
the O O
X O O
chromosomes O O
; O O
four O O
of O O
them O O
are O O
related O O
to O O
factors O O
involved O O
in O O
chromosome O O
condensation O O
during O O
mitosis O O
in O O
other O O
systems O O
. O O

While O O
the O O
maternally O O
derived O O
X O O
chromosome O O
was O O
preferentially O O
active O O
in O O
the O O
asymptomatic O O
twin O O
, O O
the O O
paternal O O
X O O
chromosome O O
was O O
active O O
in O O
the O O
other O O
, O O
affected O O
twin O O
and O O
was O O
found O O
in O O
her O O
hemizygotic O O
nephew O O
. O O

Frequencies O O
of O O
iPfam O O
domain O O
pairs O O
in O O
E. O O
coli O O
, O O
S. O O
cerevisiae O O
and O O
H. O O
sapiens O O
protein O O
interactions O O
. O O

SCF-mediated O O
ligation O O
of O O
kit/IL-4R O O
alpha O O
is O O
sufficient O O
to O O
elicit O O
IL-4-specific O O
gene O O
expression O O
, O O
including O O
up-regulation O O
of O O
CD23 O O
and O O
synthesis O O
of O O
germ-line O O
epsilon O O
transcripts O O
. O O

Sequential O O
development O O
of O O
structural O O
and O O
functional O O
alterations O O
in O O
T O O
cells O O
from O O
tumor-bearing O O
mice O O
. O O

In O O
THP-1 O O
cells O O
transfected O O
with O O
HIV O O
plasmid O O
constructs O O
, O O
both O O
organisms O O
induced O O
transcription O O
from O O
the O O
HIV O O
long O O
terminal O O
repeat O O
that O O
was O O
dependent O O
on O O
intact O O
NF-kappaB O O
binding O O
sequences O O
. O O

Cell O O
culture O O
experiments O O
demonstrated O O
that O O
the O O
natural O O
variant O O
with O O
four O O
Sp1 O O
sites O O
had O O
a O O
slightly O O
higher O O
promoter O O
activity O O
and O O
viral O O
replication O O
rate O O
than O O
the O O
isogenic O O
control O O
LTR O O
with O O
three O O
Sp1 O O
sites O O
. O O

Addition O O
of O O
activated O O
platelets O O
to O O
adherent O O
monocytes O O
had O O
a O O
similar O O
effect O O
and O O
was O O
associated O O
with O O
nuclear O O
factor-kappa O O
B O O
activation O O
. O O

A O O
well-preserved O O
4132-bp O O
Transib1_SP O O
element O O
( O O
contig O O
7839 O O
, O O
positions O O
376–4506 O O
) O O
is O O
flanked O O
by O O
a O O
5-bp O O
CGGCG O O
TSD O O
, O O
and O O
it O O
encodes O O
a O O
676-aa O O
TPase O O
( O O
two O O
exons O O
) O O
that O O
is O O
most O O
similar O O
to O O
the O O
Transib2 O O
TPase O O
( O O
34 O O
% O O
identity O O
) O O
. O O

The O O
region O O
downstream O O
of O O
the O O
enhancer O O
( O O
DEN O O
) O O
of O O
the O O
long O O
terminal O O
repeat O O
of O O
the O O
mink O O
cell O O
focus-forming O O
murine O O
leukemia O O
virus O O
is O O
important O O
for O O
viral O O
pathogenicity O O
. O O

The O O
enhanced O O
initiation O O
of O O
transcription O O
of O O
the O O
TF O O
gene O O
appears O O
to O O
require O O
engagement O O
of O O
a O O
56 O O
bp O O
LPS O O
Response O O
Element O O
, O O
an O O
enhancer O O
that O O
is O O
engaged O O
by O O
both O O
AP-1 O O
type O O
heterodimeric O O
complexes O O
as O O
well O O
as O O
NF O O
kappa O O
B O O
like O O
heterodimeric O O
complexes O O
. O O

Exposing O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
( O O
HUVECs O O
) O O
to O O
anoxia/reoxygenation O O
( O O
A/R O O
) O O
results O O
in O O
an O O
increase O O
in O O
polymorphonuclear O O
leukocyte O O
( O O
PMN O O
) O O
adhesion O O
to O O
HUVECs O O
. O O

Impaired O O
silencing O O
of O O
gamma-globin O O
expression O O
identifies O O
EKLF O O
as O O
the O O
first O O
transcription O O
factor O O
participating O O
quantitatively O O
in O O
the O O
gamma-globin O O
to O O
beta-globin O O
switch O O
. O O

MBP O O
stimulated O O
2-fold O O
increases O O
in O O
IL-8 O O
messenger O O
RNA O O
( O O
mRNA O O
) O O
after O O
1 O O
and O O
3 O O
h O O
of O O
incubation O O
, O O
which O O
were O O
blocked O O
by O O
pretreatment O O
with O O
actinomycin O O
D O O
. O O

Dots O O
indicate O O
nucleotide O O
identity O O
with O O
the O O
consensus O O
sequence O O
; O O
hyphens O O
represent O O
alignment O O
gaps O O
. O O

However O O
, O O
programs O O
for O O
tRNA O O
identification O O
are O O
based O O
on O O
the O O
features O O
of O O
known O O
tRNAs O O
and O O
do O O
not O O
necessarily O O
perform O O
well O O
on O O
unknown O O
ones O O
. O O

Although O O
GM-CSF B-Negation O
does I-Negation O
not I-Negation O
appear O O
to O O
be O O
essential O O
for O O
normal O O
hemopoiesis O O
, O O
overexpression O O
of O O
GM-CSF O O
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
some O O
diseases O O
such O O
as O O
myeloid O O
leukemia O O
and O O
chronic O O
inflammation O O
. O O

These O O
findings O O
suggest O O
that O O
there O O
is O O
no O O
primary O O
and O O
general O O
impairment O O
of O O
glucocorticoid O O
metabolism O O
in O O
the O O
asthmatics O O
, O O
but O O
the O O
number O O
of O O
GCR O O
in O O
the O O
asthmatics O O
is O O
lower O O
than O O
that O O
in O O
healthy O O
controls O O
. O O

A O O
stock O O
carrying O O
the O O
ubiquitous O O
actin-Gal4 O O
driver O O
( O O
P-actin-Gal4 O O
UAS-GFP/CyO O O
; O O
lethal O O
insertion O O
on O O
Chromosome O O
II O O
) O O
was O O
obtained O O
from O O
Dr. O O
R. O O
Sousa O O
. O O

While O O
a O O
nuclear O O
factor O O
( O O
s O O
) O O
from O O
both O O
peripheral O O
blood O O
monocytes O O
and O O
T O O
cells O O
binds O O
the O O
peri-kappa O O
B O O
site O O
, O O
electrophoretic O O
mobility O O
shift O O
assays O O
suggest O O
that O O
either O O
a O O
different O O
protein O O
binds O O
to O O
this O O
site O O
in O O
monocytes O O
versus O O
T O O
cells O O
or O O
that O O
the O O
protein O O
recognizing O O
this O O
enhancer O O
element O O
undergoes O O
differential O O
modification O O
in O O
monocytes O O
and O O
T O O
cells O O
, O O
thus O O
supporting O O
the O O
transfection O O
data O O
. O O

We O O
have O O
mapped O O
the O O
DNase-I-hypersensitive O O
( O O
HS O O
) O O
regions O O
of O O
the O O
human O O
GATA-3 O O
gene O O
in O O
T-cells O O
and O O
non-T-cells O O
and O O
studied O O
their O O
transcriptional O O
activities O O
. O O

These O O
synthetic O O
ligands O O
specifically O O
inhibit O O
DNA-binding O O
of O O
each O O
transcription O O
factor O O
and O O
HIV O O
type O O
1 O O
transcription O O
in O O
cell-free O O
assays O O
. O O

Using O O
monoclonal O O
antibodies O O
( O O
mAbs O O
) O O
and O O
flow O O
cytometry O O
, O O
we O O
studied O O
a O O
variety O O
of O O
surface O O
receptors O O
on O O
lymphocyte O O
subpopulations O O
of O O
workers O O
with O O
moderately O O
increased O O
body O O
burdens O O
of O O
2,3,7,8-tetrachlorodibenzo-p-dioxin O O
( O O
TCDD O O
) O O
and O O
of O O
other O O
polychlorinated O O
dibenzo-p-dioxins O O
and O O
dibenzofurans O O
( O O
PCDD/PCDF O O
) O O
, O O
expressed O O
here O O
as O O
International-Toxicity O O
Equivalencies O O
( O O
I-TE O O
) O O
. O O

A O O
clone O O
of O O
U937 O O
cells O O
was O O
selected O O
which O O
expressed O O
Fc O O
receptor O O
I O O
( O O
Fc O O
gamma O O
RI O O
) O O
and O O
which O O
, O O
after O O
incubation O O
with O O
IFN-gamma O O
for O O
72 O O
h O O
, O O
was O O
capable O O
of O O
generating O O
high O O
levels O O
of O O
lucigenin-enhanced O O
CL O O
. O O

The O O
protooncogene O O
p21ras O O
, O O
a O O
monomeric O O
G O O
protein O O
family O O
member O O
, O O
plays O O
a O O
critical O O
role O O
in O O
converting O O
extracellular O O
signals O O
into O O
intracellular O O
biochemical O O
events O O
. O O

BHA O O
was O O
found O O
to O O
suppress O O
not O O
only O O
PMA- O O
or O O
TNF-induced O O
, O O
but O O
also O O
constitutive O O
, O O
HIV-enhancer O O
activity O O
concomitant O O
to O O
an O O
inhibition O O
of O O
NF-kappa O O
B O O
binding O O
activity O O
in O O
both O O
lymphoblastoid O O
T O O
( O O
J.Jhan O O
) O O
and O O
monocytic O O
( O O
U937 O O
) O O
cell O O
lines O O
. O O

Mineralocorticoid O O
effector O O
mechanism O O
in O O
preeclampsia O O
. O O

Taken O O
together O O
these O O
data O O
indicate O O
that O O
carboxylesterase O O
gene O O
transcription O O
in O O
THP-1 O O
cells O O
starts O O
at O O
multiple O O
initiation O O
sites O O
and O O
that O O
Sp1 O O
and O O
IRBP O O
may O O
be O O
critical O O
factors O O
for O O
modulating O O
the O O
differentiation-dependent O O
transcription O O
of O O
this O O
human O O
carboxylesterase O O
gene O O
. O O

The O O
details O O
of O O
the O O
regulatory O O
mechanism O O
that O O
selects O O
particular O O
loci O O
for O O
rearrangement O O
are O O
still O O
not B-Negation O
known I-Negation O
. O O

The B-Negation B-Negation
levels I-Negation I-Negation
of I-Negation I-Negation
GATA-1 I-Negation I-Negation
, I-Negation I-Negation
Epo-R I-Negation I-Negation
and I-Negation I-Negation
globin I-Negation I-Negation
mRNA I-Negation I-Negation
expressed I-Negation I-Negation
were I-Negation I-Negation
not I-Negation I-Negation
affected I-Negation I-Negation
by I-Negation I-Negation
a I-Negation I-Negation
24-hour I-Negation I-Negation
incubation I-Negation I-Negation
of I-Negation I-Negation
either I-Negation I-Negation
cell I-Negation I-Negation
line I-Negation I-Negation
with I-Negation I-Negation
Epo I-Negation I-Negation
, I-Negation I-Negation
GM-CSF I-Negation I-Negation
or I-Negation I-Negation
interleukin-3 I-Negation I-Negation
( I-Negation I-Negation
IL-3 I-Negation I-Negation
) I-Negation I-Negation
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

If O O
the O O
features O O
are O O
not B-Negation B-Negation
independent I-Negation I-Negation
, O O
all O O
possible O O
combinations O O
of O O
all O O
states O O
of O O
these O O
features O O
must O O
be O O
considered O O
, O O
which O O
can O O
be O O
computationally O O
quite O O
intensive O O
. O O

One O O
notable O O
exception O O
is O O
that O O
the B-Negation O
C.elegans I-Negation O
homologs I-Negation O
of I-Negation O
IAPs I-Negation O
do I-Negation O
not I-Negation O
appear O O
to O O
function O O
in O O
programmed O O
cell O O
death O O
. O O

Both O O
non-interacting O O
protein O O
datasets O O
were O O
cleaned O O
by O O
removing O O
all O O
protein O O
pairs O O
that O O
came O O
from O O
the O O
positive O O
dataset O O
as O O
well O O
as O O
protein O O
pairs O O
that O O
were O O
annotated O O
as O O
interacting O O
in O O
other O O
databases O O
( O O
DIP O O
65 O O
: O O
679 O O
interactions O O
, O O
BIND O O
66 O O
: O O
2650 O O
interactions O O
) O O
, O O
or O O
predicted O O
to O O
interact O O
in O O
other O O
studies O O
( O O
OPHID O O
67 O O
: O O
21815 O O
interactions O O
) O O
. O O

Two O O
tyrosines O O
( O O
Y113 O O
and O O
Y128 O O
) O O
fall O O
within O O
an O O
identical O O
five O O
amino-acid O O
motif O O
and O O
are O O
shown O O
to O O
be O O
phosphorylated O O
upon O O
TCR O O
ligation O O
. O O

The O O
induction O O
of O O
promoters O O
dependent O O
on O O
these O O
elements O O
is O O
inhibitable O O
by O O
the O O
immunosuppressants O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
and O O
tacrolimus O O
( O O
FK-506 O O
) O O
. O O

Tax O O
activates O O
the O O
GM-CSF O O
promoter O O
through O O
the O O
CK-1/CD28RE O O
region O O
and O O
also O O
activates O O
nuclear O O
factor-kappa O O
B O O
binding O O
to O O
this O O
region O O
. O O

Liver O O
specimens O O
taken O O
from O O
patients O O
with O O
acute O O
fulminant O O
hepatitis O O
had O O
markedly O O
increased O O
NF-kappa O O
B O O
binding O O
activity O O
in O O
comparison O O
with O O
the O O
binding O O
of O O
normal O O
livers O O
. O O

Site-directed O O
mutagenesis O O
of O O
the O O
critical O O
guanine O O
nucleotides O O
in O O
the O O
kappaB-Sp1 O O
element O O
documented O O
the O O
essential O O
role O O
of O O
this O O
site O O
in O O
activation-dependent O O
fas O O
promoter O O
induction O O
. O O

Chromosome O O
1 O O
abnormalities O O
with O O
loss O O
of O O
1p36 O O
have O O
been O O
investigated O O
in O O
95 O O
breast-cancer O O
samples O O
by O O
means O O
of O O
a O O
dual-target O O
fluorescence O O
in-situ O O
hybridization O O
( O O
FISH O O
) O O
technique O O
using O O
the O O
pUC O O
1.77 O O
and O O
p1-79 O O
probes O O
, O O
specific O O
for O O
the O O
1q12 O O
and O O
1p36 O O
regions O O
, O O
respectively O O
. O O

Nonhuman O O
primates O O
are O O
naturally O O
infected O O
with O O
a O O
B-lymphotropic O O
herpesvirus O O
closely O O
related O O
to O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
. O O

The O O
cytoplasmic O O
domain O O
of O O
the O O
receptor O O
for O O
interleukin O O
10 O O
( O O
IL-10R O O
) O O
contains O O
two O O
box O O
3 O O
sequence O O
motifs O O
that O O
have O O
been O O
identified O O
in O O
the O O
signal-transducing O O
receptor O O
subunits O O
for O O
IL-6-type O O
cytokines O O
and O O
noted O O
to O O
be O O
required O O
for O O
activating O O
STAT3 O O
and O O
inducing O O
transcription O O
through O O
IL-6-responsive O O
elements O O
. O O

This O O
highlights O O
a O O
basic O O
assumption O O
of O O
this O O
study O O
that O O
could O O
be O O
a O O
source O O
of O O
error O O
. O O

In O O
line O O
with O O
other O O
motif O O
finders O O
, O O
we O O
have O O
used O O
statistical O O
significance O O
as O O
a O O
surrogate O O
for O O
biological O O
significance O O
. O O

The O O
effects O O
of O O
selenium O O
were O O
specific O O
for O O
NF-kappa O O
B O O
, O O
since O O
the B-Negation B-Negation
activity I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
transcription I-Negation I-Negation
factor I-Negation I-Negation
AP-1 I-Negation I-Negation
was I-Negation I-Negation
not I-Negation I-Negation
suppressed I-Negation I-Negation
. O O

Functional O O
interaction O O
between O O
the O O
two O O
zinc O O
finger O O
domains O O
of O O
the O O
v-erb O O
A O O
oncoprotein O O
. O O

Expression O O
of O O
c-fos O O
, O O
c-jun O O
and O O
jun O O
B O O
in O O
peripheral O O
blood O O
lymphocytes O O
from O O
young O O
and O O
elderly O O
adults O O
. O O

Despite O O
these O O
findings O O
, O O
the O O
molecular O O
mechanisms O O
by O O
which O O
Ets O O
and O O
NF-kappaB/NFAT O O
proteins O O
cooperatively O O
regulate O O
inducible O O
T-cell O O
gene O O
expression O O
remained O O
unknown O O
. O O

We O O
have O O
identified O O
and O O
separated O O
four O O
nuclear O O
proteins O O
from O O
C81-66-45 O O
cells O O
, O O
an O O
HTLV-I O O
immortalized O O
Tax-expressing O O
human O O
T-lymphocyte O O
line O O
( O O
Salahuddin O O
et O O
al. O O
, O O
1983 O O
) O O
, O O
that O O
interact O O
with O O
the O O
TRE-DNA O O
, O O
none B-Negation O
of I-Negation O
which I-Negation O
are I-Negation O
identical I-Negation O
with I-Negation O
the I-Negation O
Tax-protein I-Negation O
. O O

Furthermore O O
, O O
the O O
results O O
obtained O O
with O O
TNF O O
alpha O O
proved O O
that O O
NF-kappa O O
B O O
activation O O
was O O
not B-Negation B-Negation
sufficient I-Negation I-Negation
for I-Negation I-Negation
induction I-Negation I-Negation
of I-Negation I-Negation
neuroblastoma I-Negation I-Negation
differentiation I-Negation I-Negation
. O O

We O O
report O O
that O O
activation O O
of O O
the O O
two O O
transcription O O
factors O O
NF-kappa O O
B O O
and O O
AP-1 O O
is O O
crucially O O
involved O O
in O O
FasL O O
expression O O
induced O O
by O O
etoposide O O
, O O
teniposide O O
, O O
and O O
UV O O
irradiation O O
. O O

Both O O
constitutively O O
active O O
forms O O
of O O
CN O O
and O O
protein O O
kinase O O
C O O
( O O
PKC O O
) O O
synergistically O O
activated O O
transcription O O
from O O
the O O
GM-CSF O O
promoter O O
. O O

Therefore O O
, O O
we O O
asked O O
whether O O
the O O
observed O O
iPfam O O
coverage O O
is O O
larger O O
than O O
would O O
be O O
expected O O
by O O
chance O O
. O O

We O O
therefore O O
compared O O
the O O
turnover O O
of O O
I O O
kappa O O
B O O
alpha O O
and O O
I O O
kappa O O
B O O
beta O O
in O O
mature O O
B O O
cells O O
and O O
HeLa O O
cells O O
. O O

Further O O
definition O O
of O O
this O O
pathway O O
will O O
yield O O
new O O
insights O O
into O O
inflammation O O
initiated O O
by O O
TNFalpha O O
signalling O O
. O O

Similarly O O
, O O
the O O
complexes O O
binding O O
the O O
consensus O O
AP-1 O O
TRE O O
and O O
jun O O
TRE-like O O
motifs O O
in O O
cells O O
exposed O O
to O O
oxidative O O
signals O O
or O O
PHA/PMA O O
were O O
indistinguishable O O
, O O
being O O
composed O O
of O O
c-Fos O O
, O O
c-Jun O O
, O O
and O O
JunD O O
. O O

Background O O

Moreover O O
, O O
neither B-Negation B-Negation
TCR I-Negation I-Negation
or I-Negation I-Negation
Ras I-Negation I-Negation
activation I-Negation I-Negation
of I-Negation I-Negation
AP-1 I-Negation I-Negation
is I-Negation I-Negation
dependent I-Negation I-Negation
on I-Negation I-Negation
PtdIns I-Negation I-Negation
3-kinase I-Negation I-Negation
. O O

S9a O O
inhibited O O
TNF-alpha O O
promoter-driven O O
reporter O O
gene O O
activity O O
. O O

Human O O
peripheral O O
B O O
cells O O
became O O
capable O O
of O O
constitutively O O
producing O O
p40 O O
by O O
in O O
vitro O O
transformation O O
with O O
EBV O O
, O O
coincident O O
with O O
the O O
expression O O
of O O
latent O O
membrane O O
protein O O
1 O O
( O O
LMP1 O O
) O O
of O O
EBV O O
. O O

To O O
test O O
this O O
hypothesis O O
, O O
we O O
examined O O
whether O O
the O O
forced O O
ubiquitous O O
expression O O
of O O
the O O
neur O O
gene O O
can O O
suppress O O
the O O
D-mib O O
loss-of-function O O
phenotype O O
. O O

Cellular O O
activation O O
by O O
thrombin O O
leads O O
to O O
the O O
phosphorylation O O
of O O
multiple O O
proteins O O
, O O
most O O
of O O
which O O
are O O
unidentified O O
. O O

Deoxycholate O O
treatment O O
of O O
the O O
cytoplasmic O O
extract O O
prepared O O
from O O
cells O O
stimulated O O
by O O
TNF-alpha O O
in O O
the O O
presence O O
of O O
Cu2+ O O
resulted O O
in O O
the O O
release O O
of O O
NF O O
kappa O O
B O O
from O O
I O O
kappa O O
B O O
alpha O O
, O O
indicating O O
that O O
Cu2+ O O
interferes O O
with O O
the O O
dissociation O O
of O O
the O O
NF O O
kappa O O
B-I O O
kappa O O
B O O
complex O O
. O O

In O O
germinal O O
centers O O
GC O O
, O O
p50 O O
, O O
p52 O O
, O O
and O O
RelB O O
were O O
found O O
in O O
the O O
nuclei O O
of O O
FDC O O
only O O
and O O
were B-Negation O
not I-Negation B-Negation
detected I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
nuclei I-Negation I-Negation
of I-Negation I-Negation
CD68+ I-Negation I-Negation
cells I-Negation I-Negation
. O O

This O O
investigation O O
was O O
undertaken O O
to O O
determine O O
the O O
composition O O
of O O
StatG O O
in O O
mature O O
normal O O
human O O
myeloid O O
cells O O
, O O
i.e. O O
polymorphonuclear O O
neutrophilic O O
granulocytes O O
( O O
PMN O O
) O O
. O O

These O O
observations O O
suggest O O
that O O
the O O
germinal O O
center O O
reaction O O
provides O O
unique O O
activation O O
signals O O
to O O
B O O
cells O O
that O O
allow O O
for O O
continued O O
, O O
high-level O O
BCL-6 O O
expression O O
. O O

These O O
results O O
collectively O O
reveal O O
a O O
complex O O
interaction O O
of O O
STAT5 O O
with O O
other O O
signaling O O
pathways O O
and O O
illustrate O O
that O O
regulation O O
of O O
gene O O
expression O O
requires O O
integration O O
of O O
opposing O O
signals O O
. O O

As O O
early O O
as O O
2 O O
h O O
after O O
addition O O
of O O
the O O
inhibitor O O
to O O
the O O
culture O O
medium O O
, O O
there O O
was O O
an O O
inhibition O O
of O O
both O O
constitutive O O
activation O O
of O O
NF-kappaB O O
and O O
HIV-1 O O
genome O O
expression O O
. O O

The O O
latter O O
`` O O
nuclear O O
factor O O
for O O
activated O O
T O O
cells O O
'' O O
likely O O
contributes O O
to O O
the O O
tissue O O
specificity O O
of O O
IL-2 O O
gene O O
expression O O
. O O

Subsequent O O
cloning O O
of O O
TCF-1 O O
identified O O
three O O
splice O O
alternatives O O
. O O

Overall O O
taxonomy O O
, O O
including O O
common O O
and O O
Latin O O
names O O
, O O
is O O
reported O O
on O O
the O O
right O O
side O O
of O O
the O O
figure O O
. O O

The O O
immunomodulatory O O
cytokine O O
IL-4 O O
affects O O
cells O O
of O O
most O O
hemopoietic O O
lineages O O
. O O

Lists O O
of O O
high O O
scoring O O
domain O O
pairs O O
and O O
PTM O O
pairs O O
are O O
shown O O
in O O
Additional O O
Files O O
1 O O
and O O
2 O O
. O O

The O O
present O O
studies O O
have O O
examined O O
the O O
effects O O
of O O
vincristine-selected O O
, O O
multidrug O O
resistance O O
on O O
12-O-tetradecanoylphorbol-13-acetate O O
( O O
TPA O O
) O O
-induced O O
HL-60 O O
cell O O
differentiation O O
. O O

The O O
PEBP2 O O
alpha O O
A O O
and O O
PEBP2 O O
alpha O O
B O O
genes O O
encode O O
the O O
DNA-binding O O
subunit O O
of O O
a O O
murine O O
transcription O O
factor O O
, O O
PEBP2 O O
, O O
which O O
is O O
implicated O O
as O O
a O O
T-cell-specific O O
transcriptional O O
regulator O O
. O O

The O O
expression O O
of O O
reaper O O
has O O
been O O
shown O O
to O O
be O O
regulated O O
by O O
distinct O O
stimuli O O
, O O
including O O
X-irradiation O O
, O O
steroid O O
hormone O O
signaling O O
and O O
a O O
block O O
in O O
cell O O
differentiation O O
( O O
[ O O
34,35,36 O O
] O O
and O O
A.-F. O O
Lambin O O
and O O
H.S. O O
, O O
unpublished O O
observations O O
) O O
. O O

The O O
effect O O
of O O
this O O
synergism O O
was O O
perceptible O O
at O O
the O O
level O O
of O O
induction O O
of O O
the O O
IL-2 O O
gene O O
, O O
a O O
process O O
critical O O
for O O
T O O
cell O O
growth O O
. O O

We O O
have O O
investigated O O
whether O O
a O O
palmitate O O
conjugate O O
of O O
a O O
human O O
monoclonal O O
antibody O O
specific O O
for O O
thyroglobulin O O
( O O
TG O O
) O O
could O O
function O O
as O O
a O O
surrogate O O
TG O O
receptor O O
on O O
blood O O
mononuclear O O
cells O O
separated O O
into O O
fractions O O
enriched O O
for O O
T O O
cells O O
or O O
depleted O O
of O O
T O O
cells O O
( O O
non-T O O
cells O O
) O O
. O O

a O O
hitherto O O
unknown O O
mineralocorticoid O O
may O O
, O O
thus O O
, O O
be O O
responsible O O
for O O
the O O
hypertension O O
and O O
altered O O
MR O O
status O O
. O O

Resting O O
monocytes O O
contained O O
nuclear O O
factors O O
binding O O
to O O
the O O
AP-1 O O
element O O
, O O
but O O
stimulation O O
of O O
monocytes O O
with O O
LTB4 O O
induced O O
greater O O
AP-1-binding O O
activity O O
of O O
nuclear O O
proteins O O
. O O

NAC O O
not O O
only O O
blocks O O
the O O
effect O O
of O O
TPCK O O
but O O
enhances O O
mitogenesis O O
and O O
cytokine O O
production O O
( O O
> O O
2.5-fold O O
in O O
some O O
cases O O
) O O
upon O O
activation O O
of O O
unsuppressed O O
T O O
cells O O
. O O

The O O
E2A-HLF O O
( O O
for O O
hepatic O O
leukaemia O O
factor O O
) O O
fusion O O
gene O O
, O O
formed O O
by O O
action O O
of O O
the O O
t O O
( O O
17 O O
; O O
19 O O
) O O
( O O
q22 O O
; O O
p13 O O
) O O
chromosomal O O
translocation O O
, O O
drives O O
the O O
leukaemic O O
transformation O O
of O O
early O O
B-cell O O
precursors O O
, O O
but O O
the O O
mechanism O O
of O O
this O O
activity O O
remains O O
unknown O O
. O O

In O O
addition O O
, O O
forced O O
expression O O
of O O
GATA3 O O
potentiated O O
the O O
induction O O
of O O
RALDH2 O O
by O O
TAL1 O O
and O O
LMO O O
, O O
and O O
these O O
three O O
factors O O
formed O O
a O O
complex O O
in O O
vivo O O
. O O

PU.1 O O
is O O
a O O
hematopoietic O O
transcription O O
factor O O
belonging O O
to O O
the O O
Ets-family O O
. O O

Here O O
we O O
show O O
that O O
LPS O O
induces O O
nuclear O O
expression O O
of O O
c-Rel/p50 O O
heterodimers O O
as O O
well O O
as O O
p50/p65 O O
( O O
NF-kappa O O
B O O
) O O
kappa O O
B O O
DNA-binding O O
complexes O O
in O O
human O O
monocytic O O
THP-1 O O
cells O O
. O O

They O O
contained O O
many O O
of O O
the O O
known O O
proteins O O
with O O
stop-codon-encoded O O
amino O O
acids O O
, O O
but O O
almost O O
no O B-Negation
novel O I-Negation
candidates O I-Negation
were O I-Negation
identified O I-Negation
. O O

The O O
physiological O O
relevance O O
of O O
this O O
phenomenon O O
is O O
emphasized O O
by O O
similar O O
CD30-mediated O O
effects O O
in O O
naive O O
B O O
cells O O
. O O

Transfection O O
of O O
kinase-deficient O O
mutants O O
of O O
IKKalpha O O
and O O
IKKbeta O O
into O O
either O O
human O O
Jurkat O O
T O O
or O O
293 O O
cells O O
also O O
inhibits O O
NF-kappaB-dependent O O
reporter O O
gene O O
expression O O
induced O O
by O O
Tax O O
. O O

This O O
role O O
for O O
c-Myc O O
in O O
apoptosis O O
is O O
now O O
confirmed O O
in O O
studies O O
using O O
a O O
dominant O O
negative O O
form O O
of O O
its O O
heterodimeric O O
binding O O
partner O O
, O O
Max O O
, O O
which O O
we O O
show O O
here O O
inhibits O O
activation-induced O O
apoptosis O O
. O O

These O O
studies O O
examined O O
the O O
ability O O
of O O
CMV O O
IE O O
gene O O
products O O
to O O
modulate O O
IL-6 O O
production O O
. O O

After O O
the O O
DNA O O
fragment O O
containing O O
the O O
CAG O O
repeats O O
is O O
amplified O O
by O O
the O O
polymerase O O
chain O O
reaction O O
, O O
a O O
primer O O
extension O O
is O O
carried O O
out O O
; O O

Because O O
inhibition O O
of O O
DNA-binding O O
activity O O
is O O
associated O O
with O O
increasing O O
intracellular O O
glutathione O O
disulfide O O
levels O O
and O O
GSSG O O
can O O
be O O
shown O O
to O O
inhibit O O
the O O
DNA-binding O O
activity O O
directly O O
in O O
cell-free O O
systems O O
, O O
our O O
studies O O
suggest O O
that O O
GSSG O O
is O O
a O O
physiologically O O
relevant O O
inhibitor O O
in O O
intact O O
cells O O
also O O
. O O

In O O
this O O
study O O
we O O
have O O
analyzed O O
changes O O
in O O
gene O O
expression O O
associated O O
with O O
this O O
variable O O
VDR O O
expression O O
. O O

In O O
addition O O
, O O
RNase O O
protection O O
assays O O
revealed O O
that O O
anti-CD3/PMA-stimulated O O
T O O
cells O O
from O O
a O O
substantial O O
proportion O O
of O O
elderly O O
subjects O O
exhibited O O
decreased O O
levels O O
of O O
c-fos O O
and/or O O
c-jun O O
mRNA O O
compared O O
to O O
T O O
cells O O
from O O
young O O
subjects O O
. O O

We O O
postulate O O
that O O
MBP-induced O O
release O O
of O O
IL-8 O O
by O O
neutrophils O O
may O O
contribute O O
to O O
the O O
pathophysiology O O
of O O
acute O O
asthma O O
and O O
other O O
inflammatory O O
lung O O
diseases O O
. O O

The O O
binding O O
activity O O
of O O
the O O
X1 O O
box O O
DNA-binding O O
protein O O
RFX O O
was O O
examined O O
and O O
found O O
to O O
be O O
present O O
in O O
wild-type O O
B O O
cells O O
and O O
the O O
mutant O O
RJ2.2.5 O O
but O O
was O O
absent O B-Negation
in O I-Negation
SJO O I-Negation
and O I-Negation
Jurkat O I-Negation
. O O

However O O
, O O
we O O
can O O
not O O
exclude O O
the O O
role O O
of O O
elevated O O
deoxyadenosine O O
in O O
these O O
effects O O
. O O

1 O O
) O O
I O O
kappa O O
B/MAD-3 O O
completely O O
inhibits O O
NF-kappa O O
B O O
p65-dependent O O
transcriptional O O
activation O O
mediated O O
through O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
kappa O O
B O O
enhancer O O
in O O
human O O
T O O
lymphocytes O O
, O O
2 O O
) O O
the O O
binding O O
of O O
I O O
kappa O O
B/MAD-3 O O
to O O
NF-kappa O O
B O O
p65 O O
is O O
sufficient O O
to O O
retarget O O
NF-kappa O O
B O O
p65 O O
from O O
the O O
nucleus O O
to O O
the O O
cytoplasm O O
, O O
3 O O
) O O
selective O O
deletion O O
of O O
the O O
functional O O
nuclear O O
localization O O
signal O O
present O O
in O O
the O O
Rel O O
homology O O
domain O O
of O O
NF-kappa O O
B O O
p65 O O
disrupts O O
its O O
ability O O
to O O
engage O O
I O O
kappa O O
B/MAD-3 O O
, O O
and O O
4 O O
) O O
the O O
unique O O
C-terminus O O
of O O
NF-kappa O O
B O O
p65 O O
attenuates O O
its O O
own O O
nuclear O O
localization O O
and O O
contains O O
sequences O O
that O O
are O O
required O O
for O O
I O O
kappa O O
B-mediated O O
inhibition O O
of O O
NF-kappa O O
B O O
p65 O O
DNA O O
binding O O
activity O O
. O O

In O O
neutrophils O O
undergoing O O
the O O
phagocytosis O O
of O O
opsonized O O
yeasts O O
, O O
the O O
onset O O
of O O
NF-kappa O O
B O O
activation O O
was O O
paralleled O O
by O O
a O O
decline O O
in O O
immunoreactive O O
I O O
kappa O O
B-alpha O O
protein O O
levels O O
, O O
and O O
the O O
cellular O O
I O O
kappa O O
B-alpha O O
pool O O
was O O
replenished O O
by O O
30 O O
min O O
, O O
in O O
agreement O O
with O O
our O O
gel O O
shift O O
data O O
. O O

The O O
Transitive O O
module O O
considers O O
the O O
local O O
topology O O
of O O
the O O
network O O
predicted O O
by O O
the O O
group O O
A O O
modules O O
and O O
thus O O
requires O O
the O O
completion O O
of O O
their O O
analysis O O
to O O
calculate O O
its O O
own O O
likelihood O O
ratios O O
of O O
interaction O O
( O O
Figure O O
1B O O
) O O
. O O

Deletion O O
of O O
the O O
NF-kappa O O
B O O
elements O O
of O O
the O O
HIV-1 O O
LTR O O
significantly O O
inhibited O O
Tat-mediated O O
transactivation O O
in O O
T-cell O O
lines O O
, O O
as O O
well O O
as O O
in O O
a O O
monocyte O O
line O O
, O O
U937 O O
. O O

Whether O O
virus-induced O O
NF-kappa O O
B O O
activation O O
is O O
a O O
mechanism O O
that O O
favors O O
continuous O O
viral O O
replication O O
in O O
macrophages O O
remains O O
unknown O O
. O O

Numerous O O
genes O O
required O O
during O O
the O O
immune O O
or O O
inflammation O O
response O O
as O O
well O O
as O O
the O O
adhesion O O
process O O
are O O
regulated O O
by O O
nuclear O O
factor O O
kappaB O O
( O O
NF-kappaB O O
) O O
. O O

The O O
first O O
intron O O
acted O O
as O O
a O O
strong O O
transcriptional O O
activator O O
in O O
a O O
position-dependent O O
manner O O
and O O
with O O
no B-Negation B-Negation
cell-type I-Negation I-Negation
specificity I-Negation I-Negation
. O O

A O O
recent O O
large-scale O O
performance O O
comparison O O
between O O
thirteen O O
different O O
motif O O
finding O O
tools O O
used O O
expert O O
knowledge O O
in O O
setting O O
the O O
parameters O O
for O O
every O O
program O O
5 O O
. O O

The O O
area O O
under O O
all O O
ROCn O O
curves O O
considered O O
is O O
relatively O O
low O O
because O O
of O O
the O O
high O O
proportion O O
of O O
negatives O O
with O O
respect O O
to O O
positives O O
in O O
the O O
training O O
and O O
test O O
sets O O
( O O
100:1 O O
) O O
. O O

Identification O O
of O O
a O O
human O O
LIM-Hox O O
gene O O
, O O
hLH-2 O O
, O O
aberrantly O O
expressed O O
in O O
chronic O O
myelogenous O O
leukaemia O O
and O O
located O O
on O O
9q33-34.1 O O
. O O

BACKGROUND O O
& O O
AIMS O O
: O O
Entamoeba O O
histolytica O O
infection O O
of O O
the O O
intestine O O
can O O
induce O O
severe O O
gut O O
inflammation O O
. O O

Coincident O O
with O O
many O O
inflammatory O O
diseases O O
is O O
tissue O O
hypoxia O O
. O O

( O O
We O O
included O O
in O O
the O O
analysis O O
incomplete O O
relics O O
of O O
the O O
Transib2–5_AA O O
TPases O O
represented O O
by O O
single O O
DNA O O
copies O O
. O O
) O O

This O O
may O O
be O O
the O O
first O O
limitation O O
to O O
potential O O
antiviral O O
effects O O
of O O
antioxidant O O
therapies O O
. O O

It O O
binds O O
the O O
so-called O O
Pu O O
box O O
, O O
an O O
important O O
tissue-specific O O
regulatory O O
DNA O O
element O O
present O O
in O O
a O O
number O O
of O O
genes O O
expressed O O
in O O
these O O
cell O O
lineages O O
. O O

For O O
instance O O
, O O
Dl O O
( O O
but O O
not B-Negation B-Negation
Ser I-Negation I-Negation
) I-Negation I-Negation
is O O
essential O O
for O O
lateral O O
inhibition O O
during O O
early O O
neurogenesis O O
in O O
the O O
embryo O O
[ O O
4 O O
] O O
. O O

Alternative O O
splicing O O
of O O
RNA O O
transcripts O O
encoded O O
by O O
the O O
murine O O
p105 O O
NF-kappa O O
B O O
gene O O
generates O O
I O O
kappa O O
B O O
gamma O O
isoforms O O
with O O
different O O
inhibitory O O
activities O O
. O O

With O O
HBxAg-specific O O
synthetic O O
polypeptides O O
, O O
several O O
T-cell O O
epitopes O O
were O O
identified O O
. O O

Additionally O O
, O O
it O O
inhibited O O
the O O
production O O
of O O
LTB4 O O
( O O
IC50 O O
= O O
0.5 O O
microM O O
) O O
and O O
the O O
cytokines O O
IL-2 O O
, O O
IL-6 O O
and O O
TNF O O
alpha O O
( O O
IC50 O O
= O O
10-12 O O
microM O O
) O O
. O O

Although O O
the O O
average O O
performance O O
of O O
the O O
programs O O
did O O
not O B-Negation
differ O I-Negation
significantly O I-Negation
, O O
the O O
authors O O
found O O
that O O
, O O
for O O
each O O
pair O O
of O O
programs O O
, O O
each O O
program O O
performed O O
better O O
than O O
the O O
other O O
on O O
some O O
subset O O
of O O
the O O
data O O
5 O O
. O O

S-allyl O O
cysteine O O
inhibits O O
activation O O
of O O
nuclear O O
factor O O
kappa O O
B O O
in O O
human O O
T O O
cells O O
. O O

Most O O
studies O O
on O O
the O O
expression O O
of O O
these O O
proteins O O
in O O
relation O O
to O O
the O O
cell O O
cycle O O
have O O
been O O
performed O O
at O O
the O O
mRNA O O
level O O
, O O
and O O
therefore O O
do O O
not B-Negation B-Negation
give I-Negation I-Negation
direct I-Negation I-Negation
information I-Negation I-Negation
about I-Negation I-Negation
the I-Negation I-Negation
presence I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
proteins I-Negation I-Negation
during I-Negation I-Negation
the I-Negation I-Negation
cell I-Negation I-Negation
cycle I-Negation I-Negation
. O O

Pb O O
did O O
not B-Negation B-Negation
activate I-Negation I-Negation
NF-kappa I-Negation I-Negation
B I-Negation I-Negation
in I-Negation I-Negation
4 I-Negation I-Negation
different I-Negation I-Negation
T I-Negation I-Negation
cell I-Negation I-Negation
lines I-Negation I-Negation
, O O
suggesting O O
that O O
lymphoid O O
cell O O
lines O O
may O O
not O O
be O O
reliable O O
surrogates O O
for O O
the O O
study O O
of O O
transcriptional O O
activation O O
in O O
human O O
T O O
cells O O
. O O

Regulation O O
of O O
CD95 O O
( O O
Fas O O
) O O
ligand O O
expression O O
by O O
TCR-mediated O O
signaling O O
events O O
. O O

TNF-alpha O O
RNA O O
was O O
undetectable O O
in O O
U937 O O
cells O O
, O O
whereas O O
a O O
low O O
constitutive O O
level O O
was O O
detected O O
in O O
U9-IIIB O O
cells O O
. O O

In O O
addition O O
, O O
this O O
proliferative O O
parameter O O
maintained O O
its O O
prognostic O O
significance O O
when O O
the O O
patients O O
were O O
stratified O O
according O O
to O O
lymph O O
node O O
involvement O O
, O O
menopausal O O
status O O
, O O
and O O
nuclear O O
estrogen O O
receptor O O
content O O
. O O

This O O
gene O O
, O O
originally O O
named O O
AML1 O O
, O O
is O O
a O O
human O O
homologue O O
of O O
the O O
Drosophila O O
gene O O
runt O O
that O O
controls O O
early O O
events O O
in O O
fly O O
embryogenesis O O
. O O

Assuming O O
that O O
the O O
23rd O O
amino O O
acid O O
is O O
also O O
encoded O O
by O O
a O O
stop O O
codon O O
, O O
we O O
systematically O O
predicted O O
proteins O O
that O O
contain O O
stop-codon-encoded O O
amino O O
acids O O
from O O
191 O O
prokaryotic O O
genomes O O
. O O

The O O
Oct-2 O O
transcription O O
factor O O
is O O
a O O
member O O
of O O
the O O
POU O O
( O O
Pit-Oct-Unc O O
) O O
family O O
of O O
transcription O O
factors O O
and O O
is O O
expressed O O
only O O
in O O
B O O
lymphocytes O O
and O O
in O O
neuronal O O
cells O O
but O O
not B-Negation B-Negation
in I-Negation I-Negation
other I-Negation I-Negation
cell I-Negation I-Negation
types I-Negation I-Negation
. O O

NF-IL6 O O
is O O
an O O
important O O
transcriptional O O
regulator O O
of O O
genes O O
induced O O
in O O
activated O O
monocytes/macrophages O O
, O O
and O O
NF-IL6 O O
is O O
the O O
only O O
CCAAT/enhancer-binding O O
protein O O
( O O
C/EBP O O
) O O
family O O
member O O
whose O O
steady-state O O
mRNA O O
levels O O
increase O O
upon O O
activation O O
of O O
monocytes O O
( O O
1 O O
) O O
. O O

First O O
is O O
an O O
expansion O O
phase O O
prior O O
to O O
TCR O O
rearrangement O O
, O O
which O O
appears O O
to O O
be O O
correlated O O
with O O
programming O O
of O O
at O O
least O O
some O O
response O O
genes O O
for O O
inducibility O O
. O O

To O O
test O O
this O O
latter O O
possibility O O
, O O
a O O
chimeric O O
receptor O O
containing O O
the O O
extracellular O O
domain O O
of O O
c-kit O O
( O O
the O O
stem O O
cell O O
factor O O
( O O
SCF O O
) O O
receptor O O
) O O
and O O
the O O
cytoplasmic O O
and O O
transmembrane O O
domains O O
of O O
the O O
IL-4R O O
alpha O O
chain O O
was O O
generated O O
. O O

GATA-1 O O
may O O
be O O
modified O O
differently O O
during O O
development O O
so O O
that O O
the O O
locus O O
control O O
region O O
can O O
interact O O
with O O
different O O
globin O O
promoters O O
. O O

We O O
conclude O O
that O O
IL-2 O O
transcriptional O O
regulation O O
differs O O
in O O
tumor O O
cell O O
lines O O
compared O O
with O O
normal O O
T O O
cells O O
and O O
that O O
different O O
costimulatory O O
signals O O
converge O O
on O O
the O O
same O O
cis-elements O O
in O O
the O O
IL-2 O O
promoter O O
. O O

In O O
contrast O O
to O O
its O O
transient O O
pattern O O
of O O
nuclear O O
induction O O
during O O
an O O
immune O O
response O O
, O O
NF-kappaB O O
is O O
constitutively O O
activated O O
in O O
cells O O
expressing O O
the O O
Tax O O
transforming O O
protein O O
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-1 O O
) O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Gel-shift O O
analyses O O
demonstrated O O
dose-dependent O O
inhibition O O
of O O
TNF-induced O O
NF-kappa O O
B O O
mobilization O O
by O O
aspirin O O
at O O
concentrations O O
ranging O O
from O O
1 O O
to O O
10 O O
mmol/L O O
. O O

It O O
was O O
possible O O
that O O
one O O
of O O
the O O
clone O O
13 O O
CIITA O O
alleles O O
bore O O
a O O
mutation O O
that O O
allowed O O
HLA-DQ O O
, O O
but O O
not O B-Negation
HLA-DR O I-Negation
or O I-Negation
-DP O I-Negation
transcription O I-Negation
. O O

Together O O
, O O
these O O
results O O
show O O
that O O
NF-kappa O O
B O O
controls O O
the O O
expression O O
of O O
I O O
kappa O O
B O O
alpha O O
by O O
means O O
of O O
an O O
inducible O O
autoregulatory O O
pathway O O
. O O

Fly O O
strains O O
and O O
genetics O O

Stimulation O O
of O O
a O O
human O O
T-cell O O
clone O O
with O O
anti-CD3 O O
or O O
tumor O O
necrosis O O
factor O O
induces O O
NF-kappa O O
B O O
translocation O O
but O O
not B-Negation B-Negation
human I-Negation I-Negation
immunodeficiency I-Negation I-Negation
virus I-Negation I-Negation
1 I-Negation I-Negation
enhancer-dependent I-Negation I-Negation
transcription I-Negation I-Negation
. O O

The O O
virus O O
with O O
four O O
Sp1 O O
sites O O
did O O
outgrow O O
the O O
three O O
Sp1 O O
virus O O
in O O
35 O O
days O O
of O O
culture O O
and O O
CTG-monomer O O
virus O O
outcompeted O O
the O O
CTG-dimer O O
virus O O
in O O
42 O O
days O O
. O O

When O O
the O O
calcium O O
ionophore O O
was O O
used O O
in O O
conjunction O O
with O O
TPA O O
, O O
a O O
PKC O O
activator O O
, O O
the O O
Zp O O
induction O O
was O O
synergistically O O
enhanced O O
. O O

Activation O O
of O O
E2F-mediated O O
transcription O O
by O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
Tax O O
protein O O
in O O
a O O
p16 O O
( O O
INK4A O O
) O O
-negative O O
T-cell O O
line O O
. O O

Furthermore O O
, O O
we O O
show O O
that O O
the O O
ICK-1 O O
binding O O
site O O
does O O
not B-Negation B-Negation
confer I-Negation I-Negation
negative I-Negation I-Negation
regulation I-Negation I-Negation
in I-Negation I-Negation
U937 I-Negation I-Negation
cells I-Negation I-Negation
. O O

The O O
p65 O O
subunit O O
of O O
NF-kappa O O
B O O
regulates O O
I O O
kappa O O
B O O
by O O
two O O
distinct O O
mechanisms O O
. O O

The O O
enhancer O O
also O O
appeared O O
to O O
mediate O O
phorbol O O
myristate O O
acetate O O
induction O O
in O O
monocytes O O
and O O
IL-1 O O
responsiveness O O
in O O
fibroblasts O O
. O O

However O O
, O O
sequence O O
specificity O O
of O O
NF-AT O O
was O O
more O O
similar O O
to O O
that O O
of O O
NF O O
( O O
P O O
) O O
, O O
and O O
only O O
a O O
small O O
amount O O
of O O
P65 O O
was O O
detected O O
in O O
NF O O
( O O
P O O
) O O
. O O

Since O O
our O O
target O O
is O O
readthrough O O
genes O O
conserved O O
across O O
two O O
or O O
more O O
species O O
, O O
such O O
selenoprotein O O
families O O
were O O
selected O O
from O O
their O O
list O O
. O O

The O O
coverage O O
of O O
iPfam O O
on O O
experimentally O O
derived O O
protein O O
interactions O O
is O O
low O O
. O O

We O O
found O O
that O O
in O O
T O O
cells O O
, O O
anti-CD3-induced O O
c-Rel O O
expression O O
was O O
blocked O O
by O O
PF O O
, O O
whereas O O
the O B-Negation
induction O I-Negation
of O I-Negation
other O I-Negation
NF-kappaB O I-Negation
family O I-Negation
members O I-Negation
was O I-Negation
not O I-Negation
significantly O I-Negation
affected O I-Negation
. O O

Anti-CD28-stimulated O O
T O O
cells O O
produced O O
significant O O
amounts O O
of O O
IL-8 O O
; O O
additionally O O
, O O
costimulation O O
with O O
anti-CD3 O O
and O O
anti-CD28 O O
Abs O O
resulted O O
in O O
a O O
synergistic O O
induction O O
of O O
IL-8 O O
secretion O O
. O O

Induction O O
of O O
the O O
adaptive O O
immune O O
response O O
depends O O
on O O
the O O
expression O O
of O O
co-stimulatory O O
molecules O O
and O O
cytokines O O
by O O
antigen-presenting O O
cells O O
. O O

Also O O
, O O
we O O
downloaded O O
an O O
approximately O O
5-Gb O O
set O O
of O O
unassembled O O
traces O O
that O O
cover O O
almost O O
completely O O
the O O
600-Mb O O
genome O O
of O O
Florida O O
lancelet O O
( O O
ftp O O
: O O
//ftp.ncbi.nih.gov/pub/TraceDB/branchiostoma_floridae/ O O
; O O
3 O O
December O O
2004 O O
) O O
. O O

In O O
order O O
to O O
study O O
CD14 O O
gene O O
regulation O O
, O O
the O O
human O O
CD14 O O
gene O O
was O O
cloned O O
from O O
a O O
partial O O
EcoRI O O
digested O O
chromosome O O
5 O O
library O O
. O O

Furthermore O O
, O O
Id3 O O
impedes O O
expression O O
of O O
recombination O O
activating O O
genes O O
and O O
downregulates O O
pre-Talpha O O
mRNA O O
. O O

The O O
inhibitory O O
effect O O
of O O
PDTC O O
was O O
also O O
observed O O
in O O
etoposide- O O
and O O
dexamethasone-induced O O
apoptosis O O
in O O
human O O
thymocytes O O
at O O
a O O
concentration O O
of O O
1-10 O O
microM O O
. O O

These O O
results O O
indicate O O
that O O
Bcl-2 O O
acts O O
downstream O O
of O O
MAPK O O
kinase-1 O O
but O O
upstream O O
of O O
MAPK O O
and O O
suggest O O
that O O
, O O
in O O
the O O
signaling O O
pathway O O
of O O
the O O
apoptotic O O
process O O
induced O O
by O O
bufalin O O
, O O
the O O
transcriptional O O
activity O O
of O O
activator O O
protein-1 O O
may O O
be O O
down-regulated O O
through O O
the O O
inhibition O O
of O O
MAPK O O
activity O O
by O O
Bcl-2 O O
. O O

U937 O O
cells O O
and O O
human O O
peripheral O O
blood O O
monocytes O O
were O O
exposed O O
to O O
TS O O
, O O
binding O O
activities O O
of O O
the O O
respective O O
transcription O O
factors O O
were O O
analyzed O O
, O O
and O O
Hsp70 O O
expression O O
and O O
TNFalpha O O
release O O
were O O
determined O O
in O O
parallel O O
. O O

Site-directed O O
mutagenesis O O
demonstrated O O
that O O
these O O
TRAF O O
binding O O
sites O O
exhibited O O
selective O O
binding O O
for O O
different O O
TRAF O O
proteins O O
. O O

Abstract O O

In O O
conclusion O O
, O O
we O O
demonstrate O O
that O O
the O O
vitamin O O
E O O
derivative O O
TCP O O
succinate O O
prevents O O
monocytic O O
cell O O
adhesion O O
to O O
cytokine-stimulated O O
endothelial O O
cells O O
by O O
inhibiting O O
the O O
activation O O
of O O
NF-kappa O O
B O O
, O O
further O O
emphasizing O O
the O O
antiatherosclerotic O O
potential O O
of O O
lipid O O
soluble O O
antioxidants O O
. O O

They O O
later O O
fuse O O
, O O
and O O
, O O
under O O
the O O
influence O O
of O O
the O O
surrounding O O
mesenchyme O O
, O O
the O O
mature O O
organ O O
develops O O
, O O
being O O
mainly O O
composed O O
of O O
ductal O O
, O O
exocrine O O
and O O
endocrine O O
compartments O O
. O O

In O O
vitro O O
DNase O O
I O O
footprinting O O
analysis O O
revealed O O
six O O
hGATA-3 O O
binding O O
sites O O
in O O
the O O
U3 O O
region O O
( O O
the O O
transcriptional O O
regulatory O O
domain O O
) O O
of O O
the O O
HIV-1 O O
LTR O O
. O O

Addition O O
of O O
GM-CSF O O
to O O
this O O
basic O O
cocktail O O
consistently O O
increased O O
the O O
clonogenic O O
capacity O O
of O O
single O O
CD34+Thy-1+ O O
cells O O
, O O
and O O
this O O
effect O O
was O O
further O O
enhanced O O
( O O
up O O
to O O
72.3 O O
± O O
4.3 O O
% O O
on O O
day O O
7 O O
) O O
by O O
the O O
inclusion O O
of O O
TNF-alpha O O
. O O

A O O
total O O
of O O
328 O O
complete O O
genome O O
sequences O O
of O O
prokaryotes O O
were O O
downloaded O O
from O O
the O O
KEGG O O
FTP O O
site O O
25 O O
in O O
April O O
2006 O O
. O O

Charybdotoxin-sensitive O O
, O O
Ca O O
( O O
2+ O O
) O O
-dependent O O
membrane O O
potential O O
changes O O
are O O
not B-Negation B-Negation
involved I-Negation I-Negation
in I-Negation I-Negation
human I-Negation I-Negation
T I-Negation I-Negation
or I-Negation I-Negation
B I-Negation I-Negation
cell I-Negation I-Negation
activation I-Negation I-Negation
and I-Negation I-Negation
proliferation I-Negation I-Negation
. O O

Taken O O
together O O
, O O
our O O
results O O
suggest O O
that O O
IFN-alpha O O
, O O
IL-2 O O
, O O
IL-12 O O
, O O
and O O
IL-15 O O
have O O
overlapping O O
activities O O
on O O
human O O
T O O
cells O O
. O O

TCF-1 O O
alpha O O
, O O
originally O O
identified O O
and O O
purified O O
through O O
its O O
binding O O
sites O O
on O O
the O O
HIV-1 O O
promoter O O
, O O
was O O
found O O
to O O
bind O O
to O O
the O O
TCR O O
alpha O O
enhancer O O
and O O
to O O
promoters O O
for O O
several O O
genes O O
expressed O O
at O O
significantly O O
earlier O O
stages O O
of O O
T-cell O O
development O O
than O O
the O O
TCR O O
alpha O O
gene O O
( O O
e.g. O O
, O O
p56lck O O
and O O
CD3 O O
delta O O
) O O
. O O

In O O
melanoma O O
cells O O
that O O
contain O O
the O O
N-Oct-3 O O
factor O O
, O O
a B-Negation B-Negation
transfected I-Negation I-Negation
lymphocyte-specific I-Negation I-Negation
promoter I-Negation I-Negation
was I-Negation I-Negation
neither I-Negation I-Negation
activated I-Negation I-Negation
nor I-Negation I-Negation
was I-Negation I-Negation
it I-Negation I-Negation
repressed I-Negation I-Negation
upon I-Negation I-Negation
contransfection I-Negation I-Negation
with I-Negation I-Negation
an I-Negation I-Negation
Oct-2A I-Negation I-Negation
expression I-Negation I-Negation
vector I-Negation I-Negation
. O O

Thus O O
, O O
the O O
D-mib O O
wing O O
phenotype O O
may O O
result O O
from O O
defective O O
N O O
inductive O O
signaling O O
at O O
the O O
D-V O O
boundary O O
. O O

Deoxycorticosterone O O
acetate O O
had O O
an O O
intermediate O O
activity O O
with O O
an O O
apparent O O
Kd O O
of O O
100 O O
nM O O
. O O

Furthermore O O
, O O
recombinant O O
TIMP-1 O O
, O O
but O O
not B-Negation B-Negation
TIMP-2 I-Negation I-Negation
or I-Negation I-Negation
a I-Negation I-Negation
synthetic I-Negation I-Negation
metalloproteinase I-Negation I-Negation
inhibitor I-Negation I-Negation
( I-Negation I-Negation
BB-94 I-Negation I-Negation
) I-Negation I-Negation
, O O
confers O O
resistance O O
to O O
apoptosis O O
induced O O
by O O
both O O
CD95-dependent O O
and O O
-independent O O
( O O
cold O O
shock O O
, O O
serum O O
deprivation O O
, O O
and O O
gamma-radiation O O
) O O
pathways O O
in O O
TIMP-1-negative O O
BL O O
lines O O
. O O

Stimulation O O
of O O
interferon O O
beta O O
gene O O
transcription O O
in O O
vitro O O
by O O
purified O O
NF-kappa O O
B O O
and O O
a O O
novel O O
TH O O
protein O O
. O O

Some O O
methods O O
predict O O
interaction O O
from O O
sequence-motifs O O
found O O
to O O
be O O
over-represented O O
in O O
interacting O O
protein O O
pairs O O
19 O O
, O O
or O O
by O O
considering O O
the O O
physico-chemical O O
properties O O
and O O
the O O
location O O
of O O
groups O O
of O O
amino O O
acids O O
in O O
the O O
sequence O O
2021 O O
. O O

In O O
iPfam O O
version O O
21 O O
, O O
there O O
are O O
3407 O O
interchain O O
and O O
1171 O O
intrachain O O
domain O O
pairs O O
, O O
which O O
means O O
that O O
548 O O
domain O O
pairs O O
mediate O O
both O O
inter- O O
and O O
intrachain O O
interactions O O
. O O

Cell O O
cycle O O
analysis O O
of O O
E2F O O
in O O
primary O O
human O O
T O O
cells O O
reveals O O
novel O O
E2F O O
complexes O O
and O O
biochemically O O
distinct O O
forms O O
of O O
free O O
E2F O O
. O O

The O O
S. O O
cerevisiae O O
and O O
Sch. O O
pombe O O
systems O O
support O O
effects O O
of O O
acidic O O
activator O O
proteins O O
, O O
provided O O
a O O
further O O
protein O O
fraction O O
from O O
S. O O
cerevisiae O O
is O O
supplied O O
. O O

The O O
y-axis O O
shows O O
the O O
percentage O O
of O O
the O O
pupae O O
( O O
blue O O
bars O O
) O O
and O O
adult O O
flies O O
( O O
purple O O
bars O O
) O O
demonstrating O O
the O O
larval O O
and O O
pupal O O
survival O O
, O O
respectively O O
. O O

We O O
infer O O
that O O
the O O
murine O O
and O O
human O O
GATA-3 O O
proteins O O
play O O
a O O
central O O
and O O
highly O O
conserved O O
role O O
in O O
vertebrate O O
T-cell-specific O O
transcriptional O O
regulation O O
. O O

Accuracy O O
measurements O O

We O O
show O O
that O O
nNOS O O
is O O
the O O
predominant O O
isoform O O
constitutively O O
expressed O O
in O O
glia O O
. O O

If O O
so O O
, O O
detailed O O
studies O O
of O O
individual O O
components O O
, O O
including O O
active O O
Transib O O
transposons O O
and O O
invertebrate O O
proteins O O
homologous O O
to O O
RAG1 O O
elements O O
can O O
bring O O
new O O
breakthroughs O O
in O O
our O O
understanding O O
of O O
evolutionary O O
and O O
mechanistic O O
aspects O O
of O O
V O O
( O O
D O O
) O O
J O O
recombination O O
. O O

Comparative O O
analysis O O
identifies O O
conserved O O
tumor O O
necrosis O O
factor O O
receptor-associated O O
factor O O
3 O O
binding O O
sites O O
in O O
the O O
human O O
and O O
simian O O
Epstein-Barr O O
virus O O
oncogene O O
LMP1 O O
. O O

The O O
solution O O
with O O
circulating O O
hemocytes O O
was O O
mixed O O
by O O
gently O O
pipetting O O
, O O
and O O
part O O
was O O
transferred O O
into O O
the O O
chamber O O
of O O
an O O
improved O O
Neubauer O O
hemocytometer O O
. O O

The O O
inhibition O O
of O O
NF-kappa O O
B O O
by O O
PDTC O O
paralleled O O
with O O
an O O
inhibition O O
of O O
spontaneous O O
cytotoxicity O O
mediated O O
by O O
NK O O
cells O O
. O O

By O O
competition O O
analysis O O
with O O
transcription O O
factor O O
consensus O O
sequence O O
oligonucleotides O O
and O O
by O O
immunosupershift O O
, O O
transcription O O
factor O O
SP-1 O O
or O O
a O O
closely O O
related O O
protein O O
was O O
shown O O
to O O
bind O O
to O O
this O O
regulatory O O
element O O
. O O

Interleukin-1 O O
stimulated O O
U-937 O O
cell O O
adhesion O O
to O O
and O O
VCAM-1 O O
surface O O
expression O O
in O O
both O O
HUVECs O O
and O O
HUAECs O O
. O O

Elf-1 O O
physically O O
associated O O
with O O
HMG-I O O
and O O
with O O
NF-kappa O O
B O O
p50 O O
and O O
c-Rel O O
in O O
vitro O O
, O O
suggesting O O
that O O
protein-protein O O
interactions O O
might O O
functionally O O
coordinate O O
the O O
actions O O
of O O
the O O
upstream O O
and O O
downstream O O
positive O O
regulatory O O
elements O O
. O O

Carboxylesterases O O
play O O
an O O
important O O
role O O
in O O
defense O O
and O O
clearance O O
mechanisms O O
of O O
the O O
monocyte/macrophage O O
system O O
. O O

A O O
unique O O
transcriptional O O
mechanism O O
distinct O O
from O O
those O O
regulating O O
the O O
IL-2 O O
or O O
IL-4 O O
genes O O
seems O O
to O O
control O O
the O O
IL-5 O O
gene O O
. O O

Activity O O
of O O
the O O
kappa O O
B O O
enhancer O O
of O O
the O O
interleukin-2 O O
receptor O O
alpha O O
chain O O
in O O
somatic O O
cell O O
hybrids O O
is O O
accompanied O O
by O O
the O O
nuclear O O
localization O O
of O O
NF-kappa O O
B O O
. O O

It O O
also O O
likely O O
that O O
the O O
N-terminal O O
RAG1 O O
and O O
RAG1-like O O
proteins O O
share O O
an O O
additional O O
conserved O O
motif O O
W-x-p-h-x O O
( O O
3–6 O O
) O O
-C-x2-C O O
that O O
resides O O
between O O
conserved O O
motif O O
2 O O
and O O
the O O
ring O O
finger O O
( O O
Figure O O
6 O O
) O O
. O O

We O O
have O O
previously O O
identified O O
a O O
T O O
lymphocyte O O
protein O O
which O O
binds O O
to O O
a O O
site O O
within O O
the O O
LTR O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
and O O
exerts O O
an O O
inhibitory O O
effect O O
on O O
virus O O
gene O O
expression O O
. O O

In O O
contrast O O
, O O
integrin O O
ligation O O
with O O
antibodies O O
induces O O
tyrosine O O
phosphorylation O O
of O O
Syk O O
but O O
not B-Negation B-Negation
of I-Negation I-Negation
FAK I-Negation I-Negation
or I-Negation I-Negation
paxillin I-Negation I-Negation
. O O

To O O
determine O O
if O O
TPCK O O
and O O
TLCK O O
inhibited O O
LPS O O
induction O O
of O O
TF O O
expression O O
, O O
freshly O O
isolated O O
human O O
monocytes O O
and O O
monocytic O O
THP-1 O O
cells O O
were O O
pretreated O O
with O O
these O O
inhibitors O O
for O O
30 O O
min O O
before O O
LPS O O
stimulation O O
. O O

In O O
this O O
study O O
, O O
we O O
used O O
the O O
T-cell-activating O O
superantigen O O
staphylococcal O O
enterotoxin O O
A O O
( O O
SEA O O
) O O
to O O
investigate O O
molecular O O
mechanisms O O
of O O
T-lymphocyte O O
anergy O O
in O O
vivo O O
. O O

In O O
addition O O
, O O
a O O
somewhat O O
divergent O O
region O O
of O O
STP-C488 O O
is O O
critical O O
for O O
TRAF O O
association O O
. O O

Both O O
IL-4 O O
and O O
anti-CD40 O O
mAb O O
induced O O
activation O O
of O O
phosphatidylinositol O O
3-kinase O O
( O O
PI3-kinase O O
) O O
, O O
translocation O O
of O O
a O O
zeta O O
isoform O O
of O O
protein O O
kinase O O
C O O
, O O
and O O
nuclear O O
expression O O
of O O
NF-kappa O O
B O O
. O O

Similarly O O
, O O
but O O
in O O
a O O
much O O
more O O
pronounced O O
way O O
, O O
the O O
Disorder O O
module O O
is O O
only O O
slightly O O
predictive O O
of O O
interaction O O
, O O
with O O
a O O
maximum O O
likelihood O O
ratio O O
of O O
1.8 O O
. O O

The O O
proliferative O O
activity O O
of O O
tumors O O
has O O
been O O
extensively O O
investigated O O
with O O
different O O
approaches O O
, O O
among O O
which O O
the O O
use O O
of O O
the O O
monoclonal O O
antibody O O
Ki-67 O O
represents O O
an O O
easy O O
and O O
reliable O O
means O O
of O O
assessing O O
cell O O
proliferation O O
. O O

Despite O O
a O O
wide O O
range O O
, O O
the O O
mean O O
GR O O
count O O
and O O
affinity O O
in O O
MNC O O
from O O
septic O O
patients O O
did O O
not B-Negation B-Negation
differ I-Negation I-Negation
from I-Negation I-Negation
those I-Negation I-Negation
in I-Negation I-Negation
normal I-Negation I-Negation
controls I-Negation I-Negation
, O O
suggesting O O
that O O
glucocorticoids O O
could O O
still O O
be O O
effective O O
in O O
the O O
hemodynamic O O
compensatory O O
phase O O
of O O
sepsis O O
. O O

IL-12 O O
induced O O
STAT4 O O
and O O
IL-2 O O
and O O
IL-15 O O
induced O O
STAT5 O O
binding O O
to O O
the O O
GAS O O
elements O O
. O O

The O O
proliferation O O
and O O
NK O O
activity O O
of O O
YT-N17 O O
( O O
a O O
human O O
NK-like O O
cell O O
line O O
) O O
were O O
enhanced O O
by O O
17 O O
beta-estradiol O O
( O O
E2 O O
) O O
, O O
and O O
the O O
enhancement O O
was O O
blocked O O
by O O
tamoxifen O O
( O O
Tx O O
) O O
, O O
an O O
antagonist O O
of O O
E2 O O
. O O

The O O
core-like O O
sequences O O
encoded O O
by O O
the O O
sea O O
urchin O O
WGS O O
sequence O O
contigs O O
29068 O O
and O O
12509 O O
correspond O O
to O O
either O O
the O O
second O O
or O O
third O O
RAG1 O O
exon O O
in O O
teleosts O O
( O O
depending O O
on O O
the O O
number O O
of O O
introns O O
) O O
, O O
which O O
is O O
remarkably O O
consistent O O
with O O
the O O
fusion O O
model O O
. O O

However O O
, O O
other O O
transcription O O
factors O O
or O O
coactivators O O
of O O
NF-kappa O O
B O O
are O O
required O O
for O O
tax O O
activation O O
but O O
these O O
remain O O
to O O
be O O
identified O O
. O O

Third O O
, O O
results O O
from O O
an O O
in O O
vivo O O
antibody O O
uptake O O
assay O O
indicated O O
that O O
the O O
endocytosis O O
of O O
Ser O O
( O O
but O O
not O B-Negation
of O I-Negation
Dl O I-Negation
) O I-Negation
was O O
strongly O O
inhibited O O
in O O
D-mib O O
mutant O O
cells O O
. O O

We O O
have O O
hypothesized O O
that O O
such O O
defects O O
in O O
fetal/neonatal O O
T-cell O O
activation O O
may O O
be O O
due O O
to O O
lack O O
of O O
expression O O
of O O
the O O
transcriptional O O
regulatory O O
elements O O
required O O
for O O
T-cell O O
activation O O
. O O

These O O
results O O
reveal O O
a O O
central O O
role O O
for O O
CaMKIV/Gr O O
as O O
a O O
Ca O O
( O O
2+ O O
) O O
-regulated O O
activator O O
of O O
gene O O
transcription O O
in O O
T O O
lymphocytes O O
. O O

Role O O
of O O
HIV-1 O O
Nef O O
expression O O
in O O
activation O O
pathways O O
in O O
CD4+ O O
T O O
cells O O
. O O

IBR O O
is O O
a O O
503-amino-acid-long O O
acidic O O
protein O O
which O O
is O O
99.0 O O
% O O
identical O O
to O O
the O O
recently O O
reported O O
human O O
NRF-1/alpha-Pal O O
factor O O
and O O
highly O O
related O O
to O O
the O O
invertebrate O O
transcription O O
factors O O
P3A2 O O
and O O
erected O O
wing O O
gene O O
product O O
( O O
EWG O O
) O O
. O O

The O O
observation O O
that O O
a O O
mutated O O
LT-kappa O O
B O O
construct O O
( O O
M1-CAT O O
) O O
was O O
inactive O O
in O O
C81-66-45 O O
, O O
confirmed O O
the O O
importance O O
of O O
NF-kappa O O
B O O
in O O
LT O O
gene O O
expression O O
. O O

Finally O O
, O O
despite O O
impaired O O
Rel-A O O
translocation O O
, O O
T O O
cells O O
were O O
capable O O
of O O
transcribing O O
IL-2 O O
. O O

Program O O
parameters O O
( O O
such O O
as O O
motif O O
length O O
, O O
number O O
of O O
occurrences O O
and O O
orientation O O
) O O
that B-Negation O
can I-Negation O
not I-Negation O
be I-Negation O
reasonably I-Negation O
specified I-Negation O
by I-Negation O
the I-Negation O
user I-Negation O
without I-Negation B-Negation
prior I-Negation I-Negation
knowledge I-Negation I-Negation
about I-Negation I-Negation
the I-Negation I-Negation
true I-Negation I-Negation
binding I-Negation I-Negation
sites I-Negation I-Negation
are O O
referred O O
to O O
as O O
nuisance O O
parameters O O
4 O O
. O O

When O O
cells O O
were O O
preincubated O O
with O O
dihydrolipoic O O
acid O O
( O O
0.2 O O
mM O O
) O O
the O O
expression O O
of O O
c-fos O O
mRNA O O
was O O
suppressed O O
at O O
30 O O
min O O
after O O
stimulation O O
of O O
TPA O O
( O O
0.5 O O
microM O O
) O O
whereas O O
in O O
the O O
case O O
of O O
preincubation O O
of O O
alpha-lipoic O O
acid O O
( O O
0.2 O O
microM O O
) O O
, O O
the O O
expression O O
was O O
enhanced O O
at O O
30 O O
min O O
. O O

The O O
absence B-Negation B-Negation
in I-Negation I-Negation
I I-Negation I-Negation
kappa I-Negation I-Negation
B I-Negation I-Negation
gamma-1 I-Negation I-Negation
and I-Negation I-Negation
I I-Negation I-Negation
kappa I-Negation I-Negation
B I-Negation I-Negation
gamma-2 I-Negation I-Negation
of I-Negation I-Negation
a I-Negation I-Negation
protein I-Negation I-Negation
kinase I-Negation I-Negation
A I-Negation I-Negation
site I-Negation I-Negation
whose I-Negation I-Negation
phosphorylation I-Negation I-Negation
modulates I-Negation I-Negation
p70I I-Negation I-Negation
kappa I-Negation I-Negation
B I-Negation I-Negation
gamma I-Negation I-Negation
inhibitory I-Negation I-Negation
activity I-Negation I-Negation
suggests O O
that O O
alternative O O
RNA O O
splicing O O
may O O
be O O
used O O
to O O
generate O O
I O O
kappa O O
B O O
gamma O O
isoforms O O
that O O
respond O O
differently O O
to O O
intracellular O O
signals O O
. O O

Recombinant O O
human O O
tumor O O
necrosis O O
factor O O
( O O
TNF O O
) O O
binding O O
protein-1 O O
( O O
r-h O O
TBP-1 O O
) O O
and O O
recombinant O O
human O O
soluble O O
dimeric O O
TNF O O
receptor O O
( O O
rhu O O
TNFR O O
: O O
Fc O O
) O O
were O O
used O O
to O O
determine O O
the O O
relative O O
contributions O O
of O O
TNF O O
to O O
phorbol O O
myristate O O
acetate O O
( O O
PMA O O
) O O
and O O
cytokine-induced O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
replication O O
in O O
chronically O O
infected O O
cell O O
lines O O
. O O

Correlation O O
between O O
accuracy O O
and O O
Sig O O
scores O O
. O O

Dysregulation O O
of O O
cytokines O O
secreted O O
by O O
T O O
cells O O
may O O
play O O
an O O
important O O
role O O
in O O
the O O
pathogenesis O O
of O O
AIDS O O
. O O

Increasing O O
quantities O O
of O O
randomly O O
selected O O
upstream O O
regions O O
were O O
added O O
to O O
each O O
regulon O O
. O O

Tissue O O
losses O O
were O O
associated O O
with O O
a O O
dramatic O O
reduction O O
in O O
size O O
of O O
the O O
eye O O
field O O
and O O
of O O
the O O
wing O O
pouch O O
in O O
mutant O O
discs O O
of O O
third O O
instar O O
larvae O O
( O O
Figure O O
2A–2E O O
) O O
. O O

Here O O
we O O
describe O O
the O O
ability O O
of O O
these O O
factors O O
to O O
interact O O
with O O
a O O
site O O
( O O
GM5 O O
) O O
, O O
located O O
within O O
the O O
CLE0 O O
element O O
, O O
-47 O O
to O O
-40 O O
upstream O O
of O O
the O O
GM-CSF O O
transcription O O
initiation O O
site O O
. O O

IFN-gamma O O
has O O
potent O O
antiproliferative O O
and O O
apoptotic O O
effects O O
in O O
T O O
cells O O
that O O
are O O
important O O
in O O
determining O O
T O O
cell O O
development O O
and O O
polarized O O
differentiation O O
. O O

ATRA O O
also O O
induced O O
expression O O
of O O
C/EBP O O
epsilon O O
protein O O
in O O
NB4 O O
cells O O
, O O
as O O
shown O O
by O O
Western O O
blotting O O
. O O

In O O
this O O
study O O
we O O
have O O
investigated O O
the O O
effect O O
of O O
FCM O O
on O O
the O O
LPS-induced O O
DNA-binding O O
activity O O
of O O
NF-kappaB O O
, O O
by O O
means O O
of O O
electrophoretic O O
shift O O
assay O O
( O O
EMSA O O
) O O
. O O

We O O
found O O
that O O
SCOPE O O
's O O
performance O O
on O O
78 O O
experimentally O O
characterized O O
regulons O O
from O O
four O O
species O O
was O O
a O O
substantial O O
and O O
statistically O O
significant O O
improvement O O
over O O
that O O
of O O
its O O
component O O
algorithms O O
. O O

Specific O O
mRNAs O O
for O O
c-fos O O
and O O
c-jun O O
were O O
detectable O O
within O O
30 O O
min O O
after O O
cell O O
activation O O
and O O
reached O O
maximal O O
levels O O
within O O
2 O O
h O O
. O O

Lymphocyte O O
glucocorticoid O O
receptor O O
binding O O
parameters O O
were O O
studied O O
in O O
15 O O
severely O O
depressed O O
patients O O
during O O
depression O O
and O O
after O O
clinical O O
recovery O O
, O O
and O O
in O O
15 O O
healthy O O
controls O O
. O O

The O O
class O O
II O O
major O O
histocompatibility O O
complex O O
gene O O
HLA-DRA O O
is O O
expressed O O
in O O
B O O
cells O O
, O O
activated O O
T O O
lymphocytes O O
, O O
and O O
in O O
antigen-presenting O O
cells O O
. O O

Deletion O O
or O O
substitution O O
of O O
a O O
putative O O
NF-kappaB O O
binding O O
site O O
identified O O
in O O
the O O
bcl-x O O
promoter O O
significantly O O
decreased O O
Tax-induced O O
transactivation O O
. O O

The O O
LAZ3/BCL6 O O
transcript O O
was O O
found O O
in O O
a O O
variety O O
of O O
tissues O O
, O O
including O O
skeletal O O
muscle O O
, O O
peripheral O O
blood O O
leukocytes O O
, O O
and O O
weakly O O
in O O
normal O O
lymph O O
nodes O O
. O O

Band O O
A O O
contains O O
the O O
serum O O
response O O
factor O O
plus O O
additional O O
factor O O
( O O
s O O
) O O
. O O

Ligand O O
activation O O
of O O
c-ErbB O O
induced O O
the O O
tyrosine O O
phosphorylation O O
, O O
DNA-binding O O
, O O
and O O
reporter O O
gene O O
transcription O O
of O O
Stat O O
5b O O
in O O
erythroblasts O O
. O O

This O O
nonresponsiveness O O
occurs O O
because O O
of O O
a O O
lack B-Negation B-Negation
of I-Negation I-Negation
expression I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
beta-chain I-Negation I-Negation
( I-Negation I-Negation
accessory I-Negation I-Negation
factor I-Negation I-Negation
) I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
IFN-gamma I-Negation I-Negation
receptor I-Negation I-Negation
, O O
while O O
at O O
the O O
same O O
time O O
maintaining O O
IFN-gamma O O
receptor O O
alpha-chain O O
expression O O
. O O

Accordingly O O
, O O
we O O
studied O O
the O O
role O O
of O O
NF-kappaB O O
in O O
germline O O
Cepsilon O O
transcription O O
by O O
using O O
two O O
human O O
Burkitt O O
's O O
lymphoma O O
B O O
cell O O
lines O O
, O O
DND39 O O
and O O
DG75 O O
. O O

Hypertension O O
in O O
pregnancy O O
. O O

This O O
protein O O
is O O
immunologically O O
distinct O O
from O O
IRF-1/ISGF2 O O
. O O

BACKGROUND O O
: O O
Alveolar O O
macrophages O O
play O O
a O O
key O O
role O O
in O O
the O O
initiation O O
of O O
the O O
inflammatory O O
reaction O O
of O O
allergic O O
asthma O O
. O O

The O O
intracellular O O
parasite O O
Theileria O O
parva O O
secures O O
its O O
propagation O O
and O O
spreads O O
through O O
the O O
infected O O
animal O O
by O O
infecting O O
and O O
transforming O O
T O O
cells O O
, O O
inducing O O
their O O
continuous O O
proliferation O O
and O O
rendering O O
them O O
metastatic O O
. O O

The O O
elevated O O
level O O
of O O
adenosine O O
in O O
the O O
hemolymph O O
due O O
to O O
lack B-Negation O
of I-Negation O
ADGF-A I-Negation O
leads O O
to O O
apparently O O
inconsistent O O
phenotypic O O
effects O O
: O O
precocious O O
metamorphic O O
changes O O
including O O
differentiation O O
of O O
macrophage-like O O
cells O O
and O O
fat O O
body O O
disintegration O O
on O O
one O O
hand O O
, O O
and O O
delay O O
of O O
development O O
with O O
block O O
of O O
pupariation O O
on O O
the O O
other O O
. O O

However O O
, O O
like O O
normal O O
Ter O O
119 O O
erythroid O O
cells O O
, O O
these O O
Ter O O
119 O O
positive O O
cells O O
from O O
transgenic O O
mice O O
still O O
expressed O O
high O O
levels O O
of O O
beta-globin O O
and O O
very O O
low O O
or O O
undetectable O O
glycoprotein O O
IIb O O
and O O
platelet O O
factor O O
4 O O
megakaryocytic O O
transcripts O O
. O O

These O O
results O O
show O O
that O O
IL-2 O O
is O O
capable O O
of O O
inducing O O
the O O
nuclear O O
expression O O
of O O
NF-kappaB O O
in O O
primary O O
CD8+ O O
T-PLL O O
cells O O
, O O
and O O
that O O
this O O
effect O O
is O O
mediated O O
, O O
at O O
least O O
in O O
part O O
, O O
at O O
a O O
pretranslational O O
level O O
. O O

The O O
catalytic O O
DDE O O
triad O O
is O O
marked O O
by O O
black O O
rectangles O O
. O O

HMG-I O O
( O O
Y O O
) O O
also O O
binds O O
to O O
a O O
second O O
oligonucleotide O O
containing O O
a O O
BP1 O O
binding O O
site O O
located O O
in O O
a O O
negative O O
control O O
region O O
upstream O O
of O O
the O O
delta-globin O O
gene O O
, O O
suggesting O O
a O O
role O O
for O O
HMG-I O O
( O O
Y O O
) O O
in O O
repression O O
of O O
adult O O
globin O O
genes O O
. O O

These O O
findings O O
suggest O O
a O O
molecular O O
mechanism O O
of O O
positive O O
regulation O O
of O O
PAFR O O
gene O O
expression O O
by O O
PAF O O
through O O
NF-kappa O O
B O O
, O O
possibly O O
by O O
a O O
phosphorylation O O
reaction O O
involving O O
protein O O
kinase O O
C O O
by O O
PAF O O
. O O

Thus O O
these O O
results O O
suggest O O
a O O
direct O O
contribution O O
of O O
EBV O O
to O O
chronic O O
rheumatoid O O
arthritis O O
pathogenesis O O
. O O

We O O
have O O
observed O O
that O O
the O O
R24 O O
mAb O O
stimulates O O
GD3+ O O
T O O
cell O O
proliferation O O
, O O
cytotoxicity O O
, O O
and O O
surface O O
marker O O
expression O O
of O O
IL-2R O O
alpha-chain O O
, O O
IL-2R O O
beta-chain O O
, O O
HLA-DR O O
, O O
CD11a O O
, O O
and O O
CD11c O O
. O O

Bar O O
is O O
40 O O
? O O
m O O
for O O
( O O
A O O
, O O
D O O
, O O
G O O
) O O
, O O
5 O O
? O O
m O O
for O O
( O O
B–C O O
? O O
and O O
E–F O O
? O O
) O O
, O O
and O O
10 O O
? O O
m O O
for O O
( O O
H–J O O
? O O
) O O
. O O

On O O
the O O
basis O O
of O O
these O O
assays O O
, O O
all O O
N-Oct-factors O O
were O O
found O O
to O O
be O O
distinct O O
from O O
the O O
ubiquitous O O
Oct-1 O O
and O O
the O O
lymphoid-specific O O
Oct-2A O O
proteins O O
. O O

Inhibition O O
of O O
STAT6 O O
activity O O
is O O
not B-Negation B-Negation
evident I-Negation I-Negation
unless O O
cells O O
are O O
preincubated O O
with O O
IFN O O
for O O
at O O
least O O
1 O O
h O O
before O O
IL-4 O O
stimulation O O
. O O

Estrone O O
potentiates O O
myeloid O O
cell O O
differentiation O O
: O O
a O O
role O O
for O O
17 O O
beta-hydroxysteroid O O
dehydrogenase O O
in O O
modulating O O
hemopoiesis O O
. O O

It O O
can O O
be O O
deduced O O
that O O
the O O
erythroid O O
ALAS O O
precursor O O
protein O O
has O O
a O O
molecular O O
weight O O
of O O
64.6 O O
kd O O
, O O
and O O
is O O
similar O O
in O O
size O O
to O O
the O O
previously O O
isolated O O
human O O
housekeeping O O
ALAS O O
precursor O O
of O O
molecular O O
weight O O
70.6 O O
kd O O
. O O

The O O
inducibility O O
of O O
HIV O O
LTR-driven O O
luciferase O O
expression O O
constructs O O
in O O
lymphoblastoid O O
cells O O
stimulated O O
by O O
OKA O O
depended O O
on O O
both O O
functional O O
Sp1 O O
binding O O
elements O O
and O O
the O O
ability O O
of O O
the O O
TATA O O
box O O
to O O
bind O O
the O O
protein O O
TBP O O
. O O

Overlap O O
of O O
different O O
subsets O O
of O O
the O O
LR400 O O
dataset O O
with O O
the O O
HPRD-derived O O
training O O
set O O

E3 O O
, O O
a O O
hematopoietic-specific O O
transcript O O
directly O O
regulated O O
by O O
the O O
retinoic O O
acid O O
receptor O O
alpha O O
. O O

YM268 O O
and O O
pioglitazone O O
dose-dependently O O
increased O O
the O O
2-deoxyglucose O O
uptake O O
in O O
3T3-L1 O O
cells O O
. O O

The O O
differentiating O O
effects O O
of O O
the O O
other O O
C-11 O O
analogs O O
on O O
human O O
promyeloid O O
leukemia O O
cells O O
( O O
HL-60 O O
) O O
agreed O O
well O O
with O O
their O O
bone-resorbing O O
activity O O
and O O
receptor O O
affinity O O
, O O
but O O
they O O
demonstrated O O
lower O O
calcemic O O
effects O O
in O O
vivo O O
. O O

We O O
have O O
examined O O
the O O
role O O
of O O
CD28 O O
in O O
modulating O O
the O O
'naive O O
' O O
neonatal O O
T O O
cell O O
response O O
to O O
anti-CD2-mediated O O
activation O O
. O O

Several O O
cis-acting O O
regulatory O O
sites O O
are O O
required O O
for O O
induction O O
of O O
the O O
IL-2 O O
gene O O
after O O
stimulation O O
. O O

Red O O
circle O O
: O O
an O O
organism O O
with O O
pyrrolysine O O
, O O
blue O O
; O O
selenocysteine O O
, O O
yellow O O
; O O
both O O
pyrrolysine O O
and O O
selenocysteine O O
, O O
white O O
; O O
neither B-Negation B-Negation
pyrrolysine I-Negation I-Negation
nor I-Negation I-Negation
selenocysteine I-Negation I-Negation
. O O

IAPs O O
contain O O
at O O
least O O
one O O
, O O
and O O
up O O
to O O
three O O
, O O
BIR O O
domains O O
, O O
which O O
are O O
important O O
for O O
protein-protein O O
interactions O O
, O O
and O O
often O O
a O O
carboxy-terminal O O
RING O O
domain O O
( O O
reviewed O O
in O O
[ O O
27 O O
] O O
) O O
. O O

The O O
addition O O
of O O
TGF-beta O O
to O O
human O O
B O O
lymphocyte O O
cultures O O
stimulated O O
with O O
Staphylococcus O O
aureus O O
Cowan O O
strain O O
I O O
and O O
IL-2 O O
completely O O
inhibited O O
B O O
cell O O
Ig O O
secretion O O
( O O
greater O O
than O O
90 O O
% O O
) O O
and O O
decreased O O
B O O
cell O O
surface O O
IgM O O
, O O
IgD O O
, O O
kappa O O
L O O
chain O O
, O O
and O O
lambda O O
L O O
chain O O
expression O O
. O O

We O O
have O O
found O O
that O O
the O O
HTLV-1 O O
transactivator O O
protein O O
, O O
tax O O
, O O
acts O O
as O O
a O O
costimulatory O O
signal O O
for O O
GM-CSF O O
and O O
IL-2 O O
gene O O
transcription O O
, O O
in O O
that O O
it O O
can O O
cooperate O O
with O O
TCR O O
signals O O
to O O
mediate O O
high O O
level O O
gene O O
expression O O
. O O

2 O O
. O O

Upon O O
stimulation O O
by O O
various O O
agents O O
, O O
I O O
kappaB O O
is O O
proteolyzed O O
and O O
NF-kappaB O O
translocates O O
to O O
the O O
nucleus O O
, O O
where O O
it O O
activates O O
its O O
target O O
genes O O
. O O

In O O
addition O O
, O O
the O O
combination O O
of O O
a O O
NF O O
kappa O O
B/rel O O
binding O O
site O O
and O O
the O O
STAT6 O O
response O O
element O O
conferred O O
IL-4 O O
inducibility O O
to O O
a O O
heterologous O O
minimal O O
promoter O O
, O O
while O O
the O O
individual O O
sites O O
had O O
no B-Negation B-Negation
effect I-Negation I-Negation
. O O

We O O
have O O
cloned O O
a O O
group O O
of O O
cDNAs O O
representing O O
mRNAs O O
that O O
are O O
rapidly O O
induced O O
following O O
adherence O O
of O O
human O O
monocytes O O
. O O

The O O
p53 O O
paradox O O
in O O
the O O
pathogenesis O O
of O O
tumor O O
progression O O
. O O

Phosphorylation O O
and O O
degradation O O
of O O
the O O
cytoplasmic O O
inhibitor O O
I O O
kappa O O
B O O
alpha O O
are O O
crucial O O
regulatory O O
events O O
in O O
the O O
activation O O
of O O
NF-kappa O O
B O O
DNA-binding O O
activity O O
. O O

NF-kappa O O
B O O
binding O O
activity O O
was O O
inducible O O
by O O
tumor O O
necrosis O O
factor O O
and O O
phorbol O O
myristate O O
acetate O O
in O O
PLB-985 O O
. O O

Signaling O O
events O O
induced O O
by O O
lipopolysaccharide-activated O O
toll-like O O
receptor O O
2 O O
. O O

Inhibition O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
replication O O
in O O
vitro O O
by O O
a O O
novel O O
combination O O
of O O
anti-Tat O O
single-chain O O
intrabodies O O
and O O
NF-kappa O O
B O O
antagonists O O
. O O

Blocking O O
mAbs O O
against O O
CD18 O O
and O O
CD11b O O
abrogated O O
fibrinogen-induced O O
NF-kappa O O
B O O
activation O O
. O O

Our O O
results O O
support O O
the O O
idea O O
that O O
human O O
CD36 O O
mediates O O
signal O O
transduction O O
events O O
in O O
response O O
to O O
Ox O O
LDL O O
. O O

Different O O
sequence O O
requirements O O
for O O
expression O O
in O O
erythroid O O
and O O
megakaryocytic O O
cells O O
within O O
a O O
regulatory O O
element O O
upstream O O
of O O
the O O
GATA-1 O O
gene O O
. O O

Early O O
B O O
cell O O
factor O O
( O O
EBF O O
) O O
and O O
E47 O O
participate O O
in O O
the O O
transcriptional O O
control O O
of O O
early O O
B O O
lymphocyte O O
differentiation O O
. O O

An O O
additional O O
distinguishing O O
characteristic O O
of O O
HTLV-I O O
infection O O
is O O
the O O
profound O O
state O O
of O O
viral O O
latency O O
that O O
is O O
present O O
in O O
circulating O O
primary O O
leukemic O O
T O O
cells O O
. O O

The O O
frequency O O
of O O
the O O
cells O O
which O O
expressed O O
beta- O O
and O O
gamma-globin O O
genes O O
in O O
the O O
two O O
cell O O
populations O O
was O O
measured O O
by O O
immunofluorescence O O
with O O
beta- O O
and O O
gamma-specific O O
antibodies O O
. O O

The O O
HEL O O
cells O O
also O O
exhibited O O
a O O
similar O O
elevation O O
of O O
AhR O O
mRNA O O
level O O
, O O
when O O
they O O
had O O
differentiated O O
toward O O
monocyte-macrophage O O
cells O O
by O O
these O O
combined O O
inducers O O
, O O
but O O
little O O
change O O
in O O
the O O
mRNA O O
level O O
was O O
observed O O
when O O
the O O
cells O O
were O O
induced O O
to O O
differentiate O O
into O O
other O O
cell O O
types O O
. O O

Pervanadate O O
activated O O
NF-kappa O O
B O O
, O O
as O O
shown O O
by O O
an O O
increase O O
in O O
DNA-binding O O
activity O O
of O O
this O O
transcription O O
factor O O
. O O

MR O O
were O O
reduced O O
before O O
delivery O O
( O O
96 O O
± O O
27 O O
receptors/cell O O
) O O
, O O
and O O
SPD O O
increased O O
( O O
64 O O
± O O
8 O O
mV O O
) O O
, O O
with O O
both O O
parameters O O
normalizing O O
after O O
delivery O O
( O O
MR O O
, O O
242 O O
± O O
79 O O
; O O
SPD O O
, O O
14.0 O O
± O O
4 O O
mV O O
) O O
. O O

Coverage O O

Structure-function O O
studies O O
of O O
the O O
GATA-1 O O
protein O O
could O O
be O O
greatly O O
simplified O O
and O O
a O O
larger O O
number O O
of O O
mutants O O
studied O O
. O O

Protein O O
pairs O O
predicted O O
to O O
have O O
a O O
posterior O O
odds O O
ratio O O
below O O
1.0 O O
have O O
an O O
estimated O O
true O O
positive O O
rate O O
below O O
50 O O
% O O
and O O
thus O O
are O O
more O O
likely O O
not O O
to O O
interact O O
than O O
to O O
interact O O
. O O

In O O
addition O O
, O O
DNA O O
methylation O O
was O O
revealed O O
as O O
one O O
of O O
the O O
possible O O
factors O O
in O O
establishing O O
MNDA O O
expression O O
. O O

Later O O
, O O
the O O
expression O O
of O O
the O O
BSAP O O
gene O O
shifts O O
to O O
the O O
fetal O O
liver O O
where O O
it O O
correlates O O
with O O
the O O
onset O O
of O O
B O O
lymphopoiesis O O
. O O

IL-4 O O
and O O
IL-13 O O
up-regulated O O
the O O
expression O O
of O O
both O O
genomic O O
and O O
spliced O O
HIV O O
mRNA O O
in O O
monocytes O O
cultured O O
on O O
Teflon O O
, O O
as O O
determined O O
by O O
Northern O O
analysis O O
and O O
p24 O O
Ag O O
assay O O
. O O

The O O
replacement O O
of O O
p50 O O
homodimers O O
with O O
transcriptionally O O
active O O
heterodimers O O
following O O
time O O
in O O
culture O O
may O O
partially O O
explain O O
the O O
progressive O O
increase O O
in O O
susceptibility O O
of O O
monocytes O O
to O O
HIV O O
infection O O
during O O
in O O
vitro O O
culture O O
. O O

We O O
compared O O
the O O
number O O
and O O
distribution O O
of O O
hemocytes O O
stained O O
by O O
GFP O O
in O O
flies O O
carrying O O
hml-Gal4 O O
UAS-GFP O O
in O O
wild-type O O
and O O
mutant O O
backgrounds O O
. O O

Our O O
analyses O O
of O O
the O O
induction O O
of O O
nuclear O O
factor-kappaB O O
( O O
NFkappaB O O
) O O
in O O
activated O O
memory O O
( O O
CD45RO+ O O
) O O
and O O
naive O O
( O O
CD45RA+ O O
) O O
T O O
cell O O
subsets O O
from O O
young O O
and O O
elderly O O
donors O O
has O O
demonstrated O O
that O O
, O O
regardless O O
of O O
donor O O
age O O
, O O
memory O O
T O O
cells O O
are O O
not O O
significantly O O
altered O O
in O O
their O O
responsiveness O O
to O O
TNF-alpha-mediated O O
induction O O
of O O
NFkappaB O O
. O O

Hypoxia O O
enhances O O
induction O O
of O O
endothelial O O
ICAM-1 O O
: O O
role O O
for O O
metabolic O O
acidosis O O
and O O
proteasomes O O
. O O

The O O
clusters O O
predicted O O
by O O
our O O
method O O
are O O
summarized O O
in O O
Table O O
1 O O
. O O

The O O
kinetics O O
of O O
this O O
translocation O O
were O O
delayed O O
in O O
IL-7-treated O O
as O O
compared O O
to O O
IL-2-treated O O
cells O O
. O O

Thiol O O
modifying O O
agents O O
like O O
diamide O O
, O O
menadione O O
, O O
pyrrolidine O O
dithiocarbamate O O
( O O
PDTC O O
) O O
, O O
diethyl O O
dithiocarbamate O O
or O O
phenylarsine O O
oxide O O
inhibited O O
the O O
IL-1-induced O O
activation O O
of O O
the O O
IL-1RI-associated O O
protein O O
kinase O O
. O O

PRRII O O
is O O
a O O
T-cell-specific O O
enhancer O O
, O O
located O O
between O O
nucleotides O O
-137 O O
and O O
-64 O O
, O O
which O O
binds O O
the O O
T-cell-specific O O
Ets O O
protein O O
Elf-1 O O
and O O
HMG-I O O
( O O
Y O O
) O O
proteins O O
. O O

We O O
conclude O O
that O O
although O O
neither B-Negation B-Negation
of I-Negation I-Negation
the I-Negation I-Negation
two I-Negation I-Negation
5'-most I-Negation I-Negation
Ets I-Negation I-Negation
sites I-Negation I-Negation
alone I-Negation I-Negation
binds I-Negation I-Negation
nuclear I-Negation I-Negation
protein I-Negation I-Negation
, O O
they O O
appear O O
to O O
act O O
as O O
modulators O O
which O O
control O O
the O O
pattern O O
of O O
Ets O O
proteins O O
that O O
bind O O
the O O
alpha O O
4 O O
gene O O
promoter O O
. O O

Protease O O
inhibitors O O
block O O
lipopolysaccharide O O
induction O O
of O O
tissue O O
factor O O
gene O O
expression O O
in O O
human O O
monocytic O O
cells O O
by O O
preventing O O
activation O O
of O O
c-Rel/p65 O O
heterodimers O O
. O O

Positive O O
hybridization O O
was O O
found O O
in O O
thymus O O
, O O
tonsil O O
, O O
bone O O
marrow O O
, O O
developing O O
vessels O O
, O O
and O O
in O O
fetal O O
brain O O
. O O

Remarkably O O
, O O
these O O
two O O
drugs O O
inhibit O O
each O O
other O O
's O O
actions O O
, O O
raising O O
the O O
possibility O O
that O O
both O O
act O O
by O O
means O O
of O O
a O O
common O O
immunophilin O O
( O O
immunosuppressant O O
binding O O
protein O O
) O O
. O O

Regulation O O
of O O
IL-6 O O
synthesis O O
in O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
by O O
C3a O O
and O O
C3a O O
( O O
desArg O O
) O O
. O O

In O O
monocytic O O
cells O O
, O O
IL-1beta O O
treatment O O
led O O
to O O
a O O
production O O
of O O
ROIs O O
which O O
is O O
independent O O
of O O
the O O
5-LOX O O
enzyme O O
but O O
requires O O
the O O
NADPH O O
oxidase O O
activity O O
. O O

Mouse O O
thymoma O O
line O O
EL-4 O O
cells O O
produce O O
cytokines O O
such O O
as O O
interleukin O O
( O O
IL O O
) O O
-2 O O
, O O
IL-3 O O
, O O
IL-4 O O
, O O
IL-10 O O
, O O
and O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
in O O
response O O
to O O
phorbol O O
12-myristate O O
13-acetate O O
( O O
PMA O O
) O O
. O O

In O O
21 O O
of O O
27 O O
informative O O
female O O
patients O O
the O O
majority O O
of O O
the O O
granulocytes O O
were O O
clonally O O
derived O O
. O O

The O O
result O O
of O O
the O O
above O O
homology O O
searches O O
was O O
also O O
used O O
for O O
the O O
boundary O O
analysis O O
( O O
Figure O O
1b O O
) O O
. O O

To O O
delineate O O
the O O
regulatory O O
mechanisms O O
of O O
human O O
IL-5 O O
synthesis O O
, O O
we O O
established O O
allergen-specific O O
CD4+ O O
T-cell O O
clones O O
from O O
asthmatic O O
patients O O
. O O

Interleukin-6 O O
( O O
IL-6 O O
) O O
plays O O
a O O
central O O
role O O
in O O
numerous O O
inflammatory O O
and O O
immune O O
processes O O
. O O

Non-steroidal O O
anti-inflammatory O O
drugs O O
inhibit O O
the O O
expression O O
of O O
cytokines O O
and O O
induce O O
HSP70 O O
in O O
human O O
monocytes O O
. O O

Unfortunately O O
, O O
the O O
selection O O
of O O
complexes O O
in O O
the O O
PDB O O
database O O
of O O
protein O O
structures O O
14 O O
is O O
rather O O
small O O
and O O
biased O O
15 O O
. O O

Low O O
CD3+CD28-induced O O
interleukin-2 O O
production O O
correlates O O
with O O
decreased O O
reactive O O
oxygen O O
intermediate O O
formation O O
in O O
neonatal O O
T O O
cells O O
. O O

In O O
addition O O
, O O
two O O
out O O
of O O
three O O
M10-expressing O O
CEM O O
clones O O
were O O
also O O
resistant O O
to O O
highly O O
productive O O
infection O O
by O O
a O O
heterogeneous O O
HIV-1 O O
pool O O
. O O

In O O
addition O O
, O O
the O O
combined O O
inhibitory O O
effects O O
on O O
NFAT O O
and O O
NF-KB O O
support O O
a O O
potential O O
use O O
of O O
DTCs O O
as O O
immunosuppressants O O
. O O

Tal-1 O O
rearrangements O O
are O O
associated O O
with O O
nearly O O
30 O O
% O O
of O O
human O O
T O O
acute O O
lymphoblastic O O
leukemia O O
. O O

If O O
D-mib O O
is O O
required O O
for O O
Ser O O
signaling O O
during O O
wing O O
development O O
, O O
then O O
loss O O
of O O
D-mib O O
activity O O
in O O
dorsal O O
cells O O
should O O
affect O O
the O O
specification O O
of O O
the O O
wing O O
margin O O
in O O
a O O
non-autonomous O O
manner O O
. O O

There O O
was O O
a O O
good O O
correlation O O
between O O
thrombin-induced O O
tyrosine O O
phosphorylation O O
of O O
the O O
latter O O
three O O
proteins O O
and O O
Ca2+ O O
mobilization O O
. O O

Activation O O
of O O
T O O
lymphocytes O O
induces O O
an O O
NF-kappa O O
B-like O O
binding O O
activity O O
to O O
the O O
B2 O O
site O O
, O O
concomitant O O
with O O
activation O O
of O O
the O O
proenkephalin O O
promoter O O
. O O

( O O
D–H O O
) O O
Wings O O
from O O
wild-type O O
( O O
D O O
) O O
, O O
D-mib1 O O
( O O
E O O
) O O
, O O
SerRX82/Serrev6.1 O O
( O O
F O O
) O O
, O O
D-mib2/D-mib4 O O
( O O
G O O
) O O
, O O
and O O
UAS-D-mib2/+ O O
; O O
D-mib1/D-mib2 O O
flies O O
( O O
H O O
) O O
. O O

Abstract O O

Activation O O
of O O
NF-kappa O O
B O O
correlates O O
with O O
phosphorylation O O
of O O
I O O
kappa O O
B-alpha O O
and O O
requires O O
the O O
proteolysis O O
of O O
this O O
inhibitor O O
. O O

Targeted O O
degradation O O
of O O
c-Fos O O
, O O
but O O
not B-Negation B-Negation
v-Fos I-Negation I-Negation
, O O
by O O
a O O
phosphorylation-dependent O O
signal O O
on O O
c-Jun O O
. O O

The O O
repetitive O O
activation O O
of O O
T O O
cells O O
( O O
priming O O
) O O
enhances O O
the O O
expression O O
of O O
many O O
cytokines O O
, O O
such O O
as O O
IL-4 O O
, O O
but O O
not B-Negation B-Negation
others I-Negation I-Negation
, I-Negation I-Negation
such I-Negation I-Negation
as I-Negation I-Negation
IL-2 I-Negation I-Negation
. O O

This O O
paper O O
aims O O
to O O
review O O
the O O
role O O
of O O
free O O
radical-induced O O
tissue O O
damage O O
and O O
antioxidant O O
defence O O
mechanisms O O
in O O
inflammatory O O
diseases O O
that O O
involve O O
pathogenic O O
processes O O
similar O O
to O O
the O O
periodontal O O
diseases O O
. O O

These O O
results O O
indicate O O
that O O
the O O
component O O
( O O
s O O
) O O
of O O
NF-AT O O
has O O
the O O
potential O O
to O O
reconstitute O O
NF O O
( O O
P O O
) O O
whereas O O
NF-kappa O O
B O O
alone O O
can O O
not O O
account O O
for O O
NF O O
( O O
P O O
) O O
in O O
crude O O
extracts O O
. O O

On O O
the O O
other O O
hand O O
, O O
the B-Negation O
up-regulation I-Negation O
of I-Negation O
CD80 I-Negation O
Ag I-Negation O
, I-Negation O
found I-Negation O
on I-Negation O
monocytes I-Negation O
obtained I-Negation O
from I-Negation O
PBMC I-Negation O
incubated I-Negation O
with I-Negation O
OKT3 I-Negation O
, I-Negation O
is I-Negation B-Negation
not I-Negation I-Negation
detected I-Negation I-Negation
after I-Negation I-Negation
addition I-Negation I-Negation
of I-Negation I-Negation
IL-10 I-Negation I-Negation
, O O
and O O
the O O
anti-CD28 O O
mAb O O
CLB-CD28/1 O O
restores O O
the O O
NF-kappa O O
B/Rel O O
nuclear O O
activity O O
in O O
IL-10-inhibited O O
lymphocytes O O
. O O

All O O
cell O O
lines O O
examined O O
in O O
this O O
group O O
also O O
expressed O O
1,25 O O
( O O
OH O O
) O O
2D3 O O
receptors O O
. O O

Our O O
data O O
provide O O
strong O O
evidence O O
that O O
the O O
expression O O
of O O
the O O
GM-CSF O O
gene O O
following O O
T-cell O O
activation O O
is O O
controlled O O
by O O
binding O O
of O O
the O O
NF-kappa O O
B O O
transcription O O
factor O O
to O O
a O O
high-affinity O O
binding O O
site O O
in O O
the O O
GM-CSF O O
promoter O O
. O O

Stable O O
expression O O
of O O
transdominant O O
Rev O O
protein O O
in O O
human O O
T O O
cells O O
inhibits O O
human O O
immunodeficiency O O
virus O O
replication O O
. O O

Finally O O
, O O
addition O O
of O O
REF-1 O O
from O O
activated O O
monocytes O O
to O O
alveolar O O
macrophage O O
nuclear O O
proteins O O
resulted O O
in O O
a O O
marked O O
increase O O
in O O
AP-1 O O
DNA O O
binding O O
. O O

Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
infection O O
of O O
mature O O
, O O
resting O O
B O O
cells O O
drives O O
them O O
to O O
become O O
lymphoblasts O O
expressing O O
high O O
levels O O
of O O
cell O O
surface O O
molecules O O
, O O
such O O
as O O
CD48 O O
, O O
characteristically O O
expressed O O
on O O
normal O O
activated O O
B O O
cells O O
. O O

Jak3 O O
is O O
constitutively O O
associated O O
with O O
CD40 O O
, O O
and O O
this O O
interaction O O
requires O O
a O O
proline-rich O O
sequence O O
in O O
the O O
membrane-proximal O O
region O O
of O O
CD40 O O
. O O

First O O
, O O
from O O
different O O
cell O O
lines O O
three O O
or O O
all O O
four O O
of O O
the O O
nuclear O O
proteins O O
were O O
specifically O O
cross-linked O O
by O O
UV O O
irradiation O O
to O O
the O O
radioactively O O
labeled O O
TRE-DNA O O
fragment O O
. O O

Site-directed O O
mutagenesis O O
further O O
demonstrated O O
that O O
the O O
enhancer O O
function O O
of O O
one O O
of O O
the O O
two O O
NF-E2/AP1 O O
motifs O O
of O O
HS-40 O O
is O O
mediated O O
through O O
its O O
binding O O
to O O
NF-E2 O O
but O O
not B-Negation B-Negation
AP1 I-Negation I-Negation
transcription I-Negation I-Negation
factor I-Negation I-Negation
. O O

An O O
increased O O
rate O O
of O O
lysosomal O O
degradation O O
is O O
one O O
of O O
the O O
mechanisms O O
responsible O O
for O O
the O O
loss O O
of O O
zeta-chain O O
. O O

The O O
host O O
response O O
to O O
Mycobacterium O O
tuberculosis O O
includes O O
granuloma O O
formation O O
at O O
sites O O
of O O
infection O O
and O O
systemic O O
symptoms O O
. O O

In O O
HeLa O O
cells O O
as O O
well O O
as O O
in O O
B O O
cells O O
, O O
TNF-alpha O O
rapidly O O
induced O O
nuclear O O
translocation O O
primarily O O
of O O
p50-p65 O O
, O O
but O O
not B-Negation B-Negation
of I-Negation I-Negation
c-rel I-Negation I-Negation
. O O

In O O
addition O O
, O O
domains O O
that O O
exist O O
as O O
separate O O
proteins O O
in O O
some O O
genomes O O
but O O
are O O
also O O
seen O O
fused O O
in O O
a O O
single O O
protein O O
in O O
other O O
genomes O O
have O O
been O O
used O O
to O O
suggest O O
the O O
isolated O O
domains O O
may O O
interact O O
3132 O O
. O O

Within O O
the O O
3 O O
to O O
19 O O
% O O
of O O
experimental O O
interactions O O
covered O O
by O O
iPfam O O
, O O
we O O
analysed O O
the O O
conservation O O
of O O
iPfam O O
domain O O
pairs O O
between O O
species O O
. O O

Importantly O O
, O O
culture O O
of O O
MM O O
cells O O
with O O
RB O O
antisense O O
, O O
but O O
not B-Negation B-Negation
RB I-Negation I-Negation
sense I-Negation I-Negation
, O O
oligonucleotide O O
( O O
ODN O O
) O O
triggered O O
IL-6 O O
secretion O O
and O O
proliferation O O
in O O
MM O O
cells O O
; O O

We O O
studied O O
their O O
activity O O
after O O
transfection O O
into O O
K562 O O
cells O O
, O O
an O O
erythroleukemia O O
cell O O
line O O
with O O
an O O
embryonic-fetal O O
phenotype O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
mechanism O O
by O O
which O O
IL-10 O O
downregulates O O
expression O O
of O O
intercellular O O
adhesion O O
molecule-1 O O
( O O
ICAM-1 O O
) O O
on O O
the O O
cell O O
surface O O
of O O
normal O O
human O O
monocytes O O
activated O O
with O O
interferon-gamma O O
( O O
IFN-gamma O O
) O O
. O O

All O O
were O O
found O O
to O O
selectively O O
bind O O
the O O
consensus O O
sequence O O
5'-GTTACGTAAT-3 O O
' O O
with O O
high O O
affinity O O
. O O

Primer O O
extension O O
and O O
nuclease O O
S1 O O
protection O O
analysis O O
revealed O O
two O O
major O O
transcription O O
initiation O O
sites O O
. O O

An O O
age-related O O
decrease O O
in O O
the O O
number O O
of O O
GR O O
was O O
suggested O O
between O O
subjects O O
younger O O
than O O
20 O O
years O O
and O O
elderly O O
subjects O O
; O O

Precise O O
alignment O O
of O O
sites O O
required O O
for O O
mu O O
enhancer O O
activation O O
in O O
B O O
cells O O
. O O

NAC O O
also O O
inhibited O O
DC O O
responses O O
induced O O
by O O
CD40 O O
engagement O O
. O O

BACKGROUND O O
: O O
The O O
immediate O O
early O O
genes O O
( O O
IE O O
) O O
of O O
human O O
cytomegalovirus O O
( O O
CMV O O
) O O
can O O
be O O
expressed O O
in O O
monocytic O O
cells O O
and O O
are O O
known O O
to O O
regulate O O
viral O O
and O O
cellular O O
genes O O
. O O

We O O
show O O
that O O
the O O
inducible O O
nuclear O O
form O O
of O O
NF-AT O O
contains O O
Fos O O
and O O
Jun O O
proteins O O
. O O

Moreover O O
, O O
a O O
dominant O O
negative O O
form O O
of O O
CBP O O
decreased O O
the O O
activity O O
of O O
class O O
II O O
promoters O O
and O O
levels O O
of O O
class O O
II O O
determinants O O
on O O
the O O
surface O O
of O O
cells O O
. O O

In O O
summary O O
, O O
the O O
expression O O
of O O
E1A O O
gene O O
products O O
inhibited O O
IFN-MCP O O
independently O O
of O O
virus O O
infection O O
. O O

Suppression O O
of O O
c-jun O O
by O O
antisense O O
oligonucleotides O O
inhibits O O
cell O O
adhesion O O
but O O
not B-Negation B-Negation
respiratory I-Negation I-Negation
burst I-Negation I-Negation
during O I-Negation
phorbol O I-Negation
ester-induced O I-Negation
differentiation O I-Negation
of O I-Negation
U937 O I-Negation
human O I-Negation
monoblastic O I-Negation
cells O I-Negation
. O O

In O O
this O O
report O O
we O O
show O O
that O O
a O O
null O O
mutation O O
in O O
Drosophila O O
ADGF-A O O
gene O O
leads O O
to O O
dramatically O O
increased O O
levels O O
of O O
adenosine O O
and O O
deoxyadenosine O O
in O O
the O O
larval O O
hemolymph O O
. O O

107 O O
domain O O
pairs O O
are O O
shared O O
between O O
E. O O
coli O O
, O O
S. O O
cerevisiae O O
and O O
H. O O
sapiens O O
. O O

The O O
method O O
is O O
based O O
on O O
the O O
coamplification O O
of O O
VDR O O
cDNA O O
and O O
an O O
internal O O
standard O O
consisting O O
of O O
known O O
concentrations O O
of O O
a O O
human O O
VDR O O
CDNA O O
mutated O O
at O O
a O O
BglII O O
restriction O O
site O O
; O O
the O O
interassay O O
coefficient O O
of O O
variation O O
is O O
11 O O
% O O
. O O

Consistent O O
with O O
this O O
result O O
, O O
these O O
cell O O
lines O O
expressed O O
increased O O
levels O O
of O O
mRNAs O O
encoding O O
the O O
AP-1 O O
proteins O O
, O O
c-Fos O O
, O O
Fra-1 O O
, O O
c-Jun O O
, O O
JunB O O
, O O
and O O
JunD O O
. O O

Cell O O
hemoglobinization O O
was O O
accompanied O O
by O O
the O O
increased O O
expression O O
of O O
genes O O
encoding O O
gamma-globin O O
and O O
porphobilinogen O O
deaminase O O
( O O
PBGD O O
) O O
, O O
an O O
enzyme O O
of O O
heme O O
synthesis O O
. O O

We O O
conclude O O
from O O
these O O
studies O O
that O O
endothelial O O
hypoxia O O
provides O O
a O O
novel O O
, O O
proteasome-dependent O O
stimulus O O
for O O
ICAM-1 O O
induction O O
. O O

The O O
product O O
of O O
their O O
likelihood O O
ratios O O
is O O
referred O O
to O O
as O O
the O O
Preliminary O O
Score O O
. O O

On O O
the O O
other O O
hand O O
, O O
stimulation O O
of O O
T O O
cells O O
with O O
mAb O O
9.3 O O
increased O O
the O O
level O O
of O O
intracellular O O
Ca2+ O O
and O O
triggered O O
the O O
activation O O
of O O
p56 O O
( O O
lck O O
) O O
and O O
c-Raf-1 O O
, O O
but O O
was B-Negation O
unable I-Negation B-Negation
to I-Negation I-Negation
induce I-Negation I-Negation
the I-Negation I-Negation
binding I-Negation I-Negation
of I-Negation I-Negation
transcription I-Negation I-Negation
factors I-Negation I-Negation
to I-Negation I-Negation
the I-Negation I-Negation
IL-2 I-Negation I-Negation
promoter I-Negation I-Negation
. O O

Expression O O
of O O
D-mib O O
in O O
Dorsal O O
Cells O O
Is O O
Sufficient O O
to O O
Rescue O O
the O O
D-mib O O
Mutant O O
Phenotype O O

( O O
C O O
) O O
Multiple O O
melanotic O O
tumors O O
present O O
in O O
adgf-a O O
mutant O O
third-instar O O
larva O O
. O O

Structural O O
Similarities O O
between O O
the O O
Transib O O
TIRs O O
and O O
V O O
( O O
D O O
) O O
J O O
RSS O O
Signals O O

Furthermore O O
, O O
our O O
study O O
of O O
this O O
mutant O O
provides O O
strong O O
evidence O O
that O O
the O O
fat O O
body O O
disintegration O O
is O O
promoted O O
by O O
the O O
action O O
of O O
hemocytes O O
. O O

These O O
findings O O
suggest O O
that O O
bHLH O O
factors O O
are O O
required O O
to O O
control O O
T O O
cell O O
development O O
after O O
the O O
T/NK O O
developmental O O
checkpoint O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
a O O
commonly O O
prescribed O O
anti-inflammatory O O
drug O O
, O O
acetyl O O
salicylic O O
acid O O
( O O
ASA O O
) O O
, O O
on O O
IL-12 O O
production O O
and O O
Th1 O O
cell O O
development O O
. O O

Human O O
IL-5 O O
promoter/enhancer-luciferase O O
gene O O
construct O O
transfected O O
to O O
T-cell O O
clones O O
was O O
transcribed O O
on O O
either O O
TCR O O
or O O
IL-2R O O
stimulation O O
and O O
was O O
clearly O O
downregulated O O
by O O
dexamethasone O O
, O O
indicating O O
that O O
the O O
approximately O O
500-bp O O
human O O
IL-5 O O
gene O O
segment O O
located O O
5 O O
' O O
upstream O O
of O O
the O O
coding O O
region O O
contains O O
activation-inducible O O
enhancer O O
elements O O
responsible O O
for O O
the O O
regulation O O
by O O
GC O O
. O O

Oligonucleotide O O
primers O O
based O O
on O O
the O O
murine O O
sequence O O
were O O
used O O
to O O
construct O O
a O O
quantitative O O
reverse O O
transcription-PCR O O
assay O O
for O O
gene O O
expression O O
. O O

The O O
adgf-a O O
Mutant O O
Phenotype O O
Is O O
Associated O O
with O O
Elevated O O
Levels O O
of O O
Adenosine O O
and/or O O
Deoxyadenosine O O

Long-term O O
inositol O O
phosphate O O
release O O
, O O
but O O
not B-Negation B-Negation
tyrosine I-Negation I-Negation
kinase I-Negation I-Negation
activity I-Negation I-Negation
, O O
correlates O O
with O O
IL-2 O O
secretion O O
and O O
NF-AT O O
induction O O
in O O
anti-CD3-activated O O
peripheral O O
human O O
T O O
lymphocytes O O
. O O

Induction O O
of O O
cytokine O O
expression O O
in O O
leukocytes O O
by O O
binding O O
of O O
thrombin-stimulated O O
platelets O O
. O O

NF-kappa O O
B O O
activation O O
involves O O
signaled O O
phosphorylation O O
, O O
ubiquitination O O
, O O
and O O
proteolysis O O
of O O
I O O
kappa O O
B O O
. O O

The O O
NF O O
kappa O O
B2 O O
effect O O
was O O
dependent O O
on O O
the O O
presence O O
of O O
the O O
STAT6 O O
binding O O
site O O
, O O
demonstrating O O
that O O
the O O
NF O O
kappa O O
B2 O O
motif O O
is O O
necessary O O
but O O
not B-Negation B-Negation
sufficient I-Negation I-Negation
for I-Negation I-Negation
mediating I-Negation I-Negation
cytokine I-Negation I-Negation
up-regulation I-Negation I-Negation
. O O

We O O
have O O
investigated O O
several O O
molecular O O
pathways O O
that O O
are O O
known O O
to O O
be O O
activated O O
by O O
IL-2 O O
in O O
T O O
cells O O
. O O

Deletion O O
of O O
this O O
sequence O O
abolishes O O
the O O
capacity O O
of O O
CD40 O O
to O O
induce O O
expression O O
of O O
CD23 O O
, O O
ICAM-1 O O
, O O
and O O
lymphotoxin-alpha O O
genes O O
in O O
B O O
cells O O
. O O

We O O
have O O
developed O O
a O O
system O O
to O O
monitor O O
the O O
transcriptional O O
activity O O
of O O
NFAT-1 O O
at O O
the O O
single O O
cell O O
level O O
in O O
whole O O
animals O O
. O O

Glutathione-S-transferase O O
( O O
GST O O
) O O
-Grb2 O O
fusion O O
proteins O O
have O O
been O O
used O O
to O O
identify O O
the O O
potential O O
role O O
of O O
Grb2-binding O O
proteins O O
in O O
platelet O O
activation O O
by O O
the O O
platelet O O
low-affinity O O
IgG O O
receptor O O
, O O
Fc O O
gamma O O
RIIA O O
. O O

We O O
have O O
previously O O
shown O O
that O O
after O O
a O O
mutation O O
of O O
Leu122 O O
to O O
Arg O O
the O O
DNA O O
binding O O
basic O O
domain O O
of O O
MyoD O O
confers O O
c-myc-like O O
functional O O
characteristics O O
to O O
the O O
protein O O
. O O

The O O
Th2-type O O
cytokines O O
, O O
interleukin-4 O O
( O O
IL-4 O O
) O O
and O O
interleukin-13 O O
( O O
IL-13 O O
) O O
, O O
induce O O
expression O O
of O O
a O O
distinct O O
subset O O
of O O
genes O O
in O O
human O O
monocytes O O
, O O
including O O
FcepsilonRIIb O O
( O O
CD23 O O
) O O
, O O
15-lipoxygenase O O
, O O
IL-1 O O
receptor O O
antagonist O O
( O O
IL-1ra O O
) O O
, O O
and O O
type O O
I O O
and O O
type O O
II O O
IL-1 O O
receptors O O
( O O
IL-1R O O
) O O
. O O

Costimulation O O
of O O
T O O
cells O O
through O O
both O O
the O O
Ag O O
receptor O O
and O O
CD28 O O
leads O O
to O O
high O O
level O O
IL-2 O O
production O O
, O O
which O O
is O O
vital O O
to O O
the O O
development O O
of O O
an O O
immune O O
response O O
in O O
vivo O O
. O O

The O O
SH3 O O
domains O O
of O O
Grb2 O O
form O O
a O O
stable O O
complex O O
with O O
SOS1 O O
and O O
two O O
proteins O O
of O O
75 O O
kD O O
and O O
120 O O
kD O O
, O O
which O O
undergo O O
tyrosine O O
phosphorylation O O
in O O
Fc O O
gamma O O
RIIA O O
stimulated O O
cells O O
. O O

Likelihoods O O
were O O
assessed O O
using O O
a O O
PTM O O
pair O O
enrichment O O
score O O
calculated O O
as O O
the O O
probability O O
of O O
co-occurrence O O
of O O
two O O
specific O O
PTMs O O
in O O
all O O
pairs O O
of O O
interacting O O
protein O O
pairs O O
divided O O
by O O
the O O
probability O O
of O O
occurrence O O
of O O
both O O
of O O
these O O
PTMs O O
separately O O
: O O
PTM_score=P O O
( O O
PTM O O
[ O O
i O O
] O O
, O O
PTM O O
[ O O
j O O
] O O
|I O O
) O O
P O O
( O O
PTM O O
[ O O
i O O
] O O
|I O O
) O O
∗P O O
( O O
PTM O O
[ O O
j O O
] O O
|I O O
) O O
where O O
PTM O O
[ O O
i O O
] O O
and O O
PTM O O
[ O O
j O O
] O O
are O O
distinct O O
PTMs O O
and O O
I O O
is O O
the O O
set O O
of O O
all O O
interacting O O
proteins O O
that O O
were O O
used O O
to O O
train O O
the O O
predictor O O
. O O

Previous O O
studies O O
revealed O O
that O O
HSF2 O O
consists O O
of O O
two O O
alternatively O O
spliced O O
isoforms O O
, O O
HSF2-alpha O O
and O O
HSF2-beta O O
, O O
whose O O
relative O O
abundance O O
is O O
developmentally O O
regulated O O
and O O
varies O O
between O O
different O O
tissues O O
. O O

The O O
lymphoid-specific O O
transcription O O
complex O O
, O O
NF-AT O O
, O O
is O O
involved O O
in O O
early O O
gene O O
activation O O
in O O
T O O
cells O O
and O O
is O O
assembled O O
from O O
a O O
pre-existing O O
, O O
T O O
cell O O
restricted O O
cytoplasmic O O
factor O O
and O O
an O O
inducible O O
ubiquitous O O
nuclear O O
component O O
within O O
30 O O
min O O
after O O
activation O O
through O O
the O O
antigen O O
receptor O O
. O O

In O O
a O O
concentration-dependent O O
manner O O
, O O
NO O O
inhibited O O
interleukin O O
( O O
IL O O
) O O
-1 O O
alpha-stimulated O O
VCAM-1 O O
expression O O
by O O
35-55 O O
% O O
as O O
determined O O
by O O
cell O O
surface O O
enzyme O O
immunoassays O O
and O O
flow O O
cytometry O O
. O O

This O O
study O O
thus O O
supports O O
the O O
concept O O
that O O
utilization O O
of O O
distinct O O
STAT O O
proteins O O
by O O
different O O
cytokine O O
receptors O O
is O O
dependent O O
on O O
the O O
expression O O
of O O
particular O O
ligand-activatable O O
, O O
tyrosine-containing O O
STAT O O
docking O O
sites O O
in O O
receptor O O
intracellular O O
domains O O
. O O

Acute O O
ethanol O O
exposure O O
has O O
the O O
capacity O O
to O O
modulate O O
immune O O
functions O O
, O O
particularly O O
, O O
to O O
down O O
regulate O O
monocyte O O
production O O
of O O
inflammatory O O
cytokines O O
. O O

Potential O O
role O O
of O O
a O O
downstream O O
intronic O O
sequence O O
for O O
elk-1 O O
gene O O
expression O O
in O O
monocytes O O
. O O

Discussion O O

On O O
the O O
first O O
day O O
of O O
the O O
disease O O
, O O
glucocorticoid O O
receptor O O
capacity O O
was O O
significantly O O
decreased O O
without B-Negation B-Negation
alteration I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
receptor-ligand I-Negation I-Negation
affinity I-Negation I-Negation
, O O
whereas O O
on O O
days O O
4 O O
and O O
12 O O
the O O
number O O
of O O
receptor O O
sites O O
was O O
normal O O
again O O
. O O

Importantly O O
, O O
constitutive O O
expression O O
of O O
Rev O O
M10 O O
did O O
not B-Negation B-Negation
alter I-Negation I-Negation
the I-Negation I-Negation
secretion I-Negation I-Negation
of I-Negation I-Negation
interleukin I-Negation I-Negation
2 I-Negation I-Negation
in I-Negation I-Negation
response I-Negation I-Negation
to I-Negation I-Negation
mitogen I-Negation I-Negation
stimulation I-Negation I-Negation
of I-Negation I-Negation
EL-4 I-Negation I-Negation
and I-Negation I-Negation
Jurkat I-Negation I-Negation
cells I-Negation I-Negation
. O O

Finally O O
, O O
oxidants O O
are O O
believed O O
to O O
promote O O
intestinal O O
epithelial O O
cell O O
apoptosis O O
, O O
and O O
the O O
B-cell O O
lymphoma/leukemia-2 O O
gene O O
product O O
is O O
believed O O
to O O
inhibit O O
this O O
phenomenon O O
in O O
an O O
antioxidant-dependent O O
manner O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
the O O
transcription O O
factors O O
that O O
regulate O O
its O O
expression O O
. O O

It O O
is O O
surprising O O
that O O
the O O
faster-migrating O O
complex O O
was O O
composed O O
also O O
of O O
p50 O O
and O O
p65 O O
. O O

When O O
freshly O O
isolated O O
, O O
highly O O
enriched O O
( O O
> O O
98 O O
% O O
) O O
T O O
cells O O
are O O
examined O O
for O O
IFN-gamma O O
responsiveness O O
; O O

Therefore O O
, O O
the O O
human O O
androgen O O
receptor O O
assay O O
( O O
HUMARA O O
) O O
was O O
used O O
to O O
determine O O
granulocyte O O
clonality O O
. O O

Expression O O
of O O
GrpL O O
is O O
restricted O O
to O O
hematopoietic O O
tissues O O
, O O
and O O
it O O
is O O
distinguished O O
from O O
Grb2 O O
by O O
having O O
a O O
proline-rich O O
region O O
. O O

BACKGROUND O O
: O O
The O O
induction O O
of O O
vascular O O
cell O O
adhesion O O
molecule-1 O O
( O O
VCAM-1 O O
) O O
and O O
E-selectin O O
by O O
tumor O O
necrosis O O
factor-alpha O O
( O O
TNF O O
) O O
is O O
mediated O O
by O O
mobilization O O
of O O
the O O
transcription O O
factor O O
nuclear O O
factor-kappa O O
B O O
( O O
NF-kappa O O
B O O
) O O
. O O

In O O
addition O O
, O O
they O O
suggested O O
that O O
the O O
activation O O
of O O
the O O
IL-2 O O
promoter O O
is O O
under O O
the O O
control O O
of O O
not O O
only O O
NFAT O O
but O O
also O O
a O O
second O O
factor O O
whose O O
activation O O
is O O
MEK-dependent O O
. O O

Human O O
T-cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
is O O
an O O
etiological O O
agent O O
of O O
adult O O
T-cell O O
leukemia O O
( O O
ATL O O
) O O
. O O

Moreover O O
, O O
Tax1 O O
activated O O
expression O O
of O O
two O O
other O O
transcription O O
factors O O
having O O
zinc O O
finger O O
motifs O O
, O O
Egr-1 O O
and O O
Egr-2 O O
, O O
in O O
the O O
same O O
cells O O
. O O

The O O
human O O
IL-13 O O
gene O O
was O O
located O O
12.5-kb O O
upstream O O
of O O
the O O
IL-4 O O
gene O O
and O O
2-kb O O
downstream O O
of O O
a O O
CpG O O
island O O
. O O

We O O
have O O
found O O
that O O
simple O O
consensus O O
motifs O O
over O O
the O O
full O O
IUPAC O O
alphabet O O
( O O
a O O
15-letter O O
code O O
consisting O O
of O O
the O O
bases O O
A O O
, O O
T O O
, O O
C O O
, O O
G O O
and O O
all O O
possible O O
combinations O O
) O O
provide O O
enough O O
representational O O
power O O
to O O
adequately O O
describe O O
Û O O
, O O
while O O
still O O
allowing O O
for O O
an O O
efficient O O
search O O
34 O O
. O O

Role O O
of O O
cellular O O
tumor O O
necrosis O O
factor O O
receptor-associated O O
factors O O
in O O
NF-kappaB O O
activation O O
and O O
lymphocyte O O
transformation O O
by O O
herpesvirus O O
Saimiri O O
STP O O
. O O

Colinear O O
triplex O O
formation O O
acts O O
as O O
a O O
selective O O
transcriptional O O
repressor O O
of O O
the O O
GM-CSF O O
gene O O
and O O
may O O
have O O
potential O O
therapeutic O O
application O O
in O O
cases O O
of O O
undesirable O O
overexpression O O
of O O
this O O
protein O O
. O O

The O O
concentration O O
of O O
corticosteroid O O
producing O O
50 O O
% O O
inhibition O O
( O O
IC50 O O
) O O
was O O
600 O O
nM O O
, O O
70 O O
nM O O
, O O
and O O
0.5 O O
nM O O
for O O
hydrocortisone O O
, O O
methylprednisolone O O
, O O
and O O
dexamethasone O O
, O O
respectively O O
, O O
in O O
monocytes O O
from O O
CS O O
individuals O O
. O O

The O O
y-axis O O
shows O O
the O O
average O O
accuracy O O
for O O
each O O
group O O
of O O
regulons O O
. O O

Irrespective O O
of O O
the O O
human O O
cell O O
partner O O
used O O
for O O
fusion O O
, O O
a O O
certain O O
number O O
of O O
hybrids O O
lost O O
CD5 O O
surface O O
expression O O
over O O
a O O
period O O
of O O
time O O
in O O
culture O O
. O O

Point O O
mutations O O
within O O
the O O
eed O O
gene O O
that O O
are O O
responsible O O
for O O
severe O O
embryonic O O
development O O
abnormalities O O
abolished O O
the O O
transcriptional O O
repressor O O
activity O O
of O O
Eed O O
. O O

It O O
may O O
be O O
possible O O
to O O
produce O O
such O O
cells O O
by O O
first O O
expressing O O
the O O
Epo O O
receptor O O
under O O
the O O
influence O O
of O O
a O O
constitutive O O
promoter O O
and O O
then O O
targeting O O
the O O
GATA-1 O O
gene O O
. O O

RESULTS O O
: O O
Both O O
all-trans O O
and O O
9-cis O O
RA O O
inhibited O O
virus O O
replication O O
in O O
HIV-1 O O
IIIB-infected O O
monocytoid O O
cells O O
, O O
in O O
the O O
presence O O
and O O
absence B-Negation O
of I-Negation O
the I-Negation O
co-stimulatory I-Negation O
agent I-Negation O
phorbol I-Negation O
myristate I-Negation O
acetate I-Negation O
( I-Negation O
PMA I-Negation O
) I-Negation O
. O O

Hence O O
, O O
PPAR O O
can O O
positively O O
or O O
negatively O O
influence O O
TH O O
action O O
depending O O
on O O
TRE O O
structure O O
and O O
THR O O
isotype O O
. O O

Two O O
of O O
these O O
are O O
potential O O
binding O O
sites O O
for O O
STAT O O
proteins O O
. O O

In O O
this O O
study O O
, O O
the O O
influence O O
of O O
the O O
sequences O O
located O O
between O O
-3134 O O
and O O
-2987 O O
on O O
the O O
transcriptional O O
activity O O
of O O
the O O
proIL-1beta O O
gene O O
in O O
LPS-stimulated O O
Raw O O
264.7 O O
cells O O
was O O
examined O O
in O O
detail O O
. O O

The O O
Rhodes O O
dataset O O
was O O
trained O O
using O O
an O O
earlier O O
version O O
of O O
the O O
HPRD O O
. O O

Our O O
results O O
suggest O O
that O O
constitutive O O
ETS1 O O
, O O
and O O
inducible O O
NFkappaB O O
and O O
AP1 O O
, O O
cooperate O O
as O O
part O O
of O O
a O O
higher O O
order O O
transcriptional O O
complex O O
in O O
activated O O
T O O
cells O O
. O O

This O O
arrangement O O
of O O
Ets O O
sites O O
, O O
coupled O O
with O O
the O O
tissue- O O
and O O
developmental-specific O O
expression O O
of O O
Ets O O
members O O
, O O
likely O O
play O O
a O O
key O O
role O O
in O O
defining O O
the O O
pattern O O
of O O
alpha O O
4 O O
integrin O O
. O O

To O O
investigate O O
the O O
role O O
of O O
Stat6 O O
in O O
regulating O O
IL-4 O O
transcription O O
, O O
we O O
used O O
Stat6-deficient O O
Jurkat O O
T O O
cells O O
with O O
different O O
intact O O
IL-4 O O
promoter O O
constructs O O
in O O
cotransfection O O
assays O O
. O O

this O O
activity O O
is O O
potentiated O O
by O O
coexpression O O
of O O
constitutively O O
active O O
calcineurin O O
and O O
is O O
inhibited O O
by O O
CsA O O
. O O

TPA-GR O O
synergism O O
was O O
determined O O
to O O
have O O
occurred O O
at O O
the O O
GR-responsive O O
element O O
( O O
GRE O O
) O O
level O O
by O O
functional O O
analysis O O
of O O
deletion O O
mutants O O
or O O
synthetic O O
GRE O O
oligonucleotides O O
driving O O
chloramphenicol O O
acetyl-transferase O O
expression O O
. O O

PDBu O O
+ O O
iono O O
induced O O
equally O O
high O O
IL-2 O O
levels O O
in O O
both O O
groups O O
and O O
, O O
when O O
stimulated O O
with O O
plate-bound O O
anti-CD3 O O
monoclonal O O
antibody O O
( O O
mAb O O
) O O
, O O
the O O
IL-2 O O
secretion O O
by O O
neonatal O O
cells O O
was O O
undetectable O O
and O O
adult O O
cells O O
produced O O
low O O
amounts O O
of O O
IL-2 O O
( O O
mean O O
331 O O
± O O
86 O O
pg/ml O O
) O O
. O O

Soluble O O
factors O O
secreted O O
by O O
activated O O
T-lymphocytes O O
modulate O O
the O O
transcription O O
of O O
the O O
immunosuppressive O O
cytokine O O
TGF-beta O O
2 O O
in O O
glial O O
cells O O
. O O

Egr-1 O O
expression O O
correlates O O
with O O
the O O
cellular O O
phenotype O O
and O O
the O O
specific O O
pattern O O
of O O
viral O O
latency O O
established O O
within O O
the O O
individual O O
cell O O
lines O O
. O O

Thus O O
, O O
STAT1 O O
may O O
be O O
a O O
useful O O
target O O
in O O
the O O
development O O
of O O
new O O
immunosuppressive O O
and O O
antineoplastic O O
agents O O
. O O

No B-Negation B-Negation
effect I-Negation I-Negation
was I-Negation I-Negation
seen I-Negation I-Negation
with I-Negation I-Negation
non I-Negation I-Negation
transfected I-Negation I-Negation
cells I-Negation I-Negation
or I-Negation I-Negation
with I-Negation I-Negation
cells I-Negation I-Negation
transfected I-Negation I-Negation
with I-Negation I-Negation
a I-Negation I-Negation
control I-Negation I-Negation
plasmid I-Negation I-Negation
. O O

χS O O
The O O
number O O
of O O
iPfam O O
domain O O
pairs O O
observed O O
in O O
species O O
S O O

We O O
further O O
demonstrate O O
the O O
impact O O
of O O
platelet-activating O O
factor O O
binding O O
to O O
B O O
cells O O
by O O
measuring O O
platelet-activating O O
factor O O
induced O O
arachidonic O O
acid O O
release O O
and O O
5-hydroxyeicosatetraenoic O O
acid O O
production O O
. O O

Of O O
the O O
23 O O
cases O O
, O O
19 O O
were O O
classified O O
as O O
NK-cell O O
and O O
4 O O
as O O
T-cell O O
tumours O O
. O O

Mammal O O
pyruvate O O
kinases O O
are O O
encoded O O
by O O
two O O
genes O O
. O O

Promoter O O
sequences O O
responsive O O
to O O
cyclic O O
AMP O O
( O O
cAMP O O
) O O
are O O
found O O
in O O
a O O
number O O
of O O
cellular O O
genes O O
, O O
and O O
bind O O
transcription O O
factors O O
of O O
the O O
cAMP O O
response O O
element O O
binding O O
protein O O
( O O
CREB O O
) O O
/activating O O
transcription O O
factor-1 O O
( O O
ATF-1 O O
) O O
family O O
. O O

The O O
prior O O
odds O O
ratio O O
( O O
Oprior O O
) O O
is O O
difficult O O
to O O
estimate O O
because O O
we O O
do O O
not B-Negation O
know I-Negation O
all I-Negation O
the I-Negation O
true I-Negation O
interactions I-Negation O
, I-Negation O
even I-Negation O
for I-Negation O
a I-Negation O
small I-Negation O
subset I-Negation O
of I-Negation O
proteins I-Negation O
. O O

The O O
third O O
site O O
was O O
occupied O O
in O O
quiescent O O
cells O O
or O O
in O O
cells O O
stimulated O O
by O O
anti O O
CD2 O O
or O O
anti O O
CD28 O O
alone O O
. O O

On O O
synthetic O O
datasets O O
, O O
we O O
found O O
SCOPE O O
's O O
component O O
algorithms O O
to O O
be O O
quite O O
robust O O
to O O
the O O
settings O O
of O O
these O O
hyperparameters O O
. O O

This O O
superfamily O O
was O O
discovered O O
recently O O
based O O
on O O
computational O O
analysis O O
of O O
the O O
fruit O O
fly O O
and O O
African O O
malaria O O
mosquito O O
genomes O O
. O O

Bcl-2 O O
inhibits O O
apoptosis O O
induced O O
by O O
a O O
variety O O
of O O
stimuli O O
, O O
including O O
chemotherapy O O
drugs O O
and O O
glucocorticoids O O
. O O

Using O O
the O O
tyrosine O O
kinase O O
inhibitor O O
genistein O O
( O O
10 O O
microM O O
) O O
a O O
complete O O
inhibition O O
of O O
IL-10 O O
induced O O
c-fos O O
expression O O
was O O
observed O O
. O O

Epithelial O O
cell-initiated O O
inflammation O O
plays O O
a O O
crucial O O
role O O
in O O
early O O
tissue O O
damage O O
in O O
amebic O O
infection O O
of O O
human O O
intestine O O
. O O

Bootstrap O O
values O O
higher O O
than O O
60 O O
% O O
are O O
reported O O
at O O
the O O
corresponding O O
nodes O O
. O O

Thymocyte-thymic O O
epithelial O O
cell O O
interaction O O
leads O O
to O O
high-level O O
replication O O
of O O
human O O
immunodeficiency O O
virus O O
exclusively O O
in O O
mature O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
- O O
) O O
CD3 O O
( O O
+ O O
) O O
thymocytes O O
: O O
a O O
critical O O
role O O
for O O
tumor O O
necrosis O O
factor O O
and O O
interleukin-7 O O
. O O

Furthermore O O
, O O
it O O
demonstrates O O
that O O
aging O O
does O O
not B-Negation B-Negation
influence I-Negation I-Negation
the I-Negation I-Negation
sensitivity I-Negation I-Negation
of I-Negation I-Negation
this I-Negation I-Negation
phosphatase I-Negation I-Negation
. O O

We O O
previously O O
established O O
a O O
critical O O
role O O
for O O
the O O
transcription O O
factor O O
GATA-3 O O
in O O
IL-5 O O
promoter O O
activation O O
in O O
EL-4 O O
cells O O
, O O
which O O
express O O
both O O
Th1- O O
and O O
Th2-type O O
cytokines O O
. O O

By O O
comparison O O
, O O
there O O
was O O
no B-Negation B-Negation
modification I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
expression I-Negation I-Negation
of I-Negation I-Negation
CD4 I-Negation I-Negation
antigen I-Negation I-Negation
, O O
which O O
is O O
expressed O O
at O O
high O O
levels O O
in O O
these O O
cells O O
. O O

Thus O O
the O O
response O O
of O O
K562 O O
cells O O
to O O
HMBA O O
may O O
provide O O
a O O
useful O O
experimental O O
system O O
for O O
studying O O
the O O
molecular O O
mechanisms O O
responsible O O
for O O
downmodulation O O
of O O
lineage-restricted O O
transcription O O
factors O O
during O O
hemopoietic O O
lineage O O
commitment O O
. O O

The O O
influence O O
of O O
the O O
anti-allergy O O
agent O O
azelastine O O
hydrochloride O O
( O O
Azeptin O O
) O O
on O O
NF-kappa O O
B O O
activation O O
associated O O
with O O
the O O
generation O O
of O O
cytokines O O
and O O
nitric O O
oxide O O
( O O
NO O O
) O O
was O O
investigated O O
in O O
various O O
kinds O O
of O O
human O O
and O O
mouse O O
cells O O
. O O

The O O
in O O
vitro O O
transendothelial O O
migration O O
of O O
circulating O O
filarial O O
antigen-specific O O
T-cells O O
was O O
examined O O
in O O
Wuchereria O O
banerofti O O
infection O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
central O O
nervous O O
system O O
may O O
regulate O O
IL-12 O O
and O O
IL-10 O O
secretion O O
and O O
, O O
hence O O
, O O
TH1/TH2 O O
balance O O
via O O
the O O
peripheral O O
end-effectors O O
of O O
the O O
stress O O
system O O
. O O

Pretreatment O O
with O O
IFN-gamma O O
potentiates O O
the O O
IFN-alpha-induced O O
protection O O
, O O
but O O
IFN-gamma O O
alone O O
does O O
not B-Negation B-Negation
have I-Negation I-Negation
any I-Negation I-Negation
antiviral I-Negation I-Negation
activity I-Negation I-Negation
. O O

RESULTS O O
: O O
After O O
nonspecific O O
stimulation O O
, O O
IL-5 O O
production O O
by O O
CD4+ O O
T O O
cells O O
from O O
both O O
atopic O O
and O O
nonatopic O O
subjects O O
with O O
asthma O O
was O O
significantly O O
enhanced O O
compared O O
with O O
that O O
by O O
cells O O
from O O
healthy O O
controls O O
. O O

The O O
truncation O O
resulted O O
from O O
limited O O
proteolysis O O
of O O
p65 O O
during O O
cellular O O
extraction O O
which O O
released O O
particular O O
lysosomal O O
serine O O
proteases O O
, O O
such O O
as O O
elastase O O
, O O
cathepsin O O
G O O
, O O
and O O
proteinase O O
3 O O
. O O

Molecular O O
basis O O
of O O
a O O
multiple O O
lymphokine O O
deficiency O O
in O O
a O O
patient O O
with O O
severe O O
combined O O
immunodeficiency O O
. O O

Rel-deficient O O
T O O
cells O O
exhibit O O
defects O O
in O O
production O O
of O O
interleukin O O
3 O O
and O O
granulocyte-macrophage O O
colony-stimulating O O
factor O O
. O O

CD40- B-Negation B-Negation
or I-Negation I-Negation
pervanadate-mediated I-Negation I-Negation
I I-Negation I-Negation
kappa I-Negation I-Negation
B I-Negation I-Negation
tyrosine I-Negation I-Negation
phosphorylation I-Negation I-Negation
was I-Negation I-Negation
not I-Negation I-Negation
detected I-Negation I-Negation
. O O

Tyrosine O O
kinases O O
are O O
not B-Negation B-Negation
required I-Negation I-Negation
for I-Negation I-Negation
lipopolysaccharide-mediated I-Negation I-Negation
nuclear I-Negation I-Negation
translocation I-Negation I-Negation
of I-Negation I-Negation
NFkappaB I-Negation I-Negation
. O O

Cellular O O
mechanisms O O
contributing O O
to O O
inadequate O O
response O O
to O O
glucocorticoid O O
therapy O O
. O O

In O O
parallel O O
, O O
increased O O
levels O O
of O O
transcripts O O
for O O
IP-10 O O
, O O
a O O
murine O O
homologue O O
in O O
the O O
chemokine O O
family O O
related O O
to O O
IL-8 O O
, O O
were O O
observed O O
in O O
hypoxic O O
lung O O
tissue O O
. O O

Activation O O
of O O
the O O
transcription O O
factor O O
nuclear O O
factor-kappaB O O
( O O
NF-kappaB O O
) O O
determined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
and O O
kappaB-dependent O O
transcriptional O O
activity O O
was O O
enhanced O O
in O O
the O O
presence O O
of O O
activated O O
platelets O O
. O O

Although O O
the O O
TNF-alpha O O
level O O
in O O
culture O O
supernatants O O
was O O
below O O
the O O
sensitivity O O
of O O
an O O
ELISA O O
assay O O
system O O
, O O
addition O O
of O O
anti-TNF-alpha O O
antibody O O
in O O
culture O O
medium O O
could O O
partially O O
suppress O O
the O O
heat O O
shock O O
induced O O
HIV-1 O O
production O O
. O O

Our O O
experiments O O
also O O
show O O
that O O
activated O O
PR O O
does O O
not B-Negation B-Negation
confer I-Negation I-Negation
direct I-Negation I-Negation
transcriptional I-Negation I-Negation
control I-Negation I-Negation
on I-Negation I-Negation
the I-Negation I-Negation
dPRL I-Negation I-Negation
promoter I-Negation I-Negation
. O O

Our O O
findings O O
are O O
compatible O O
with O O
a O O
competitive O O
model O O
of O O
switching O O
in O O
which O O
EKLF O O
mediates O O
an O O
adult O O
stage-specific O O
interaction O O
between O O
the O O
beta-globin O O
gene O O
promoter O O
and O O
the O O
locus O O
control O O
region O O
that O O
excludes O O
the O O
gamma-globin O O
gene O O
. O O

The O O
false O O
positive O O
rate O O
( O O
FPR O O
) O O
of O O
our O O
predictor O O
was O O
estimated O O
by O O
the O O
method O O
of O O
D'Haeseleer O O
and O O
Church O O
1855 O O
and O O
used O O
to O O
compare O O
it O O
to O O
other O O
prediction O O
datasets O O
. O O

In O O
contrast O O
, O O
a O O
mutant O O
of O O
Tax O O
termed O O
M22 O O
, O O
which O O
does O O
not B-Negation B-Negation
induce I-Negation I-Negation
NF-kappaB I-Negation I-Negation
, O O
fails B-Negation B-Negation
to I-Negation I-Negation
activate I-Negation I-Negation
either I-Negation I-Negation
IKKalpha I-Negation I-Negation
or I-Negation I-Negation
IKKbeta I-Negation I-Negation
. O O

Our O O
data O O
constitute O O
a O O
starting O O
point O O
for O O
studies O O
to O O
elucidate O O
the O O
molecular O O
mechanism O O
by O O
which O O
TGF-beta O O
regulates O O
IgA O O
production O O
. O O

Specifically O O
, O O
we O O
examined O O
nuclear O O
factor-kappa O O
B O O
( O O
NF-kappa O O
B O O
) O O
activation O O
because O O
it O O
is O O
crucial O O
in O O
transcriptional O O
regulation O O
of O O
many O O
inflammatory O O
cytokine O O
genes O O
including O O
TNF O O
, O O
IL-1 O O
, O O
and O O
IL-6 O O
. O O

RESULTS O O
. O O

The O O
IL-12 O O
nonresponsiveness O O
of O O
the O O
Th2 O O
clones O O
was O O
further O O
evident O O
by O O
the O O
total O O
lack B-Negation B-Negation
of I-Negation I-Negation
IL-12-induced I-Negation I-Negation
phosphorylation I-Negation I-Negation
of I-Negation I-Negation
STAT4 I-Negation I-Negation
( I-Negation I-Negation
signal I-Negation I-Negation
transducer I-Negation I-Negation
and I-Negation I-Negation
activator I-Negation I-Negation
of I-Negation I-Negation
transcription-4 I-Negation I-Negation
) I-Negation I-Negation
, O O
a O O
transcription O O
factor O O
that O O
is O O
typically O O
involved O O
in O O
IL-12 O O
signaling O O
. O O

An O O
IL-2 O O
promoter O O
bearing O O
a O O
defective O O
NF-chi O O
B O O
site O O
was O O
completely O O
inactive O O
in O O
EBV-transformed O O
B O O
cells O O
, O O
while O O
it O O
still O O
had O O
activity O O
in O O
Jurkat O O
T O O
cells O O
. O O

Positive O O
regulatory O O
element O O
I O O
( O O
PRE-I O O
) O O
is O O
a O O
strong O O
enhancer O O
element O O
essential O O
for O O
expression O O
of O O
the O O
human O O
IL-4 O O
gene O O
. O O

In O O
the O O
present O O
report O O
, O O
we O O
studied O O
the O O
role O O
of O O
the O O
stromal-derived O O
cytokine O O
interleukin-7 O O
( O O
IL-7 O O
) O O
in O O
the O O
IL-2-gene O O
regulation O O
in O O
activated O O
T O O
lymphocytes O O
. O O

Cytokine O O
rescue O O
from O O
glucocorticoid O O
induced O O
apoptosis O O
in O O
T O O
cells O O
is O O
mediated O O
through O O
inhibition O O
of O O
IkappaBalpha O O
. O O

This O O
indicates O O
an O O
increase O O
in O O
either O O
episomal O O
DNA O O
or O O
concatameric O O
linear O O
DNA O O
. O O

Pregnancy-induced O O
hypertension O O
( O O
PIH O O
) O O
is O O
a O O
frequent O O
cause O O
of O O
maternal O O
and O O
neonatal O O
morbidity O O
and O O
mortality O O
. O O

Although O O
IL-2 O O
secretion O O
was O O
increased O O
in O O
the O O
presence O O
of O O
anti-CD28 O O
MoAb O O
, O O
neonatal O O
T O O
cell O O
IL-2 O O
production O O
remained O O
lower O O
than O O
in O O
adults O O
. O O

Finally O O
, O O
an O O
abbreviated O O
TSP O O
1 O O
promoter/5'-flank O O
, O O
containing O O
the O O
SRE- O O
and O O
NF-Y-binding O O
sites O O
, O O
mediated O O
a O O
serum O O
response O O
that O O
was O O
close O O
in O O
magnitude O O
to O O
that O O
of O O
the O O
parent O O
promoter O O
. O O

Despite O O
the O O
dual O O
specificity O O
of O O
HTLV-1 O O
Tax O O
for O O
IkappaBalpha O O
and O O
IkappaBbeta O O
at O O
the O O
protein O O
level O O
, O O
Tax O O
selectively O O
stimulates O O
NF-kappaB-directed O O
transcription O O
of O O
the O O
IkappaBalpha O O
gene O O
. O O

The O O
inhibiting O O
effect O O
of O O
IL-4 O O
was O O
slightly O O
more O O
pronounced O O
than O O
that O O
of O O
IL-10 O O
. O O

A O O
murine O O
T O O
cell O O
line O O
, O O
EL4 O O
, O O
was O O
stimulated O O
with O O
IL-1 O O
with O O
and O O
without B-Negation B-Negation
pretreatment I-Negation I-Negation
with I-Negation I-Negation
different I-Negation I-Negation
compounds I-Negation I-Negation
known I-Negation I-Negation
to I-Negation I-Negation
influence I-Negation I-Negation
the I-Negation I-Negation
cellular I-Negation I-Negation
redox I-Negation I-Negation
status I-Negation I-Negation
. O O

TNF O O
increased O O
VCAM-1 O O
protein O O
and O O
mRNA O O
in O O
HUVECs O O
that O O
was O O
blocked O O
by O O
pyrrolidinedithiocarbamate O O
. O O

Cytokine O O
modulation O O
of O O
HIV O O
expression O O
. O O

CD4+ O O
macrophages O O
in O O
tissues O O
such O O
as O O
lung O O
, O O
skin O O
, O O
and O O
lymph O O
nodes O O
, O O
promyelocytic O O
cells O O
in O O
bone O O
marrow O O
, O O
and O O
peripheral O O
blood O O
monocytes O O
serve O O
as O O
important O O
targets O O
and O O
reservoirs O O
for O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
replication O O
. O O

The O O
cytokines O O
interleukin-1 O O
beta O O
( O O
IL-1 O O
beta O O
) O O
and O O
tumor O O
necrosis O O
factor O O
alpha O O
( O O
TNF-alpha O O
) O O
are O O
released O O
by O O
mononuclear O O
phagocytes O O
in O O
vitro O O
after O O
stimulation O O
with O O
mycobacteria O O
and O O
are O O
considered O O
to O O
mediate O O
pathophysiologic O O
events O O
, O O
including O O
granuloma O O
formation O O
and O O
systemic O O
symptoms O O
. O O

Once O O
in O O
the O O
nucleus O O
, O O
NF-ATc O O
interacts O O
with O O
NF-ATn O O
to O O
form O O
an O O
active O O
transcriptional O O
complex O O
. O O

Expression O O
of O O
Tax O O
protein O O
in O O
19D O O
and O O
9J O O
resulted O O
in O O
transcription O O
of O O
the O O
endogenous O O
NF-kappa O O
B-dependent O O
granulocyte-macrophage O O
colony O O
stimulating O O
factor O O
gene O O
and O O
increased O O
basal O O
level O O
expression O O
of O O
transfected O O
NF-kappa O O
B-regulated O O
promoters O O
. O O

In O O
conclusion O O
, O O
AIDS O O
patients O O
with O O
hypercortisolism O O
and O O
clinical O O
features O O
of O O
peripheral O O
resistance O O
to O O
glucocorticoids O O
are O O
characterized O O
by O O
abnormal O O
glucocorticoid O O
receptors O O
on O O
lymphocytes O O
. O O

If O O
the O O
intergenic O O
distance O O
between O O
two O O
genes O O
in O O
an O O
operon O O
happens O O
to O O
be O O
a O O
multiple O O
of O O
three O O
, O O
they O O
look O O
like O O
a O O
conserved O O
readthrough O O
gene O O
. O O

Electrophoretic O O
mobility O O
supershift O O
assays O O
determine O O
that O O
members O O
of O O
the O O
NF-kappa O O
B/Rel O O
family O O
of O O
transcription O O
factors O O
can O O
bind O O
to O O
this O O
site O O
in O O
vitro O O
and O O
that O O
DNA-binding O O
complexes O O
that O O
contain O O
p50 O O
, O O
p52 O O
, O O
p65 O O
, O O
and O O
cRel O O
correlate O O
with O O
positive O O
regulation O O
whereas O O
the O O
presence O O
of O O
p50 O O
correlates O O
with O O
negative O O
regulation O O
. O O

We O O
thus O O
chose O O
to O O
attach O O
a O O
flag O O
to O O
each O O
motif O O
, O O
indicating O O
whether O O
or O O
not O O
the O O
motif O O
should O O
be O O
orientation-neutral O O
. O O

They O O
also O O
appear O O
to O O
be O O
conserved O O
between O O
species O O
. O O

In O O
contrast O O
, O O
high O O
levels O O
of O O
anti-Ser O O
antibodies O O
were O O
detected O O
at O O
the O O
cell O O
surface O O
of O O
D-mib O O
mutant O O
epithelial O O
cells O O
whereas O O
anti-Dl O O
antibodies O O
were O O
efficiently O O
internalized O O
. O O

Human O O
phagocytes O O
recognize O O
bacterial O O
LPS O O
( O O
endotoxin O O
) O O
through O O
membrane O O
CD14 O O
( O O
mCD14 O O
) O O
, O O
a O O
proinflammatory O O
LPS O O
receptor O O
. O O

VDR O O
is O O
functionally O O
active O O
in O O
ATRA-treated O O
Kasumi-1 O O
cells O O
because O O
it O O
efficiently O O
heterodimerizes O O
with O O
retinoid O O
X O O
receptor O O
, O O
binds O O
to O O
a O O
DR3-type O O
vitamin O O
D-responsive O O
element O O
, O O
and O O
activates O O
the O O
transcription O O
of O O
a O O
vitamin O O
D-responsive O O
element-regulated O O
reporter O O
gene O O
. O O

These O O
results O O
indicate O O
that O O
DNA O O
binding O O
by O O
VDR O O
is O O
necessary O O
but O O
not O B-Negation
sufficient O I-Negation
to O I-Negation
mediate O I-Negation
IL-2 O I-Negation
repression O I-Negation
. O O

The O O
effect O O
of O O
GH O O
appears O O
to O O
occur O O
in O O
an O O
autocrine O O
fashion O O
, O O
since O O
the O O
inhibitory O O
effect O O
on O O
TNF-alpha O O
secretion O O
by O O
constitutive O O
GH O O
production O O
could O O
be O O
abolished O O
in O O
the O O
presence O O
of O O
anti-hGH O O
mAb O O
. O O

Methods O O

BCL-6 O O
expression O O
during O O
B-cell O O
activation O O
. O O

APLs O O
with O O
the O O
PML-RAR O O
alpha O O
or O O
the O O
PLZF-RAR O O
alpha O O
fusion O O
protein O O
are O O
phenotypically O O
indistinguishable O O
except O O
that O O
they O O
differ O O
in O O
their O O
sensitivity O O
to O O
retinoic O O
acid O O
( O O
RA O O
) O O
-induced O O
differentiation O O
: O O
PML-RAR O O
alpha O O
blasts O O
are O O
sensitive O O
to O O
RA O O
and O O
patients O O
enter O O
disease O O
remission O O
after O O
RA O O
treatment O O
, O O
while O O
patients O O
with O O
PLZF-RAR O O
alpha O O
do O O
not B-Negation B-Negation
. O O

The O O
protein O O
was O O
found O O
in O O
untreated O O
cells O O
at O O
low O O
levels O O
, O O
whereas O O
induction O O
of O O
the O O
lytic O O
replication O O
cycle O O
by O O
TPA O O
treatment O O
or O O
by O O
providing O O
the O O
immediate O O
early O O
transactivator O O
BZLF1 O O
in O O
trans O O
resulted O O
in O O
increased O O
expression O O
. O O

The O O
AP-1 O O
binding O O
proteins O O
contained O O
c-Jun O O
, O O
Jun-D O O
, O O
and O O
Fra-1 O O
, O O
but O O
marginal O O
amounts O O
of O O
Jun-B O O
and O O
c-Fos O O
. O O

In O O
1991 O O
, O O
we O O
demonstrated O O
, O O
using O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
that O O
3 O O
different O O
factors O O
( O O
termed O O
B1 O O
, O O
B2 O O
and O O
B3 O O
) O O
with O O
affinity O O
for O O
the O O
KB-enhancer O O
target O O
sequence O O
were O O
specifically O O
detected O O
in O O
nuclear O O
extracts O O
from O O
HIV1-infected O O
monocytes O O
and O O
macrophages O O
. O O

Epstein-Barr O O
virus-transforming O O
protein O O
latent O O
infection O O
membrane O O
protein O O
1 O O
activates O O
transcription O O
factor O O
NF-kappaB O O
through O O
a O O
pathway O O
that O O
includes O O
the O O
NF-kappaB-inducing O O
kinase O O
and O O
the O O
IkappaB O O
kinases O O
IKKalpha O O
and O O
IKKbeta O O
. O O

Methods O O

In O O
this O O
study O O
, O O
we O O
examined O O
the O O
molecular O O
mechanism O O
by O O
which O O
agents O O
that O O
elevate O O
intracellular O O
cAMP O O
inhibit O O
the O O
expression O O
of O O
the O O
tumor O O
necrosis O O
factor O O
alpha O O
( O O
TNFalpha O O
) O O
, O O
tissue O O
factor O O
, O O
endothelial O O
leukocyte O O
adhesion O O
molecule-1 O O
, O O
and O O
vascular O O
cell O O
adhesion O O
molecule-1 O O
genes O O
. O O

Taken O O
together O O
, O O
these O O
data O O
indicated O O
that O O
inhibiting O O
nuclear O O
translocation O O
of O O
c-Rel/p65 O O
heterodimers O O
prevented O O
LPS O O
induction O O
of O O
TF O O
gene O O
transcription O O
in O O
monocytic O O
cells O O
. O O

However O O
, O O
the O O
p65 O O
antisense O O
phosphorothioate O O
oligodeoxynucleotide O O
had O O
no B-Negation B-Negation
significant I-Negation I-Negation
effect I-Negation I-Negation
on I-Negation I-Negation
the I-Negation I-Negation
production I-Negation I-Negation
of I-Negation I-Negation
reactive I-Negation I-Negation
oxygen I-Negation I-Negation
intermediates I-Negation I-Negation
or I-Negation I-Negation
on I-Negation I-Negation
phagocytosis I-Negation I-Negation
by I-Negation I-Negation
these I-Negation I-Negation
cells I-Negation I-Negation
. O O

Kuiper O O
's O O
variation O O
was O O
used O O
to O O
increase O O
sensitivity O O
in O O
the O O
tails O O
of O O
the O O
distribution O O
31 O O
. O O

By O O
deleted O O
and O O
mutated O O
analysis O O
of O O
the O O
IL-8 O O
promoters O O
, O O
the O O
AP-1 O O
and O O
kappa O O
B-like O O
sites O O
were O O
identified O O
as O O
the O O
responsive O O
elements O O
for O O
PMA O O
and O O
ionomycin O O
. O O

The O O
iPfam O O
coverage O O
, O O
shown O O
in O O
blue O O
, O O
is O O
much O O
smaller O O
, O O
ranging O O
from O O
2.92 O O
% O O
in O O
D. O O
melanogaster O O
to O O
19.02 O O
% O O
in O O
H. O O
sapiens O O
. O O

This O O
induction O O
was O O
abolished O O
by O O
PD-135,158 O O
. O O

The O O
PMA O O
induction O O
of O O
c-fos O O
mRNA O O
correlated O O
well O O
with O O
TNF O O
gene O O
induction O O
; O O

We O O
have O O
examined O O
the O O
effect O O
of O O
leukotriene O O
B4 O O
( O O
LTB4 O O
) O O
, O O
a O O
potent O O
lipid O O
proinflammatory O O
mediator O O
, O O
on O O
the O O
expression O O
of O O
the O O
proto-oncogenes O O
c-jun O O
and O O
c-fos O O
. O O

Our O O
data O O
showed O O
that O O
TNF O O
resistance O O
in O O
vitro O O
correlates O O
with O O
the O O
increased O O
level O O
of O O
transcription O O
factor O O
NF-kappaB O O
. O O

Characterization O O
of O O
CD40 O O
signaling O O
determinants O O
regulating O O
nuclear O O
factor-kappa O O
B O O
activation O O
in O O
B O O
lymphocytes O O
. O O

Inhibition O O
of O O
cytokine O O
production O O
by O O
PBMC O O
was O O
observed O O
also O O
when O O
other O O
inducers O O
were O O
used O O
( O O
staphylococci O O
, O O
silica O O
, O O
zymosan O O
) O O
. O O

In O O
addition O O
to O O
its O O
rapid O O
time O O
course O O
the O O
unique O O
characteristics O O
of O O
this O O
new O O
pathway O O
for O O
steroid O O
action O O
include O O
a O O
10000-fold O O
selectivity O O
for O O
aldosterone O O
over O O
cortisol O O
and O O
the O O
ineffectiveness O O
of O O
spironolactones O O
, O O
classical O O
mineralocorticoid O O
antagonists O O
, O O
as O O
antagonists O O
of O O
the O O
response O O
. O O

Proteins O O
of O O
the O O
ATF/CREB O O
class O O
of O O
transcription O O
factors O O
stimulate O O
gene O O
expression O O
of O O
several O O
cell O O
growth-related O O
genes O O
through O O
protein O O
kinase O O
A-related O O
cAMP O O
response O O
elements O O
. O O

Furthermore O O
, O O
p50 O O
protein O O
was O O
detected O O
in O O
the O O
cytoplasm O O
of O O
all O O
lymphocytes O O
. O O

Transcription O O
factor O O
NF-kappaB O O
regulation O O
of O O
renal O O
fibrosis O O
during O O
ureteral O O
obstruction O O
. O O

One O O
of O O
the O O
isolated O O
genes O O
, O O
that O O
for O O
retinaldehyde O O
dehydrogenase O O
2 O O
( O O
RALDH2 O O
) O O
, O O
was O O
regularly O O
expressed O O
in O O
most O O
of O O
the O O
T-ALL O O
cell O O
lines O O
that O O
coexpressed O O
TAL1 O O
and O O
LMO O O
. O O

Taken O O
together O O
, O O
our O O
data O O
indicate O O
that O O
MS-2 O O
mediates O O
induction O O
of O O
the O O
CD11b O O
gene O O
as O O
cells O O
of O O
the O O
monocytic O O
lineage O O
mature O O
. O O

This O O
phenomenon O O
is O O
correlated O O
with O O
inhibition O O
of O O
GATA1 O O
induction O O
in O O
the O O
early O O
stages O O
of O O
erythropoietic O O
differentiation O O
. O O

Both O O
are O O
true O O
for O O
the O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
. O O

The O O
interleukin-2 O O
IL-2 O O
receptor O O
beta-chain O O
( O O
IL-2Rbeta O O
) O O
is O O
an O O
essential O O
component O O
of O O
the O O
receptors O O
for O O
IL-2 O O
and O O
IL-15 O O
. O O

Hence O O
, O O
these O O
cytokines O O
do O O
not O B-Negation
simply O I-Negation
enhance O I-Negation
monocyte O I-Negation
differentiation O I-Negation
, O O
but O O
have O O
complex O O
and O O
slightly O O
divergent O O
effects O O
that O O
impact O O
on O O
HIV O O
replication O O
probably O O
through O O
cell O O
signaling O O
pathways O O
and O O
nuclear O O
factor-kappaB O O
translocation O O
. O O

In O O
contrast O O
, O O
activated O O
T O O
lymphocytes O O
from O O
older O O
individuals O O
show O O
a O O
significant O O
reduction O O
in O O
the O O
induction O O
of O O
NF O O
kappa O O
B O O
in O O
response O O
to O O
the O O
same O O
stimuli O O
. O O

EL-4 O O
cells O O
also O O
produce O O
low O O
levels O O
of O O
IL-5 O O
when O O
stimulated O O
by O O
PMA O O
alone O O
; O O
however O O
, O O
cAMP O O
greatly O O
augments O O
PMA-dependent O O
IL-5 O O
production O O
. O O

The O O
initiating O O
event O O
is O O
still O O
uncertain O O
, O O
but O O
activation O O
of O O
a O O
recently O O
described O O
receptor-associated O O
protein O O
kinase O O
is O O
one O O
of O O
the O O
earliest O O
events O O
detectable O O
( O O
Martin O O
et O O
al. O O
, O O
Eur.J.Immunol.1994.24 O O
: O O
1566 O O
) O O
. O O

THP O O
decreased O O
the O O
concentration O O
of O O
the O O
transcription O O
factors O O
NF-kappa O O
B O O
and O O
AP-1 O O
detected O O
in O O
nuclear O O
extracts O O
of O O
PBMC O O
cultured O O
in O O
the O O
presence O O
or O O
absence B-Negation B-Negation
of I-Negation I-Negation
LPS I-Negation I-Negation
. O O

We O O
now O O
find O O
that O O
LMP1 O O
signaling O O
through O O
TRADD O O
differs O O
from O O
TNFR1 O O
signaling O O
through O O
TRADD O O
. O O

Once O O
we O O
identify O O
the O O
functional O O
domains O O
of O O
the O O
GATA-binding O O
proteins O O
, O O
we O O
hope O O
to O O
learn O O
what O O
proteins O O
GATA-1 O O
binds O O
to O O
in O O
the O O
basic O O
transcription O O
machinery O O
or O O
in O O
chromatin O O
. O O

At O O
least O O
fourteen O O
mammalian O O
caspases O O
have O O
been O O
identified O O
, O O
and O O
they O O
are O O
grouped O O
into O O
two O O
classes O O
on O O
the O O
basis O O
of O O
their O O
proteolytic O O
specificities O O
( O O
reviewed O O
in O O
[ O O
6 O O
] O O
) O O
. O O

We O O
have O O
analyzed O O
the O O
distribution O O
of O O
NF-AT O O
transcriptional O O
activity O O
among O O
T O O
cells O O
undergoing O O
activation O O
by O O
using O O
a O O
construct O O
in O O
which O O
three O O
tandem O O
copies O O
of O O
the O O
NF-AT-binding O O
site O O
directs O O
transcription O O
of O O
the O O
lacZ O O
gene O O
. O O

ΘS O O
The O O
total O O
number O O
of O O
observed O O
interactions O O
in O O
species O O
S O O

We O O
demonstrate O O
the O O
utility O O
of O O
using O O
primary O O
lymphocyte O O
models O O
to O O
study O O
HTLV-I O O
transcription O O
in O O
the O O
context O O
of O O
cell O O
signaling O O
and O O
suggest O O
that O O
activated O O
PBMC O O
maintain O O
elevated O O
levels O O
of O O
P-CREB O O
, O O
which O O
promote O O
basal O O
HTLV-I O O
transcription O O
and O O
enhance O O
viral O O
persistence O O
in O O
vivo O O
. O O

Selective O O
activation O O
and O O
functional O O
significance O O
of O O
p38alpha O O
mitogen-activated O O
protein O O
kinase O O
in O O
lipopolysaccharide-stimulated O O
neutrophils O O
. O O

The O O
purified O O
NF-GM2 O O
consists O O
of O O
50 O O
( O O
p50 O O
) O O
and O O
65 O O
kDa O O
( O O
p65 O O
) O O
polypeptides O O
and O O
has O O
a O O
binding O O
activity O O
specific O O
for O O
both O O
the O O
GM-CSF O O
and O O
immunoglobulin O O
kappa O O
( O O
GGAAAGTCCC O O
) O O
enhancers O O
. O O

The O O
formation O O
of O O
a O O
stable O O
tetrameric O O
DCoH-HNF-1 O O
alpha O O
complex O O
, O O
which O O
required O O
the O O
dimerization O O
domain O O
of O O
HNF-1 O O
alpha O O
, O O
did O O
not B-Negation B-Negation
change I-Negation I-Negation
the I-Negation I-Negation
DNA I-Negation I-Negation
binding I-Negation I-Negation
characteristics I-Negation I-Negation
of I-Negation I-Negation
HNF-1 I-Negation I-Negation
alpha I-Negation I-Negation
, O O
but O O
enhanced O O
its O O
transcriptional O O
activity O O
. O O

Proteins O O
that O O
bind O O
this O O
octamer O O
have O O
been O O
purified O O
, O O
and O O
cDNAs O O
encoding O O
octamer-binding O O
proteins O O
have O O
been O O
cloned O O
. O O

For O O
each O O
family O O
, O O
DNA O O
copies O O
of O O
transposons O O
are O O
aligned O O
to O O
the O O
corresponding O O
consensus O O
sequence O O
. O O

The O O
rapid O O
up-regulation O O
of O O
RP1 O O
mRNA O O
in O O
properly O O
activated O O
T O O
cells O O
suggests O O
that O O
this O O
gene O O
might O O
belong O O
to O O
the O O
immediate/early O O
gene O O
family O O
, O O
which O O
controls O O
the O O
signal O O
transduction O O
cascade O O
downstream O O
of O O
the O O
TCR O O
. O O

Induction O O
of O O
CD8 O O
antigen O O
and O O
suppressor O O
activity O O
by O O
glucocorticoids O O
in O O
a O O
CEM O O
human O O
leukemic O O
cell O O
clone O O
. O O

The O O
zinc O O
finger O O
transcription O O
factor O O
Egr-1 O O
is O O
essential O O
for O O
and O O
restricts O O
differentiation O O
along O O
the O O
macrophage O O
lineage O O
. O O

A O O
carboxy O O
terminal O O
Tax O O
deletion O O
mutant O O
was O O
deficient O O
in O O
transactivation O O
of O O
both O O
the O O
PTHrP O O
and O O
IL2R O O
alpha O O
promoters O O
but O O
not B-Negation B-Negation
the I-Negation I-Negation
HTLV-I I-Negation I-Negation
long I-Negation I-Negation
terminal I-Negation I-Negation
repeat I-Negation I-Negation
( I-Negation I-Negation
LTR I-Negation I-Negation
) I-Negation I-Negation
. O O

Adenosine O O
deaminase O O
( O O
ADA O O
) O O
is O O
an O O
enzyme O O
present O O
in O O
all O O
organisms O O
that O O
catalyzes O O
the O O
irreversible O O
deamination O O
of O O
adenosine O O
and O O
deoxyadenosine O O
to O O
inosine O O
and O O
deoxyinosine O O
. O O

Although O O
both O O
kinases O O
participate O O
in O O
regulating O O
cell O O
growth O O
, O O
there O O
was O O
no B-Negation B-Negation
detectable I-Negation I-Negation
activation I-Negation I-Negation
of I-Negation I-Negation
pp70S6K I-Negation I-Negation
during I-Negation I-Negation
TPA- I-Negation I-Negation
or I-Negation I-Negation
okadaic I-Negation I-Negation
acid-induced I-Negation I-Negation
monocytic I-Negation I-Negation
differentiation I-Negation I-Negation
. O O

To O O
further O O
dissect O O
p95vav O O
involvement O O
in O O
TCR O O
signaling O O
, O O
we O O
analyzed O O
various O O
Jurkat O O
mutants O O
deficient O O
in O O
TCR O O
signaling O O
function O O
or O O
TCR O O
expression O O
and O O
showed O O
that O O
an O O
intact O O
TCR O O
signaling O O
pathway O O
is O O
required O O
for O O
p95vav O O
to O O
function O O
. O O

A O O
similar O O
half-life O O
was O O
determined O O
in O O
IM-9 O O
cells O O
and O O
was O O
also O O
unaffected O O
by O O
steroid O O
treatment O O
. O O

Cellular O O
activation O O
by O O
thrombin O O
led O O
to O O
a O O
marked O O
shift O O
in O O
the O O
proportion O O
of O O
protein O O
from O O
the O O
27-kDa O O
unphosphorylated O O
form O O
to O O
the O O
29-kDa O O
phosphoprotein O O
species O O
. O O

We O O
report O O
here O O
that O O
the O O
HIV-1-encoded O O
Nef O O
protein O O
inhibits O O
the O O
induction O O
of O O
NF-kappa O O
B O O
DNA-binding O O
activity O O
by O O
T-cell O O
mitogens O O
. O O

Sjogren O O
's O O
syndrome O O
( O O
SS O O
) O O
is O O
characterized O O
by O O
lymphocytic O O
infiltrates O O
of O O
exocrine O O
glands O O
, O O
remarkable O O
B O O
cell O O
hyperreactivity O O
and O O
a O O
strong O O
predisposition O O
to O O
B O O
cell O O
neoplasia O O
. O O

Immunoelectron O O
microscopy O O
revealed O O
LANDs O O
to O O
be O O
globular O O
, O O
electron-dense O O
structures O O
morphologically O O
distinct O O
from O O
the O O
annular O O
structures O O
characteristic O O
of O O
PML O O
NBs O O
. O O

Eligible O O
iORFs O O
were O O
then O O
clustered O O
using O O
BLASTCLUST O O
with O O
score O O
density O O
0.5 O O
and O O
minimum O O
length O O
coverage O O
0.6 O O
. O O

The O O
transcription O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
is O O
under O O
the O O
control O O
of O O
cellular O O
proteins O O
that O O
bind O O
to O O
the O O
viral O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
. O O

In O O
addition O O
, O O
we O O
demonstrate O O
that O O
NF-kappaB O O
may O O
be O O
required O O
for O O
human O O
CD34 O O
( O O
+ O O
) O O
bone O O
marrow O O
cell O O
clonogenic O O
function O O
and O O
survival O O
. O O

HIV-1 O O
replication O O
was O O
determined O O
by O O
p24 O O
antigen O O
level O O
. O O

Finally O O
, O O
the O O
ManLAM-mediated O O
activation O O
of O O
HIV-1 O O
LTR O O
transcription O O
was O O
found O O
to O O
be O O
independent O O
of O O
the O O
autocrine O O
or O O
paracrine O O
action O O
of O O
endogenous O O
TNF-alpha O O
. O O

When O O
tested O O
for O O
its O O
ability O O
to O O
block O O
calcineurin-dependent O O
signaling O O
in O O
Jurkat O O
cells O O
, O O
expression O O
of O O
this O O
`` O O
B-subunit O O
knock-out O O
'' O O
( O O
BKO O O
) O O
construct O O
suppressed O O
reporter O O
gene O O
activity O O
driven O O
by O O
NF-AT O O
, O O
the O O
pivotal O O
promoter O O
element O O
for O O
interleukin O O
( O O
IL O O
) O O
-2 O O
gene O O
induction O O
. O O

Several O O
forms O O
of O O
EGR-1 O O
protein O O
are O O
found O O
within O O
the O O
different O O
groups O O
of O O
cell O O
lines O O
, O O
and O O
the O O
binding O O
activity O O
to O O
DNA O O
consensus O O
sequences O O
was O O
investigated O O
. O O

However O O
, O O
under O O
some O O
conditions O O
, O O
engagement O O
of O O
the O O
TCR O O
leads O O
instead O O
to O O
apoptosis O O
. O O

DNase O O
footprinting O O
analysis O O
corroborated O O
the O O
functional O O
data O O
showing O O
that O O
a O O
lymphoid-specific O O
protein O O
binds O O
to O O
the O O
microB O O
DNA O O
motif O O
. O O

We O O
propose O O
a O O
model O O
in O O
which O O
stimulation O O
of O O
monocytes O O
by O O
IFN O O
activates O O
de O O
novo O O
synthesis O O
of O O
an O O
inhibitory O O
factor O O
, O O
possibly O O
one O O
or O O
more O O
members O O
of O O
the O O
SOCS/ O O
SSI/CIS O O
gene O O
family O O
, O O
capable O O
of O O
suppressing O O
activation O O
of O O
STAT6 O O
by O O
IL-4 O O
and O O
IL-13 O O
. O O

Third O O
, O O
TCF-1 O O
bound O O
specifically O O
to O O
a O O
functional O O
T O O
cell-specific O O
element O O
in O O
the O O
T O O
cell O O
receptor O O
alpha O O
( O O
TCR-alpha O O
) O O
enhancer O O
. O O

Finally O O
, O O
a O O
novel O O
positive O O
regulatory O O
element O O
has O O
been O O
mapped O O
in O O
the O O
IL-3 O O
promoter O O
between O O
nucleotide O O
-180 O O
and O O
-210 O O
that O O
leads O O
to O O
increased O O
expression O O
in O O
T O O
cells O O
. O O

The O O
Dot-Gal411C O O
on O O
Chromosome O O
II O O
, O O
which O O
shows O O
weak O O
expression O O
[ O O
24 O O
] O O
, O O
did O O
not B-Negation B-Negation
rescue I-Negation I-Negation
the I-Negation I-Negation
phenotype I-Negation I-Negation
, O O
but O O
a O O
Dot-Gal443A O O
insertion O O
on O O
Chromosome O O
X O O
, O O
which O O
shows O O
stronger O O
expression O O
, O O
rescued O O
approximately O O
half O O
of O O
the O O
mutant O O
animals O O
( O O
Figure O O
2 O O
) O O
. O O

In O O
these O O
transfected O O
CL-01 O O
cells O O
, O O
CD40 O O
: O O
CD40L O O
engagement O O
and O O
exposure O O
to O O
IL-4 O O
synergistically O O
induced O O
gamma O O
3 O O
ECS-dependent O O
luciferase O O
reporter O O
gene O O
activation O O
. O O

The O O
founding O O
member O O
of O O
this O O
subfamily O O
is O O
encoded O O
by O O
insect-derived O O
growth O O
factor O O
( O O
IDGF O O
) O O
[ O O
10 O O
] O O
, O O
and O O
homologs O O
have O O
been O O
described O O
in O O
various O O
organisms O O
[ O O
11–14 O O
] O O
. O O

The O O
D-mib O O
and O O
neur O O
Genes O O
Have O O
Distinct O O
Functions O O
during O O
Wing O O
Development O O

Pervanadate O O
induced O O
activation O O
of O O
the O O
tyrosine O O
kinases O O
lck O O
and O O
fyn O O
( O O
4- O O
and O O
3-fold O O
respectively O O
) O O
and O O
a O O
dramatic O O
increase O O
in O O
tyrosine O O
phosphorylation O O
of O O
cellular O O
proteins O O
, O O
notably O O
phospholipase O O
C O O
gamma O O
1 O O
. O O

these O O
include O O
a O O
serum O O
response O O
element O O
. O O

In O O
these O O
studies O O
, O O
we O O
have O O
identified O O
DNA O O
sequences O O
and O O
specific O O
protein O O
interactions O O
necessary O O
for O O
transcriptional O O
regulation O O
of O O
the O O
human O O
prointerleukin O O
1 O O
beta O O
( O O
proIL-1 O O
beta O O
) O O
gene O O
. O O

Normal O O
human O O
monocytes O O
were O O
isolated O O
, O O
carefully O O
washed O O
, O O
and O O
incubated O O
for O O
36 O O
to O O
48 O O
h O O
in O O
fetal O O
bovine O O
serum-containing O O
medium O O
. O O

These O O
results O O
indicate O O
that O O
the O O
BCL-6 O O
protein O O
can O O
function O O
as O O
a O O
sequence-specific O O
transcriptional O O
repressor O O
and O O
have O O
implications O O
for O O
the O O
role O O
of O O
BCL6 O O
in O O
normal O O
lymphoid O O
development O O
and O O
lymphomagenesis O O
. O O

Supershift O O
analysis O O
revealed O O
these O O
proteins O O
to O O
be O O
Egr-1 O O
and O O
Egr-2 O O
( O O
Krox-20 O O
) O O
; O O
Egr-3 B-Negation B-Negation
was I-Negation I-Negation
not I-Negation I-Negation
detected I-Negation I-Negation
. O O

In O O
these O O
cells O O
, O O
the O O
expression O O
of O O
MHC-class O O
I O O
antigens O O
is O O
repressed O O
and O O
might O O
allow O O
them O O
to O O
escape O O
from O O
recognition O O
by O O
cytotoxic O O
T O O
lymphocytes O O
( O O
CTL O O
) O O
and O O
to O O
develop O O
in O O
tumor O O
. O O

The O O
second O O
enhancer O O
interacts O O
with O O
two O O
nuclear O O
binding O O
proteins O O
( O O
85 O O
kD O O
and O O
27 O O
kD O O
mobility O O
) O O
that O O
appear O O
to O O
be O O
required O O
for O O
optimal O O
enhancer O O
function O O
and O O
activation O O
. O O

In O O
the O O
first O O
male O O
patient O O
, O O
the O O
number O O
of O O
receptors O O
was O O
very O O
low O O
, O O
while O O
the O O
affinity O O
was O O
lower O O
than O O
that O O
in O O
controls O O
. O O

This O O
process O O
requires O O
calcium-dependent O O
dephosphorylation O O
of O O
NFAT O O
caused O O
by O O
the O O
phosphatase O O
calcineurin O O
. O O

Taken O O
together O O
, O O
these O O
results O O
provide O O
a O O
new O O
aspect O O
to O O
our O O
knowledge O O
of O O
monocyte O O
differentiation O O
and O O
provide O O
evidence O O
that O O
human O O
monocytes O O
are O O
flexible O O
in O O
their O O
differentiation O O
potential O O
and O O
are O O
precursors O O
not O O
only O O
of O O
macrophages O O
but O O
also O O
of O O
CD1+relB+DC O O
and O O
TRAP-positive O O
MGC O O
. O O

Surface O O
expression O O
of O O
ICAM-1 O O
, O O
P-selectin O O
, O O
and O O
E-selectin O O
on O O
HUVECs O O
correlated O O
with O O
the O O
phase-1 O O
and O O
-2 O O
neutrophil O O
adhesion O O
responses O O
. O O

An O O
IL-2 O O
response O O
element O O
in O O
the O O
human O O
IL-2 O O
receptor O O
alpha O O
chain O O
promoter O O
is O O
a O O
composite O O
element O O
that O O
binds O O
Stat5 O O
, O O
Elf-1 O O
, O O
HMG-I O O
( O O
Y O O
) O O
and O O
a O O
GATA O O
family O O
protein O O
. O O

The O O
additional O O
function O O
that O O
is O O
required O O
for O O
initiation O O
of O O
the O O
lytic O O
viral O O
life O O
cycle O O
is O O
likely O O
to O O
require O O
phosphorylation O O
of O O
serine O O
186 O O
of O O
the O O
ZEBRA O O
protein O O
, O O
which O O
may O O
influence O O
either O O
DNA O O
recognition O O
or O O
transcriptional O O
activation O O
of O O
lytic O O
viral O O
promoters O O
in O O
a O O
chromatinized O O
viral O O
episome O O
. O O

The O O
promoter O O
of O O
the O O
CD19 O O
gene O O
is O O
a O O
target O O
for O O
the O O
B-cell-specific O O
transcription O O
factor O O
BSAP O O
. O O

The O O
present O O
studies O O
have O O
examined O O
the O O
effects O O
of O O
pokeweed O O
mitogen O O
( O O
PWM O O
) O O
on O O
the O O
induction O O
of O O
early O O
growth O O
response-1 O O
gene O O
( O O
EGR-1 O O
) O O
in O O
normal O O
human O O
B O O
cells O O
. O O

HTLV-I O O
encodes O O
a O O
potent O O
transactivator O O
protein O O
termed O O
Tax O O
that O O
appears O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
process O O
of O O
T-cell O O
immortalization O O
. O O

Sterol O O
dependent O O
LDL-receptor O O
gene O O
transcription O O
in O O
lymphocytes O O
from O O
normal O O
and O O
CML O O
patients O O
. O O

Previous O O
studies O O
have O O
demonstrated O O
that O O
some O O
of O O
the O O
features O O
considered O O
here O O
are O O
indeed O O
independent O O
43 O O
. O O

NF-kappa O O
B O O
is O O
a O O
pleiotropic O O
regulator O O
of O O
a O O
variety O O
of O O
genes O O
implicated O O
in O O
the O O
cellular O O
response O O
to O O
injury O O
. O O

Active O O
suppression O O
of O O
the O O
class O O
II O O
transactivator-encoding O O
AIR-1 O O
locus O O
is O O
responsible O O
for O O
the O O
lack B-Negation O
of I-Negation O
major I-Negation O
histocompatibility I-Negation O
complex I-Negation O
class I-Negation O
II I-Negation O
gene I-Negation O
expression I-Negation O
observed O O
during O O
differentiation O O
from O O
B O O
cells O O
to O O
plasma O O
cells O O
. O O

Thrombopoietin O O
supports O O
in O O
vitro O O
erythroid O O
differentiation O O
via O O
its O O
specific O O
receptor O O
c-Mpl O O
in O O
a O O
human O O
leukemia O O
cell O O
line O O
. O O

NF-kappa O O
B O O
is O O
a O O
rapidly O O
inducible O O
transcriptional O O
activator O O
that O O
responds O O
to O O
a O O
variety O O
of O O
signals O O
and O O
influences O O
the O O
expression O O
of O O
many O O
genes O O
involved O O
in O O
the O O
immune O O
response O O
. O O

Taken O O
together O O
, O O
the O O
results O O
indicate O O
that O O
M-CSF O O
treatment O O
is O O
associated O O
with O O
differential O O
activation O O
of O O
multiple O O
members O O
of O O
the O O
jun/fos O O
family O O
and O O
that O O
expression O O
of O O
these O O
genes O O
could O O
contribute O O
to O O
nuclear O O
signaling O O
mechanisms O O
that O O
regulate O O
a O O
specific O O
program O O
of O O
monocyte O O
differentiation O O
. O O

Homozygous O O
pupae O O
usually O O
die O O
soon O O
after O O
pupariation O O
; O O
in O O
some O O
cases O O
they O O
develop O O
normal O O
head O O
and O O
thorax O O
imaginal O O
structures O O
; O O
however O O
, O O
abdominal O O
parts O O
usually O O
do O O
not B-Negation B-Negation
develop I-Negation I-Negation
. O O

Lastly O O
, O O
we O O
demonstrated O O
that O O
p38 O O
kinase O O
activity O O
played O O
a O O
central O O
role O O
in O O
IL-1beta O O
production O O
and O O
that O O
it O O
was O O
rapidly O O
up-regulated O O
following O O
infection O O
. O O

Here O O
we O O
have O O
therefore O O
examined O O
the O O
effect O O
of O O
the O O
phorbol O O
ester O O
PMA O O
( O O
phorbol O O
12-myristate O O
13-acetate O O
) O O
which O O
stimulates O O
PKC O O
and O O
a O O
combination O O
of O O
the O O
adenosine O O
receptor O O
agonist O O
NECA O O
( O O
5'- O O
( O O
N-ethyl O O
) O O
-carboxamido O O
adenosine O O
) O O
and O O
forskolin O O
to O O
raise O O
cAMP O O
, O O
on O O
the O O
levels O O
of O O
c-Fos O O
and O O
Jun O O
and O O
on O O
the O O
binding O O
and O O
transcriptional O O
activity O O
of O O
the O O
transcription O O
factor O O
, O O
activator O O
protein-1 O O
( O O
AP-1 O O
) O O
. O O

Dibutyryl O O
cAMP O O
also O O
increased O O
c-fos O O
mRNA O O
and O O
protein O O
, O O
and O O
levels O O
remained O O
elevated O O
even O O
after O O
12 O O
hr O O
of O O
treatment O O
. O O

YFP O O
: O O
:D-mib O O
co-localized O O
with O O
Dl O O
and O O
Ser O O
at O O
the O O
apical O O
cortex O O
of O O
cells O O
expressing O O
low O O
levels O O
of O O
YFP O O
: O O
:D-mib O O
. O O

True O O
positive O O
rate O O
versus O O
false O O
positive O O
rate O O
for O O
different O O
estimated O O
posterior O O
odds O O
ratios O O
. O O

One O O
of O O
these O O
enhancers O O
is O O
, O O
in O O
part O O
, O O
identical O O
to O O
the O O
HIV-1 O O
enhancer O O
. O O

In O O
human O O
monocytes O O
, O O
interleukin O O
1beta O O
protein O O
production O O
and O O
steady O O
state O O
mRNA O O
levels O O
are O O
increased O O
in O O
response O O
to O O
lipopolysaccharide O O
, O O
predominantly O O
as O O
a O O
result O O
of O O
increased O O
transcription O O
of O O
the O O
interleukin O O
1beta O O
gene O O
. O O

The O O
work O O
reviewed O O
in O O
this O O
article O O
separates O O
T O O
cell O O
development O O
into O O
four O O
phases O O
. O O

Our O O
results O O
demonstrate O O
that O O
1.3E2 O O
is O O
a O O
cellular O O
transduction O O
mutant O O
exhibiting O O
a O O
defect O O
in O O
a O O
step O O
that O O
is O O
required O O
by O O
several O O
different O O
stimuli O O
to O O
activate O O
NF-kappaB O O
. O O

Clinicians O O
are O O
only O O
just O O
beginning O O
to O O
recognize O O
subclinical O O
markers O O
of O O
response O O
, O O
and O O
it O O
may O O
soon O O
be O O
possible O O
to O O
predict O O
response O O
on O O
the O O
basis O O
of O O
genetic O O
composition O O
. O O

Western O O
blotting O O
analysis O O
with O O
anti-I O O
kappa O O
B-alpha O O
antibody O O
indicated O O
that O O
E3330 O O
inhibited O O
degradation O O
of O O
I O O
kappa O O
B-alpha O O
, O O
which O O
is O O
an O O
inhibitory O O
protein O O
of O O
NF-kappa O O
B O O
, O O
in O O
LPS-stimulated O O
monocytes O O
. O O

AP-1 O O
, O O
the O O
polypeptide O O
product O O
of O O
c-jun O O
, O O
recognizes O O
and O O
binds O O
to O O
specific O O
DNA O O
sequences O O
and O O
stimulates O O
transcription O O
of O O
genes O O
responsive O O
to O O
certain O O
growth O O
factors O O
and O O
phorbol O O
esters O O
such O O
as O O
12-O-tetradecanoylphorbol-13-acetate O O
( O O
TPA O O
) O O
. O O

In O O
addition O O
, O O
the O O
presence O O
of O O
an O O
alternative O O
promoter O O
site O O
, O O
which O O
exists O O
within O O
the O O
intron O O
downstream O O
of O O
the O O
exon O O
1 O O
, O O
became O O
evident O O
. O O

Here O O
, O O
we O O
compare O O
three O O
human O O
interaction O O
prediction O O
datasets O O
: O O
the O O
Rhodes O O
probabilistic O O
dataset O O
46 O O
, O O
the O O
Lehner O O
orthology-derived O O
dataset O O
36 O O
and O O
the O O
most O O
accurate O O
of O O
our O O
predictors O O
( O O
the O O
LR400 O O
subset O O
of O O
the O O
predictor O O
considering O O
the O O
Expression O O
, O O
Orthology O O
, O O
Combined O O
and O O
Transitive O O
modules O O
) O O
. O O

Protein O O
intrinsic O O
disorder O O
was O O
predicted O O
for O O
all O O
proteins O O
considered O O
by O O
using O O
the O O
VSL2B O O
predictor O O
78 O O
. O O

Exons O O
2 O O
to O O
8 O O
of O O
the O O
androgen O O
receptor O O
gene O O
were O O
analyzed O O
using O O
a O O
combination O O
of O O
single O O
strand O O
conformation O O
polymorphism O O
analysis O O
and O O
direct O O
DNA O O
sequencing O O
. O O

Since O O
the O O
human O O
genomic O O
sterol O O
regulatory O O
element O O
( O O
SRE O O
) O O
has O O
been O O
shown O O
to O O
regulate O O
various O O
key O O
genes O O
involved O O
in O O
this O O
phenomenon O O
, O O
the O O
present O O
study O O
revealed O O
the O O
existence O O
of O O
a O O
unique O O
47 O O
kDa O O
protein O O
factor O O
having O O
affinity O O
for O O
this O O
SRE O O
sequence O O
in O O
lymphocytes O O
from O O
normal O O
subjects O O
, O O
as O O
well O O
as O O
its O O
absence O O
in O O
lymphocytes O O
from O O
untreated O O
CML O O
patients O O
. O O

For O O
example O O
, O O
once O O
the O O
complex O O
is O O
formed O O
, O O
removal O O
( O O
for O O
example O O
, O O
by O O
high O O
ionic O O
strength O O
) O O
of O O
a O O
single O O
component O O
brought O O
in O O
relatively O O
early O O
( O O
such O O
as O O
MLE O O
) O O
might O O
be O O
possible O O
without B-Negation B-Negation
affecting I-Negation I-Negation
the I-Negation I-Negation
rest I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
complex I-Negation I-Negation
. O O

The O O
distribution O O
of O O
this O O
integral O O
membrane O O
protein O O
is O O
restricted O O
to O O
certain O O
tissues O O
where O O
its O O
level O O
of O O
expression O O
is O O
modulated O O
by O O
multiple O O
exogenous O O
stimuli O O
. O O

Two O O
distinct O O
elements O O
have O O
been O O
implicated O O
in O O
function O O
of O O
the O O
HTLV-I O O
enhancer O O
. O O

Depletion O O
of O O
intracellular O O
TRAF2 O O
and O O
its O O
coassociated O O
proteins O O
also O O
increased O O
the O O
sensitivity O O
of O O
the O O
cell O O
to O O
undergoing O O
apoptosis O O
during O O
activation O O
of O O
death-inducing O O
receptors O O
such O O
as O O
TNFR1 O O
. O O

Human O O
class O O
II O O
MHC O O
Ag O O
are O O
a O O
family O O
of O O
cell O O
surface O O
glycoproteins O O
. O O

We O O
previously O O
demonstrated O O
that O O
G-CSF O O
activated O O
a O O
distinct O O
Stat3-like O O
protein O O
in O O
immature O O
and O O
mature O O
normal O O
myeloid O O
cells O O
, O O
StatG O O
. O O

Tyrosine O O
phosphorylation O O
of O O
this O O
protein O O
could O O
also O O
be O O
induced O O
in O O
Balb/c3T3 O O
cells O O
using O O
a O O
supernatant O O
from O O
the O O
B O O
line O O
, O O
which O O
was O O
associated O O
with O O
induction O O
of O O
cell O O
proliferation O O
. O O

The O O
promoter O O
region O O
between O O
-173 O O
and O O
-60 O O
contained O O
the O O
strongest O O
activating O O
elements O O
. O O

Thrombin O O
receptor O O
activation O O
peptide O O
, O O
a O O
14-amino-acid O O
peptide O O
representing O O
the O O
new O O
NH2 O O
terminus O O
of O O
proteolytically O O
activated O O
receptor-1 O O
, O O
mimicked O O
thrombin O O
's O O
action O O
in O O
inducing O O
ICAM-1 O O
expression O O
. O O

The O O
notion O O
that O O
Dl O O
and O O
Ser O O
have O O
similar O O
signaling O O
properties O O
has O O
, O O
however O O
, O O
recently O O
been O O
challenged O O
by O O
the O O
observation O O
that O O
human O O
homologs O O
of O O
Dl O O
and O O
Ser O O
have O O
distinct O O
instructive O O
signaling O O
activity O O
[ O O
15 O O
] O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
whether O O
activities O O
of O O
these O O
phosphatases O O
are O O
necessary O O
for O O
the O O
expression O O
of O O
the O O
IL-2 O O
gene O O
. O O

On O O
first O O
encounter O O
with O O
antigen O O
, O O
naive O O
CD4+ O O
T O O
helper O O
( O O
Th O O
) O O
cells O O
differentiate O O
into O O
cytokine-producing O O
effector O O
cells O O
. O O

At O O
10 O O
microM O O
, O O
both O O
compounds O O
inhibited O O
IL-2 O O
mRNA O O
and O O
protein O O
levels O O
in O O
the O O
NFAT-1-linked O O
lac-Z O O
transfectants O O
, O O
and O O
in O O
human O O
lymphocytes O O
. O O

However O O
, O O
the O O
p65 O O
subunit O O
was O O
COOH-terminally O O
truncated O O
, O O
as O O
shown O O
by O O
immunoprecipitation O O
. O O

However O O
, O O
Nef O O
does O O
not B-Negation B-Negation
affect I-Negation I-Negation
the I-Negation I-Negation
DNA-binding I-Negation I-Negation
activity I-Negation I-Negation
of I-Negation I-Negation
other I-Negation I-Negation
transcription I-Negation I-Negation
factors I-Negation I-Negation
implicated I-Negation I-Negation
in I-Negation I-Negation
HIV-1 I-Negation I-Negation
regulation I-Negation I-Negation
, I-Negation I-Negation
including I-Negation I-Negation
SP-1 I-Negation I-Negation
, I-Negation I-Negation
USF I-Negation I-Negation
, I-Negation I-Negation
URS I-Negation I-Negation
, I-Negation I-Negation
and I-Negation I-Negation
NF-AT I-Negation I-Negation
. O O

Therefore O O
, O O
we O O
conclude O O
that O O
IL-4 O O
and O O
IL-10 O O
inhibit O O
IL-6 O O
production O O
by O O
different O O
mechanisms O O
in O O
human O O
monocytic O O
cell O O
lines O O
. O O

Thus O O
these O O
data O O
suggest O O
that O O
the O O
phorbol O O
myristate-induced O O
signal O O
( O O
prolonged O O
protein O O
kinase O O
C O O
activation O O
? O O
) O O
can O O
not O O
be O O
inhibited O O
by O O
prior O O
incubation O O
with O O
dexamethasone O O
and O O
it O O
also O O
protects O O
the O O
induced O O
mRNA O O
for O O
the O O
degradative O O
action O O
of O O
dexamethasone O O
. O O

Bacterial O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-mediated O O
immune O O
responses O O
, O O
including O O
activation O O
of O O
monocytes O O
, O O
macrophages O O
, O O
and O O
endothelial O O
cells O O
, O O
play O O
an O O
important O O
role O O
in O O
the O O
pathogenesis O O
of O O
Gram-negative O O
bacteria-induced O O
sepsis O O
syndrome O O
. O O

2. O O
Danazol O O
did O O
not B-Negation B-Negation
alter I-Negation I-Negation
the I-Negation I-Negation
degradation I-Negation I-Negation
rate I-Negation I-Negation
of I-Negation I-Negation
ER I-Negation I-Negation
mRNA I-Negation I-Negation
in I-Negation I-Negation
monocytes I-Negation I-Negation
. O O

Neur O O
and O O
Mib O O
proteins O O
completely O O
differ O O
in O O
primary O O
structure O O
. O O

Key O O
components O O
of O O
the O O
programmed O O
cell O O
death O O
pathway O O
are O O
conserved O O
between O O
Caenorhabditis O O
elegans O O
, O O
Drosophila O O
melanogaster O O
and O O
humans O O
. O O

The O O
rapid O O
progress O O
of O O
the O O
various O O
genome O O
sequencing O O
projects O O
has O O
greatly O O
accelerated O O
the O O
discovery O O
of O O
homologs O O
for O O
key O O
components O O
of O O
the O O
cell O O
death O O
pathway O O
as O O
well O O
as O O
for O O
its O O
regulators O O
. O O

The O O
results O O
( O O
see O O
Figure O O
2 O O
and O O
Table O O
1 O O
) O O
clearly O O
demonstrate O O
that O O
expression O O
of O O
ADGF-A O O
in O O
the O O
lymph O O
glands O O
( O O
driven O O
by O O
Cg-Gal4 O O
, O O
e33C-Gal4 O O
, O O
or O O
c564-Gal4 O O
) O O
, O O
but O O
not B-Negation B-Negation
in I-Negation I-Negation
any I-Negation I-Negation
other I-Negation I-Negation
tissue I-Negation I-Negation
examined I-Negation I-Negation
, O O
is O O
necessary O O
and O O
sufficient O O
to O O
fully O O
rescue O O
the O O
adgf-a O O
lethality O O
. O O

These O O
genes O O
may O O
then O O
play O O
a O O
role O O
in O O
altering O O
the O O
physiologic O O
status O O
of O O
the O O
cells O O
in O O
response O O
to O O
CSF O O
. O O

We O O
show O O
that O O
in O O
S194 O O
plasma O O
cells O O
the O O
activity O O
of O O
each O O
element O O
correlates O O
well O O
with O O
the O O
relative O O
affinity O O
of O O
B-cell-derived O O
NF-kappa O O
B O O
for O O
that O O
element O O
. O O

These O O
data O O
suggest O O
that O O
the O O
paternal O O
X O O
chromosome O O
carries O O
the O O
de O O
novo O O
alpha-galactosidase O O
A O O
mutation O O
and O O
that O O
uneven O O
X O O
inactivation O O
is O O
the O O
underlying O O
mechanism O O
for O O
disease O O
expression O O
in O O
this O O
novel O O
female O O
MZ O O
twin O O
pair O O
. O O

Abnormalities O O
of O O
p16 O O
, O O
p15 O O
and O O
CDK4 O O
genes O O
in O O
recurrent O O
malignant O O
astrocytomas O O
. O O

In O O
transient O O
expression O O
and O O
in O O
vitro O O
degradation O O
experiments O O
, O O
the O O
stability O O
of O O
c-Fos O O
was O O
decreased O O
when O O
the O O
protein O O
was O O
dimerized O O
with O O
phosphorylated O O
c-Jun O O
. O O

[ O O
The O O
trend O O
of O O
molecular O O
biology O O
study O O
on O O
eosinophils O O
] O O

Most O O
were O O
located O O
in O O
the O O
carboxyterminal O O
half O O
of O O
the O O
HBxAg O O
protein O O
. O O

Higher O O
concentrations O O
of O O
A O O
beta O O
( O O
25-35 O O
) O O
were O O
effective O O
by O O
themselves O O
in O O
inducing O O
NF-kappa O O
B O O
activation O O
, O O
both O O
in O O
the O O
N9 O O
microglial O O
cell O O
line O O
and O O
in O O
rat O O
primary O O
microglia O O
, O O
as O O
well O O
as O O
in O O
human O O
monocytes O O
. O O

The O O
autologous O O
DE O O
LCL O O
containing O O
a O O
transduced O O
pml/RAR O O
alpha O O
fusion O O
gene O O
and O O
expressing O O
a O O
bcr1 O O
type O O
of O O
the O O
pml/RAR O O
alpha O O
hybrid O O
protein O O
induced O O
the O O
proliferation O O
of O O
DE O O
anti-BCR1/25 O O
T O O
cell O O
clones O O
. O O

Here O O
we O O
report O O
that O O
the O O
tissue O O
specificity O O
of O O
this O O
promoter O O
is O O
also O O
mediated O O
by O O
sequences O O
in O O
a O O
region O O
II O O
( O O
bp O O
-88 O O
to O O
- O O
59 O O
) O O
, O O
which O O
lies O O
10 O O
bp O O
upstream O O
from O O
the O O
PU.1-binding O O
site O O
. O O

Tip O O
of O O
herpesvirus O O
saimiri O O
associates O O
with O O
Lck O O
and O O
down-regulates O O
Lck-mediated O O
activation O O
. O O

The O O
Epstein-Barr O O
virus O O
nuclear O O
antigen O O
2 O O
interacts O O
with O O
an O O
EBNA2 O O
responsive O O
cis-element O O
of O O
the O O
terminal O O
protein O O
1 O O
gene O O
promoter O O
. O O

By O O
enumerating O O
ORFs O O
that O O
have O O
an O O
inframe O O
stop O O
codon O O
from O O
genomes O O
and O O
examining O O
their O O
evolutionary O O
conservation O O
, O O
candidate O O
proteins O O
can O O
be O O
predicted O O
. O O

In O O
addition O O
, O O
the O O
SIV O O
TATA O O
box O O
was O O
shown O O
to O O
be O O
stronger O O
than O O
that O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
. O O

Treatment O O
of O O
endothelial O O
cells O O
with O O
LPS O O
( O O
1 O O
microgram/ml O O
) O O
stimulated O O
transcription O O
of O O
ELAM-1 O O
, O O
as O O
shown O O
by O O
Northern O O
blot O O
analysis O O
, O O
and O O
expression O O
of O O
membrane-associated O O
ELAM-1 O O
and O O
ICAM-1 O O
, O O
as O O
shown O O
by O O
quantitative O O
immunofluorescence O O
( O O
both O O
P O O
< O O
0.001 O O
, O O
n O O
= O O
9 O O
) O O
. O O

We O O
have O O
found O O
that O O
a O O
region O O
in O O
both O O
genes O O
( O O
-276 O O
to O O
-250 O O
for O O
IL-2-R O O
alpha O O
and O O
-203 O O
to O O
-183 O O
for O O
IL-2 O O
) O O
, O O
which O O
corresponds O O
to O O
a O O
kappa O O
B O O
enhancer O O
element O O
, O O
is O O
specifically O O
protected O O
by O O
nuclear O O
proteins O O
from O O
IARC O O
301 O O
. O O

Their O O
products O O
are O O
mitogenic O O
on O O
Drosophila O O
cells O O
, O O
and O O
at O O
least O O
two O O
of O O
them O O
( O O
ADGF-A O O
and O O
ADGF-D O O
) O O
exhibit O O
strong O O
ADA O O
activity O O
, O O
which O O
is O O
necessary O O
for O O
their O O
mitogenic O O
function O O
. O O

In O O
addition O O
, O O
no B-Negation B-Negation
CIITA I-Negation I-Negation
protein I-Negation I-Negation
is I-Negation I-Negation
detectable I-Negation I-Negation
in I-Negation I-Negation
clone I-Negation I-Negation
13 I-Negation I-Negation
nuclear I-Negation I-Negation
extracts I-Negation I-Negation
. O O

The O O
eukaryotic O O
transcription O O
factor O O
nuclear O O
factor-kappa O O
B O O
( O O
NF-kappa O O
B O O
) O O
participates O O
in O O
many O O
parts O O
of O O
the O O
genetic O O
program O O
mediating O O
T O O
lymphocyte O O
activation O O
and O O
growth O O
. O O

This O O
ORF O O
does O O
not B-Negation B-Negation
contain I-Negation I-Negation
the I-Negation I-Negation
characteristic I-Negation I-Negation
DNA-binding I-Negation I-Negation
domain I-Negation I-Negation
found I-Negation I-Negation
in I-Negation I-Negation
members I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
forkhead I-Negation I-Negation
protein I-Negation I-Negation
family I-Negation I-Negation
. O O

In O O
contrast O O
, O O
we O O
work O O
directly O O
on O O
the O O
protein O O
sequences O O
and O O
so O O
related O O
the O O
gene O O
annotations O O
to O O
our O O
protein O O
identifiers O O
by O O
extracting O O
Entrez O O
Gene O O
IDs O O
corresponding O O
to O O
the O O
IPI O O
protein O O
entries O O
from O O
the O O
IPI O O
cross-reference O O
files O O
( O O
for O O
the O O
IPI O O
release O O
3.24 O O
) O O
64 O O
. O O

Moreover O O
, O O
the O O
effects O O
of O O
IFN-gamma O O
and O O
LPS O O
could O O
be O O
reproduced O O
by O O
priming O O
, O O
whereas O O
IFN-beta O O
and O O
IL-4 O O
were O O
required O O
simultaneously O O
with O O
GC O O
. O O

They O O
also O O
showed O O
that O O
the O O
interaction O O
of O O
hemocytes O O
with O O
the O O
fat O O
body O O
is O O
mediated O O
by O O
a O O
120-kDa O O
membrane O O
protein O O
localized O O
specifically O O
on O O
pupal O O
hemocytes O O
[ O O
40 O O
] O O
. O O

Protein O O
phosphorylation O O
has O O
an O O
important O O
role O O
in O O
the O O
regulation O O
of O O
these O O
two O O
factors O O
: O O
( O O
1 O O
) O O
it O O
induces O O
the O O
transactivating O O
capacity O O
of O O
the O O
AP-1 O O
protein O O
c-Jun O O
; O O
and O O
( O O
2 O O
) O O
it O O
is O O
involved O O
in O O
the O O
release O O
of O O
the O O
cytoplasmic O O
inhibitor O O
, O O
I O O
kappa O O
B O O
, O O
from O O
NF-kappa O O
B O O
, O O
allowing O O
translocation O O
of O O
the O O
latter O O
into O O
the O O
nucleus O O
. O O

Acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
is O O
a O O
specific O O
type O O
of O O
acute O O
myeloid O O
leukemia O O
characterized O O
by O O
the O O
morphology O O
of O O
the O O
blast O O
cells O O
, O O
a O O
specific O O
t O O
( O O
15 O O
; O O
17 O O
) O O
translocation O O
, O O
and O O
risks O O
of O O
definite O O
coagulopathy O O
. O O

Species O O
distribution O O
of O O
iPfam O O
domain O O
pairs O O
. O O

Treatment O O
of O O
HL-60 O O
eosinophilic O O
sublines O O
with O O
either O O
interleukin-5 O O
or O O
butyric O O
acid O O
increased O O
the O O
expression O O
of O O
GATA-1 O O
mRNA O O
concomitant O O
with O O
the O O
expression O O
of O O
eosinophil-specific O O
genes O O
, O O
whereas O O
levels O O
of O O
GATA-2 O O
mRNA O O
remained O O
relatively O O
constant O O
. O O

Oct-1 O O
and O O
Oct-2 O O
can O O
bind O O
specifically O O
to O O
a O O
site O O
at O O
base O O
pair O O
-55 O O
in O O
vitro O O
, O O
and O O
this O O
site O O
is O O
specifically O O
protected O O
in O O
B O O
cells O O
in O O
vivo O O
. O O

The O O
effect O O
of O O
Tax O O
on O O
VCAM-1 O O
gene O O
transcription O O
was O O
next O O
confirmed O O
in O O
JPX-9 O O
cells O O
, O O
a O O
subclone O O
of O O
Jurkat O O
cells O O
, O O
carrying O O
the O O
tax O O
sequences O O
under O O
the O O
control O O
of O O
an O O
inducible O O
promoter O O
. O O

It O O
has O O
been O O
proposed O O
that O O
their O O
expression O O
is O O
controlled O O
by O O
the O O
non-clonal O O
, O O
or O O
innate O O
, O O
component O O
of O O
immunity O O
that O O
preceded O O
in O O
evolution O O
the O O
development O O
of O O
an O O
adaptive O O
immune O O
system O O
in O O
vertebrates O O
. O O

Different O O
amounts O O
of O O
the O O
various O O
isoforms O O
are O O
present O O
within O O
the O O
same O O
B-cell O O
regardless O O
of O O
the O O
developmental O O
stage O O
of O O
B-cell O O
differentiation O O
and O O
at O O
least O O
some O O
of O O
the O O
isoforms O O
are O O
conserved O O
between O O
mouse O O
and O O
humans O O
. O O

These O O
results O O
show O O
that O O
PEBP2betaMYH11 O O
can O O
impair O O
neutrophil O O
development O O
and O O
provide O O
evidence O O
that O O
alterations O O
of O O
Pebp2 O O
can O O
contribute O O
to O O
the O O
genesis O O
of O O
myelodysplasia O O
. O O

Presence O O
and O O
absence B-Negation O
of I-Negation O
corresponding I-Negation O
residues I-Negation O
in I-Negation O
the I-Negation O
Transib I-Negation O
TPases I-Negation O
are O O
indicated O O
by O O
+ O O
and O O
- O O
, O O
respectively O O
. O O

In O O
parallel O O
with O O
the O O
decreased O O
cytokine O O
generation O O
, O O
each O O
cytokine O O
mRNA O O
was O O
less O O
expressed O O
in O O
the O O
presence O O
of O O
10 O O
( O O
-5 O O
) O O
M O O
Azeptin O O
. O O

For O O
example O O
, O O
`` O O
GSU2293 O O
+ O O
downstream O O
'' O O
means O O
that O O
the O O
iORF O O
consists O O
of O O
the O O
gene O O
GSU2293 O O
and O O
its O O
downstream O O
sequence O O
. O O

Both O O
the O O
5 O O
' O O
and O O
3 O O
' O O
untranslated O O
regions O O
of O O
the O O
TNF O O
gene O O
were O O
required O O
to O O
elicit O O
maximal O O
translational O O
suppression O O
by O O
CNI-1493 O O
. O O

These O O
data O O
collectively O O
suggest O O
that O O
PAO O O
interferes O O
with O O
the O O
phosphorylation O O
and O O
the O O
regulated O O
degradation O O
of O O
IkappaB-alpha O O
, O O
induced O O
by O O
TNF O O
, O O
without O B-Negation
affecting O I-Negation
the O I-Negation
chymotryptic O I-Negation
activity O I-Negation
of O I-Negation
the O I-Negation
proteasome O I-Negation
, O O
independent O O
of O O
age O O
. O O

OBJECTIVE O O
: O O
To O O
create O O
monoclonal O O
anti-endothelial O O
cell O O
antibodies O O
( O O
mAECA O O
) O O
from O O
a O O
patient O O
with O O
Takayasu O O
arteritis O O
to O O
evaluate O O
their O O
ability O O
to O O
activate O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
( O O
HUVEC O O
) O O
, O O
and O O
to O O
characterize O O
the O O
mechanism O O
of O O
EC O O
activation O O
. O O

Biphasic O O
control O O
of O O
nuclear O O
factor-kappa O O
B O O
activation O O
by O O
the O O
T O O
cell O O
receptor O O
complex O O
: O O
role O O
of O O
tumor O O
necrosis O O
factor O O
alpha O O
. O O

No B-Negation B-Negation
such I-Negation I-Negation
increase I-Negation I-Negation
was I-Negation I-Negation
observed I-Negation I-Negation
in I-Negation I-Negation
control I-Negation I-Negation
U937 I-Negation I-Negation
cells I-Negation I-Negation
. O O

At O O
least O O
four O O
different O O
specific O O
NF-kappaB O O
complexes O O
are O O
present O O
in O O
the O O
nucleus O O
of O O
these O O
cells O O
. O O

Cross-linking O O
CD40 O O
on O O
B O O
cells O O
can O O
lead O O
to O O
homotypic O O
cell O O
adhesion O O
, O O
IL-6 O O
production O O
, O O
and O O
, O O
in O O
combination O O
with O O
cytokines O O
, O O
to O O
Ig O O
isotype O O
switching O O
. O O

A O O
cDNA O O
library O O
was O O
prepared O O
from O O
peripheral O O
blood O O
lymphocytes O O
of O O
an O O
autoimmune O O
patient O O
with O O
primary O O
Sjogrens O O
' O O
syndrome O O
. O O

trans-activation O O
of O O
the O O
HIV O O
promoter O O
by O O
a O O
cDNA O O
and O O
its O O
genomic O O
clones O O
of O O
human O O
herpesvirus-6 O O
. O O

Experiments O O
have O O
been O O
conducted O O
to O O
identify O O
second O O
messengers O O
involved O O
in O O
this O O
PGE2-dependent O O
up-regulating O O
effect O O
on O O
the O O
regulatory O O
element O O
of O O
HIV-1 O O
. O O

The O O
CMAT O O
protein O O
appears O O
to O O
be O O
a O O
novel O O
inducible O O
protein O O
involved O O
in O O
the O O
regulation O O
of O O
c-myb O O
expression O O
during O O
T-cell O O
activation O O
. O O

However O O
, O O
the B-Negation B-Negation
nature I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
subunit I-Negation I-Negation
involved I-Negation I-Negation
in I-Negation I-Negation
this I-Negation I-Negation
mechanism I-Negation I-Negation
has I-Negation I-Negation
not I-Negation I-Negation
been I-Negation I-Negation
defined I-Negation I-Negation
. O O

NM23 O O
was O O
identified O O
in O O
a O O
system O O
of O O
murine O O
melanoma O O
cell O O
lines O O
, O O
in O O
which O O
an O O
inverse O O
relationship O O
was O O
found O O
between O O
NM23 O O
expression O O
and O O
metastatic O O
ability O O
. O O

In O O
addition O O
, O O
mild O O
detergent O O
treatment O O
of O O
cell O O
extracts O O
indicated O O
that O O
a O O
substantial O O
amount O O
of O O
cytoplasmic O O
NF-kappaB O O
is O O
complexed O O
with O O
IkappaB O O
alpha O O
or O O
some O O
other O O
inhibitory O O
factor O O
. O O

Immunosuppression O O
by O O
glucocorticoids O O
: O O
inhibition O O
of O O
NF-kappa O O
B O O
activity O O
through O O
induction O O
of O O
I O O
kappa O O
B O O
synthesis O O
[ O O
see O O
comments O O
] O O

Although O O
the O O
transgenic O O
mice O O
had O O
normal O O
numbers O O
of O O
circulating O O
neutrophils O O
, O O
their O O
bone O O
marrow O O
contained O O
increased O O
numbers O O
of O O
immature O O
neutrophilic O O
cells O O
, O O
which O O
exhibited O O
abnormal O O
characteristics O O
. O O

We O O
have O O
previously O O
shown O O
that O O
a O O
DNA-binding O O
factor O O
specific O O
to O O
adult O O
hematopoietic O O
cells O O
( O O
polypryrimidine-binding O O
factor O O
, O O
PYBF O O
) O O
binds O O
to O O
a O O
pyrimidine-rich O O
region O O
1 O O
kb O O
upstream O O
from O O
the O O
human O O
delta-globin-encoding O O
gene O O
( O O
HBD O O
) O O
. O O

Mutations O O
at O O
the O O
B2 O O
site O O
abolish O O
this O O
transcriptional O O
activation O O
. O O

There O O
was O O
considerable O O
excitement O O
in O O
the O O
field O O
when O O
potential O O
mammalian O O
and O O
Drosophila O O
homologs O O
for O O
ced-3 O O
, O O
ced-4 O O
, O O
ced-9 O O
, O O
and O O
egl-1 O O
were O O
discovered O O
. O O

Each O O
site O O
is O O
functionally O O
important O O
and O O
contributes O O
independently O O
to O O
transcription O O
of O O
the O O
NF-IL6 O O
gene O O
in O O
U937 O O
cells O O
. O O

However O O
, O O
all O O
these O O
cell O O
types O O
still O O
gave O O
strong O O
Ca2+ O O
and O O
tyrosine O O
phosphorylation O O
responses O O
to O O
H2O2 O O
. O O

Enhancer O O
replacement O O
is O O
therefore O O
an O O
effective O O
strategy O O
to O O
target O O
expression O O
of O O
a O O
retroviral O O
transgene O O
to O O
a O O
specific O O
progeny O O
of O O
transduced O O
hematopoietic O O
stem O O
cells O O
. O O

Interaction O O
of O O
nuclear O O
extracts O O
from O O
various O O
cell O O
lines O O
and O O
tissue O O
with O O
the O O
MNP O O
site O O
leads O O
to O O
the O O
formation O O
of O O
fast-migrating O O
protein-DNA O O
complexes O O
with O O
similar O O
but O O
distinct O O
electrophoretic O O
mobilities O O
. O O

Although O O
MKK3 O O
, O O
MKK4 O O
, O O
and O O
MKK6 O O
all O O
activated O O
p38 O O
MAPk O O
in O O
experimental O O
models O O
, O O
only O O
MKK3 O O
was O O
found O O
to O O
activate O O
recombinant O O
p38 O O
MAPk O O
in O O
LPS-treated O O
neutrophils O O
. O O

The O O
human O O
toll O O
signaling O O
pathway O O
: O O
divergence O O
of O O
nuclear O O
factor O O
kappaB O O
and O O
JNK/SAPK O O
activation O O
upstream O O
of O O
tumor O O
necrosis O O
factor O O
receptor-associated O O
factor O O
6 O O
( O O
TRAF6 O O
) O O
. O O

Human O O
MCM5 O O
and O O
MCM6 O O
promoters O O
with O O
mutation O O
in O O
the O O
E2F O O
sites O O
failed B-Negation B-Negation
in I-Negation I-Negation
promoter I-Negation I-Negation
regulation I-Negation I-Negation
following I-Negation I-Negation
serum I-Negation I-Negation
stimulation I-Negation I-Negation
and I-Negation I-Negation
exogenous I-Negation I-Negation
E2F I-Negation I-Negation
expression I-Negation I-Negation
. O O

Structure O O
and O O
function O O
analysis O O
of O O
the O O
human O O
myeloid O O
cell O O
nuclear O O
differentiation O O
antigen O O
promoter O O
: O O
evidence O O
for O O
the O O
role O O
of O O
Sp1 O O
and O O
not B-Negation B-Negation
of I-Negation I-Negation
c-Myb I-Negation I-Negation
or I-Negation I-Negation
PU.1 I-Negation I-Negation
in O I-Negation
myelomonocytic O I-Negation
lineage-specific O I-Negation
expression O I-Negation
. O O

Briefly O O
, O O
dissected O O
wing O O
discs O O
were O O
cultured O O
for O O
15 O O
min O O
in O O
the O O
presence O O
of O O
antibodies O O
that O O
recognize O O
the O O
extracellular O O
part O O
of O O
Ser O O
or O O
Dl O O
, O O
then O O
washed O O
, O O
cultured O O
for O O
another O O
45 O O
min O O
in O O
medium O O
without B-Negation B-Negation
antibodies I-Negation I-Negation
, O O
and O O
then O O
fixed O O
. O O

All O O
mAECA O O
possessed O O
high O O
activity O O
against O O
macrovascular O O
EC O O
, O O
but O O
none B-Negation B-Negation
had I-Negation I-Negation
significant I-Negation I-Negation
antimicrovascular I-Negation I-Negation
EC I-Negation I-Negation
activity I-Negation I-Negation
. O O

A O O
large O O
amount O O
of O O
detailed O O
information O O
about O O
the O O
intracellular O O
proteins O O
regulating O O
NF-kappa O O
B O O
activation O O
and O O
the O O
cellular O O
response O O
to O O
NF-kappa O O
B O O
activation O O
has O O
emerged O O
recently O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
analysis O O
we O O
demonstrated O O
that O O
the O O
promoter O O
region O O
spanning O O
base O O
pairs O O
-1 O O
to O O
-275 O O
, O O
which O O
contains O O
several O O
putative O O
binding O O
sites O O
for O O
transcription O O
factors O O
, O O
is O O
bound O O
by O O
nuclear O O
factors O O
Sp1 O O
and O O
IRBP O O
but O O
not B-Negation B-Negation
by I-Negation I-Negation
C/EBPs I-Negation I-Negation
. O O

We O O
found O O
that O O
: O O
( O O
i O O
) O O
both O O
CTCF O O
mRNA O O
and O O
protein O O
are O O
down-regulated O O
during O O
terminal O O
differentiation O O
in O O
most O O
cell O O
lines O O
tested O O
; O O
( O O
ii O O
) O O
CTCF O O
down-regulation O O
is O O
retarded O O
and O O
less O O
pronounced O O
than O O
that O O
of O O
c-myc O O
; O O
( O O
iii O O
) O O
CTCF O O
protein O O
is O O
differentially O O
phosphorylated O O
and O O
the O O
phosphorylation O O
profiles O O
depend O O
on O O
the O O
differentiation O O
pathway O O
. O O

HIV-1 O O
replication O O
was O O
increased O O
by O O
dopamine O O
, O O
which O O
correlated O O
with O O
the O O
increased O O
levels O O
of O O
HIV-1 O O
transactivation O O
. O O

These O O
conditions O O
reduced O O
the O O
number O O
of O O
clusters O O
to O O
273 O O
. O O

Our O O
finding O O
that O O
Vpr O O
can O O
regulate O O
NF-kappa O O
B O O
supports O O
the O O
hypothesis O O
that O O
some O O
aspects O O
of O O
viral O O
pathogenesis O O
are O O
the O O
consequence O O
of O O
cell O O
dysregulation O O
by O O
Vpr O O
. O O

In O O
addition O O
, O O
we O O
looked O O
at O O
the O O
modulation O O
of O O
nuclear O O
factors O O
binding O O
specifically O O
to O O
the O O
AP-1 O O
element O O
after O O
LTB4 O O
stimulation O O
. O O

The O O
data O O
strongly O O
suggest O O
an O O
endocrine O O
, O O
autocrine O O
and/or O O
paracrine O O
role O O
for O O
calcitriol O O
in O O
immune O O
regulation O O
. O O

Analysis O O
of O O
a O O
series O O
of O O
5'-truncations O O
showed O O
several O O
peaks O O
of O O
basal O O
and O O
PMA O O
induced O O
activity O O
suggesting O O
the O O
presence O O
of O O
several O O
positive O O
and O O
negative O O
regulatory O O
elements O O
. O O

The O O
product O O
of O O
the O O
murine O O
homolog O O
of O O
the O O
Drosophila O O
extra O O
sex O O
combs O O
gene O O
displays O O
transcriptional O O
repressor O O
activity O O
. O O

Work O O
using O O
adenosine-receptor O O
deficient O O
mammalian O O
cells O O
also O O
suggested O O
the O O
existence O O
of O O
a O O
novel O O
, O O
undefined O O
adenosine O O
signaling O O
mechanism O O
[ O O
44 O O
] O O
. O O

-TCPTP O O
was O O
predicted O O
to O O
interact O O
with O O
STAT6 O O
at O O
a O O
posterior O O
odds O O
ratio O O
of O O
4300 O O
. O O

To O O
provide O O
a O O
frame O O
of O O
reference O O
for O O
SCOPE O O
's O O
performance O O
, O O
we O O
ran O O
ten O O
other O O
popular O O
motif O O
finders O O
on O O
these O O
datasets O O
( O O
for O O
details O O
and O O
references O O
see O O
Table O O
2 O O
) O O
. O O

In O O
contrast O O
to O O
the O O
first O O
cluster O O
, O O
no B-Negation B-Negation
homolog I-Negation I-Negation
was I-Negation I-Negation
identified I-Negation I-Negation
from I-Negation I-Negation
other I-Negation I-Negation
species I-Negation I-Negation
. O O

In O O
a O O
converse O O
experiment O O
, O O
we O O
found O O
that O O
the O O
neur-driven O O
expression O O
of O O
D-mib O O
, O O
using O O
neurPGAL4 O O
, O O
did O O
not B-Negation B-Negation
rescue I-Negation I-Negation
the I-Negation I-Negation
cuticular I-Negation I-Negation
neurogenic I-Negation I-Negation
phenotype I-Negation I-Negation
of I-Negation I-Negation
neurPGAL4/neur1F65 I-Negation I-Negation
embryos I-Negation I-Negation
. O O

While O O
Rel O O
proteins O O
play O O
the O O
dominant O O
role O O
in O O
RANTES O O
gene O O
expression O O
in O O
fibroblasts O O
, O O
RFLAT-1 O O
is O O
a O O
strong O O
transactivator O O
for O O
RANTES O O
in O O
T O O
cells O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
role O O
of O O
serine/threonine O O
phosphatases O O
in O O
the O O
regulation O O
of O O
I O O
kappa O O
B O O
alpha O O
phosphorylation O O
was O O
investigated O O
. O O

The O O
potencies O O
of O O
the O O
transactivation O O
domains O O
of O O
Stat5 O O
, O O
Stat6 O O
, O O
and O O
viral O O
protein O O
VP16 O O
were O O
compared O O
. O O

Clonal O O
assay O O
showed O O
that O O
the O O
suppression O O
was O O
irreversible O O
and O O
appeared O O
analogous O O
to O O
the O O
commitment O O
of O O
murine O O
erythroleukemia O O
( O O
MEL O O
) O O
cells O O
to O O
terminal O O
differentiation O O
. O O

Together O O
, O O
these O O
results O O
suggest O O
that O O
in O O
future O O
clinical O O
gene O O
therapy O O
trials O O
, O O
a O O
combined O O
pharmacologic O O
and O O
genetic O O
strategy O O
like O O
the O O
one O O
reported O O
here O O
may O O
improve O O
the O O
survival O O
of O O
transduced O O
cells O O
and O O
prolong O O
clinical O O
benefit O O
. O O

A O O
deletion O O
construct O O
that O O
contains O O
a O O
NF-kappa O O
B O O
site O O
but O O
is O O
missing B-Negation O
the I-Negation O
multiple I-Negation O
response I-Negation O
region I-Negation O
demonstrated O O
a O O
continued O O
increase O O
in O O
IL-6 O O
luciferase O O
activity O O
in O O
LPS-stimulated O O
CMV O O
transfected O O
cells O O
. O O

Although O O
absent O B-Negation
in O I-Negation
nonexpressing O I-Negation
erythroleukemia O I-Negation
cell O I-Negation
lines O I-Negation
, O O
the O O
DNase O O
I O O
site O O
is O O
present O O
in O O
uninduced O O
myelomonocytic O O
cell O O
lines O O
and O O
is B-Negation B-Negation
not I-Negation I-Negation
changed I-Negation I-Negation
after I-Negation I-Negation
PMA I-Negation I-Negation
induction I-Negation I-Negation
. O O

We O O
report O O
here O O
that O O
the O O
nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFATp O O
) O O
, O O
a O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
-sensitive O O
factor O O
that O O
regulates O O
the O O
transcription O O
of O O
several O O
cytokines O O
, O O
mediates O O
CD16-induced O O
activation O O
of O O
cytokine O O
genes O O
in O O
human O O
NK O O
cells O O
. O O

Hypertranscription O O
is O O
a O O
consequence O O
of O O
at O O
least O O
one O O
chromatin O O
modification O O
: O O
the O O
acetylation O O
of O O
histone O O
H4 O O
at O O
Lys16 O O
, O O
which O O
is O O
thought O O
to O O
`` O O
loosen O O
'' O O
chromatin O O
structure O O
, O O
thereby O O
allowing O O
the O O
general O O
transcription O O
machinery O O
easier O O
access O O
to O O
the O O
regulatory O O
regions O O
of O O
most O O
X-linked O O
genes O O
[ O O
13 O O
] O O
. O O

These O O
findings O O
suggest O O
that O O
a O O
signal O O
transduction O O
molecule O O
in O O
the O O
LPS O O
receptor O O
complex O O
may O O
belong O O
to O O
the O O
IL-1 O O
receptor/toll-like O O
receptor O O
( O O
TLR O O
) O O
super O O
family O O
, O O
and O O
the O O
LPS O O
signaling O O
cascade O O
uses O O
an O O
analogous O O
molecular O O
framework O O
for O O
signaling O O
as O O
IL-1 O O
in O O
mononuclear O O
phagocytes O O
and O O
endothelial O O
cells O O
. O O

Preliminary O O
A. O O
aegypti O O
sequence O O
data O O
were O O
obtained O O
from O O
The O O
Institute O O
for O O
Genomic O O
Research O O
through O O
the O O
Web O O
site O O
at O O
http O O
: O O
//www.tigr.org O O
on O O
4 O O
March O O
2004 O O
. O O

Several O O
distinct O O
roles O O
for O O
hsp90 O O
in O O
modulating O O
dioxin O O
receptor O O
function O O
are O O
therefore O O
likely O O
: O O
correct O O
folding O O
of O O
the O O
ligand-binding O O
domain O O
, O O
interference O O
with O O
Arnt O O
heterodimerization O O
, O O
and O O
folding O O
of O O
a O O
DNA-binding O O
conformation O O
of O O
the O O
bHLH O O
domain O O
. O O

RXR O O
, O O
RAR O O
, O O
and O O
c-erbA/TR-specific O O
ligands O O
were O O
found O O
to O O
induce O O
erythroid-specific O O
gene O O
expression O O
and O O
to O O
accelerate O O
erythroid O O
differentiation O O
in O O
culture O O
, O O
with O O
T3 O O
being O O
most O O
effective O O
. O O

Human O O
LDL O O
induces O O
the O O
vascular O O
cell O O
adhesion O O
molecule-1 O O
( O O
VCAM-1 O O
) O O
transcriptionally O O
with O O
an O O
increase O O
in O O
mRNA O O
levels O O
through O O
activation O O
of O O
the O O
VCAM O O
promoter O O
. O O

Furthermore O O
, O O
CD28-dependent B-Negation B-Negation
elevation I-Negation I-Negation
of I-Negation I-Negation
c-jun I-Negation I-Negation
mRNA I-Negation I-Negation
does I-Negation I-Negation
not I-Negation I-Negation
appear O O
to O O
be O O
mediated O O
at O O
the O O
level O O
of O O
mRNA O O
stability O O
. O O

NF-AT O O
is O O
thought O O
to O O
consist O O
of O O
two O O
components O O
: O O
a O O
ubiquitous O O
, O O
inducible O O
nuclear O O
component O O
that O O
we O O
have O O
identified O O
as O O
Fos O O
and O O
Jun O O
proteins O O
, O O
and O O
a O O
preexisting O O
, O O
T O O
cell-specific O O
component O O
( O O
NF-ATp O O
) O O
which O O
is O O
the O O
target O O
for O O
the O O
immunosuppressive O O
agents O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
and O O
FK506 O O
. O O

In O O
addition O O
, O O
these O O
mAECA O O
stimulated O O
the O O
nuclear O O
translocation O O
of O O
the O O
NF-kappaB O O
transcription O O
factor O O
. O O

In O O
FCS- O O
liquid-suspension O O
culture O O
supplemented O O
with O O
saturating O O
Ep O O
level O O
and O O
low-dose O O
IL-3/GM-CSF O O
, O O
adult O O
HPC O O
undergo O O
unilineage O O
erythropoietic O O
differentiation O O
: O O

Transcriptional O O
activation O O
of O O
the O O
HIV O O
enhancer O O
was O O
also O O
subject O O
to O O
regulation O O
by O O
recently O O
cloned O O
I O O
kappa O O
B-alpha O O
( O O
MAD-3 O O
) O O
. O O

Because O O
it O O
is O O
not O O
clear O O
at O O
which O O
point O O
in O O
cell O O
cycle O O
the O O
peripheral O O
B O O
lymphocytes O O
are O O
arrested O O
, O O
we O O
characterized O O
the O O
expression O O
of O O
several O O
cell O O
cycle-associated O O
genes O O
in O O
quiescent O O
and O O
stimulated O O
cells O O
. O O

However O O
, O O
taking O O
the O O
subset O O
of O O
5164 O O
proteins O O
from O O
the O O
September O O
2005 O O
version O O
that O O
are O O
seen O O
in O O
the O O
June O O
2006 O O
version O O
( O O
20842 O O
distinct O O
interactions O O
) O O
, O O
gave O O
a O O
prior O O
odds O O
of O O
interaction O O
estimate O O
of O O
1/639 O O
. O O

A O O
more O O
precise O O
definition O O
of O O
the O O
role O O
of O O
BCL-6 O O
in O O
normal O O
and O O
neoplastic O O
B-cell O O
development O O
is O O
the O O
goal O O
of O O
ongoing O O
study O O
of O O
transgenic O O
mice O O
engineered O O
either O O
to O O
express O O
BCL-6 O O
under O O
heterologous O O
promoters O O
or O O
lacking B-Negation B-Negation
BCL-6 I-Negation I-Negation
function I-Negation I-Negation
due O O
to O O
targeted O O
deletions O O
. O O

Furthermore O O
, O O
GcR O O
were O O
unaltered O O
after O O
these O O
patients O O
received O O
ketoconazole O O
, O O
in O O
spite O O
of O O
a O O
marked O O
reduction O O
in O O
morning O O
plasma O O
cortisol O O
and O O
urinary O O
free O O
cortisol O O
. O O

To O O
better O O
understand O O
the O O
AP-1-dependent O O
luciferase O O
expression O O
in O O
Jurkat O O
T O O
cells O O
, O O
we O O
tested O O
two O O
specific O O
inhibitors O O
of O O
serine/threonine O O
phosphatases-1 O O
and O O
-2A O O
: O O
okadaic O O
acid O O
and O O
calyculin O O
A O O
. O O

cis-acting O O
sequences O O
required O O
for O O
inducible O O
interleukin-2 O O
enhancer O O
function O O
bind O O
a O O
novel O O
Ets-related O O
protein O O
, O O
Elf-1 O O
. O O

Activation O O
of O O
NK-kappa O O
B O O
and O O
upregulation O O
of O O
ICAM-1 O O
occurred O O
within O O
24 O O
h O O
and O O
were O O
followed O O
at O O
48 O O
to O O
72 O O
h O O
by O O
upregulation O O
of O O
Bcl-2 O O
. O O

The O O
expression O O
of O O
p45 O O
megakaryocytic O O
lineage O O
cells O O
, O O
p45 O O
mRNA O O
is O O
transcribed O O
only O O
from O O
aNF-E2 O O
promoter O O
. O O

In O O
addition O O
, O O
T O O
cell O O
proliferation O O
was O O
completely O O
resistant O O
to O O
the O O
actions O O
of O O
the O O
immunosuppressant O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
. O O

Adult O O
humans O O
certainly O O
are O O
less O O
susceptible O O
to O O
this O O
action O O
of O O
PCDDs/PCDFs O O
than O O
adolescent O O
Callithrix O O
jacchus O O
. O O

We O O
therefore O O
conclude O O
that O O
D-mib O O
and O O
neur O O
have O O
distinct O O
and O O
complementary O O
functions O O
in O O
Drosophila O O
. O O

This O O
inducer O O
can O O
act O O
in O O
concert O O
with O O
the O O
HIV-2 O O
tat O O
gene O O
and O O
T-cell O O
activation O O
in O O
enhancing O O
gene O O
expression O O
in O O
human O O
CD4+ O O
lymphocytes O O
. O O

PGG-glucan O O
, O O
a O O
soluble O O
beta- O O
( O O
1,3 O O
) O O
-glucan O O
, O O
enhances O O
the O O
oxidative O O
burst O O
response O O
, O O
microbicidal O O
activity O O
, O O
and O O
activates O O
an O O
NF-kappa O O
B-like O O
factor O O
in O O
human O O
PMN O O
: O O
evidence O O
for O O
a O O
glycosphingolipid O O
beta- O O
( O O
1,3 O O
) O O
-glucan O O
receptor O O
. O O

A O O
55-kDa O O
isoform O O
, O O
I O O
kappa O O
B O O
gamma-2 O O
, O O
lacks B-Negation B-Negation
the I-Negation I-Negation
190 I-Negation I-Negation
C-terminal I-Negation I-Negation
amino I-Negation I-Negation
acids I-Negation I-Negation
of I-Negation I-Negation
p70I I-Negation I-Negation
kappa I-Negation I-Negation
B I-Negation I-Negation
gamma I-Negation I-Negation
. O O

Thyroid O O
hormone O O
( O O
T3 O O
) O O
alone O O
caused O O
similar O O
but O O
weaker O O
effects O O
. O O

We O O
have O O
demonstrated O O
that O O
the O O
cross-linking O O
of O O
cell O O
surface O O
CD4 O O
by O O
gp120-anti-gp120 O O
immune O O
complexes O O
or O O
heat-inactivated O O
HIV-1 O O
( O O
iHIV-1 O O
) O O
is O O
sufficient O O
to O O
trigger O O
activation O O
signals O O
leading O O
to O O
virus O O
reactivation O O
( O O
9 O O
) O O
. O O

These O O
findings O O
suggest O O
that O O
LTR O O
sequence O O
changes O O
can O O
significantly O O
affect O O
basal O O
LTR O O
function O O
and O O
transcription O O
factor O O
recruitment O O
, O O
which O O
may O O
, O O
in O O
turn O O
, O O
alter O O
the O O
course O O
of O O
viral O O
replication O O
in O O
cells O O
of O O
CNS O O
and O O
immune O O
system O O
origin O O
. O O

Flies O O
heterozygous O O
for O O
the O O
cact O O
mutation O O
were O O
used O O
as O O
a O O
control O O
. O O

Analysis O O
of O O
mRNA O O
suggested O O
that O O
Tat O O
exerts O O
its O O
effect O O
on O O
IL-2 O O
primarily O O
at O O
the O O
transcriptional O O
level O O
. O O

When O O
cotransfected O O
with O O
the O O
HIV O O
LTR O O
CAT O O
into O O
CV-1 O O
cells O O
, O O
both O O
the O O
pCD41 O O
and O O
pGD41 O O
clones O O
trans-activated O O
the O O
HIV O O
LTR O O
. O O

These O O
data O O
suggest O O
that O O
NF-kappa O O
B O O
may O O
be O O
an O O
important O O
molecular O O
mediator O O
of O O
Pb-induced O O
immunotoxicity O O
. O O

These O O
results O O
suggests O O
that O O
both O O
proximal O O
steps O O
in O O
CD8+ O O
T-cell O O
activation O O
as O O
well O O
as O O
the O O
later O O
phases O O
are O O
unresponsive O O
to O O
A6H O O
ligation O O
. O O

Basing O O
on O O
these O O
experiments O O
, O O
trans-cellular O O
activation O O
of O O
EBV O O
was O O
tested O O
by O O
cocultivation O O
of O O
BZLF O O
1-expressing O O
R59Z O O
activator O O
cells O O
with O O
the O O
R7-57 O O
reporter O O
line O O
. O O

They O O
also O O
display O O
constitutively O O
high O O
levels O O
of O O
p59fyn O O
and O O
CD3 O O
zeta O O
tyrosine O O
phosphorylation O O
. O O

Approximately O O
40 O O
% O O
of O O
diffuse O O
large O O
cell O O
lymphoma O O
are O O
associated O O
with O O
chromosomal O O
translocations O O
that O O
deregulate O O
the O O
expression O O
of O O
the O O
BCL6 O O
gene O O
by O O
juxtaposing O O
heterologous O O
promoters O O
to O O
the O O
BCL-6 O O
coding O O
domain O O
. O O

Target O O
antigens O O
defined O O
by O O
autoantibodies O O
in O O
IDDM O O
include O O
insulin O O
, O O
a O O
putative O O
glycolipid O O
that O O
reacts O O
with O O
islet O O
cell O O
antibodies O O
, O O
and O O
a O O
64,000-M O O
( O O
r O O
) O O
protein O O
recently O O
identified O O
as O O
glutamic O O
acid O O
decarboxylase O O
. O O

Analyzed O O
DNA O O
sequences O O
included O O
delta O O
and O O
beta O O
5 O O
' O O
flanking O O
regions O O
extending O O
from O O
approximately O O
-500 O O
to O O
+50bp O O
( O O
promoter O O
regions O O
) O O
, O O
truncated O O
delta O O
and O O
beta O O
5 O O
' O O
flanking O O
regions O O
extending O O
from O O
approximately O O
-250 O O
to O O
+50 O O
bp O O
, O O
and O O
chimeric O O
promoter O O
constructions O O
, O O
which O O
consisted O O
of O O
a O O
distal O O
delta O O
or O O
beta O O
fragment O O
fused O O
to O O
a O O
proximal O O
beta O O
or O O
delta O O
sequence O O
. O O

By O O
contrast O O
, O O
treatment O O
of O O
cells O O
with O O
pyrrolidine O O
dithiocarbamate O O
( O O
PDTC O O
) O O
will O O
only O O
block O O
LPS-induced O O
NF-kappa O O
B O O
, O O
but O O
not B-Negation B-Negation
the I-Negation I-Negation
constitutive I-Negation I-Negation
binding I-Negation I-Negation
protein I-Negation I-Negation
. O O

The O O
comparisons O O
to O O
other O O
motif O O
finding O O
programs O O
in O O
this O O
study O O
are O O
provided O O
to O O
place O O
SCOPE O O
's O O
performance O O
in O O
the O O
broader O O
context O O
of O O
the O O
motif O O
finding O O
field O O
, O O
particularly O O
when O O
viewed O O
from O O
the O O
standpoint O O
of O O
the O O
practicing O O
`` O O
bench O O
'' O O
biologist O O
. O O

Estrogens O O
and O O
anti-estrogens O O
enhance O O
the O O
number O O
of O O
immunoglobulin O O
( O O
Ig O O
) O O
-secreting O O
cells O O
in O O
pokeweed O O
mitogen O O
( O O
PWM O O
) O O
-stimulated O O
lymphocyte O O
cultures O O
. O O

Thus O O
, O O
between O O
the O O
two O O
releases O O
of O O
the O O
HPRD O O
, O O
there O O
was O O
a O O
large O O
increase O O
in O O
the O O
number O O
of O O
interactions O O
for O O
this O O
subset O O
of O O
proteins O O
and O O
this O O
is O O
likely O O
to O O
continue O O
for O O
at O O
least O O
the O O
next O O
few O O
releases O O
. O O

In O O
addition O O
, O O
sodium O O
salicylate O O
and O O
additional O O
NSAIDs O O
used O O
at O O
concentrations O O
that O O
activate O O
HSF1 O O
also O O
inhibited O O
the O O
expression O O
of O O
other O O
monocytic O O
genes O O
( O O
TNF-alpha O O
, O O
IL-1beta O O
, O O
IL-6 O O
, O O
IL-8 O O
, O O
IL-10 O O
, O O
ICAM-1 O O
) O O
activated O O
by O O
exposure O O
to O O
a O O
pro-inflammatory O O
stimulus O O
( O O
lipopolysaccharide O O
, O O
LPS O O
) O O
. O O

In O O
addition O O
, O O
RFX1 O O
can O O
bind O O
simultaneously O O
, O O
most O O
likely O O
as O O
a O O
heterodimer O O
, O O
with O O
the O O
transcription O O
factor O O
MIBP1 O O
to O O
NRE O O
gamma O O
. O O

The O O
first O O
male O O
patient O O
presented O O
with O O
mild O O
hypertension O O
. O O

Endothelial O O
cell O O
activation O O
and O O
leukocyte O O
infiltration O O
are O O
a O O
consistent O O
feature O O
of O O
discordant O O
xenograft O O
rejection O O
. O O

Zinc O O
is O O
an O O
important O O
trace O O
element O O
for O O
immune O O
function O O
. O O

Human O O
TAFII O O
105 O O
is O O
a O O
cell O O
type-specific O O
TFIID O O
subunit O O
related O O
to O O
hTAFII130 O O
. O O

Both O O
these O O
responses O O
are O O
inhibited O O
by O O
CsA O O
. O O

Although O O
four O O
specific O O
complexes O O
can O O
be O O
detected O O
binding O O
to O O
this O O
sequence O O
, O O
only O O
one O O
of O O
these O O
complexes O O
is O O
specific O O
for O O
both O O
the O O
CD28RE O O
and O O
the O O
adjacent O O
AP-1 O O
site O O
. O O

Transcriptional O O
activity O O
and O O
constitutive O O
nuclear O O
localization O O
of O O
the O O
ETS O O
protein O O
Elf-1 O O
. O O

Liposomal O O
transfection O O
of O O
a O O
double-stranded O O
kappaB O O
phosphorothioate O O
oligonucleotide O O
, O O
but O O
not B-Negation B-Negation
of I-Negation I-Negation
the I-Negation I-Negation
mutated I-Negation I-Negation
form I-Negation I-Negation
, O O
inhibited O O
MCP-1 O O
secretion O O
and O O
surface O O
expression O O
of O O
ICAM-1 O O
on O O
activated O O
endothelium O O
( O O
P O O
< O O
0.05 O O
) O O
. O O

TNFalpha O O
cooperates O O
with O O
the O O
protein O O
kinase O O
A O O
pathway O O
to O O
synergistically O O
increase O O
HIV-1 O O
LTR O O
transcription O O
via O O
downstream O O
TRE-like O O
cAMP O O
response O O
elements O O
. O O

We O O
conclude O O
, O O
rather O O
, O O
that O O
alpha O O
4 O O
beta O O
1 O O
in O O
freshly O O
isolated O O
T O O
cells O O
delivers O O
a O O
distinct O O
signal O O
that O O
synergizes O O
early O O
with O O
signals O O
initiated O O
by O O
TCR/CD3 O O
ligation O O
to O O
induce O O
DNA O O
binding O O
of O O
multiple O O
transcription O O
factors O O
required O O
for O O
cytokine O O
gene O O
induction O O
. O O

Discussion O O

BACKGROUND O O
: O O
Adhesion O O
molecule O O
expression O O
on O O
the O O
endothelial O O
cell O O
( O O
EC O O
) O O
surface O O
is O O
critical O O
for O O
leukocyte O O
recruitment O O
to O O
atherosclerotic O O
lesions O O
. O O

At O O
the O O
same O O
time O O
, O O
recently O O
sequenced O O
genomes O O
of O O
honeybee O O
, O O
roundworms O O
, O O
fish O O
, O O
frog O O
, O O
mammals O O
, O O
sea O O
squirts O O
, O O
plants O O
, O O
and O O
fungi O O
( O O
except O O
soybean O O
rust O O
) O O
do O O
not B-Negation B-Negation
contain I-Negation I-Negation
any I-Negation I-Negation
detectable I-Negation I-Negation
Transib I-Negation I-Negation
transposons I-Negation I-Negation
( O O
see O O
Figure O O
1 O O
) O O
. O O

Flavonoids O O
are O O
a O O
group O O
of O O
naturally-occurring O O
phenolic O O
compounds O O
in O O
the O O
plant O O
kingdom O O
, O O
and O O
many O O
flavonoids O O
are O O
found O O
with O O
vascular O O
protective O O
properties O O
. O O

An O O
amino-terminal O O
fragment O O
of O O
OCA-B O O
binds O O
the O O
octamer O O
site O O
in O O
the O O
absence O O
of O O
a O O
POU O O
domain O O
with O O
the O O
same O O
sequence O O
specificity O O
. O O

Also O O
, O O
in O O
a O O
promonocyte O O
cell O O
line O O
chronically O O
infected O O
with O O
HIV O O
, O O
NF-kappa O O
B O O
expression O O
and O O
HIV O O
transcription O O
were O O
enhanced O O
on O O
stimulation O O
with O O
phorbol O O
ester O O
or O O
TNF O O
alpha O O
. O O

These O O
data O O
suggest O O
that O O
NF-kappaB O O
plays O O
a O O
key O O
role O O
in O O
low O O
shear-induced O O
VCAM-1 O O
expression O O
and O O
that O O
pathways O O
mediating O O
low O O
shear- O O
and O O
cytokine-induced O O
EC-Mn O O
adhesion O O
may O O
be O O
differentially O O
regulated O O
. O O

By O O
contrast O O
, O O
Oct-2A O B-Negation
is O I-Negation
not B-Negation I-Negation
involved I-Negation I-Negation
in I-Negation I-Negation
the I-Negation I-Negation
IFN-gamma I-Negation I-Negation
induction I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
HLA-DRA I-Negation I-Negation
gene I-Negation I-Negation
in I-Negation I-Negation
HeLa I-Negation I-Negation
cells I-Negation I-Negation
, O O
but O O
antisense O O
HMG O O
I/Y O O
dramatically O O
decreases O O
the O O
level O O
of O O
induction O O
. O O

In O O
contrast O O
, O O
cotransfection O O
with O O
a O O
combination O O
of O O
NF-kappa O O
B O O
and O O
AP-1 O O
significantly O O
augmented O O
transcription O O
from O O
the O O
GM-CSF O O
promoter O O
containing O O
the O O
GM-kappa O O
B/GC-box O O
and O O
the O O
CLE0 O O
( O O
AP-1/NF-AT O O
) O O
. O O

The O O
implications O O
, O O
in O O
particular O O
, O O
in O O
relation O O
to O O
future O O
prognosis O O
of O O
the O O
patient O O
, O O
remain O O
obscure O O
. O O

Furthermore O O
, O O
compounds O O
such O O
as O O
tosylphenylalanyl O O
chloromethyl O O
ketone O O
and O O
pyrrolidinedithiocarbamate O O
that O O
are O O
known O O
to O O
selectively O O
inhibit O O
NF O O
kappa O O
B O O
activation O O
block O O
cytokine O O
gene O O
transcription O O
in O O
LPS-stimulated O O
monocytes O O
. O O

Novel O O
aldosterone O O
receptors O O
: O O
specificity-conferring O O
mechanism O O
at O O
the O O
level O O
of O O
the O O
cell O O
membrane O O
. O O

These O O
data O O
are O O
perfectly O O
compatible O O
with O O
major O O
properties O O
of O O
steroidal O O
effects O O
on O O
the O O
sodium-proton-antiport O O
in O O
HML O O
and O O
thus O O
very O O
likely O O
represent O O
membrane O O
receptors O O
for O O
aldosterone O O
. O O

These O O
data O O
suggest O O
that O O
ERP O O
might O O
play O O
a O O
role O O
in O O
B-cell O O
development O O
and O O
in O O
IgH O O
gene O O
regulation O O
. O O

One O O
major O O
and O O
one O O
minor O O
transcription O O
start O O
site O O
were O O
identified O O
101 O O
and O O
130 O O
base O O
pairs O O
( O O
bp O O
) O O
upstream O O
, O O
respectively O O
, O O
from O O
the O O
protein O O
translation O O
start O O
ATG O O
. O O

Transfection O O
of O O
an O O
AP-2 O O
expression O O
construct O O
into O O
T-lymphocytes O O
activated O O
gene O O
expression O O
from O O
the O O
HTLV-I O O
LTR O O
. O O

Congruous O O
with O O
the O O
involvement O O
of O O
a O O
Stat O O
protein O O
, O O
IL-4 O O
induced O O
robust O O
Janus O O
kinase O O
3 O O
( O O
JAK3 O O
) O O
activity O O
in O O
BL-2 O O
cells O O
. O O

AFR O O
behaves O O
like O O
ascorbate O O
, O O
while O O
DHA O O
and O O
ascorbate O O
phosphate O O
do O O
not B-Negation B-Negation
affect I-Negation I-Negation
TNF-alpha-mediated I-Negation I-Negation
NF-kappaB I-Negation I-Negation
activation I-Negation I-Negation
. O O

Together O O
, O O
these O O
findings O O
suggest O O
that O O
LITAF O O
plays O O
an O O
important O O
role O O
in O O
the O O
activation O O
of O O
the O O
human O O
TNF-alpha O O
gene O O
and O O
proposes O O
a O O
new O O
mechanism O O
to O O
control O O
TNF-alpha O O
gene O O
expression O O
. O O

saturating O O
amounts O O
of O O
the O O
inhibitory O O
I O O
kappa O O
B-alpha O O
protein O O
are O O
destroyed O O
upon O O
stimulation O O
, O O
allowing O O
rapid O O
activation O O
of O O
NF-kappa O O
B O O
. O O

An O O
intact O O
paired O O
domain O O
was O O
shown O O
to O O
be O O
both O O
necessary O O
and O O
sufficient O O
for O O
DNA O O
binding O O
of O O
BSAP O O
. O O

In O O
contrast O O
, O O
analysis O O
of O O
pp90rsk O O
activity O O
by O O
phosphorylation O O
of O O
a O O
peptide O O
derived O O
from O O
S6 O O
protein O O
demonstrated O O
stimulation O O
of O O
this O O
kinase O O
in O O
TPA-treated O O
U-937 O O
, O O
and O O
not B-Negation B-Negation
TUR I-Negation I-Negation
, O O
cells O O
. O O

Although O O
phenotypically O O
normal O O
, O O
the O O
proliferative O O
response O O
of O O
the O O
childrens O O
' O O
T O O
cells O O
was O O
strongly O O
reduced O O
but O O
could O O
be O O
improved O O
by O O
the O O
addition O O
of O O
interleukin-2 O O
( O O
IL-2 O O
) O O
. O O

By O O
promoter O O
deletion O O
and O O
mutation O O
analyses O O
, O O
we O O
established O O
this O O
region O O
as O O
a O O
positive O O
regulatory O O
element O O
. O O

HIV-1 O O
Vpr O O
suppresses O O
immune O O
activation O O
and O O
apoptosis O O
through O O
regulation O O
of O O
nuclear O O
factor O O
kappa O O
B O O
[ O O
see O O
comments O O
] O O

Their O O
relative O O
levels O O
were O O
very O O
similar O O
for O O
the O O
duration O O
of O O
proliferation O O
. O O

To O O
confirm O O
the O O
physiological O O
relevance O O
of O O
these O O
findings O O
, O O
we O O
carried O O
out O O
in O O
vivo O O
footprinting O O
experiments O O
which O O
showed O O
that O O
stimulation O O
of O O
IL-2R O O
alpha O O
expression O O
correlated O O
with O O
occupancy O O
of O O
the O O
GASd O O
element O O
. O O

These O O
initial O O
changes O O
are O O
followed O O
by O O
the O O
eventual O O
loss O O
of O O
TCR O O
zeta O O
chain O O
and O O
p56 O O
( O O
lck O O
) O O
and O O
a O O
marked O O
decrease O O
in O O
cytotoxic O O
function O O
. O O

Studies O O
on O O
RA O O
time-response O O
or O O
pulse O O
treatment O O
in O O
semisolid O O
or O O
liquid O O
culture O O
show O O
that O O
early O O
RA O O
addition O O
is O O
most O O
effective O O
, O O
thus O O
indicating O O
that O O
early O O
but O O
not O O
late O O
HPC O O
are O O
sensitive O O
to O O
its O O
action O O
. O O

Decreased O O
transcriptional O O
activation O O
by O O
N-terminal O O
deletions O O
of O O
CIITA O O
is O O
correlated O O
directly O O
with O O
their O O
reduced O O
binding O O
to O O
TAFII32 O O
. O O

Analysis O O
of O O
targets O O
that O O
could O O
mediate O O
these O O
phenotypic O O
changes O O
indicated O O
that O O
c-Maf O O
likely O O
plays O O
a O O
key O O
role O O
in O O
myeloid O O
cell O O
development O O
through O O
dual O O
mechanisms O O
; O O
inhibition O O
of O O
a O O
select O O
set O O
of O O
c-Myb O O
regulated O O
targets O O
, O O
such O O
as O O
Bcl-2 O O
and O O
CD13/APN O O
, O O
coupled O O
with O O
the O O
activation O O
of O O
as O O
yet O O
undefined O O
differentiation-promoting O O
genes O O
. O O

The O O
chi-square O O
test O O
was O O
used O O
as O O
a O O
measure O O
of O O
the O O
likelihood O O
of O O
co-occurrence O O
of O O
specific O O
InterPro O O
domains O O
and O O
motifs O O
73 O O
in O O
protein O O
pairs O O
. O O

Here O O
we O O
report O O
that O O
the O O
type O O
II O O
IL-1R O O
does O O
not B-Negation B-Negation
mediate I-Negation I-Negation
gene I-Negation I-Negation
activation I-Negation I-Negation
in I-Negation I-Negation
Jurkat I-Negation I-Negation
cells I-Negation I-Negation
. O O

Identification O O
of O O
the O O
pathways O O
activated O O
by O O
LMP-1 O O
to O O
result O O
in O O
posttranslational O O
modifications O O
of O O
I O O
kappa O O
B O O
alpha O O
will O O
aid O O
in O O
determining O O
the O O
role O O
of O O
this O O
virus-host O O
cell O O
protein O O
interaction O O
in O O
Epstein-Barr O O
virus-mediated O O
oncogenesis O O
. O O

By O O
running O O
the O O
same O O
( O O
stochastic O O
) O O
algorithm O O
multiple O O
times O O
and O O
using O O
a O O
voting O O
method O O
, O O
those O O
subsequences O O
of O O
the O O
binding O O
sites O O
that O O
are O O
repeatedly O O
reported O O
become O O
clear O O
while O O
the O O
spurious O O
bases O O
are O O
eliminated O O
. O O

Calcineurin O O
, O O
a O O
Ca2+/calmodulin-dependent O O
protein O O
phosphatase O O
, O O
is O O
the O O
FK-506- O O
and O O
CsA-sensitive O O
enzyme O O
required O O
for O O
TcR O O
mediated O O
activation O O
of O O
the O O
IL-2 O O
promoter O O
. O O

In O O
particular O O
, O O
staurosporine O O
achieved O O
approximately O O
90 O O
% O O
inhibition O O
of O O
the O O
HIV-1 O O
antigen O O
expression O O
in O O
heat O O
shock-treated O O
OM10.1 O O
at O O
a O O
non-toxic O O
concentration O O
. O O

Nuclear O O
extracts O O
assayed O O
for O O
the O O
presence O O
of O O
ISRE O O
binding O O
factors O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
show O O
that O O
ISGF3 O O
is O O
induced O O
by O O
IFN-alpha O O
within O O
6 O O
h O O
from O O
undetectable O O
basal O O
levels O O
in O O
untreated O O
U937 O O
cells O O
. O O

The O O
right-hand O O
portion O O
of O O
Table O O
3 O O
shows O O
the O O
accuracy O O
measures O O
for O O
the O O
highest O O
scoring O O
subset O O
of O O
predictors O O
that O O
consider O O
the O O
Transitive O O
module O O
. O O

Inhibition O O
of O O
NF-kappaB O O
activity O O
in O O
a O O
T O O
cell O O
hybridoma O O
leads O O
to O O
decreased O O
FasL O O
expression O O
and O O
apoptosis O O
upon O O
T O O
cell O O
receptor O O
stimulation O O
. O O

We O O
raise O O
the O O
hypothesis O O
that O O
delta O O
Spi-B O O
might O O
affect O O
Spi-B O O
function O O
by O O
recruiting O O
factors O O
involved O O
in O O
Spi-B O O
activity O O
. O O

Fos O B-Negation
proteins O I-Negation
are O I-Negation
not B-Negation I-Negation
needed I-Negation I-Negation
for I-Negation I-Negation
this I-Negation I-Negation
reconstitution I-Negation I-Negation
, O O
and O O
although O O
JunB O B-Negation
is O I-Negation
not B-Negation I-Negation
functional I-Negation I-Negation
, O O
it O O
can O O
participate O O
in O O
the O O
NF-AT O O
DNA O O
binding O O
complex O O
. O O

C5a O O
, O O
a O O
potent O O
peptide O O
chemoattractant O O
, O O
stimulates O O
interleukin-8 O O
( O O
IL-8 O O
) O O
secretion O O
from O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
. O O

One O O
gene O O
encodes O O
a O O
protein O O
, O O
RFX5 O O
, O O
that O O
is O O
a O O
member O O
of O O
the O O
RFX O O
family O O
of O O
DNA O O
binding O O
proteins O O
. O O

they O O
bind O O
endogenous O O
intracellular O O
receptors O O
, O O
the O O
immunophilins O O
, O O
and O O
the O O
resulting O O
complex O O
targets O O
the O O
protein O O
phosphatase O O
, O O
calcineurin O O
, O O
to O O
exert O O
the O O
immunosuppressive O O
effect O O
. O O

Finally O O
, O O
we O O
conclude O O
that O O
this O O
effect O O
of O O
CIITA O O
is O O
cell-type O O
specific O O
, O O
since O O
expression O B-Negation
of O I-Negation
CIITA O I-Negation
is O I-Negation
not B-Negation I-Negation
required I-Negation I-Negation
for I-Negation I-Negation
normal I-Negation I-Negation
occupation I-Negation I-Negation
of I-Negation I-Negation
MHC I-Negation I-Negation
class I-Negation I-Negation
II I-Negation I-Negation
promoters I-Negation I-Negation
in I-Negation I-Negation
B I-Negation I-Negation
lymphocytes I-Negation I-Negation
. O O

In O O
T O O
cells O O
, O O
HIV O O
transcription O O
is O O
poorly O O
detected O O
in O O
vivo O O
. O O

The O O
average O O
accuracies O O
of O O
BEAM O O
, O O
PRISM O O
and O O
SPACER O O
on O O
this O O
dataset O O
were O O
similar O O
to O O
those O O
of O O
the O O
ten O O
other O O
programs O O
. O O

Targeted O O
disruption O O
of O O
the O O
MyD88 O O
gene O O
results O O
in O O
loss O O
of O O
IL-1- O O
and O O
IL-18-mediated O O
function O O
. O O

Retinoic O O
acid O O
( O O
RA O O
) O O
, O O
a O O
vitamin O O
A O O
derivative O O
, O O
exerts O O
a O O
wide O O
range O O
of O O
biological O O
effects O O
related O O
to O O
cell O O
proliferation O O
and O O
differentiation O O
. O O

Peripheral O O
blood O O
mononuclear O O
cells O O
from O O
atopic O O
asthma O O
patients O O
both O O
proliferated O O
and O O
produced O O
IL-5 O O
after O O
incubation O O
with O O
mite O O
allergen O O
, O O
suggesting O O
that O O
mite-specific O O
helper O O
T O O
cells O O
were O O
involved O O
in O O
the O O
eosinophilic O O
inflammation O O
of O O
atopic O O
asthma O O
. O O

This B-Negation B-Negation
multiple I-Negation I-Negation
cytokine I-Negation I-Negation
production I-Negation I-Negation
deficiency I-Negation I-Negation
could I-Negation I-Negation
not I-Negation I-Negation
be I-Negation I-Negation
restored I-Negation I-Negation
by I-Negation I-Negation
IL-2 I-Negation I-Negation
or I-Negation I-Negation
co-stimulatory I-Negation I-Negation
signals I-Negation I-Negation
provided I-Negation I-Negation
by I-Negation I-Negation
antigen-presenting I-Negation I-Negation
cells I-Negation I-Negation
( I-Negation I-Negation
APC I-Negation I-Negation
) I-Negation I-Negation
. O O

It O O
may O O
be O O
encoded O O
by O O
a O O
separate O O
exon O O
that O O
is O O
difficult O O
to O O
detect O O
given O O
its O O
short O O
length O O
and O O
the O O
high O O
level O O
of O O
sequence O O
divergence O O
between O O
these O O
species O O
and O O
vertebrates O O
, O O
or O O
it O O
might O O
have O O
been O O
added O O
in O O
vertebrates O O
. O O

CL-01 O O
cells O O
are O O
IgM+ O O
IgD+ O O
CD30+ O O
and O O
switch O O
to O O
IgG O O
, O O
IgA O O
, O O
and O O
IgE O O
when O O
exposed O O
to O O
CD40L O O
and O O
IL-4 O O
. O O

Cepharanthine O O
is O O
a O O
biscoclaurine O O
alkaloid O O
isolated O O
from O O
Stephania O O
cepharantha O O
Hayata O O
and O O
has O O
been O O
shown O O
to O O
have O O
antiinflammatory O O
, O O
antiallergic O O
, O O
and O O
immunomodulatory O O
activities O O
in O O
vivo O O
. O O

TCDD O O
mediates O O
atrophy O O
induction O O
through O O
its O O
specific O O
receptor O O
( O O
the O O
AhR O O
) O O
and O O
not B-Negation B-Negation
through I-Negation I-Negation
effects I-Negation I-Negation
on I-Negation I-Negation
the I-Negation I-Negation
estrogen I-Negation I-Negation
receptor I-Negation I-Negation
. O O

Transcriptional O O
factors O O
of O O
the O O
NFAT O O
family O O
play O O
an O O
important O O
role O O
in O O
regulating O O
the O O
expression O O
of O O
several O O
cytokine O O
genes O O
during O O
the O O
immune O O
response O O
, O O
such O O
as O O
the O O
genes O O
for O O
interleukin O O
2 O O
( O O
IL-2 O O
) O O
and O O
IL-4 O O
, O O
among O O
others O O
. O O

This O O
raises O O
the O O
possibility O O
that O O
adenosine O O
plays O O
a O O
role O O
in O O
the O O
control O O
of O O
metamorphosis O O
as O O
well O O
as O O
in O O
the O O
response O O
to O O
stress O O
. O O

The O O
decreased O O
expression O O
of O O
immunoglobulin O O
genes O O
indicates O O
that O O
the O O
ras O O
oncogene O O
blocks O O
terminal O O
differentiation O O
to O O
plasma O O
cells O O
, O O
possibly O O
by O O
inhibiting O O
the O O
activity O O
of O O
lymphocyte-specific O O
transcription O O
factors O O
. O O

These O O
data O O
demonstrate O O
that O O
DMDTC O O
is O O
a O O
potent O O
immunosuppressive O O
compound O O
in O O
vitro O O
. O O

LPS-induced B-Negation B-Negation
NF-kappaB I-Negation I-Negation
activation I-Negation I-Negation
was I-Negation I-Negation
not I-Negation I-Negation
inhibited I-Negation I-Negation
by I-Negation I-Negation
a I-Negation I-Negation
dominant I-Negation I-Negation
negative I-Negation I-Negation
mutant I-Negation I-Negation
of I-Negation I-Negation
TRAF2 I-Negation I-Negation
that I-Negation I-Negation
is I-Negation I-Negation
involved I-Negation I-Negation
in I-Negation I-Negation
TNF I-Negation I-Negation
signaling I-Negation I-Negation
. O O

In O O
the O O
present O O
work O O
, O O
we O O
investigated O O
the O O
molecular O O
events O O
leading O O
to O O
NF-kappa O O
B O O
activation O O
by O O
TNF O O
alpha O O
in O O
a O O
human O O
T O O
cell O O
line O O
( O O
Jurkat O O
) O O
and O O
its O O
subclone O O
JCT6 O O
, O O
which O O
presents O O
a O O
deficiency O O
in O O
the O O
PKA O O
transduction O O
pathway O O
. O O

[ O O
NGFI-B/nur77 O O
family O O
involved O O
in O O
T-cell O O
apoptosis O O
] O O

Glucocorticoid-mediated O O
inhibition O O
of O O
interleukin-2 O O
receptor O O
alpha O O
and O O
-beta O O
subunit O O
expression O O
by O O
human O O
T O O
cells O O
. O O

Strikingly O O
, O O
costimulation O O
with O O
EC O O
results O O
in O O
a O O
dramatic O O
increase O O
( O O
up O O
to O O
15-fold O O
) O O
in O O
the O O
c-Fos O O
content O O
of O O
AP-1 O O
. O O

Receptor O O
transcripts O O
were O O
4.6 O O
kilobases O O
( O O
kb O O
) O O
, O O
and O O
no B-Negation B-Negation
variant I-Negation I-Negation
sizes I-Negation I-Negation
were I-Negation I-Negation
observed I-Negation I-Negation
. O O

In O O
comparison O O
, O O
UT-7 O O
Epo O O
cells O O
expressed O O
alpha-globin O O
and O O
higher O O
levels O O
of O O
gamma-globin O O
( O O
5-fold O O
) O O
and O O
beta-globin O O
( O O
from O O
barely O O
to O O
clearly O O
detectable O O
) O O
. O O

However O O
, O O
it O O
was O O
only O O
the O O
IL-2 O O
promoter O O
whose O O
activation O O
by O O
Tpl-2 O O
was O O
fully O O
blocked O O
by O O
the O O
dominant O O
negative O O
mutant O O
MEK1S218/222A O O
and O O
the O O
MEK1/MEK2 O O
inhibitor O O
PD098059 O O
. O O

To O O
understand O O
why O O
iPfam O O
domain O O
pairs O O
occur O O
more O O
often O O
in O O
experimental O O
interactions O O
than O O
expected O O
by O O
chance O O
, O O
we O O
analysed O O
the O O
two O O
largest O O
data O O
sets O O
, O O
S. O O
cerevisiae O O
and O O
H. O O
sapiens O O
in O O
more O O
detail O O
. O O

Tissue-specific O O
regulation O O
of O O
the O O
rabbit O O
15-lipoxygenase O O
gene O O
in O O
erythroid O O
cells O O
by O O
a O O
transcriptional O O
silencer O O
. O O

The O O
rest O O
is O O
a O O
cluster O O
of O O
TetR-like O O
transcriptional O O
regulators O O
from O O
Methanosarcina O O
acetivorans O O
and O O
M. O O
barkeri O O
. O O

Here O O
we O O
demonstrate O O
that O O
NF-AT O O
is O O
formed O O
when O O
a O O
signal O O
from O O
the O O
antigen O O
receptor O O
induces O O
a O O
pre-existing O O
cytoplasmic O O
subunit O O
to O O
translocate O O
to O O
the O O
nucleus O O
and O O
combine O O
with O O
a O O
newly O O
synthesized O O
nuclear O O
subunit O O
of O O
NF-AT O O
. O O

The O O
negative-acting O O
sequences O O
repress O O
enhancer O O
activity O O
in O O
a O O
position- O O
and O O
orientation-independent O O
manner O O
at O O
the O O
pre-B-cell O O
stage O O
. O O

In O O
addition O O
, O O
positive O O
to O O
negative O O
ratios O O
of O O
1:1 O O
and O O
1:100 O O
were O O
considered O O
. O O

These O O
results O O
suggest O O
that O O
IFN-alpha5 O O
and O O
IFN-beta O O
are O O
produced O O
at O O
low O O
levels O O
in O O
normal O O
tissues O O
and O O
play O O
an O O
important O O
role O O
in O O
the O O
regulation O O
of O O
cell O O
function O O
and O O
in O O
the O O
maintenance O O
of O O
homeostasis O O
. O O

When O O
all O O
the O O
asthmatic O O
patients O O
were O O
analyzed O O
together O O
, O O
there O O
was O O
a O O
significant O O
correlation O O
between O O
the O O
degree O O
of O O
sensitivity O O
of O O
T O O
cells O O
to O O
dexamethasone O O
and O O
the O O
clinical O O
responsiveness O O
to O O
prednisolone O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
. O O

In O O
contrast O O
, O O
somatic O O
cell O O
fusion O O
between O O
clone O O
13 O O
and O O
RJ2.2.5 O O
restored O O
expression O O
of O O
the O O
HLA-DQ O O
haplotype O O
encoded O O
by O O
the O O
RJ2.2.5 O O
DQB O O
gene O O
. O O

A O O
novel O O
primer O O
extension O O
method O O
to O O
detect O O
the O O
number O O
of O O
CAG O O
repeats O O
in O O
the O O
androgen O O
receptor O O
gene O O
in O O
families O O
with O O
X-linked O O
spinal O O
and O O
bulbar O O
muscular O O
atrophy O O
. O O

B O O
cells O O
were O O
prestimulated O O
with O O
SAC O O
for O O
48 O O
hrs O O
. O O

Furthermore O O
, O O
our O O
studies O O
showed O O
association O O
of O O
the O O
IKK-alpha/beta O O
heterodimer O O
with O O
NIK O O
, O O
IkappaB-alpha O O
and O O
-epsilon O O
in O O
unstimulated O O
cells O O
. O O

DNase O O
I O O
footprinting O O
of O O
the O O
upstream O O
delta-globin O O
region O O
revealed O O
protected O O
sequences O O
corresponding O O
to O O
consensus O O
binding O O
sites O O
for O O
GATA-1 O O
and O O
BP2 O O
. O O

These O O
procedures O O
, O O
which O O
greatly O O
reduced O O
the O O
number O O
of O O
retrievable O O
alveolar O O
macrophages O O
, O O
suppressed O O
activation O O
of O O
lung O O
NF-kappaB O O
in O O
the O O
inflammatory O O
model O O
. O O

In O O
infected O O
monocytes O O
, O O
which O O
die O O
by O O
apoptosis O O
, O O
the O O
expression O O
of O O
CREB O O
, O O
CTF O O
, O O
and O O
OTF-2 O O
was O O
rather O O
suppressed O O
8 O O
hours O O
after O O
infection O O
. O O

The O O
ability O O
of O O
BHRF1 O O
to O O
inhibit O O
apoptosis O O
is O O
dependent O O
on O O
stimulus O O
and O O
cell O O
type O O
. O O

Human O O
alveolar O O
macrophages O O
are O O
markedly O O
deficient O O
in O O
REF-1 O O
and O O
AP-1 O O
DNA O O
binding O O
activity O O
. O O

Stronger O O
c-myc O O
mRNA O O
expression O O
was O O
detected O O
in O O
labial O O
salivary O O
glands O O
of O O
patients O O
with O O
longer O O
disease O O
duration O O
( O O
p O O
less O O
than O O
or O O
equal O O
to O O
0.002 O O
) O O
and O O
more O O
intense O O
T O O
lymphocyte O O
infiltrates O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
although O O
these O O
patients O O
revealed O O
no B-Negation B-Negation
hypergammaglobulinemia I-Negation I-Negation
. O O

Third O O
, O O
only O O
the O O
50 O O
kD O O
protein O O
was O O
retained O O
on O O
a O O
biotinylated O O
DNA-streptavidin O O
matrix O O
when O O
the O O
DNA O O
fragment O O
contained O O
the O O
TRE-DNA O O
. O O

All-trans O O
retinoic O O
acid O O
( O O
ATRA O O
) O O
is O O
successfully O O
used O O
in O O
the O O
cyto-differentiating O O
treatment O O
of O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
. O O

This O O
study O O
demonstrates O O
that O O
changes O O
in O O
endothelial O O
cell O O
GSSG/GSH O O
cause O O
transcription-independent O O
and O O
transcription-dependent O O
surface O O
expression O O
of O O
different O O
endothelial O O
cell O O
adhesion O O
molecules O O
, O O
which O O
leads O O
to O O
a O O
2-phase O O
neutrophil-endothelial O O
adhesion O O
response O O
. O O

Induction O O
of O O
NF-kappaB-dependent O O
gene O O
expression O O
in O O
transiently O O
transfected O O
human O O
monocytic O O
THP-1 O O
cells O O
and O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
was O O
inhibited O O
by O O
elevated O O
cAMP O O
and O O
by O O
overexpression O O
of O O
the O O
catalytic O O
subunit O O
of O O
protein O O
kinase O O
A O O
( O O
PKA O O
) O O
. O O

NF-kappaB O O
is O O
a O O
potent O O
cellular O O
activator O O
of O O
HIV-1 O O
gene O O
expression O O
. O O

However O O
, O O
the O O
intensity O O
of O O
p65 O O
labeling O O
was O O
much O O
higher O O
in O O
several O O
thymocytes O O
from O O
the O O
medulla O O
. O O

A O O
single O O
BCS O O
had O O
little O O
effect O O
either O O
on O O
the O O
minimal O O
B29 O O
promoter O O
or O O
on O O
a O O
heterologous O O
promoter O O
. O O

Abstract O O

Retinoic O O
acid O O
can O O
directly O O
modulate O O
gene O O
expression O O
via O O
binding O O
to O O
its O O
nuclear O O
receptors O O
, O O
which O O
can O O
, O O
in O O
turn O O
, O O
activate O O
transcription O O
of O O
target O O
genes O O
. O O

Expression O O
of O O
CD30 O O
by O O
these O O
cells O O
is O O
induced O O
by O O
CD40L O O
but O O
is O O
inhibited O O
by O O
B O O
cell O O
receptor O O
coengagement O O
and/or O O
exposure O O
to O O
IL-6 O O
and O O
IL-12 O O
. O O

This O O
regulation O O
takes O O
place O O
mainly O O
at O O
the O O
level O O
of O O
nuclear O O
translocation O O
of O O
p65 O O
and O O
c-rel O O
, O O
at O O
immediate O O
and O O
early O O
time O O
points O O
. O O

We O O
initiated O O
this O O
study O O
to O O
determine O O
1 O O
) O O
the O O
prevalence O O
of O O
one O O
or O O
more O O
breast O O
tissue O O
abnormalities O O
in O O
a O O
group O O
of O O
women O O
at O O
high O O
risk O O
for O O
breast O O
cancer O O
, O O
and O O
2 O O
) O O
if O O
the O O
prevalence O O
of O O
biomarker O O
abnormalities O O
is O O
greater O O
in O O
high O O
risk O O
than O O
in O O
low O O
risk O O
women O O
. O O

NF-kappaB O O
regulates O O
Fas/APO-1/CD95- O O
and O O
TCR- O O
mediated O O
apoptosis O O
of O O
T O O
lymphocytes O O
. O O

StatG O O
in O O
normal O O
immature O O
human O O
myeloid O O
cells O O
, O O
i.e. O O
adult O O
CD34+ O O
bone O O
marrow O O
cells O O
, O O
was O O
composed O O
of O O
Stat3beta O O
. O O

Nuclear O O
factor-kappaB-dependent O O
induction O O
of O O
interleukin-8 O O
gene O O
expression O O
by O O
tumor O O
necrosis O O
factor O O
alpha O O
: O O
evidence O O
for O O
an O O
antioxidant O O
sensitive O O
activating O O
pathway O O
distinct O O
from O O
nuclear O O
translocation O O
. O O

Stimulation O O
of O O
the O O
CD28 O O
cell O O
surface O O
molecule O O
delivers O O
costimulatory O O
signals O O
essential O O
for O O
lymphokine O O
production O O
in O O
activated O O
T O O
cells O O
via O O
a O O
conserved O O
sequence O O
element O O
found O O
in O O
the O O
promoter O O
of O O
several O O
lymphokine O O
genes O O
. O O

By O O
contrast O O
, O O
treatment O O
of O O
HL-60/vinc O O
cells O O
with O O
okadaic O O
acid O O
, O O
an O O
inhibitor O O
of O O
serine/threonine O O
protein O O
phosphatases O O
, O O
induces O O
c-jun O O
transcription O O
, O O
growth O O
arrest O O
, O O
and O O
expression O O
of O O
the O O
c-fms O O
gene O O
. O O

An O O
ensemble O O
motif O O
finder O O
with O O
a O O
learning O O
rule O O
that O O
is O O
no B-Negation B-Negation
better I-Negation I-Negation
than I-Negation I-Negation
random I-Negation I-Negation
will O O
provide O O
an O O
accuracy O O
that O O
is O O
equal O O
to O O
the O O
average O O
of O O
its O O
three O O
component O O
algorithms O O
. O O

Tax1 O O
strongly O O
activates O O
the O O
enhancer O O
activity O O
of O O
this O O
motif O O
, O O
in O O
both O O
epithelial O O
HeLa O O
and O O
lymphoid O O
Jurkat O O
cells O O
. O O

NGFI-B/nur77 O O
is O O
a O O
member O O
of O O
the O O
steroid O O
receptor O O
superfamily O O
. O O

These O O
increases O O
occur O O
in O O
the O O
absence B-Negation O
of I-Negation O
protein I-Negation O
synthesis I-Negation O
but O O
are O O
dependent O O
on O O
inactivation O O
of O O
the O O
v-abl O O
protein O O
tyrosine O O
kinase O O
. O O

In O O
all O O
rescue O O
experiments O O
, O O
30 O O
freshly O O
hatched O O
homozygous O O
first-instar O O
larvae O O
were O O
selected O O
using O O
a O O
GFP O O
dissecting O O
microscope O O
and O O
transferred O O
into O O
fresh O O
vials O O
( O O
at O O
least O O
four O O
vials O O
for O O
each O O
variant O O
) O O
. O O

This O O
resulted O O
in O O
26896 O O
distinct O O
human O O
protein O O
interactions O O
involving O O
7531 O O
distinct O O
human O O
proteins O O
present O O
in O O
the O O
initial O O
IPI O O
dataset O O
. O O

Primary O O
structure O O
analysis O O
showed O O
that O O
the O O
encoded O O
protein O O
contains O O
three O O
tandem O O
zinc-finger O O
sequences O O
of O O
the O O
type O O
Cys2-Xaa12-His2 O O
. O O

Stimulation O O
of O O
HUVEC O O
with O O
thrombin O O
resulted O O
in O O
dose- O O
and O O
time-dependent O O
increases O O
in O O
ICAM-1 O O
mRNA O O
and O O
cell O O
surface O O
expression O O
and O O
in O O
ICAM-1-dependent O O
endothelial O O
adhesivity O O
toward O O
polymorphonuclear O O
leukocytes O O
. O O

Jagged1 O O
belongs O O
to O O
the O O
DSL O O
family O O
of O O
ligands O O
for O O
Notch O O
receptors O O
that O O
control O O
the O O
proliferation O O
and O O
differentiation O O
of O O
various O O
cell O O
lineages O O
. O O

The O O
chemokine O O
RANTES O O
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
allergic O O
inflammatory O O
diseases O O
including O O
asthma O O
and O O
rhinitis O O
which O O
are O O
frequently O O
treated O O
with O O
glucocorticoids O O
. O O

The O O
direct O O
sequence O O
comparison O O
was O O
performed O O
using O O
pmatch O O
, O O
a O O
very O O
fast O O
pairwise O O
alignment O O
algorithm O O
developed O O
by O O
Richard O O
Durbin O O
( O O
unpublished O O
, O O
source O O
code O O
available O O
34 O O
) O O
. O O

Four O O
of O O
the O O
6 O O
mAECA O O
activated O O
EC O O
, O O
manifested O O
by O O
increased O O
IL-6 O O
and O O
vWF O O
secretion O O
. O O

The O O
rate O O
of O O
transcription O O
initiation O O
directed O O
by O O
the O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
of O O
HIV-1 O O
increases O O
in O O
response O O
to O O
mitogenic O O
stimuli O O
of O O
T O O
cells O O
. O O

Because O O
the O O
DSE O O
are O O
also O O
TRE O O
sites O O
, O O
we O O
assessed O O
the O O
effect O O
of O O
the O O
agonist O O
combinations O O
on O O
AP-1-dependent O O
transcription O O
. O O

The O O
described O O
conditions O O
which O O
inhibited O O
or O O
prevented O O
the O O
activation O O
of O O
the O O
IL-1RI-associated O O
kinase O O
similarly O O
impaired O O
the O O
activation O O
of O O
NF-kappa O O
B O O
in O O
EL4 O O
cells O O
. O O

We O O
found O O
that O O
transactivation O O
of O O
the O O
HIV-1 O O
LTR O O
by O O
v-src O O
was O O
more O O
sensitive O O
to O O
mutations O O
of O O
the O O
proximal O O
, O O
rather B-Negation B-Negation
than I-Negation I-Negation
the I-Negation I-Negation
distal I-Negation I-Negation
, O I-Negation
kappa O I-Negation
B O I-Negation
element O I-Negation
. O O

An O O
isotype-specific O O
activator O O
of O O
major O O
histocompatibility O O
complex O O
( O O
MHC O O
) O O
class O O
II O O
genes O O
that O O
is O O
independent O O
of O O
class O O
II O O
transactivator O O
. O O

Furthermore O O
, O O
we O O
found O O
that O O
unassembled O O
WGS O O
trace O O
sequences O O
encode O O
two O O
other O O
proteins O O
, O O
P4_SP O O
and O O
P5_SP O O
, O O
similar O O
to O O
the O O
N-terminal O O
RAG1 O O
domain O O
( O O
Figure O O
6 O O
) O O
. O O

As O O
reported O O
here O O
, O O
structure-function O O
analysis O O
of O O
the O O
CAML O O
gene O O
in O O
Jurkat O O
T O O
cells O O
indicates O O
that O O
two O O
of O O
CAML O O
's O O
putative O O
membrane-spanning O O
domains O O
are O O
necessary O O
and O O
sufficient O O
for O O
the O O
modulation O O
of O O
intracellular O O
calcium O O
. O O

Furthermore O O
overexpression O O
of O O
exogenous O O
c-fos O O
has O O
an O O
inhibitory O O
effect O O
on O O
GR-dependent O O
transcription O O
from O O
GRE O O
in O O
T O O
cells O O
. O O

Tepoxalin O O
also O O
inhibits O O
the O O
activation O O
of O O
NF O O
kappa O O
B O O
, O O
a O O
transcription O O
factor O O
which O O
acts O O
on O O
several O O
cytokine O O
genes O O
. O O

PMA O O
, O O
which O O
directly O O
activates O O
PKC O O
, O O
mimicked O O
the O O
effect O O
of O O
the O O
lectins O O
on O O
c-Fos O O
and O O
c-Jun O O
, O O
but O O
elevation O O
of O O
either O O
intracellular O O
Ca2+ O O
or O O
cAMP O O
levels O O
had O O
little O O
or O O
no B-Negation B-Negation
effect I-Negation I-Negation
. O O

Images O O
were O O
acquired O O
on O O
a O O
Leica O O
( O O
Wetzlar O O
, O O
Germany O O
) O O
SP2 O O
microscope O O
and O O
assembled O O
using O O
Adobe O O
Photoshop O O
( O O
Adobe O O
Systems O O
, O O
San O O
Jose O O
, O O
California O O
, O O
United O O
States O O
) O O
. O O

The O O
effects O O
of O O
these O O
substitutions O O
on O O
viral O O
replication O O
in O O
transfected O O
HeLa O O
cells O O
and O O
on O O
HIV O O
infection O O
of O O
human O O
peripheral O O
blood O O
lymphocytes O O
or O O
continuous O O
T-leukemia O O
cell O O
lines O O
were O O
evaluated O O
. O O

These O O
findings O O
may O O
help O O
in O O
understanding O O
the O O
pathogenesis O O
of O O
the O O
immunodeficiency O O
that O O
occurs O O
with O O
mutations O O
of O O
JAK3 O O
and O O
may O O
suggest O O
a O O
mechanism O O
for O O
the O O
pleiotropic O O
effects O O
of O O
IL-4 O O
. O O

This O O
statistical O O
overrepresentation O O
suggests O O
that O O
certain O O
iPfam O O
domain O O
pairs O O
constitute O O
modules O O
of O O
molecular O O
recognition O O
which O O
are O O
reused O O
in O O
different O O
protein O O
interactions O O
2 O O
. O O

In O O
contrast O O
, O O
although O O
the O O
Janus O O
kinase O O
3 O O
tyrosine O O
kinase O O
was O O
associated O O
with O O
CD40 O O
molecules O O
in O O
both O O
monocytes O O
and O O
resting O O
B O O
cells O O
, O O
Janus O O
kinase O O
3 O O
phosphorylation O O
induction O O
was O O
observed O O
only O O
in O O
CD40-activated O O
monocytes O O
, O O
with O O
subsequent O O
induction O O
of O O
STAT5a O O
DNA O O
binding O O
activity O O
in O O
the O O
nucleus O O
. O O

By O O
immunofluorescence O O
, O O
LYSP100 O O
was O O
localized O O
to O O
nuclear O O
dots O O
that O O
were O O
surprisingly O O
largely O O
nonoverlapping O O
with O O
PML O O
NBs O O
. O O

In O O
T O O
lymphocytes O O
these O O
drugs O O
disrupt O O
an O O
unknown O O
step O O
in O O
the O O
transmission O O
of O O
signals O O
from O O
the O O
T-cell O O
antigen O O
receptor O O
to O O
cytokine O O
genes O O
that O O
coordinate O O
the O O
immune O O
response O O
. O O

Finally O O
, O O
immunoblot O O
analysis O O
of O O
nuclear O O
extracts O O
showed O O
decreased O O
or O O
absent B-Negation B-Negation
p65 I-Negation I-Negation
protein I-Negation I-Negation
levels I-Negation I-Negation
. O O

Some O O
iPfam O O
domain O O
pairs O O
are O O
seen O O
to O O
form O O
interactions O O
between O O
distinct O O
peptide O O
chains O O
in O O
the O O
structure O O
( O O
interchain O O
) O O
, O O
while O O
others O O
form O O
an O O
interaction O O
between O O
two O O
distinct O O
domains O O
within O O
the O O
same O O
chain O O
( O O
intrachain O O
) O O
. O O

The O O
underlying O O
mechanisms O O
by O O
which O O
the O O
corresponding O O
genes O O
are O O
transcriptionally O O
initiated O O
after O O
virus O O
infection O O
are O O
still O O
poorly O O
understood O O
. O O

Hemocyte O O
morphology O O
was O O
observed O O
by O O
differential O O
interference O O
contrast O O
microscopy O O
of O O
living O O
cells O O
in O O
Shields O O
and O O
Sang O O
Insect O O
Medium O O
( O O
Sigma-Aldrich O O
) O O
obtained O O
by O O
the O O
same O O
procedure O O
as O O
for O O
counting O O
. O O

SCOPE O O
takes O O
as O O
input O O
a O O
set O O
of O O
sequences O O
U O O
that O O
are O O
upstream O O
of O O
a O O
set O O
of O O
genes O O
G O O
that O O
are O O
thought O O
to O O
be O O
coregulated O O
. O O

Therefore O O
, O O
in O O
an O O
ideal O O
situation O O
the O O
presence O O
or O O
absence B-Negation O
of I-Negation O
the I-Negation O
21 I-Negation O
residues I-Negation O
in I-Negation O
alignments I-Negation O
will O O
be O O
synchronized O O
. O O

This O O
suggests O O
that O O
the O O
activation O O
mechanism O O
of O O
the O O
GM-CSF O O
gene O O
through O O
the O O
GM2/GC-box O O
sequence O O
is O O
different O O
from O O
that O O
of O O
genes O O
carrying O O
the O O
kappa O O
B O O
enhancer O O
alone O O
. O O

CD30 O O
ligation O O
induces O O
nuclear O O
factor-kappa O O
B O O
activation O O
in O O
human O O
T O O
cell O O
lines O O
. O O

Moreover O O
, O O
the O O
combination O O
of O O
activated O O
MAPKK-1 O O
and O O
Rac-1 O O
could B-Negation O
not I-Negation B-Negation
substitute I-Negation I-Negation
for I-Negation I-Negation
activated I-Negation I-Negation
p21ras I-Negation I-Negation
and I-Negation O
synergize I-Negation O
with I-Negation O
calcium I-Negation O
signals I-Negation O
to I-Negation O
induce I-Negation O
NFAT I-Negation O
. O O

The O O
main O O
activity O O
of O O
the O O
silencer O O
has O O
been O O
mapped O O
to O O
the O O
first O O
900 O O
bp O O
of O O
5 O O
' O O
flanking O O
DNA O O
, O O
which O O
contains O O
nine O O
binding O O
sites O O
for O O
a O O
nuclear O O
factor O O
present O O
in O O
non-erythroid O O
cells O O
but O O
not B-Negation B-Negation
in I-Negation I-Negation
erythroid I-Negation I-Negation
cells I-Negation I-Negation
. O O

PG490 O O
also O O
inhibits O O
PMA-stimulated O O
activation O O
of O O
a O O
chimeric O O
transcription O O
factor O O
in O O
which O O
the O O
C-terminal O O
TA1 O O
transactivation O O
domain O O
of O O
NF-kappaB O O
p65 O O
is O O
fused O O
to O O
the O O
DNA O O
binding O O
domain O O
of O O
GAL4 O O
. O O

The O O
T O O
cell O O
tyrosine O O
kinase O O
ZAP-70 O O
was O O
found O O
to O O
be O O
highly O O
responsive O O
to O O
UV O O
and O O
H2O2 O O
treatment O O
. O O

CsA O O
neither B-Negation B-Negation
inhibits I-Negation I-Negation
the I-Negation I-Negation
processing I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
NF-kappa I-Negation I-Negation
B1 I-Negation I-Negation
precursor I-Negation I-Negation
p105 I-Negation I-Negation
to I-Negation I-Negation
p50 I-Negation I-Negation
, I-Negation I-Negation
nor I-Negation I-Negation
does I-Negation I-Negation
it I-Negation I-Negation
`` I-Negation I-Negation
stabilize I-Negation I-Negation
'' I-Negation I-Negation
the I-Negation I-Negation
C-terminal I-Negation I-Negation
portion I-Negation I-Negation
of I-Negation I-Negation
p105 I-Negation I-Negation
, I-Negation I-Negation
I I-Negation I-Negation
kappa I-Negation I-Negation
B I-Negation I-Negation
gamma I-Negation I-Negation
, I-Negation I-Negation
which I-Negation I-Negation
is I-Negation I-Negation
degraded I-Negation I-Negation
during I-Negation I-Negation
p105 I-Negation I-Negation
processing I-Negation I-Negation
to I-Negation I-Negation
mature I-Negation I-Negation
p50 I-Negation I-Negation
. O O

These O O
results O O
suggest O O
that O O
Oct-2 O O
participates O O
in O O
transcriptional O O
regulation O O
during O O
T-cell O O
activation O O
. O O

The O O
reduced O O
cytoplasmic O O
staining O O
seen O O
in O O
D-mib O O
mutant O O
cells O O
( O O
Figure O O
3F–3F O O
? O O
? O O
) O O
'' O O
suggests O O
that O O
D-mib O O
is O O
also O O
present O O
in O O
the O O
cytoplasm O O
. O O

An O O
iORF O O
was O O
discarded O O
if O O
there O O
were O O
any O O
BLAST O O
hits O O
that O O
do O O
not B-Negation B-Negation
cover I-Negation I-Negation
the I-Negation I-Negation
inframe I-Negation I-Negation
stop I-Negation I-Negation
codon I-Negation I-Negation
. O O

ETS1 O O
transactivates O O
the O O
human O O
GM-CSF O O
promoter O O
in O O
Jurkat O O
T O O
cells O O
stimulated O O
with O O
PMA O O
and O O
ionomycin O O
. O O

Such O O
repressive O O
function O O
is O O
similar O O
to O O
that O O
seen O O
in O O
IRF-2 O O
or O O
ICSBP O O
. O O

To O O
approach O O
this O O
issue O O
, O O
we O O
used O O
CD36 O O
transfected O O
Chinese O O
hampster O O
ovary O O
( O O
CHO O O
) O O
cells O O
, O O
exposed O O
them O O
to O O
Ox O O
LDL O O
, O O
and O O
determined O O
changes O O
in O O
the O O
activity O O
of O O
the O O
transcription O O
factor O O
NF-kappaB O O
. O O

Gel O O
shift O O
assay O O
studies O O
with O O
synthetic O O
oligonucleotides O O
corresponding O O
to O O
partial O O
sequences O O
of O O
the O O
latter O O
region O O
and O O
nuclear O O
extracts O O
from O O
stimulated O O
cells O O
revealed O O
specific O O
protein O O
binding O O
sites O O
between O O
-3110 O O
and O O
-3090 O O
and O O
between O O
-3079 O O
and O O
-3059 O O
. O O

CD40 O O
ligation O O
leads O O
to O O
B O O
cell O O
activation O O
events O O
such O O
as O O
proliferation O O
, O O
Ig O O
secretion O O
, O O
isotype O O
switching O O
, O O
and O O
up-regulation O O
of O O
cell O O
surface O O
molecules O O
, O O
as O O
well O O
as O O
the O O
generation O O
of O O
memory O O
B O O
cells O O
. O O

Both O O
c-Fos O O
and O O
c-Jun O O
protein O O
levels O O
were O O
increased O O
after O O
Con O O
A O O
and O O
PHA O O
stimulation O O
. O O

To O O
evaluate O O
the O O
PML/RARalpha O O
role O O
in O O
myelopoiesis O O
, O O
transgenic O O
mice O O
expressing O O
PML/RARalpha O O
were O O
engineered O O
. O O

Long-lasting O O
IL-2 O O
receptivity O O
is O O
associated O O
with O O
high-level O O
expression O O
of O O
the O O
inducible O O
IL-2 O O
receptor O O
alpha O O
chain O O
( O O
IL-2R O O
alpha O O
) O O
gene O O
that O O
is O O
regulated O O
at O O
both O O
transcriptional O O
and O O
posttranscriptional O O
levels O O
. O O

To O O
determine O O
whether O O
EBNA-2 O O
also O O
trans-activates O O
the O O
LMP O O
promoter O O
by O O
protein-protein O O
interactions O O
, O O
we O O
performed O O
a O O
series O O
of O O
gel O O
retardation O O
assays O O
and O O
competition O O
experiments O O
with O O
LMP O O
promoter O O
fragments O O
of O O
different O O
sizes O O
. O O

Furthermore O O
, O O
no B-Negation B-Negation
modification I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
suppressor I-Negation I-Negation
function I-Negation I-Negation
in I-Negation I-Negation
CEM I-Negation I-Negation
C1 I-Negation I-Negation
cells I-Negation I-Negation
by I-Negation I-Negation
dexamethasone I-Negation I-Negation
was I-Negation I-Negation
observed I-Negation I-Negation
. O O

This O O
study O O
tested O O
the O O
hypothesis O O
that O O
anti-LPS O O
Abs O O
neutralize O O
endotoxin O O
by O O
blocking O O
cellular O O
uptake O O
through O O
mCD14 O O
. O O

Furthermore O O
, O O
the O O
receptor O O
changes O O
observed O O
are O O
opposite O O
of O O
those O O
reported O O
in O O
major O O
depressive O O
disorder O O
. O O

Nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
was O O
originally O O
described O O
as O O
a O O
T-cell-specific O O
transcription O O
factor O O
athat O O
supported O O
the O O
activation O O
of O O
cytokine O O
gene O O
expression O O
and O O
mediated O O
the O O
immunoregulatory O O
effects O O
of O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
. O O

We O O
demonstrate O O
here O O
that O O
beta-catenin O O
can O O
be O O
imported O O
into O O
the O O
nucleus O O
independently O O
of O O
LEF/TCF O O
binding O O
, O O
and O O
it O O
may O O
also O O
be O O
exported O O
from O O
nuclei O O
. O O

NAC O O
and O O
other O O
thiol O O
compounds O O
also O O
blocked O O
the O O
activation O O
of O O
NF-kappa O O
B O O
by O O
cycloheximide O O
, O O
double-stranded O O
RNA O O
, O O
calcium O O
ionophore O O
, O O
TNF-alpha O O
, O O
active O O
phorbol O O
ester O O
, O O
interleukin-1 O O
, O O
lipopolysaccharide O O
and O O
lectin O O
. O O

The O O
sequence O O
shows O O
high O O
homology O O
with O O
the O O
murine O O
FOSB O O
gene O O
, O O
which O O
encodes O O
a O O
component O O
of O O
the O O
AP1 O O
transcriptional O O
regulator O O
. O O

IkappaB O O
alpha O O
phosphorylation O O
on O O
Ser-32 O O
and O O
Ser-36 O O
is O O
followed O O
by O O
its O O
degradation O O
and O O
NF-kappaB O O
activation O O
. O O

Many O O
transcription O O
factors O O
will O O
bind O O
motifs O O
on O O
either O O
DNA O O
strand O O
. O O

Interleukin-4 O O
( O O
IL-4 O O
) O O
plays O O
a O O
major O O
role O O
in O O
this O O
process O O
by O O
promoting O O
the O O
differentiation O O
of O O
IL-4-secreting O O
Th2 O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
demonstrate O O
that O O
the O O
expression O O
of O O
jun O O
and O O
fos O O
gene O O
family O O
members O O
is O O
induced O O
with O O
variable O O
kinetics O O
during O O
12-O-tetradecanoylphorbol-13-acetate O O
induced O O
differentiation O O
, O O
with O O
c-jun O O
expression O O
best O O
paralleling O O
differentiation O O
. O O

Triggering O O
of O O
the O O
T-cell O O
receptor-CD3 O O
complex O O
activates O O
two O O
major O O
signal O O
cascades O O
in O O
T O O
lymphocytes O O
, O O
( O O
i O O
) O O
Ca2+-dependent O O
signal O O
cascades O O
and O O
( O O
ii O O
) O O
protein O O
kinase O O
cascades O O
. O O

UT-7 O O
Epo O O
and O O
UT-7 O O
expressed O O
similar O O
levels O O
of O O
GATA-1 O O
mRNA O O
and O O
binding O O
activity O O
. O O

By O O
dividing O O
the O O
search O O
space O O
into O O
tractable O O
domains O O
, O O
SCOPE O O
mitigates O O
the O O
potential O O
liabilities O O
associated O O
with O O
ensemble O O
methods O O
, O O
resulting O O
in O O
a O O
program O O
that O O
is O O
capable O O
of O O
finding O O
cis-regulatory O O
elements O O
of O O
arbitrary O O
length O O
, O O
degree O O
of O O
degeneracy O O
, O O
motif O O
orientation O O
and O O
frequency O O
of O O
occurrence O O
. O O

No B-Negation B-Negation
rescue I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
phenotype I-Negation I-Negation
, I-Negation I-Negation
including I-Negation I-Negation
body I-Negation I-Negation
shape I-Negation I-Negation
of I-Negation I-Negation
escaping I-Negation I-Negation
pupae I-Negation I-Negation
, I-Negation O
was I-Negation O
observed I-Negation O
. O O

Interleukin O O
2 O O
( O O
IL-2 O O
) O O
stimulates O O
IL-2R O O
alpha. O O
transcription O O
, O O
thereby O O
amplifying O O
expression O O
of O O
its O O
own O O
high-affinity O O
receptor O O
. O O

Whereas O O
IL-4 O O
had O O
little O O
or O O
no B-Negation B-Negation
effect I-Negation I-Negation
, O O
IL-7 O O
delayed O O
both O O
the O O
apoptosis O O
and O O
cell O O
cycle O O
arrest O O
that O O
occur O O
upon O O
v-Abl O O
kinase O O
inactivation O O
. O O

A O O
nuclear O O
factor-kappaB-mediated O O
phenomenon O O
. O O

The O O
purified O O
NF-GM2 O O
activated O O
in O O
vitro O O
transcription O O
from O O
the O O
kappa O O
B O O
enhancer O O
, O O
while O O
it O O
failed B-Negation B-Negation
to I-Negation I-Negation
stimulate I-Negation I-Negation
transcription I-Negation I-Negation
from I-Negation I-Negation
the I-Negation I-Negation
GM-CSF I-Negation I-Negation
promoter I-Negation I-Negation
harboring I-Negation I-Negation
the I-Negation I-Negation
GM2 I-Negation I-Negation
sequence I-Negation I-Negation
. O O

The O O
ability O O
of O O
interferon O O
alpha O O
to O O
up-regulate O O
MNDA O O
mRNA O O
in O O
phorbol O O
ester O O
treated O O
myeloid O O
cell O O
lines O O
is O O
consistent O O
with O O
the O O
observations O O
made O O
in O O
primary O O
monocytes O O
. O O

Hemocyte O O
Development O O
Is O O
Affected O O
in O O
the O O
adgf-a O O
Mutant O O

Further O O
, O O
Vpr O O
suppresses O O
expression O O
of O O
IL-2 O O
, O O
IL-10 O O
, O O
IL-12 O O
, O O
TNF O O
alpha O O
and O O
IL-4 O O
, O O
all O O
of O O
which O O
are O O
NF-kappa O O
B-dependent O O
. O O

These O O
results O O
indicate O O
that O O
Fc O O
gamma O O
R O O
can O O
mediate O O
a O O
TNF-alpha-dependent O O
induction O O
of O O
HIV-1 O O
gene O O
transcription O O
and O O
suggest O O
that O O
immune O O
complexes O O
may O O
contribute O O
to O O
the O O
pathophysiology O O
of O O
HIV-1 O O
infection O O
by O O
augmenting O O
viral O O
replication O O
in O O
monocytes O O
. O O

To O O
determine O O
whether O O
CIF O O
blocks O O
at O O
the O O
level O O
of O O
IL2 O O
transcription O O
, O O
we O O
introduced O O
reporter O O
plasmids O O
into O O
the O O
human O O
T O O
leukemia O O
cell O O
line O O
Jurkat O O
by O O
transient O O
transfection O O
. O O

This O O
cluster O O
is O O
probably O O
an O O
artifact O O
of O O
close O O
phylogenetic O O
relationship O O
. O O

( O O
b O O
) O O
Cumulative O O
distribution O O
of O O
accuracy O O
for O O
each O O
program O O
. O O

Stimulation O O
of O O
neutrophils O O
with O O
granulocyte-colony O O
stimulating O O
factor O O
( O O
G-CSF O O
) O O
results O O
in O O
an O O
enhanced O O
respiratory O O
burst O O
, O O
prolonged O O
survival O O
, O O
and O O
increased O O
tumor O O
cell O O
killing O O
. O O

For O O
yeast O O
( O O
whose O O
upstream O O
regions O O
are O O
standardized O O
to O O
800 O O
bp O O
) O O
, O O
BEAM O O
and O O
PRISM O O
use O O
the O O
overrepresentation-KS O O
objective O O
function O O
( O O
so/ks O O
) O O
, O O
while O O
SPACER O O
's O O
slower O O
running O O
time O O
requires O O
the O O
simpler O O
overrepresentation O O
objective O O
function O O
( O O
so O O
) O O
. O O

We O O
eliminate O O
both O O
Stat5 O O
and O O
Raf/MEK O O
pathways O O
from O O
E2F O O
regulation O O
. O O

We O O
identified O O
a O O
novel O O
cellular O O
Tip-associated O O
protein O O
( O O
Tap O O
) O O
by O O
a O O
yeast O O
two-hybrid O O
screen O O
. O O

When O O
transcriptionally O O
active O O
, O O
the O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
promoter O O
contains O O
a O O
nucleosome-free O O
region O O
encompassing O O
both O O
the O O
promoter/enhancer O O
region O O
and O O
a O O
large O O
region O O
( O O
255 O O
nucleotides O O
[ O O
nt O O
] O O
) O O
downstream O O
of O O
the O O
transcription O O
start O O
site O O
. O O

In O O
contrast O O
, O O
the O O
RelA O O
( O O
p65 O O
) O O
subunit O O
was O O
barely O O
detectable O O
in O O
monocytes O O
, O O
but O O
its O O
level O O
increased O O
markedly O O
in O O
MDMs O O
. O O

In O O
contrast O O
, O O
a O O
high O O
level O O
of O O
bcl-2 O O
protects O O
cells O O
in O O
vitro O O
and O O
in O O
vivo O O
from O O
the O O
viral O O
protease O O
and O O
prevents O O
cell O O
death O O
following O O
HIV O O
infection O O
of O O
human O O
lymphocytes O O
, O O
while O O
reducing O O
the O O
yields O O
of O O
viral O O
structural O O
proteins O O
, O O
infectivity O O
, O O
and O O
tumor O O
necrosis O O
factor O O
alpha O O
. O O

Enhancing O O
effect O O
of O O
17 O O
beta-estradiol O O
on O O
human O O
NK O O
cell O O
activity O O
. O O

These B-Negation B-Negation
results I-Negation I-Negation
can I-Negation I-Negation
not I-Negation I-Negation
be I-Negation I-Negation
explained I-Negation I-Negation
by I-Negation I-Negation
receptor I-Negation I-Negation
down-regulation I-Negation I-Negation
due I-Negation I-Negation
to I-Negation I-Negation
higher I-Negation I-Negation
level I-Negation I-Negation
of I-Negation I-Negation
mineralocorticoids I-Negation I-Negation
of I-Negation I-Negation
the I-Negation I-Negation
zona I-Negation I-Negation
glomerulosa I-Negation I-Negation
. O O

